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1. Department 3 
Head:  Prof. Dr. Gérard Krause  
Deputy:  Dr. Osamah Hamouda  
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2.  Tasks and Goals of the Department 
2.1.  Summary 
The mission of the department is to prevent, detect and control infections in the population in 
Germany. In addition to the legally mandated duties in this context the department is also actively 
engaged in epidemiological research and training.  
The department supports the local public health service by building up a comprehensive national 
surveillance system, maintaining a 24/7 on call duty system and the Epidemiological Situation 
Centre, providing scientific support for pandemic management, deploying epidemiological teams 
for outbreak investigations and offering special training for the respective target groups. The 
department hosts the majority of the national advisory committees affiliated at the RKI, was in 
charge of 54 % of all ministerial decrees directed to the 4 technical departments of the Robert Koch 
Institute 2009-2012, authors more than half of all RKI-reports in the epidemiological bulletin and 
coordinates all RKI- fact sheets for physicians (Ratgeber). The department executes the nation’s 
reporting obligation with the European Union and the World Health Organization and represents 
Germany in many international networks. 
The department’s scientific activities have clearly increased in quantity and level of sophistication. 
All these activities are a result of joint contribution by all units of the department. Scientists of the 
department are renowned experts visible through publications, memberships in international 
advisory groups, and invited presentations. Furthermore the department has created the first 
Master of Science programme to be run by a federal institution and has initiated the instalment of 
the first joint professorship appointment in the remit of the Federal Ministry of Health, both 
indications for the scientific liaison between academia and the RKI.  
In addition to strategic orientation, coordination and quality control of the above mentioned 
activities the director and staff of the director’s office initiated or carried out a number of these 
activities directly. 
2.2.  Current status of the work and summary of relevant results 
2.2.1 Service 
The mission of the department is to prevent, detect and control infections in Germany’s population 
(see 4.3., AL3) through 
• Continuous surveillance and assessment of the epidemic situation 
• Implementation and support of outbreak investigations 
• Development and evaluation of strategies for prevention and intervention 
• Research and method development in the field of infectious disease epidemiology 
• Execution of legal duties in the field of infectious disease control  
• Support and advice for other partners of the public health service and political decision 
makers 
• Development of evidence-based recommendations for the public health service 
• Information for the public 
• Exchange with other national and international health authorities 
• Qualification and further training in the field of public health with emphasis on infectious 
disease epidemiology 
The legally mandated task and duties of the department include among others notifiable disease 
surveillance, complementary monitoring and surveillance of non-notifiable disease, international 
reporting obligations within the Early Warning and Response System (EWRS) of the European 
Union and the International Health Regulations (IHR) (see 2.5.2., AL3) and coordination of the 
response to public health emergencies of infectious origin (see 2.5.3-2.5.5., AL3). An important task 
of the department is the risk assessment and scientific advice for the government and policy 
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makers as reflected by the large and increasing number of ministerial decrees directed to the 
department (see 2.5.8., AL3). Six different national advisory committees are hosted and 
scientifically supported by respective units of the department. All units of the department 
contribute to the yearly epidemiological report (coordinated by unit 32) and together they have 
published more than half of all RKI-reports in the epidemiological bulletin. Additionally the 
department maintains a 24/7 on call duty service centrally for the whole institute. Upon request the 
department provides immediate technical support to the local public health service, ranging from 
scientific advice on the phone, to provision of technical tools up to the deployment of epidemiology 
teams on site (see 2.5.3., AL3). Although not formally a task of the institute the department engages 
in multiple activities of training (see Unit PAE and the respective chapters 2.6 of each unit) and 
capacity building in order to support dissemination of skills in the public health service, to 
strengthen liaison with academia and to generate a pool of qualified scientists for this field. The 
director and his office coordinate and supervise these activities. The director’s office runs the 
network of national reference centres and consiliary laboratories and edits and co-authors a large 
portfolio of guidelines and recommendations for the public health service and for medical staff (see 
2.5.6. and 2.5.7., AL3) 
2.2.2. Research  
In order to provide the above described service at the best available scientific level the department 
engages in own epidemiological research. This research goes way beyond descriptive analysis of 
surveillance data, and is mostly funded by competitively acquired external funding. While most of 
this is being done by the respective units, the director himself and staff of the director’s office are 
also personally engaged in initiation and execution of research projects and acquisition of external 
grants (e.g. REACT see 2.2.7., Unit 32, ARS see 2.2.4, Unit 32).  
2.2.3. Organisation 
The department was created in 2002 as successor of the former centre for infectious disease 
epidemiology (as part of Dept. 2) which was founded in consequence of the new infectious disease 
control law enacted in 2001. During the reporting period of this report the department contained a 
dedicated unit for surveillance related data management (Unit 31) and another for generic 
surveillance (Unit 32). In international comparison this set-up is unique and makes Germany one 
of the few large federal countries with a generic electronic surveillance platform comprising all 
notifiable diseases and all administrational levels of the public health service. This contributes to 
user friendliness, standardisation, data safety and efficiency. In 2006 the former unit for respiratory 
and vaccine preventable disease was divided up into one unit dedicated to vaccine preventable 
diseases (Unit 33) and another to respiratory infections (Unit 36) complementing the already 
existing disease specific unit for HIV AIDS and other blood transmitted infections (Unit 34), and 
the unit for gastroenteric and zoonotic infections (Unit 35). In 2009 with the creation of the 
postgraduate programme for applied epidemiology training (PAE) and its establishment as a 
masters of since programme at the Charité the PAE-unit was created reporting directly to the 
director of the department (see PAE).  
While organisational substructures are essential to allow for the development of specialised 
expertise the above mentioned duties require a multidisciplinary approach across units. This is 
particularity true in outbreak situations during which extreme thematic flexibility and immediate 
reallocation of surge capacity is essential. The need for high level disease specific expertise on one 
hand and the ability to mobilise all staff for the investigation of unexpected public health 
emergencies on the other hand is a challenge for staff and management. 
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Figure 1: Organogram before and after reorganisation in 2012 
 
2.3.  Major goals and contribution to the goals of the department  
In the recent years Germany has experienced some extraordinary challenges and also opportunities 
in the area of infectious disease epidemiology which result in the following emerging issues: 
a) The implementation of the New International Health Regulations (IHR) requires faster, 
more detailed and more reliable information exchange internationally. 
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b) Public communication (e.g. through Web 2.0) has become increasingly decentralised, 
accelerated, and widespread resulting in dramatically reduced turn-around time for 
response and communication. 
c) Antimicrobial resistance and its respective public attention and regulations have gained 
importance.  
d) The attention to nosocomial infections particularly in vulnerable settings such as 
neonatology is rising. 
e) The potential but also complexity in the field of immunisations is increasing. 
f) The world first experience with a pandemic in the era of modern virological surveillance and 
pandemic vaccine availability has had a major impact on the societal expectations to public 
health response. 
g) Globalised market of food and other potential vehicles of infectious pathogens raise the 
risk for larger point source outbreaks with international implications. 
h) Social inequalities and public health programmes for difficult to reach populations are 
gaining attention also in the field of infectious diseases. 
i) The demand for fully evidence based recommendations is increasing including in areas for 
which conventional methods of evidence-based medicine are hardly applicable.  
j) Modelling, health economics and burden of disease assessments are gaining importance 
for health policy recommendations. 
k) There is an increasing societal demand for transparent, participatory recommendations 
with full control of conflicts of interest. 
l) Emerging issues in infectious disease prevention require increasing involvement of and 
coordination with scientific associations and other academic institutions, as the experience 
with 2009 influenza pandemic and the EHEC/HUS outbreak in 2011 has made evident. 
m) Increasing budgetary constraints and regulation in the health care sector lead to potential 
reduction of hygienic and microbiological laboratory capacity and expertise. 
n) The public health service, especially at local community level, is challenged by budgetary 
constraints and has difficulties to attract qualified staff. 
o) Appearance of new research networks in the field of infectious disease epidemiology such 
as the German Centre for Infection Research (DZIF) and the National Cohort have created 
new research opportunities as well as competitors in the field. 
Following the implementation of the IHR, the experience with the 2009 influenza pandemic and 
the 2011 EHEC/HUS outbreak the director has initiated and conducted a variety of evaluations and 
has participated as invited expert in international evaluation activities. Those activities resulted in 
useful recommendations (e.g. Krause et al., Bundesgesundheitsbl-Gesundheitsforsch-
Gesundheitsschutz 2010; Krause et al., Bundesgesundheitsbl-Gesundheitsforsch-
Gesundheitsschutz,  2013). These recommendations and the above listed challenges have been 
addressed in various ways. Those changes initiated by the director or executed throughout the 
department are exemplified by the following: 
2.3.1.  Reassigning the portfolio of the surveillance unit (addressing the emerging 
issues a, b, f, g, h, j, l) 
After installing one dedicated expert for international scientific coordination reporting directly to 
the director in 2008, it was now decided to have all generic issues of international coordination 
including surveillance and IHR in the remit of unit 32. In addition the coordination of the 
epidemiological situation centre was also transferred from the director’s office to the new 
surveillance unit in order to assure a critical mass of officers able to cover the task in high load 
situations (see 2.5.5., AL3). The former expert for international scientific coordination (Andreas 
Gilsdorf) was appointed head of the new surveillance unit (Unit 32), thus assuring full continuity 
and synergy. One of the future focus activities of the new unit will be work on burden of disease. 
This evaluation report covers past activities until September 2012; therefore activities only recently 
Evaluation Report (Public Version) Unit AL3: Director’s Office 
10 
transferred to the surveillance unit will not be presented in the Unit 32 chapter but under 2.5.2 and 
2.5.5., AL3 below. 
2.3.2.  Instalment of the task force for DEMIS (German electronic notification system 
for infectious diseases) (addressing the emerging issues a, b, f) 
In the aftermath of the EHEC/HUS outbreak in 2011 a law was drafted in which the RKI was 
requested to design a new surveillance system which integrates all relevant digital documentations 
from peripheral health care providers in order to reduce manual work load, reporting delay and 
transmission errors. For this task a consortium of a private consulting enterprise, the Fraunhofer 
Institute and the Robert Koch Institute was created to conceptualise a new information architecture 
which would liaise with the electronic health documentation system currently being developed at 
national level (e-card). In order to assure competent representation in this complex endeavour the 
department created a taskforce which is being coordinated by the deputy head of the data 
management unit 31 (G. Kirchner) and the deputy head of the surveillance unit 32 (J. Benzler).  
2.3.3.  Creation of a new unit for nosocomial infections and surveillance of 
antimicrobial resistance and usage (Unit 37) (to address emerging issues c and d) 
The director of the department was member of the drafting group of the national strategic plan for 
the prevention of antimicrobial resistance which was officially adopted by the Germany government 
in 2008. In 2006 the director has acquired a large ministerial grant to build up a national laboratory 
based antimicrobial resistance surveillance system. The implementation of this grant was taken in 
charge by unit for surveillance (Unit 32) which was later staffed with regular positions created 
through the RKI2010 programme (see 2.2.4., Unit 32). Since then various pathogens with 
antimicrobial resistance have been made notifiable by law and a new committee is being installed 
to monitor the provision of scientific recommendations in this field. In light of the increased 
demand in and attention to this field the above named unit was installed in the department named 
unit for health care associated infections, and surveillance of antimicrobial resistance and 
consumption (Unit 37). The head of this unit is the former head of Unit 32 (T. Eckmanns), who was 
previously in charge of the topic, thus assuring best possible competency and continuity. Because 
this unit was founded November 1, 2012, all activities referring to antimicrobial resistance will be 
described under the chapter Unit 32, the unit in charge of this topic from 2006 up to the recent 
reorganisation.  
2.3.4.  Establishment of the Epidemiological Situation Centre (addressing emerging 
issues a, b, k, l)  
In 2009, upon the move to the provisional facility in Weissensee the RKI has installed a special 
facility for the Epidemiological Situation Centre (ESC). This centre was designed and organised by 
the department based on the experience with the SARS outbreak 2003 and various pandemic 
preparedness exercises. It proved immediate utility during the 2009 H1N1 pandemic and the 2011 
HUS/EHEC outbreak (see 2.5.5., AL3). 
2.3.5.  Initiating developments of evidence based methods for public health 
recommendations (addressing emerging issues e, f, i, k, l) 
It is largely acknowledged that for population based public health interventions new methods of 
investigation but also of evidence grading must be developed. In 2006 the director of the 
department has started to address this challenge by organising a workshop of international experts 
and has remained collaborative expert of ECDC when it engaged in coordinating further 
developments in this field. In addition, the unit for immunisation in the department (Unit 33) 
organised several international workshops in this context with a particular focus on vaccinology. It 
was therefore decided to create a methodological nucleus for evidence based public health (EBPH) 
in the unit FG 33 and one of the last vacant scientist positions created by the RKI 2010 programme 
was dedicated for this function. Recently FG 33 acquired an ECDC sponsored tender for developing 
the methodology of evidence-based public health (EBPH) and has engaged in an number of 
research projects in the field of health economics (see 2.2., Unit 33).  
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2.3.6.  Focusing on advanced study designs to assess effectiveness of interventions 
(addressing emerging issues e, f, g, i, j) 
In the first years of its existence the research work of the department was dominated by descriptive 
analyses of epidemiological trends and investigations of outbreaks. In the recent years five 
additional types of study designs have gained importance in the department’s research: 
1. Interventional studies or prospective observational studies comparing the effectiveness of 
different kinds of public health interventions e.g. the role of masks for the prevention of 
influenza transmission in households (Suess et al., BMC Infect Dis 2012) or the 
effectiveness of the pandemic vaccine in the prevention of the 2009 pandemic influenza 
(Wichmann O et al., Euro Surveill 2010). 
2. Study designs using secondary data analysis to validate data on surveillance or vaccination 
coverage (Böhmer MM et al., Vaccine 2011). 
3. Customised population based surveys, behavioural surveillance and qualitative methods to 
study burden of disease, knowledge, attitude and behaviour towards prevention of 
infectious diseases e.g. attitude towards vaccines and adherence to recommendations 
(Böhmer MM et al., BMC Public Health 2012; Walter D et al., Euro Surveill 2012; Marcus U 
et al., Sexual Health 2011; Velasco E et al., BMJ Open 2012). 
4. Epidemiologic modelling (see 2.3.7., AL3) to interpret acute epidemic phenomena such as 
pandemics as well as complex associations of risk factors for sporadic diseases (Meyer S et 
al., Biometrics 2012; Höhle M et al., Epidem Infect 2011; an der Heiden M et al., PLoS One 
2009). 
5. Serosurveys either custom designed for a specific research question or conducted with 
existing health surveys in cooperation with department 2 of the RKI (Dudareva S et al., PloS 
One 2011; Bätzing-Feigenbaum J. et al., HIV Medicine 2009). 
While the above mentioned publications represent only selected examples co-authored by the 
director’s office, the diversity and the level of sophistication of research activities have increased 
throughout the department, which can be seen by the publication output of the respective units 
and also by the fact that the number of studies that required and received approval by the ethics 
committee has increased in the recent years (from less than 3 during 2005 -2008 to more than 13 
during 2009-2012). 
2.3.7.  Creating a professorship and a project group for infectious disease modelling 
(addresses emerging issues i, j, l) 
In January 2011 the director of the department jointly with the Humboldt University Berlin (HU) 
successfully applied for a grant of the Federal Ministry for Education and Research (BMBF) through 
which instalment of epidemiological professorships are being sponsored for a period of 5 years. In 
a highly competitive selection process Prof. Dirk Brockman from Northwestern University 
Evanston, USA was offered and has accepted the professorship in a joint appointment between RKI 
and HU. This will result in the creation of an independent research group within the RKI. Although 
organisationally not part of the department, this group will be physically located in the same facility 
as the department for infectious disease epidemiology to assure best possible interaction. The 
project description of the second phase of the BMBF tender will be jointly written by the director of 
the department and the newly installed professor. With this professorship the RKI will be the first 
federal institute in the remit of the Federal Ministry of Health to appoint a professorship jointly 
with a university. 
2.3.8.  Installing new advisory committees and strengthening scientific support of 
existing ones (addressing emerging issues c, e, f, i, k, l) 
In the attempt to have a more external participation and quality control in public health 
recommendations and policy advice the following new external advisory committees have been 
installed (hosting/coordinating unit in parentheses): Committee for the Measles Elimination (Unit 
33); Committee for Antimicrobial Therapy (Unit 32), Expert Advisory Group for Influenza and 
Pandemic Preparedness (Unit 36). At the same time the intensity of scientific support for the 
already existing external advisory committees has significantly increased in recent years, particularly 
for the National Standing Committee on Immunisations (Unit 33) and the Blood Safety Committee 
(Unit 34).  
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2.3.9.  Strengthening evaluation and networking for national reference centres 
(addressing emerging issues l and m) 
In order to strengthen the reference laboratory capacity the director’s office has made the 
procedures for selection and evaluation of national reference centres (NRC) more stringent and has 
created monetary and organisational incentives for NRC and national consiliar laboratories (NCL) 
to create networks through which they can share access to patients and samples, exchange 
methodological expertise and have stronger interaction with the RKI (see 2.5.6., AL3) 
2.3.10. Prioritisation of pathogens for surveillance and epidemiological research 
(addressing emerging issues m and n) 
The director’s office has developed a systematic, evidence based methodology to prioritise 
pathogens for surveillance and epidemiological research in order to address the challenge of 
budgetary constraints within the department and the public health service at large (see 2.4.2., AL3).  
2.3.11. Foundation of Master of Science Programme for Applied Epidemiology and 
other improvements in the training offer (addressing emerging issue n, l) 
Through various formats and initiatives the training activities in the public health service and in 
medical and public health schools has been continuously expanded and intensified. The most 
important mile stone in this context is the Masters of Science Programme for Applied 
Epidemiology founded and directed by the director of the department (see PAE). (Bremer et al., 
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009, Krause G et al., Euro Surveill 
2009a,Krause G et al., Euro Surveill 2009b) 
2.3.12. Co-appointment with the Helmholtz Centre for Infection Research and the 
Hanover Medical School (addressing emerging issues l, n, o) 
In August 2011 the director of the department was appointed head of the newly founded 
department for epidemiology at the Helmholtz Centre for Infection Research (HZI) in Brunswick 
and chair for infectious disease epidemiology (W3) at the Hannover Medical School. Both 
institutions and the RKI as well as the two affected federal ministries propagated this multiple 
appointment while the director’s duties at RKI are fully maintained. In the meanwhile HZI and RKI 
have signed a cooperation contract (December 2012). The director’s multiple affiliation has also 
helped to assure access and participation of the RKI department for infectious disease 
epidemiology in the National Cohort (see 2.4.1, AL3) and the newly created German Centre for 
Infection Research (DZIF) (see 3.2., AL3). 
2.4.  Additional work and methods for investigations 
2.4.1. National Cohort 
The National Cohort is a prospective cohort study in Germany run by several Helmholtz centres, 
other public research centres and universities to study risk factors and etiologic mechanisms of 
widespread diseases at the population level. It is one of the few if not only large cohort studies of 
its kind that also addresses infectious diseases. A total of 200,000 adult individuals will be 
recruited through a network of 18 study centres within Germany. After four years, all participants 
will be re-invited for follow-up examinations. This will allow the correlation of the incidence of 
diseases of different aetiologies with clinical, socio-behavioural and laboratory findings from earlier 
examinations. Furthermore the cohort will serve as a population study for the association between 
infections and non-communicable diseases.  
In 2008 the Helmholtz Association as initiator of the National Cohort has asked the department for 
infectious disease epidemiology at RKI to provide its expertise in the concept and design of the 
cohort. The director of the department then was given the task to coordinate the working group on 
immunity and infection within the national cohort. In this role the director’s office has organised a 
number of workshops with participation of various relevant research institutions in Germany in 
order to conceptualise research priorities. Together with the Helmholtz centre for Infection 
Research (HZI) the department then developed the respective epidemiological instruments such as 
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questionnaires and study proposals. Now through his dual affiliation (see above) the director of the 
department is member of the epidemiological steering committee and delegate in the members’ 
assembly. This assures linkage of first-hand information between RKI and HZI, together with B. 
Kurth (Dept. 2), who is a personally nominated representative of the RKI in the National Cohort. 
Through this liaison the department has had privileged participation in the methodological design 
and scientific analysis of the national cohort involving all units of the department. Already several 
joints projects in the context of the National Cohort have been initiated between the HZI and the 
department. 
2.4.2. Prioritising pathogens for surveillance and epidemiological research 
The large number of infectious agents to be potentially covered by the department for infectious 
disease epidemiology exceeds by far its capacity, thus it is necessary to prioritise the resources 
dedicated for surveillance and epidemiological research of infectious diseases. Since 2005 the 
director and staff (A. Gilsdorf and Y. Lenz) have developed a tool which would allow standardised, 
transparent and reproducible prioritisation and also involvement of all relevant stakeholders. This 
included a Delphi process with internal (RKI) and external experts and a metric-consensus 
approach to score pathogens according to ten three-tiered criteria. Additional experts were invited 
to weight each criterion, leading to the calculation of a median weight by which each score was 
multiplied. The 127 pathogens were ranked according to the total weighted score and divided into 
four priority groups. Twenty-six pathogens were ranked in the highest priority group (see 4.3., AL3); 
among those were pathogens with internationally recognised importance (e.g., Human 
Immunodeficiency Virus, Mycobacterium tuberculosis, Influenza virus, Hepatitis C virus, Neisseria 
meningitides), pathogens frequently causing large outbreaks (e.g., Campylobacter spp.), and 
nosocomial pathogens associated with antimicrobial resistance. Other pathogens in the highest 
priority group included Helicobacter pylori, Respiratory Syncytial Virus, Varicella zoster virus and 
Hantavirus. While several pathogens from the highest priority group already have a high profile in 
national and international health policy documents, high scores for other pathogens (e.g., 
Helicobacter pylori, Respiratory syncytial virus or Hantavirus) have resulted in shifting more 
attention and resources towards those previously less acknowledged pathogens. The methodology 
and the results have been published in 5 international scientific publications and are being referred 
to by various research institutions within and outside Germany (Gilsdorf et al., Euro Surveill 2011a, 
Gilsdorf et al., Euro Surveill 2011b, Balabanova et al., PLoS One 2011).  
2.5.  Scientific advice and consulting services 
2.5.1. 24/7 on call duty system 
The department maintains a 24/7 on call duty system staffed with infectious disease 
epidemiologists (pool of approx. 35 volunteers coordinated by the director’s office) to immediately 
respond to requests from the peripheral public health service or international public health 
agencies. The on call duty officer is supported by senior experts (usually director and heads of 
units), likewise available 24/7. The duty system is intended to assist local and state public health 
departments in infection control activities either by immediate consultation or by referral to more 
specialised units at the RKI. Another important function of the duty system is to assure continuous 
availability for notifications according to the International Health Regulations (IHR) and the 
European Early Warning and Response System (EWRS). The availability is assured through 
telephone, fax and e-mail and all communication by the duty system is being logged for 
documentation and quality control.  
Next to the public health service, hospital emergency rooms, physician practices, fire departments, 
and ambulances also frequently request advice after regular working hours. Typical questions here 
include hygienic measures after transporting infectious patients, post exposure prophylaxis after 
exposures to blood, patients with meningococcal disease or rabies suspected animals. 
On average the duty officer receives 8-10 telephone calls per week (300-500 calls per year) and 
spends an average of 5 hours per week of active duty responding to requests and notifications. At 
the beginning of public health emergencies or outbreaks this workload can temporarily increase 
drastically until the Epidemiological Situation Centre is being activated and takes over the service. 
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2.5.2.  Early Warning and Response System and International Health Regulations 
The department is focal point for the reporting and assessments of biological threats within the 
scope of the Early Warning and Response System (EWRS, EU) and International Health 
Regulations (IHR, WHO). All notifications made through the local and regional public health 
authorities that might constitute an international public health event are reported and followed up 
through these two reporting systems.  
From 2009 to September 2012 747 events were notified by EU Member States through EWRS, not 
including respective follow-up notifications. For example the EHEC outbreak notification alone 
triggered 246 follow up notifications. All of these notifications are assessed by the on call duty 
officer and then managed by the respective unit in the department.  
The German national focal point for IHR is the Situation Centre of the German Federal Office for 
Civil Protection and Disaster Assistance, which forwards all incoming international notifications to 
the respective federal agency in charge. For the vast majority of these notifications the RKI is the 
agency in charge, represented by the department for infectious disease epidemiology of the RKI. 
Figure 2: The role of the department for infectious disease epidemiology at RKI in international reporting 
networks of the European Early Warning and Response System (EWRS, left) and the International Health 
Regulations (IHR, right) 
 
2.5.3. Support or coordination of outbreak investigations  
From 2009 to Sept. 2012 the department has responded to roughly 60 requests by the state health 
departments to assist or coordinate in outbreak investigations. In most of these, this involved 
deployment of a team of epidemiologists on site. In these situations RKI staff functions in the 
status of a seconded expert, and reports to the local health authority. Most deployments last 
several days and often require repeated field activities on site. An outbreak investigation team of 
the RKI generally consist of one or two senior epidemiologists and one to three PAE fellows (see 
PAE). The list containing selected documented outbreak investigations in which PAE fellows from 
RKI or the regional health authorities have participated can be found in 4.1.10, AL3. 
2.5.4. Outbreak and Pandemic Response 
During larger outbreak investigations or public health emergencies forces from all units of the 
department are gathered for epidemiological investigations, surveillance, support of the public 
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health service and communication. During the large EHEC/HUS outbreak in 2011 for example the 
department alone had the following workforce involved (FTE=full time equivalent):  
• Situation room: 24(14)/7; 1-2 shifts/day 5-15 Full Time Equivalent (FTE) / day 
• Field teams: 18 teams; 1-4 day duration 2-15 FTE /team 
• Data entry:  4-14 FTE/day 
• Surveillance: 5- 10 FTE/day 
• Trace back, cluster and food liaison: 2-6 FTE /day 
• Study and analysis: 6 - 10 FTE/day 
• Lab-epi liaison: 1-2 FTE /day 
• Logistics:  1-4 FTE/day 
• Press-epi liaison: 1 FTE /day  
• International and federal liaison: 2 FTE /day 
2.5.5. Epidemiological Situation Centre 
When the department moved to the provisional facility in Weissensee in 2009 an Epidemiological 
Situation Centre (ESC) was installed (Lagezentrum). This proved to be very useful for the 
tremendous information management and also coordination of RKI investigation logistics during 
the 2009 influenza pandemic and also during the 20011 EHEC/HUS outbreak. The main function 
of the ESC is to collect epidemiologic information, to organise the national response, to triage all 
information requests, and to collate the case-reports for Germany. During the two EHEC /HUS 
outbreak and the 2009 flu pandemic the ESC was staffed mainly with personnel from all units of 
the department with some support from other departments of the RKI. As the workload 
diminished, functions of the ESC were continued in a “virtual ESC”, by staff working decentralized 
from their individual offices, which allowed to continue other duties. During the H1N1-pandemic 94 
different persons were involved in the ESC, in 642 people shifts, including 127 weekend shifts 
resulting in 4500 person hours, or 560 person working days. During the EHEC/HUS outbreak the 
ESC was running for about 2 months with an average staffing of 5-15 daily fulltime equivalents.  
The technical equipment of the ESC is fairly basic compared to similar structures in other 
organisations. Until 2012 the director’s office had the organisational responsibility of the ESC and 
started closer cooperation with the ECDC, Stockholm and the Centres of Disease Prevention and 
Control (CDC), Atlanta to exchange best practices. In September 2012 the organisational 
responsibility of the ESC was transferred to the new surveillance unit (see 2.3.1., AL3). 
2.5.6.  National Reference Centres and Consiliary Laboratories 
In 1995 the German Federal Ministry for Health started to fund National Reference Centres (NRC) 
for the laboratory surveillance of important pathogens and syndromes. Since then the selection and 
evaluation process has been gradually transferred to the RKI. Since 2009 the RKI is in charge of the 
management of the budget currently comprising 2.6 million Euros. The number of NRC has 
increased from 15 in 2009 to 19 in 2012. In addition there are now 49 (previously 47) nominated 
national consiliary laboratories (NCL) which cover additional aspects or pathogens with a special 
laboratory focus. 
From 2009 to 2012 a number of important changes have been introduced to the system: The 
tendering and selection process has been made more transparent and competitive, following a 
strict prioritisation process upon need and not upon offer. The evaluation process also has become 
more rigorous, following a list of published criteria and involving not only the committee for 
infectious disease epidemiology but also topic specific external experts. In order to enhance the 
effectiveness and cooperation of the system, 10 National Reference Networks were launched in 
2009 (see 4.4., AL3). The aim of these networks is to facilitate exchange on diagnostic methods 
and prevention concepts and to improve the geographic coverage of the services. In a competitive 
grant process, the RKI awards financial support for cooperation projects with networks. Scientific 
coordination and administration is executed by the director’s office. The committee for infectious 
disease epidemiology - hosted by the director’s office as well - plays a pivotal role in the quality 
assurance by being majorly involved in selection, evaluation and prioritisation of the NRC and CL 
(Laude G et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009, Laude G et al., 
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2012.) 
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2.5.7.  Fact sheets for physicians 
The RKI fact sheets for physicians are a very popular source of information for clinicians and public 
health officers alike as they contain in a very brief format all the information necessary for the 
management of infectious diseases. They are coordinated and edited by the director’s office (G. 
Laude) together with the editor of the Epidemiological Bulletin (J. Seedat) but are based on 
contributions of the departments’ units, the national reference centres and consiliary laboratories, 
the respective scientific associations and other disease specific experts throughout Germany. They 
are published in the Epidemiologic Bulletin and updates can be accessed through the RKI 
homepage and on the RKI document server. From January to September 2012 the 48 fact sheets 
were downloaded 38,466 times from this server. This equals a proportion of 7.4% of all downloads, 
even though they only constitute 1.8% of the documents available on the document server, 
showing the high impact these fact sheets have. According to need the updating cycle of fact sheets 
ranges from every 4-5 years up to multiple times in one year (see 4.1.4., AL3). 
2.5.8.  Scientific advice to the Ministry of Health 
The Ministry of Health is issuing decrees to RKI to ask for scientific advice. Reports to ministerial 
decrees range from brief assessments on specific epidemiological situations up to rather complex 
analysis which are similar to a scientific review as far as complexity and size is concerned. From 
January 2009 to September 2012 1,147 ministerial decrees have been directed to the four scientific 
departments of the RKI, of which 622 (54%) were primarily answered/reported by the department 
for infectious disease epidemiology. Figure 3 shows also that the number of decrees is increasing 
over the years.  
Figure 3: Number of decrees, 2009-2012, by leading department of RKI, not including reports initiated by RKI 
 
2.6.  Training and teaching activities 
2.6.1.  Intensive course “Epi for action” for the Public Health Service 
In 1996 a two week course in infectious disease epidemiology for public health officers has been 
established. While the first week of this course was dedicated to introduce basic concepts of 
infectious disease epidemiology the second week was dedicated to train the technical skills needed 
for outbreak investigations. This also includes the usage of Epi Info (until 2006) and Epi Data 
(since 2007). The course is characterised by a very participatory and intensively supervised format: 
A total of over 27 facilitator work days is being invested for the first and 32 work days for the second 
week of the course. Throughout the years 2006 to 2011 the participants satisfaction has always 
been 7 or above on a scale from 0 to 9. From 2001 to 2011 746 participants were trained with 22 to 
61 participants per course; about 70% were from the public health service, 8% from the veterinary 
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participants from the public health service has diminished in recent years and the department has 
decided to reassess the current training need. A team of scientists of the department is now 
systematically evaluating the course using quantitative and qualitative methods. The results are 
going to be used to adapt or completely re-design the format and content of the course. 
2.6.2.  University-course „Infectious disease epidemiology“ 
Since 2011 the director’s office (Y. Lenz) together with other colleagues of the department has 
established the university course „Infectious disease epidemiology“ for under- and postgraduate 
students of Humboldt University (within the ZIBI Graduate School “Research in Infection Biology 
and Immunology”). The course is a mandatory module within the programme of the International 
Research Training Group GRK1673 “Functional Molecular Infection Epidemiology” in Berlin. The 
course addresses the link between epidemiology, laboratory science and clinical practice. It covers 
key concepts of pathogen transmission dynamics, infectious disease surveillance, prevention and 
control strategies, as well as study design and the fundamentals of statistical analysis. The material 
is presented in 14 lectures and interactive seminars. The course is also open for guests. 
2.6.3.  License for board certified training in hygiene and environmental health  
The Berlin Physicians Associations has renewed the license of the director for two years of the 
board certified training in hygiene and environmental health. This allows physicians working in the 
department to get up to two years of their work acknowledged for their medical board certification. 
2.6.4.  Other academic teaching activities 
• Master of Science programme for applied epidemiology, member of examination committee 
(founded and directed by G. Krause, coordinated by K. Alpers) 
• Lecture practical course “Hygiene”, 2nd semester, 18 hours per semester until 2010, Charité 
medical school (G. Krause) 
• Lecture “outbreak investigation”, 5th semester, 1 hour per semester until 2009, obligatory 
lecture Charité medical school (G. Krause) 
• Lecture “surveillance”, 3rd semester, 1 hour per semester, until 2009, obligatory lecture 
Charité medical school (G. Krause) 
• Lecture “vaccinations”, 3rd semester, 1 hour per semester, until 2009, obligatory lecture 
Charité medical school (G. Krause) 
• Lecture “waterborne infections” 1 hour per semester, continuously from winter semester 
2008/2009 until summer semester 2009, obligatory lecture Charité medical school (G. 
Krause) 
• Lecture “airborne infections” 1 hour per semester, continuously from winter semester 
2008/2009 until summer semester 2009, obligatory lecture Charité medical school (G. 
Krause) 
• Lecture “federal duties in public health”, 1 hour per year, until present, obligatory lecture for 
MSAE course since 2009 (G. Krause) 
• Lecture “outbreak investigations”, “Surveillance” and “pandemic preparedness” total 4 
hours per year, Bielefeld summer school “infectious disease epidemiology”, university 
Bielefeld (G. Krause) 
• Supervisor for PhD/dissertations and master theses (currently 3 PhD/dissertation projects in 
the unit and 2 master thesis projects)(G. Krause). 
• Course “International principles of TB and HIV control: modern laboratory diagnosis, 
management and surveillance.” Intensive Course for professionals from Eastern European 
countries, 5 hours teaching, 16 – 20 Feb 2009, National Mycobacterium Reference 
Laboratory, London (Y. Lenz) 
• Lecture and facilitation of a seminar “Discussion, conclusions and recommendations of a 
scientific manuscript”, EPIET/PAE Module "Communication and Scientific writing", 3 hours, 
24 – 28 Jan 2011 (Y. Lenz) 
• Lecture “Introduction to the infectious disease epidemiology”, ZIBI Summer School, 
Humboldt University, 1 hour, 24 Jun 2011 (Y. Lenz) 
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• "Infectious diseases epidemiology", conducted by RKI jointly with Humboldt and Freie 
Universität, mandatory module within the GRK1673, winter semester 2011/2012, (established 
and coordinated Y. Lenz) 
• Seminar “Introduction to the infectious disease epidemiology”, teaching module "Infectious 
diseases epidemiology", conducted by RKI jointly with Humboldt and Freie Universities, 
mandatory module within the GRK1673, 24 Oct 2011, 1.5 hours (Y. Lenz) 
• Seminar “Link between laboratory and infectious diseases epidemiology”, teaching module 
"Infectious diseases epidemiology", conducted by RKI jointly with Humboldt and Freie 
Universities, mandatory module within the GRK1673, 31 Oct 2011, 1.5 hours (Y. Lenz) 
• Seminar “Main principles of diagnostic trials and epidemiological/clinical study design”, 
teaching module "Infectious diseases epidemiology", conducted by RKI jointly with 
Humboldt and Freie Universities, mandatory module within the GRK1673, 21 Nov 2011, 1.5 
hours (Y. Lenz) 
• Seminar "Good epidemiological practice". How to report results properly: scientific writing 
and presenting, teaching module "Infectious diseases epidemiology", conducted by RKI 
jointly with Humboldt and Freie Universities, mandatory module within the GRK1673, 5 Dec 
2011, 1.5 hours (Y. Lenz) 
• Lecture “Introduction to the aims and scope of infection epidemiology”, ZIBI, Lecture Series 
„Infection Biology" (Ringvorlesung), Humboldt University, 2 Jan 2012, 1.5 hours (Y. Lenz) 
• Lecture “Diagnostic accuracy studies: not to be biased about a bias”, PAE/EPIET Laboratory 
Module, 1 Feb 2012, 1 hour (Y. Lenz) 
• Lecture “Diagnostic accuracy studies: not to be biased about a bias”, PAE/EPIET Laboratory 
Module, 21 Feb 2012, 1 hour (Y. Lenz) 
• Lecture “Introduction to the infectious disease epidemiology”, ZIBI, Summer School 
„Pathogen – Host Interplay“, Humboldt University, 15 Jun 2012, 1 hour (Y. Lenz) 
• Lecture “Epidemiology of drug resistant tuberculosis”, ZIBI, Scientific Symposium "Global 
Challenges of Acute and Chronic Tropical Infections", Humboldt University, 19 Jun 2012, 40 
min (Y. Lenz) 
• Established and organized the series; teaching of the following seminars: teaching module 
"Infectious diseases epidemiology", conducted by RKI jointly with Humboldt and Freie 
Universities, mandatory module within the GRK1673, winter semester 2012/2013, (Y. Lenz) 
• Seminar “Introduction to the aims and scope of infection epidemiology”, teaching module 
"Infectious diseases epidemiology", conducted by RKI jointly with Humboldt and Freie 
Universities, mandatory module within the GRK1673, 16 Oct 2012, 1.5 hours (Y. Lenz) 
• Seminar “Link between laboratory and infectious diseases epidemiology”, teaching module 
"Infectious diseases epidemiology", conducted by RKI jointly with Humboldt and Freie 
Universities, mandatory module within the GRK1673, 27 Oct 2012, 1.5 hours (Y. Lenz)  
• Seminar “Surveillance”, teaching module "Infectious diseases epidemiology", conducted by 
RKI jointly with Humboldt and Freie Universities, mandatory module within the GRK1673), 23 
Oct 2012, 1.5 hours (A. Gilsdorf) 
• Seminar “Types of epidemiological studies”, teaching module "Infectious diseases 
epidemiology", conducted by RKI jointly with Humboldt and Freie Universities, mandatory 
module within the GRK1673, Nov 2011, 1.5 hours (A. Gilsdorf) 
• Course “Introduction to epidemiology – IntoEpi”, Annecy February 2009 and 2010, in 
cooperation with ECDC and EpiConcept, 3 weeks course: Concept and one week training (A. 
Gilsdorf) 
• Facilitator in EPIET Module “Project Review”, one week, August 2009 and 2010, Rome (A. 
Gilsdorf) 
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3. Cooperation with other scientists or research institutions 
3.1. Internal (within RKI) 
• Gérard Krause is member of various RKI internal committees. 
• Andreas Gilsdorf is member of the strategic group on internationalization at the RKI. 
• Yanina Lenz coordinated a serosurvey on EHEC jointly with ZBS. (Manuscript submitted) 
For further cooperations see unit specific chapters 
3.2.  External / National 
Epidemiological Steering Committee of the National Cohort  
See 2.4.1., AL3 
German Centre for Infection Research 
The German centre for infection research (Deutsches Zentrum für Infektionsforschung, DZIF) is an 
integrated multi-centre structure bringing together selected universities, university hospitals, and 
non-university research institutes to link their research and clinical infrastructure. DZIF aims to 
foster translational efforts aiming at novel diagnostic, preventive and therapeutic measures against 
the most important infectious diseases. Although the Berlin consortium (of which RKI was part of) 
was not selected for the DZIF, the director of the department for infectious disease epidemiology at 
RKI is providing epidemiological expertise within the DZIF through his HZI and RKI affiliation. This 
has not yet resulted in integration of RKI as a full member of DZIF, but the liaison function will at 
least help to avoid redundancies or interferences of respective research activities (see 2.3.12., AL3).  
Working Group on Infectious Disease Epidemiology of the German Society for Epidemiology 
(DG Epi) 
The director is active member of the Working Group on Infectious Disease Epidemiology of the 
German Society for Epidemiology (DG Epi) and the department has organised various meetings of 
the working group. 
Assembly of the Highest Health Administrations of the 16 federal states in Germany (AOLG) 
and Working Group on Infectious Disease Control (AGI) of the AOLG 
The director represents the RKI in the assembly of the Highest Health Administrations of the 16 
federal states in Germany (AOLG) and in a specific Working Group on Infectious Disease Control 
(AGI) of that assembly. Since public health management lies within the federal states, 
representation of the RKI in these groups and providing scientific advice is of particular 
importance.  
• Gottschalk R et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009  
• Krause G et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2010 
Humboldt University and Free University, Berlin  
The department cooperates with Humboldt University, Berlin and Free University, Berlin for the 
university-course „Infectious disease epidemiology“ (see 2.6.2., AL3). 
Children Hospital University Hospital, Freiburg 
Together with Prof R. Berner, Children Hospital University Hospital Freiburg (now University 
Hospital Dresden) the director is supervising a doctoral thesis on invasive group B streptococcal 
(GBS) infections in adults, Germany. In a national prospective active surveillance study during a 2-
year period (2009-2010) monthly questionnaires were sent by the RKI to 111 participating 
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microbiological laboratories to report isolation of GBS in any sample obtained from a normally 
sterile site in patients aged > 1 year.  
University Hospital Frankfurt 
Together with Priv. Doz. Dr. S. Wicker, head of occupational health at the Frankfurt University 
Hospital and Prof. R. Gottschalk, head of the Frankfurt Health Department the director is working 
on concepts to improve influenza vaccination coverage in medical personnel  
• Wicker S et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2012  
• Wicker S et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2010 
Ministry of Health 
In the aim to gather scientific evidence for the drafting of the national plan for the prevention for 
antimicrobial resistance the director was actively involved (e.g. as thesis supervisor) in studies on 
surveillance and on patients’ and physicians’ attitudes and behaviour with respect to antimicrobial 
resistance. 
• Velasco E et al., Infection 2011 
• Velasco E et al., BMJ Open 2012 
• Schweickert B et al., Eur J Clin Microbiol Infect Dis 2012 
Paul Ehrlich Institute and the Federal Institute for Drugs and Medical Devices 
Particularly during the pandemic the director interacted very intensively with the Paul Ehrlich 
Institute and the Federal Institute for Drugs and Medical Devices to assure the best available 
evidence regarding medical counter measures and vaccination. 
• RKI & PEI, Epid Bull 2009 
Federal Office of Consumer Protection and Food Safety (BVL), Federal Institute for Risk 
Assessment (BfR) 
During planning and managing of food borne outbreaks the cooperation with the Federal Office of 
Consumer Protection and Food Safety and the Federal Institute for Risk Assessment under the 
Ministry of Agriculture is very important to allow fast and competent outbreak investigations both 
from a public health and a food safety side. This cooperation is mainly dealt with in the respective 
unit, but high level interactions require the involvement of the director of the department. 
• Frank C et al., N Engl J Med 2011 
• Buchholz U et al., N Engl J Med 2011  
• Stark K et al., Euro Surveill 2012 
3.3.  External / International 
General aspects of cooperation within the European Union  
Since 2008 the director’s office had one epidemiologist (A. Gilsdorf) in charge of the scientific 
coordination of international cooperation. This was an important step to align the overall 
international cooperation between the RKI, the European Centre for Disease Prevention and 
Control (ECDC) in Stockholm, and the European Commission. The continuity in content and 
presence at these institutions assures a strong constructive contribution of Germany, especially in 
the Advisory Forum, the Competent Body Working Group at ECDC, as well as in the Early Warning 
and Response System network. The director is permanent member of the Advisory Forum at ECDC 
(alternate: A. Gilsdorf). A. Gilsdorf is also co-founder of a small informal group of international 
coordinators of the Public Health Institutes of France, the Netherlands, United Kingdom and 
Germany, facilitating a better exchange of best practice among the institutes. 
• Gottschalk R et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009 
• Hollmeyer H et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009 
• Schreck S et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009  
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• Wiese-Posselt M et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009 
World Health Organization 
The director was invited expert in a working group on the International Health Regulations (IHR) by 
WHO and in the IHR Review Committee of WHO, which also reviewed the H1N1 Flu pandemic in 
2009.  
• Amato-Gauci A et al., Euro Surveill 2011  
• van Kerkhove MD et al., PLoS Med 2011 
• Devaux I et al., Euro Surveill 2011 
• Krause G et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2010 
• ECDC working group et al., Euro Surveill 2009 
Risk Assessment Guidelines for Diseases transmitted on Aircraft (RAGIDA),  
Response to Emerging Infectious Disease: Assessment and Development of Core Capacities 
and Tools (REACT) 
The director was scientific lead of the REACT Projekt and A. Gilsdorf was involved in the RAGIDA 
project. Both projects were executed by unit 32 (see 2.2.7., Unit 32).  
• Leitmeyer K et al., Euro Surveill 2011  
• Mohr O et al., Euro Surveill 2012  
• Askar M et al., Euro Surveill 2012 
European Programme for Intervention Epidemiology Training (EPIET), ECDC 
As an important national training site the director’s office is involved in the activities regarding 
EPIET (see PAE). 
• Bremer V et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009; 
• Krause G et al., Euro Surveill 2009a 
• Krause G et al., Euro Surveill 2009b  
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4. Appendix 
4.1  Overview on achievements of the director’s office, 2009-2012 
4.1.1.  Scientific publications, 2009 – 2012 
Number of peer-review publications co-authored by members of the director’s office: 67 
Impact factor (IF) according to JCR (for 2012 according to 2011) 
2009:   26,1  
2010:   18,0 
2011: 199,9 
2012:   42,7 
Cumulative 2009-12: 286,8 
A) Original research articles in peer-review journals 
2012 (until Sept.) 
Böhmer MM, Walter D, Falkenhorst G, Müters S, Krause G, Wichmann O: Barriers to pandemic 
influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in 
Germany. BMC Public Health 2012; 12(1):938. 
Dehnert M, Fingerle V, Klier C, Talaska T, Schlaud M, Krause G, Wilking H, Poggensee G: 
Seropositivity of Lyme Borreliosis and Associated Risk Factors: A Population-Based Study in 
Children and Adolescents in Germany (KiGGS). PLoS One 2012; 7(8):e41321. 
Klein S, Schöneberg I, Krause G: Vom Zwang zur Pockenschutzimpfung zum Nationalen Impfplan 
- Die Entwicklung des Impfwesens vom Deutschen Kaiserreich bis heute [The historical 
development of Immunisation in Germany : From compulsory smallpox vaccination to a National 
Action Plan on Immunisation]. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2012, 
55(11-12):1512-1523. 
Laude G, Kist M, Krause G: Referenznetzwerke aus Nationalen Referenzzentren mit assoziierten 
Konsiliarlaboratorien in Deutschland. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 
2012; 55(2):223–230. 
Mohr O, Askar M, Schink S, Eckmanns T, Krause G, Poggensee G: Evidence for airborne infectious 
disease transmission in public ground transport – a literature review. Euro Surveill 2012; 
17(35):pii=20255. 
Schweickert B, Noll I, Feig M, Claus H, Krause G, Velasco E, Eckmanns T: MRSA-surveillance in 
Germany: data from the Antibiotic Resistance Surveillance System (ARS) and the mandatory 
surveillance of MRSA in blood. Eur J. Clin Microbiol Infect Dis 2012; 31(8): 1855-1865.  
Stark K, Bauerfeind R, Bernard H, Eckmanns T, Ethelberg S, Flieger A, Giesecke J, Greiner M, Karch 
H, Krause G, Mielke M, O'Brien SJ, Pulz M, Scheutz F, Schielke A, Stahl RA, Takkinen J, Tarr PI, 
Tauxe RV, Werber D: Experiences from the shiga toxin-producing Escherichia coli O104:H4 
outbreak in Germany and research needs in the field, Berlin, 28-29 November 2011. Euro Surveill 
2012; 17(7):pii=20091. 
Suess T, Remschmidt C, Schink SB, Schweiger B, Nitsche A, Schroeder K, Doellinger J, Milde J, 
Haas W, Koehler I, Krause G, Buchholz U: The role of facemasks and hand hygiene in the 
prevention of influenza transmission in households: results from a cluster randomised trial; Berlin, 
Germany, 2009–2011. BMC Infect Dis 2012; 12(1):26. 
Velasco E, Ziegelmann A, Eckmanns T, Krause G: Eliciting views on antibiotic prescribing and 
resistance among hospital and outpatient care physicians in Berlin, Germany: results of a 
qualitative study. BMJ Open 2012; 2(1):e000398. 
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Walter D, Böhmer MM, Reiter S, Krause G, Wichmann O: Risk perception and information-seeking 
behaviour during the 2009/10 influenza A(H1N1)pdm09 pandemic in Germany. Euro Surveill 2012; 
17(13):pii=20131. 
Werber D, Krause G, Frank C, Fruth A, Flieger A, Mielke M, Schaade L, Stark K: Outbreaks of 
virulent diarrhoeagenic Escherichia coli – are we in control? BMC Med 2012; 10(1):11. 
Wicker S, Gottschalk R, Wolff U, Krause G, Rabenau HF: Influenzaimpfquoten in hessischen 
Krankenhäusern. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2012; 55(8): 932–
936. 
Wilking H, Götsch U, Meier H, Thiele D, Askar M, Dehnert M, Frank C, Fruth A, Krause G, Prager 
R, Stark K, et al.: Identifying risk factors for Shiga toxin-producing Escherichia coli by payment 
information. Emerg Infect Dis 2012: 18(01):169-170. 
2011 
Altmann M, Wadl M, Altmann D, Benzler J, Eckmanns T, Krause G, Spode A, an der Heiden M: 
Timeliness of surveillance during outbreak of Shiga toxin–producing Escherichia coli, Germany, 
2011. Emerg Infect Dis 2011; 17(10):1906–1909. 
Amato-Gauci A, et al., European Influenza Surveillance Network EISN (for Germany: Gilsdorf A, 
Schweiger B, Poggensee G, Krause G, Buda S, Eckmanns T): Surveillance trends of the 2009 
influenza A(H1N1) pandemic in Europe. Euro Surveill 2011; 16(26): pii: 19903. 
Askar M, Faber MS, Frank C, Bernard H, Gilsdorf A, Fruth A, Prager R, Höhle M, Suess T, Wadl M, 
Krause G, Stark K, Werber D: Update on the ongoing outbreak of haemolytic uraemic syndrome 
due to Shiga toxin-producing Escherichia coli (STEC) serotype O104, Germany, May 2011. Euro 
Surveill 2011; 16(22):pii=19883. 
Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gärtner B, Groß U, Haas W, Hamouda 
O, Hübner J, Jänisch T, Kist M, Kramer MH, Ledig T, Mielke M, Pulz M, Stark K, Suttorp N, Ulbrich 
U, Wichmann O, Krause G: Communicable Diseases Prioritized for Surveillance and 
Epidemiological Research: Results of a Standardized Prioritization Procedure in Germany, 2011. 
PLoS One 2011; 6(10):e25691. 
Böhmer MM, Walter D, Müters S, Krause G, Wichmann O: Seasonal influenza vaccine uptake in 
Germany 2007/2008 and 2008/2009: Results from a national health update survey. Vaccine 2011; 
29(27):4492-4498. 
Böhmer MM, Walter D, Krause G, Müters S, Gößwald A, Wichmann O: Determinants of tetanus 
and seasonal influenza vaccine uptake in adults living in Germany. Hum Vaccin 2011; 7(12):1317–
1325. 
Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, Deleré Y, an der 
Heiden M, Adlhoch C, Dreesman J, Ehlers J, Ethelberg S, Faber M, Frank C, Fricke G, Greiner M, 
Höhle M, Ivarsson S, Jark U, Kirchner M, Koch J, Krause G, Luber P, Rosner B, Stark K, Kühne M, 
RKI HUS investigation team: German Outbreak of Escherichia coli O104:H4 Associated with 
Sprouts. N Engl J Med 2011; 365(19):1763-1770. 
Dudareva S, Schweiger B, Thamm M, Höhle M, Stark K, Krause G, Buda S, Haas W: Prevalence of 
Antibodies to 2009 Pandemic Influenza A (H1N1) Virus in German Adult Population in Pre- and 
Post-Pandemic Period. PLoS One 2011; 6(6):e21340. 
Frank C, Faber MS, Askar M, Bernard H, Fruth A, Gilsdorf A, Höhle M, Karch H, Krause G, Prager 
R, Spode A, Stark K, Werber D, on behalf of the HUS investigation team: Large and ongoing 
outbreak of haemolytic uraemic syndrome, Germany, May 2011. 
Euro Surveill 2011; 16(21):pii=19878. 
Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, 
Spode A, Wadl M, Zoufaly A, Jordan S, Stark K, Krause G, for the HUS Investigation Team: 
Epidemic Profile of Shiga-Toxin–Producing Escherichia coli O104:H4 Outbreak in Germany - 
Preliminary Report. N Engl J Med 2011; 365(19):1771-1780. 
Gagliotti C, Balode A, Baquero F, et al., EARS-Net Participants (Disease Specific Contact Points for 
AMR; for Germany, Altmann D, Gilsdorf A, Noll I, Tille A, Witte W): Escherichia coli and 
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Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance 
Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 2011 16 (11): pii: 
19819. 
Gilsdorf A, Krause G: Prioritisation of infectious diseases in public health: feedback on the 
prioritisation methodology, 15 July 2008 to 15 January 2009. Euro Surveill 2011; 16(18):pii=19861. 
Gilsdorf A, Krause G: Authors reply: Prioritisation of infectious diseases in public health: feedback 
on the prioritisation methodology, 15 July 2008 to 15 January 2009. 
Euro Surveill 2011; 16 (27): pii=19912.  
Leitmeyer K, (Participants from RKI, Schenkel K, Amorosa R, Mücke I, Dias-Ferrao V, Diercke M, 
Krause G, Eckmanns T, (RAGIDA Part 1), Interviewed experts, Brodhun B, Buchholz U, Buda S, 
Frank C, Haas W, Hellenbrand W, Koch J, Poggensee G, Sagebiel D, Siedler A, Stark K, et al. 
Participants for RAGIDA Part 2, Eckmanns T, Gilsdorf A, Grunow R, Hellenbrand W, Siedler A, et 
al.): European Risk Assessment Guidance for Infectious Diseases transmitted on Aircraft – the 
RAGIDA project. Euro Surveill 2011; 16 (16): pii=19845. 
Siedler A, Mankertz A, Feil F, Ahlemeyer G, Hornig A, Kirchner M, Beyrer K, Dreesman J, Scharkus 
S, Marcic A, Reiter S, Matysiak-Klose D, Santibanez S, Krause G, Wichmann O: Closer to the Goal: 
Efforts in Measles Elimination in Germany 2010. J Infect Dis 2011; 204(Suppl.1):S373-S380. 
Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O: Herpes zoster in Germany: 
Quantifying the burden of disease. BMC Infect Dis 2011; 11:173. 
van Kerkhove MD, et al. (for Germany, Buda S, Krause G, Haas W), on behalf of the WHO Working 
Group for Risk Factors for Severe H1N1pdm Infection: Risk Factors for Severe Outcomes following 
2009 Influenza A (H1N1) Infection: A Global Pooled Analysis. PLoS Med 2011; 8 (7): e1001053. 
Velasco E, Espelage W, Faber M, Noll I, Ziegelmann A, Krause G, Eckmanns T: A national cross-
sectional study on socio-behavioural factors that influence physicians' decisions to begin 
antimicrobial therapy. Infection 2011; 39(4):289-297. 
Wadl M, Rieck T, Nachtnebel M, Greutélaers B, an der Heiden M, Altmann D, Hellenbrand W, 
Faber M, Frank C, Schweickert B, Krause G, Benzler J, Eckmanns T, on behalf of the HUS 
surveillance and laboratory team: Enhanced surveillance during a large outbreak of bloody 
diarrhoea and haemolytic uraemic syndrome caused by Shiga toxin/verotoxin-producing 
Escherichia coli in Germany, May to June 2011. Euro Surveill 2011; 16(24):pii=19893. 
Walter D, Böhmer MM, an der Heiden M, Reiter S, Krause G, Wichmann O (2011): Monitoring 
pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10 - Results from thirteen 
consecutive cross-sectional surveys. Vaccine 2011; 29(23):4008-4012. 
2010 
Devaux I, Kreidl P, Penttinen P, Salminen M, Zucs P, Ammon A, on behalf of the ECDC influenza 
surveillance group, and the national coordinators for influenza surveillance (for Germany: Gilsdorf 
A, Schweiger B, Poggensee G, Krause G, Buda S, Eckmanns T): Initial surveillance of 2009 
influenza A(H1N1) pandemic in the European Union and European Economic Area, April - 
September 2009. Euro Surveill 2010; 15(49):pii=19740. Erratum in: Euro Surveill 2011; 16(3): pii: 
19769. 
Gilsdorf A, Poggensee G, Working Group Pandemic Influenza A(H1N1)v: Influenza A(H1N1)v in 
Germany: the first 10,000 cases. Euro Surveill 2010; 15(34):pii: 19318. 
Gilsdorf A, Hofmann A, Hamouda O, Bremer V: Highly variable use of diagnostic methods for 
sexually transmitted infections – results of a nationwide survey, Germany 2005. BMC Infect Dis 
2010; 10(1):98. 
Krause G, Gilsdorf A, Becker J, Bradt K, Dreweck C, Gärtner B, Löwer J, Marcic A, Nicoll A, Pott E, 
Schaade L, et al.: Erster Erfahrungsaustausch zur H1N1-Pandemie in Deutschland 2009/2010: 
Bericht über einen Workshop am 22. und 23. März 2010 in Berlin. 
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2010; 53(5):510-519. 
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Poggensee G, Gilsdorf A, Buda S, Eckmanns T, Claus H, Altmann D, RKI Working Group 
Pandemic Influenza, Krause G, Haas W: The first wave of pandemic influenza (H1N1) 2009 in 
Germany: from initiation to acceleration. BMC Infect Dis 2010; 10: 155. 
Radun D, Bernard H, Altmann M, Schöneberg I, Bochat V, van Treeck U, Rippe R, Grunow R, 
Elschner M, Biederbick W, Krause G: Preliminary case report of fatal anthrax in an injecting drug 
user in North-Rhine-Westphalia, Germany, December 2009. Euro Surveill 2010; 15(2):pii=19464. 
Schaade L, Reuß A, Haas W, Krause G: Pandemieplanung – Was haben wir aus der Pandemie 
(H1N1) 2009 gelernt? Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2010; 53:1277–
1282.  
Spackova M, Altmann D, Eckmanns T, Koch J, Krause G: High level of gastrointestinal nosocomial 
infections in the German surveillance system, 2002-2008. Infect. Control Hosp Epidemiol 2010; 
31(12):1273-1278. 
Suess T, Buchholz U, Dupke S, Grunow R, an der Heiden M, Heider A, Biere B, Schweiger B, Haas 
W, Krause G, on Behalf of the Robert Koch Institute Shedding Investigation Group: Shedding and 
Transmission of Novel Influenza Virus A/H1N1 Infection in Households--Germany, 2009. Am J 
Epidemiol 2010; 171(11):1157-1164. 
Wichmann O, Stöcker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns 
T: Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine 
effectiveness in Germany 2009-2010. Euro Surveill 2010; 15(18):pii=19561. 
Wicker S, Rabenau HF, Gottschalk R, Krause G, McLennan S Niedrige Influenzaimpfquoten bei 
Mitarbeitern im Gesundheitswesen – Zeit für einen neuen Ansatz. 
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2010; 53(12): 1298-1303. 
Wilking H, Buda S, von der Lippe E, Altmann D, Krause G, Eckmanns T, Haas W: Mortality of 2009 
pandemic influenza A(H1N1) in Germany. Euro Surveill 2010; 15(49):pii=19741. 
Williams CJ, Schweiger B, Diner G, Gerlach F, Haaman F, Krause G, Nienhaus A, Buchholz U: 
Seasonal influenza risk in hospital healthcare workers is more strongly associated with household 
than occupational exposures: results from a prospective cohort study in Berlin, Germany, 2006/07. 
BMC Infect Dis 2010; 10(1):8. 
2009 
an der Heiden M, Buchholz U, Krause G, Kirchner G, Claus H, Haas WH: Breaking the waves: 
modelling the potential impact of Public Health measures to defer the epidemic peak of novel 
influenza A/H1N1. PLoS One 2009; 4(12):e8356. 
Bremer V, Alpers K, Krause: Ausbildungsprogramme für angewandte Epidemiologie in 
Deutschland und Europa Eine lohnende Investition für die Zukunft. Bundesgesundheitsbl-
Gesundheitsforsch-Gesundheitsschutz 2009; 52(2):203-207. 
ECDC working group on influenza A(H1N1)v (for Germany, Gilsdorf A, Schweiger B, Poggensee G, 
Krause G, Buda S, Eckmanns T): Preliminary analysis of influenza A(H1N1)v individual and 
aggregated case reports from EU and EFTA countries. Euro Surveill 2009; 14(23):pii=19238. 
The ESCAIDE Scientific Committee (für D, Krause G): The European Scientific Conference on 
Applied Infectious Disease Epidemiology (ESCAIDE) - selected papers from the conference 2008. 
Euro Surveill 2009; 14(43):pii=19377. 
Faber M, Christiansen H, Kohlstock C, Oppermann H, Irmscher H-M, Willer H, Schweiger B, 
Dupke S, Klee S, Grunow R, Haas W, Buchholz U, Süss T, Krause G, Jansen A: Untersuchungen zu 
einem familiären Cluster von Infektionen durch Influenza A/H1N1 in Deutschland, 2009. 
Gesundheitswesen 2009; 71(10):675-679. 
Gilsdorf A, Poggensee G, Working Group Pandemic Influenza A(H1N1)v: Influenza A(H1N1)v in 
Germany: the first 10,000 cases. Euro Surveill 2009; 14(34):pii= 19318. 
Gilsdorf A, Dettmann M, Poggensee G, Haas W: Neue Influenza. Aktuelle Situation und Strategie. 
Dtsch Arztebl 2009; 106(33): A1608-A1609. 
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Gottschalk R, Dreesman J, Leitmeyer K, Krause G: Kommunen, Länder, Bund und Europäische 
Gemeinschaft - Zuständigkeiten und Aufgaben bei Seuchennotfällen im Kontext der neuen 
Internationalen Gesundheitsvorschriften. Bundesgesundheitsbl-Gesundheitsforsch-
Gesundheitsschutz 2009; 52(2):183-192. 
Haas W, Köpke K, Schweiger B, Buda S, Buchholz U, Harder T, Krause G: Neue Grippe: Die 
Primärversorger sind gefragt. Dt Ärztebl 2009; 106(19):A-918. 
Hollmeyer H, Eckmanns T, Krause G: Surveillance gemäß der Internationalen 
Gesundheitsvorschriften (2005). Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 
2009; 52(2):168-175. 
Karsten C, Baumgarte S, Friedrich AW, von Eiff C, Becker K, Wosniok W, Ammon A, Bockemühl J, 
Karch H, Huppertz HI: Incidence and risk factors for community-acquired acute gastroenteritis in 
north-west Germany in 2004. Eur J Clin Microbiol Infect Dis 2009; 28(8):935-943. 
Krause G: Investigating outbreaks: medical imperative or academic indulgence? Wien Klin 
Wochenschr 2009; 121(3-4):73-76. 
Krause G, Aavitsland P, Alpers K, Barrasa A, Bremer V, Helynck B, Perra A: Differences and 
Commonalities of National Field Epidemiology Training Programmes in Europe. Euro Surveill 
2009; 14(43):pii=19378. 
Krause G, Stefanoff P, Moren A: Applied epidemiology training in Europe: quite a success - but 
more to be done. Euro Surveill 2009; 14(43):pii=19375. 
Laude G, Kist M, Krause G: Etablierung von Referenznetzwerken aus Nationalen Referenzzentren 
mit assoziierten Konsiliarlaboratorien in Deutschland. Bundesgesundheitsbl-Gesundheitsforsch-
Gesundheitsschutz 2009; 52(10):919-926. 
Novel influenza A(H1N1) investigation team: Description of the early stage of pandemic (H1N1) 
2009 in Germany, 27 April-16 June 2009. Euro Surveill 2009; 14(31):pii=19295. 
Rachael T, Schubert K, Hellenbrand W, Krause G, Stuart JM: Risk of transmitting meningococcal 
infection by transient contact on aircraft and other transport. Epidemiol Infect 2009; 137(8):1057-
1061. 
Schreck S, Strauss R, Lücking G, Krause G: EU-Strukturen zur Überwachung und Bekämpfung von 
Infektionskrankheiten. Wer sie macht, wie sie entstehen und wie sie funktionieren. 
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009; 52(2):149-156. 
Stäger K, Legros F, Krause G, et al. : Imported Malaria in children in industrialized countries, 1992–
2002. Emerg Infect Dis 2009; 15(2):185-191. 
Wichmann O, Siedler A, Sagebiel D, Hellenbrand W, Santibanez S, Mankertz A, Vogt G, van Treeck 
U, Krause G: Further efforts needed to achieve measles elimination in Germany: results of 
outbreak investigation. Bull World Health Organ 2009; 87(2):108-115. 
Wiese-Posselt M, Reiter S, Gilsdorf A, Krause G: Notwendigkeiten und Hürden einheitlicher 
Impfempfehlungen in der Europäischen Union. Bundesgesundheitsbl-Gesundheitsforsch-
Gesundheitsschutz 2009: 52(11):1099-1104. 
Williams CJ, Schenkel K, Eckmanns T, Altmann D, Krause G: FIFA World Cup 2006 in Germany: 
Enhanced surveillance improved timeless and detection. Epidemiol Infect 2009; 139(4):597-605. 
B) Overview articles or systematic reviews (incl. non peer-review articles) 
Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gärtner B, Groß U, Haas W, Hamouda 
O, Hübner J, Jänisch T, Kist M, Kramer MH, Ledig T, Mielke M, Pulz M, Stark K, Suttorp N, Ulbrich 
U, Wichmann O, Krause G: Priorisierung übertragbarer Infektionserreger unter dem Aspekt der 
Surveillance und epidemiologischen Forschung. 
Hyg Med 2011; 36(12):503. 
Buda S, Burger R, Eckmanns T, Gilsdorf A, Haas W, Hamouda O, Lenz Y, Mielke M, Stark K, 
Krause G, Wichmann O, et al.: Prioritization of communicable infectious agents in terms of 
surveillance and epidemiological research: Results of a standardized procedure in Germany in 2011. 
Hyg Med 2011; 36(12):503-509. 
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Dettmann M, Poggensee G, Buda S, Claus H, Krause G, und die AG Pandemie am RKI: Verlauf der 
Neuen Grippe. Trifft es bald mehr ältere Patienten? MMW - Fortschr Med 2009; 151(40):35-37. 
Krause G: Risiko für den Menschen, Pandemieplanung: „Schweinegrippe” (Influenza A / H1N1): 
Berlin Medical 2009; 6(Suppl.2):16.  
Krause G, Abteilung 3 des Robert Koch Institutes: Rückblick: Epidemiologie und Infektionsschutz 
im zeitlichen Verlauf der Influenzapandemie (H1N1) 2009. UMID Umwelt und Mensch – 
Informationsdienst 2010; 3: 35-40. 
Rosner B, Bernard H, Werber D, Faber M, Stark K, Krause G (2011): Epidemiologie des EHEC 
O104:H4/HUS-Ausbruchs in Deutschland, Mai bis Juli 2011. J Verbr Lebensm 2011; 6(4):473-481. 
C) Book chapters 
Krause G. Electronic Reporting in Infectious Disease Surveillance, In: M’ikanatha N, Lynfield R, 
Van Beneden C, de Valk H. Infectious Disease Surveillance. Blackwell, London, in print 
D) Articles in the Epidemiological Bulletin 
From issue 1, 2009 to issue 49, 2012 of the Epidemiological Bulletin, the department has 
contributed 150 of the 341 articles (not including fact sheets for physicians). This amounts to 43% 
of all and 63% of all RKI-contributions. The detailed list of Bulletin articles can be found under the 
respective unit chapters. 
Figure 4: Number of articles contributed by department for infectious disease epidemiology, compared to 
other internal and external contributors 2009-2012 to the Epidemiological Bulletin (44%, fact sheets for 
physicians not included) (n=341) 
 
Contributions to the Epidemiological Bulletin by the director’s office alone: 
Priorisierung übertragbarer Infektionserreger unter dem Aspekt der Surveillance und 
epidemiologischen Forschung. Epid Bull 2011; 44:397-404. 
Aktuelle Initiativen zur Bewertung der im Verlauf der Pandemie geleisteten Arbeit. Epid Bull 2010; 
19: 171-173. 
Etablierung von Referenznetzwerken aus Nationalen Referenzzentren mit assoziierten 
Konsiliarlaboratorien in Deutschland. Epid Bull 2009; 44:455-458´. 
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4.1.2. Selected relevant publications  
Five important publications for the scientific community 2009–2012 
1. Velasco E, Ziegelmann A, Eckmanns T, Krause G. Eliciting views on antibiotic prescribing 
and resistance among hospital and outpatient care physicians in Berlin, Germany: results 
of a qualitative study. BMJ Open 2012; 2(1):e000398. 
2. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, 
Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Müller L, King LA, 
Rosner B, Buchholz U, Stark K, Krause G; Epidemic profile of Shiga-toxin-producing 
Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365(19):1771-1780. 
3. Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gärtner B, Groß U, Haas W, 
Hamouda O, Hübner J, Jänisch T, Kist M, Kramer MH, Ledig T, Mielke M, Pulz M, Stark K, 
Suttorp N, Ulbrich U, Wichmann O, Krause G: Communicable Diseases Prioritized for 
Surveillance and Epidemiological Research: Results of a Standardized Prioritization 
Procedure in Germany, 2011. PLoS One 2011; 6(10):e25691. 
4. Suess T, Buchholz U, Dupke S, Grunow R, an der Heiden M, Heider A, Biere B, Schweiger 
B, Haas W, Krause G; Shedding and transmission of novel influenza virus A/H1N1 
infection in households--Germany, 2009. Am J Epidemiol 2010;171(11):1157-1164. 
5. Wichmann O, Siedler A, Sagebiel D, Hellenbrand W, Santibanez S, Mankertz A, Vogt G, 
Krause G. Further efforts needed to achieve measles elimination in Germany: Results of an 
outbreak investigation Bulletin of the World Health Organization 2009; 87(2):108-115. 
Five important publications for the public 2009–2012 
1. RKI & PEI: Vorläufige Empfehlungen des Paul-Ehrlich-Instituts und des Robert Koch 
Institutes zur Anzahl der benötigten Teildosen des pandemischen Impfstoffs Pandemrix® 
(GSK) zum Schutz gegen die Neue Influenza A (H1N1) und zu dessen Anwendung in der 
Schwangerschaft. Epid Bull 2009; 41:425-426. 
2. Vorläufige Ergebnisse der EHEC/HUS-Studie. EHEC O104:H4-Ausbruchsgeschehen in 
Deutschland aufgeklärt: Auslöser waren Sprossen von aus Ägypten importierten 
Bockshornkleesamen. Gemeinsame Pressemitteilungen von BfR und RKI 25.5.2011 und 
vom BfR, BVL und RKI am 5.7.2011 
3. Krause G, Gilsdorf A, Becker J, Bradt K, Dreweck C, Gärtner B, Löwer J, Marcic A, Nicoll A, 
Pott E, Schaade L, Schoeller A, Stollorz V, Träder C, Razum O. Erster Erfahrungsaustausch 
zur H1N1-Pandemie in Deutschland 2009/2010. Bundesgesundheitsbl-Gesundheitsforsch-
Gesundheitsschutz 2010; 53:510-519. 
4. Krause G, Frank C, Gilsdorf G, Mielke M, Schaade L, Stark K, Burger R, Der HUS-Ausbruch 
2011 in Deutschland - Herausforderungen für den Infektionsschutz: Was sollte verbessert 
werden? Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2013;  
5. 48 Fact sheets physicians: 
http://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/merkblaetter_node.html 




Influenza 1999 2001; 2004; 2006; 2008; 5/2009; 7/2009; 
10/2009; 2011 
Meningococcal disease 1999 2002; 2003; 2004; 2007; 2009; 2010; 2011 
Early summer meningoencephalitis 1999 2001; 2003; 2004; 2007; 2009; 2010; 2011 
Lyme borreliosis 1999 2001; 2007 
Hepatitis A 1999 2001; 2006; 1/2008; 3/2008; 9/2008 
EHEC 1999 2001; 2007; 2008; 2011 
Campylobacter 1999 2001; 2005 
Rabies  1999 2002; 2005; 1/2009; 4/2009; 2010 
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Measles 1999 2002; 2004; 2009; 4/2010; 9/2010 
Legionella 1999 2001; 2006 
Norovirus 2000 2002; 2005; 2007; 2008 
MRSA 2000 2003; 2007; 2009 
Tuberculosis 2000 2002; 2009 
Listeria 2000 2003; 2010 
Malaria 2000 2003; 2006; 2012 
Poliomyelitis 2000 2004; 2008; 2009;2011 
Hepatitis B 2000 2002; 2004; 2011 
Abdominal typhoid, paratyphoid 2000 2005; 2007; 2008 
Scarlet fever 2000 2008 
Varicella 2000 2002; 2004; 2010 
Diphtheria  2001 2007; 2009 
Chlamydia trachomatis 2001 2009 
Chlamydia psittaci, pneumoniae 2001 2009 
Rubella 2001 2003; 2010 
Yellow fever 2001 2010 
Shigellosis  2001 2007; 2012 
Mumps 2001 2003 
Pertussis 2001 2006; 2008; 3/2010; 9/2010 
Trichinellosis 2002 - 
Rotavirus  2002 2007; 2010 
Tetanus 2002 2004; 2010 
Q Fever 2002 2003; 2009 
Lassa fever 2002 2011 
Epidemic keratoconjunctivitis 2003 2004; 2010 
Syphilis 2003 2004; 2007 
Head lice 2003 2007; 2008 
RSV 2004 2011 
Hepatitis C 2004 2011; 2012 
Cryptosporidiosis 2004 - 
Brucellosis 2005 2008 
Echinococcosis 2005 - 
HIV/AIDS 2006 2011 
Hantavirus 2006 - 
Toxoplasmosis 2007 12/2007; 2009 
Salmonellosis 2009 - 
Scabies 2009 - 
Clostridium difficile 2009 - 
Anthrax  2012 - 
4.1.4. Overview on collaborations in networks 
See 3. AL3 
4.1.5. Memberships and participation in Advisory Boards 
Dr. Andreas Gilsdorf 
• Advisory Forum of the ECDC, Deputy 
• EWRS Focal Points at European Commission 
• Network Committee Generic Preparedness Section 
Prof. Dr. Gérard Krause 
• Advisory Forum of the ECDC 
• Competent body for Threat Detection of the ECDC 
• Competent body for Response of the ECDC 
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• Competent body for Preparedness of the ECDC 
• Competent body for Preparing Guidelines of the ECDC 
• Competent body for Scientific Advice of the ECDC 
• Expert group for evidence based public health recommendations at ECDC 
• External expert in the IHR review committee at WHO 
• Coordinator of the infectious disease working group of the National Cohort 
• Member of Scientific Advisory Board of the German Association for Infectiology (DGI) 
• Member of Advisory Board for the National Reference Centres in Belgium 
• Steering committee for the European Programme for Intervention Epidemiology Training 
(EPIET), chairman: 2006-2007 
• Member of EPIET training site forum 2005 - 2007 
• German Society for Epidemiology (DGepi)  
• EPIET Alumni network 
• EIS Alumni Network 
• Representative of founding member of national cohort association 
• Member of epidemiological steering committee of national cohort 
• Member of steering committee of HZI 
• Member of scientific committee of HZI 
4.1.6. List of completed dissertation or master theses in the director’s office, 2009 – 
2012 
Year Title Name Degree University/ 
Supervisor RKI 
2012 Population based serial cros-sectional 




Dr. rer. medic. Charité / Krause 
2012 Prescribing habits for antimicrobial 
treatment in Germany 
Edward 
Velasco 
Dr. rer. medic. Charité / Krause 
2012 Polio eradication Analysis of entervirus 






Berlin School of 
Public Health / 
Krause 





Berlin School of 
Public Health / 
Krause 
2012 Das Landesgesundheitsamt als 
Schnittstelle zwischen Gesundheits-
ämtern und Robert Koch Institute im 
öffentlichen Gesundheitsdienst in 
Deutschland. Ausgewählte Aufgaben 
des niedersächsischen 
Landesgesundheitsamt (NLGA) am 
Beispiel von wissenschaftlichen Studien 
im Bereich der angewandten 
Epidemiologie 
M. Diercke Master of 
Science in 
Epidemiology 
Berlin School of 





2011 Das Erkennen, Bekämpfen und 
Verhüten von Infektionskrankheiten 
C. Adlhoch Master of 
Science in 
Epidemiology 
Berlin School of 
Public Health / 
Krause, Eckmanns  
2009 Identification of risk factors for 






Berlin School of 
Public Health / 
Krause 




Dr. med. Charité / Krause 
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4.1.7.  Reports and written scientific advice to the Ministry of Health 
There were 211 reports and written scientific advice to the Ministry of Health between 2009 and 
30.09.2012. The overall number of reports varies from the sum of reports in the respective unit 
sections due to the contribution of multiple units to many reports.  
4.1.8. Presentations as invited speaker, 2009-2012 
Staff from the Director’s Office were invited to speak at 55 conferences. 
4.1.9. Outbreak investigations with on site participation of staff of the department 
(including PAE fellows of the department assigned to the regional health authorities) 
2009-2012 
Title Place Year 
RSV outbreak Heidelberg, Baden-
Wuerttemberg 
2012 
Investigation of a pointsource gastroenteritis outbreak in a 
canteen 
Berlin 2012 
Salmonella Muenchen outbreak Bavaria 2012 
Salmonella Typhimurium outbreak Lauenburg 2012 
Gastrointestinal outbreak in a kindergarten Rhineland-Palatinate 2012 
Adenovirus outbreak in Germany Baden-
Wuerttemberg 
2012 
Nosocomial outbreak of resistant Klebsiella spp Leipzig 2012 
Nosocomial outbreak of Salmonella aureus Berlin 2012 
Legionella spp. outbreak Rhineland-Palatinate 2012 
Risk assessment in a training and research institute for animal 
husbandry affected by Q fever  
Schleswig-Holstein 2012 
Measles outbreak Landau 2012 
CA-MRSA-cases in a asylum seeker shelter Neumünster, 
Schleswig-Holstein 
2011 
Gastroenteritis outbreak after a scientific workshop Berlin 2011 
Shiga-toxin-producing Escherichia coli O104:H4 outbreak Northern Germany 
plus exported cases 
2011 
Recipe-based restaurant cohort study of ten groups of diners 
during a large STEC-outbreak 
Lübeck 2011 
Investigation of a satellite outbreak within a large Shiga-toxin-
producing Escherichia coli (STEC) O104 outbreak in a company 
cafeterias 
Frankfurt 2011 
Measles outbreak after a school trip Berlin 2011 
Mumps outbreak at a school Nueremberg 2011 
Salmonella Senftenberg outbreak Germany 2011 
Increase of Hepatitis E cases Germany 2011 
Salmonella Typhimurium outbreak  Saxony-Anhalt 2011 
EHEC/HUS outbreak Northern Germany 2011 
Cohort study on cluster of STEC O104:H4 cases Göttingen 2011 
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Gastrointestinal outbreak in a teaching conference Menorca, Spain 2011 
ESBL-Klebsiella-outbreak on a neonatal care unit in Germany Bremen 2011 
EHEC/HUS-outbreak after a birthday celebration Lower Saxony 2011 
Salmonella Newport German federal 
states 
2011 







Nosocomial MRSA outbreak in a neonatology ward Berlin 2010 
Nationwide outbreak of Salmonella Panama Germany 2010 
Measles outbreak at school Berlin 2010 
Anthrax outbreak in Europe, an active surveillance study  Aachen region 2010 
Severe infections of Salmonella Enteritidis after BBQ  Rhineland Palatinate 2010 
Outbreak of Salmonella Montevideo associated with a dietary 
food supplement flagged in the Rapid Alert System for Food and 
Feed (RASFF) 
Western Germany 2010 
Varicella in an asylum seeker home Bavaria 2010 
Salmonella Montevideo German federal 
states 
2010 
Food-borne Listeria monocytogenes outbreak associated with a 
traditional herring product 
Germany 2010 
Shigella sonnei in two kindergartens and several families Landau 2010 
Norovirus outbreak Bavaria 2010 
Hepatitis B outbreak in a nursing home for elderly  Lower Saxony 2010 
Measles outbreak in an asylum seeker shelter Neumünster, 
Schleswig-Holstein 
2010 
Community Legionella outbreak  Ulm/Neu-Ulm 2010 
Outbreak of Salmonella Enteritidis in a kindergarten Bavaria 2010 
Cluster of pertussis cases in schoolchildren Bavaria 2010 
Varicella outbreak in asylum seekers hostels Bavaria 2010 
Gastroenteritis outbreak in a holiday camp Bavaria 2010 
Outbreak of gastroenteritis after a wedding party,  Bavaria 2010 
Adenovirus-Keratoconjunctivitis outbreak Germany 2010 
Case-control study of a large (~350 cases) outbreak of 
gastrointestinal disease amongst hill walkers frequenting an 
alpine hut 
Oberallgäu, Bavaria 2009 
Influenza A/H1N1 outbreak after a teenage party Würzburg, Bavaria 2009 
Tuberculosis in a school Wilhellshaven, 
Lower Saxony 
2009 
Salmonella Enteritidis in a bakery Bavaria 2009 
Outbreak of Salmonella Enteritidis in a bakery North-Rhine- 2009 
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Westphalia 
Norovirus-gastroenteritis in a military barrack Leipzig 2009 
Preliminary case report of fatal anthrax in an injecting drug user North-Rhine-
Westphalia 
2009 
HUS outbreak due to sorbitol-fermenting EHEC O157:H- Hamburg 2009 
Pertussis in a physician’s practice Saxony-Anhalt 2009 
Salmonella Infantis in a rehab centre Calw, Baden-
Wuerttemberg 
2009 
Nosocomial Enterobacter Homburg, Saarland 2009 
Legionellosis on a cruise ship Dubai 2009 
Salmonella Ohio Germany 2009 
4.2.  Mission statement 
The department’s superior goal is 
Prevention, Detection and Control of Infectious Diseases in  Germany’s Population 
through 
• Continuous surveillance and assessment of the epidemic situation 
• Implementation and support of outbreak investigations 
• Development and evaluation of strategies for prevention and intervention 
• Research and method development in the field of infectious disease epidemiology 
• Execution of legal duties in the field of infectios disease control  
• Support and advice for other partners of the public health service and political decision 
makers 
• Development of evidence-based recommendations for the public health service  
• Information for the public 
• Exchange with other national and international health authorities 
• Qualification and further training in the field of public health with emphasis on infectious 
disease epidemiology 
 
We pursue that objective with the following self-conception: 
• We foster intensive scientific exchange and cooperation with partners within and outside 
the institute. 
• We are a partner in the national and international public health service. 
• Urgent threats to public health have high priority and we react quickly, flexibly and with high 
commitment.  
• We conduct scientific projects according to good epidemiological practice and 
acknowledged ethical standards. 
• Our recommendations and decisions are based on academic evidence. 
• We assure for continuity in regards of content.  
• We work scientifically independent. 
• We communicate new findings quickly. 
• We make our procedures and decisions transparent. 
• We are a team. 
• We appreciate our team’s diversity and stand up for each other. 
• Further qualification and personal development are important to us. 
• We are able to make use of flexibility in work time and content.  
• We use interdisciplinary approaches and take on responsibility. 
• All technical and professional areas contribute equally to the success of our work.   
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4.3.  Pathogens Prioritised for Surveillance and Epidemiological 
Research 
From Balabanova Y et al. PLoS One 2011; 6(10):e25691 
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4.4.  Networks of National Reference Centres and Consiliary 
Laboratories (German Version) 
Network for parasites, tropical and vectro transmitted diseases (spokesperson: B. Fleischer, 
Hamburg) 
Regular members: NRC Tropical infectious agents, NRC Borreliosis, CL Ehrlichia, CL Echinococces, 
CL Filoviruses, CL Early Summer Meningo-Encephalitis  
Additional members: CL Cryptococcus neoformans, Pseudallescheria boydii/Scedosporium sp. and 
non-european systemic mycotic pathogens 
Network for enteric infections (Spokesperson: A. Flieger, Wernigerode) 
Regular members: NRC Salmonella and other bacterial enteric pathogens, CL Bacterial 
gastrointestial infections, CL Haemolytic uremic syndrome (HUS), CL Listeria, CL Noroviruses, CL 
Rotaviruses, CL Hepatitis-A-Virus, Hepatitis-E-Virus, CL Clostridium difficile, CL Electron-
microscopial diagnosis of pathogens, CL Treponema, CL Whipple-Bacterium 
Additional members: NRC Tropical infectious agents, CL Adenoviruses 
Network for invasive bacterial infections (spokesperson: M. Frosch/ U. Vogel, Würzburg) 
Regular members: NRC Meningococci, NRC Streptococci, CL diphtheria, CL Haemophilus 
influenzae 
Additional member: CL Anaerobic bacteria 
Network for respiratory infections(spokesperson: B. Schweiger, Berlin) 
Regular members: NRC Influenza, NRC Mycobacteria, CL Adenoviruses, CL Klebsiella, CL 
Legionella, CL Bordetella pertussis, CL Mykoplasm, CL Respiratory syncytial viruses 
Parainfluenzaviruses, Metapneumoviruses, CL Actinomyzes CL Chlamydia 
Additional members: NRC Streptococci,CL Parvoviuses, CL Cryptococcus neoformans, 
Pseudallescheria boydii/Scedosporium sp. and non-european systemic mycotic pathogens, CL 
Aspergillus, CL Mukoviszidosis-bacteriology 
Network for mykoses (spokesperson: U. Groß, Göttingen) 
Regular members: NRC Systemic mycoses, CL Aspergillus, CL Cryptococcus neoformans, 
Pseudallescheria boydii/Scedosporium sp. and non-European systemic mycotic pathogens, CL 
dermatophytes 
Additional member: CL Mukoviszidosisi bacteriology 
Network for sexually or blood transmitted infections (spokesperson: H. Pfister, Köln) 
Regular members: NRC Hepatitis-C-Virus, NRC Retroviruses, NRC Papilloma and  Polyomaviruses, 
NRC Hepatitis-B-Virus und Hepatitis-D-Virus, CL Treponema, CL Gonococci 
Additional members: CL Parvoviruses, CL Chlamydia 
Network for infections during immune deficiency or pregnancy (spokesperson: T. Mertens, 
Ulm) 
Regular members: NRC Measles, Mumps, Rubella , NRC Poliomyelitis and enteroviruses, CL 
Epstein-Barr-Virus, Human Herpes-Virus 6, 7, 8, CL Herpes-simplex-Virus, Varizella-Zoster-Virus, 
CL Humanes cytomegalyvirus (HCMV),CL Congenital virus infections(HCMV), CL Parvoviruses, CL 
Toxoplasma  
Additional members: NRC Streptococci, NRC Papilloma- and polyomaviruses, CL Adenoviruses, CL 
Listeria, CL Treponema 
Network for antimicrobial resistence (spokesperson: G. Werner, Wernigerode) 
Regular members: NRC Staphylococciand enterococci, NRC Helicobacter pylori, NRC Surveillance 
of nosocomial infections, NRC Gramnegative hospital pathogens, CL Anaerobic bacteria, CL 
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Mukoviszidosis bacteriology  
Additional members: NRC Systemicmycoses, NRC Salmonella and other  bacterial enteric 
pathogens, CL Klebsiella 
Network for zoonoses (spokesperson: V. Kempf, Frankfurt/Main) 
Regular members: CL Bartonella, CL Brucella, CL Coxiella burnetii, CL Hantavirus, CL Smallpox 
viruses, CL Rabies, CL Tularemia, CL Yersinia pestis, CL Leptospirosis, CL Elektron microscopic 
diagnosis of pathogens 
Additional members: NRC Tropical pathogens, NRC Streptococci, NRC Salmonella and other 
bacterial enteric pathogens, CL Early summer meningo encephalitis, CL Chlamydia, CL 
Toxoplasmosis, CL Filoviruses 
Network for infections of the central nervous system (spokesperson: I. Zerr, Göttingen) 
Regular members: NRC Surveillance of transmissible spongiform enzephalopathies, NRC 
Poliomyelitis und enteroviruses, CL Viral CNS infections 
Additional members: CL Cryptococcus neoformans, pseudallescheria boydii/scedosporium sp. and 
non-european systemic mycotic pathogens, CL Early summer meningo encephalitis, CL 
Toxoplasma, CL Treponema  
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1. General information - PAE 
Postgraduate Training for Applied Epidemiology (PAE) and European Programme for 
Intervention Epidemiology Training (EPIET) 
Head:  Dr. Katharina Alpers 
Deputy:  Dr. Manuel Dehnert 
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2.  Tasks and goals of the unit 
2.1.  Summary 
The major goal of the unit “training programmes in infectious disease epidemiology” is 
competency based and service-oriented training of experts in infectious disease control and 
prevention in order to create a national and international network of experts who employ the 
appropriate resources and epidemiologic methods to identify the source of public health problems 
and to establish immediate and long term control and prevention measures. 
The postgraduate training for applied epidemiology (PAE) is a 2- year fellowship programme which 
provides training in field epidemiology by supervised learning-by-doing. 
The fellows in training and the alumni form a task force which responds to outbreaks and other 
public health challenges in a timely and competent manner.  
2.2.  Current status of the work and summary of relevant results 
When the German Ministry of Health (MOH) initiated a number of measures to strengthen the 
capacity in the field of infectious disease epidemiology in the 1990s, training in infectious disease 
epidemiology was one of the central initiatives to provide the German public health service (ÖGD) 
with scientists who are skilled to use epidemiological methods for the prevention of infectious 
diseases. 
The main pillar was the installation of a two-year national field epidemiology training programme 
(FETP) in 1996 following the successful model of the Epidemic Intelligence Service (EIS) at the 
Unites States’ Centers for Disease Control and Prevention (US CDC), which had been founded in 
1951 by Alexander Langmuir. The German FETP is based at the department for Infectious Disease 
Epidemiology at the Robert Koch Institute. In 2009 the (PAE) PAE-unit (Postgraduate Training for 
Applied Epidemiology) was created reporting directly to the director of the department. In order to 
link with the European network for infectious disease control it has been organisationally closely 
linked to the 'European Programme for Intervention Epidemiology Training' (EPIET) as a so-called 
EPIET-associated programme since the very beginning. 
The independent use of acquired techniques under close expert supervision is a central feature of 
both programmes and makes up 90% of the training period while only 10% are covered by classical 
academic forms of education (lectures, seminars and case studies). The programme focuses 
particularly on the investigation of outbreaks in cooperation with the respective authorities of the 
ÖGD, the analysis of infectious disease surveillance data, the evaluation of surveillance systems as 
well as the development and implementation of application-orientated epidemiological research 
projects. All aspects of the training are practice-oriented and aimed at finding and implementing 
appropriate action for the prevention of infectious diseases.  
In addition to the practical training, theoretical knowledge is communicated through different 
training modules, most of which are offered in cooperation with EPIET and take place in the 
different member states of the European Union. In addition to the EPIET modules RKI is 
conducting a one-week introductory module and a laboratory module for PAE at the RKI 
laboratories (bacteriology and virology) as well as additional activities such as journal clubs and 
scientific seminars. 
The PAE primarily targets individuals with fairly advanced training and work experience in a medical 
or related discipline and aims to attract young professionals from outside the public health service, 
with a scientific background to dedicate and strengthen their skills for public health epidemiology. 
The programme started with two participants and - due to various kinds of additional government 
funding - has had up to nine participants per cohort. Meanwhile, the cohort size has been 
stabilised at 5 participants per year. 
PAE fellows function as an essential resource for the investigation of outbreaks and the control of 
other infectious disease threats and they participate as duty officer in the RKI 24/7 hotline for 
public health emergencies. 
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Since 2006 PAE around two PAE fellows per cohort are seconded to state public health agencies 
and thus play an important role in the collaboration with the federal states. Up to now the state 
public health agencies of Baden Wuerttemberg, Bavaria, Hesse, Lower Saxony and Rhineland-
Palatinate have been recognised as EPIET-training sites. 
Since the winter term 2009/2010 a Master of Science programme in Applied Epidemiology (MSAE) 
was newly established in cooperation with the Charité in Berlin and the Berlin School of Public 
Health (BSPH). The two-year fulltime course of 120 ECTS credit points is integrated into the PAE 
and EPIET training programmes. So far, two cohorts of students have graduated with a master 
degree (9 in 2011 and 6 in 2012)  
Of the 64 graduates of the programme 1996-2012, 55 (86%) have taken positions in public health 
after completion the programme, many of them in leading functions.  
2.3.  Major goals and contribution to the goals of the department  
The fellows, supervisors and coordinators of the Training Programmes in Infectious Disease 
Epidemiology (PAE/EPIET) make a fundamental contribution to the major goal of the department. 
They participate in the management of national crises (such as the pandemic influenza 2009 and 
the HUS/EHEC outbreak 2010) and perform outbreak investigations. Additionally, they conduct 
projects in the fields of surveillance and applied research and participate in routine activities 
dictated by the German Infection Prevention Act (IfSG). Through these projects they help to 
develop prevention strategies and give evidence-based recommendations for policy makers and the 
German public health service. 
By working in the federal states and assisting local public health units they help to strengthen the 
network within the German national public health-system and they function as multipliers who help 
to teach the concepts of infectious disease epidemiology to a broader audience within the German 
public health system. Furthermore, through their involvement in the EPIET network they advance 
the exchange with other players in the European public health system. 
PAE- and EPIET- fellows have participated in nearly all of the over 60 outbreak investigations in 
which the department was involved during the years 2009-2012 (for list see 4.1.9., AL3). A 
considerable proportion of these outbreak investigations were conducted by fellows based in the 
federal states.  
PAE- and EPIET- fellows have conducted the following projects during the years 2009-2012: 
• Report on actual situation of Lyme borelliosis in the new federal states of Germany, 2007-
2008 
• Implementation and Conduction of a timely limited hospital surveillance of cases with 
Pandemic Influenza A(H1N1)v infections and associated cases of death in Germany, 2009-
2010 
• Implementation and Conduction of a timely limited Rotavirus surveillance of cases with 
Rotavirus vaccination in children between 0-24 months living in Mecklenburg-West 
Pomerania (MV), 1. July 2010- 30. June 2011 
• Hospitalisation and death rates of notified salmonellosis by serotype, age and federal state 
in Germany, 2004-2008 
• Pilot study regarding the use of Nuclein acid-amplification tests to detect Chlamydia and 
Gonococci from pharyngeal and rectal swabs collected in STI screenings among MSM and 
FSW in German cities 
• Surveillance project on severe cases by 2009 H1N1 influenza among children in Germany 
• HCV Surveillance 
• AIDS defining illnesses in the HIV-1 seroconverter cohort 
• implementation of a lab-based Chlamydia-sentinel system accompanying the existent, 
opportunistic screening program in Germany 
• Analysis of Pandemic influenza A H1N1 breakthrough infections and estimates for vaccine 
effectiveness 
• Hepatitis E Surveillance 
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• Knowledge, acceptance and status of HPV-vaccination in students in 10th grade of school 
in Berlin 
• Comparison of disease burden of infections with Salmonella Typhimurium DT 193 
(monophasic S. Typhimurium) and other Lysotypes (in particular DT104) on the basis of 
hospital data of notified infections in Germany, January 2008-June 2010 
• Implementation of an SARI surveillance system in 9 Berlin hospitals to monitor SARI and 
to depict Influenza activity 
• BorderNETwork project at RKI 
• Comparative analysis and characterisation of the IfSG surveillance data of noro- and 
rotavirus outbreaks  
• Surveillance of bloody diarrhoea in emergency departments during the outbreak of bloody 
diarrhoea and haemolytic uraemic syndrome caused by Shiga toxin/verotoxin-producing 
Escherichia coli in Germany, 2011 
• Clinical manifestations and risk factors in patients with A(H1N1) infection 
• Evaluation of the influenza surveillance in Bavaria and investigation of the potential 
calculation of the population denominator for the influenza sentinel network in Bavaria 
• Risk of acquisition of a Granulocytic Anaplasmosis in comparison to the risk of acquiring 
Lyme disease after tick exposure in Bavaria 
• Trends in incidence of gastroenteric infections in refugees (asylum seekers) in Rhineland-
Palatinate (TIGIR)  
• Prospective assessment of Clostridium difficile incidence in hospital patients and staff 
(PACIPS)  
• Novel Influenza prevalence in intensive care units of a community hospital in Rhineland-
Palatinate (NIPI)  
• Incidence of Pandemic and Seasonal Influenza in hospitalised children (IPSI)  
• Factors associated with fatal outcome of 2009 pandemic influenza (H1N1) infections in 
Germany 
• Screening for information of infection sources and evidence of secondary infections among 
patients in nephrology department during the large HUS-outbreak, 2011 
• Social environment and infectious diseases in Berlin 
• Descriptive analysis of SurvNet and laboratory data of Norovirus cases and clusters in 
Lower Saxony 
• Intensified Hantavirus surveillance in Lower Saxony 
• ARMIN (antibiotic drug resistance monitoring in Niedersachsen/Lower Saxony) 
• MRSA prevalence study (EurSafety project) 23-27th May 2011 
• Capture-recapture study on adverse events following immunisation in Lower Saxony, 2001-
2010 
• Optimising the analysis and reporting of the TB TOM in Germany (2010-2011) 
• Evaluation of current achievement of Rubella elimination in Germany (2010-2012) 
• STEC Sero-epidemiological study (2011) 
• Study of Pandemrix effectiveness in preventing infection with influenza (2011) 
• Underreporting of enteropathic E. coli (2011) 
• Evaluation of the E.-coli-enteritis notifications (laboratory methods used, serogrouping, 
pathogenicity factors, etc.) in order to analyse completeness of reporting, and identify if the 
surveillance system is useful in its present state (2010-2012) 
• Survey among AGI sentinel-doctors concerning praxis and information management during 
2009 H1N1 Influenza Pandemic 
• IfSG-Influenza-surveillance - mortality and hospitalisation, vaccine-effectiveness (2011) 
• Influenza-Project: paper and pencil survey amongst all AGI sentinel-doctors concerning 
praxis and information management during 2009 H1N1 Pandemic 
• Intensified surveillance of HEV with integrated case control study (2011-2012) 
• Epidemiology of typhoid fever in Germany 1995-2010 
• Implementation of an enhanced surveillance system for the Women’s FIFA World Cup 2011 
in Germany 
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• Development of a new mumps case definition as part of the newly introduced nationwide 
mandatory reporting (Infection Against Protection Act 2001) 
• Mumps epidemiology in Germany 2001-2011 
• Estimation of mumps incidence in Germany based on insurance data 2007-2010 
• Household transmission of Shiga-toxin producing E. coli (STEC) (2011-2012) 
• Further development of a web-based surveillance to monitor the flu status in Germany 
(Grippe-Web) 
• Contact-tracing in international public transportation 
• Descriptive analysis of extra pulmonary TB data from 2002-2009 
• Serological survey of Schmallenberg virus antibodies in farmers from NRW, Germany 
• Implementation of a surveillance system for nosocomial outbreaks in Germany 
• Hantavirus & Q-fever Surveillance – control of notifiable cases in Bavaria 
• Estimating the vaccine effectiveness of the pertussis vaccination in the five eastern German 
states. 
• Analysis of mandatory notification data on Varicella infection in the German New Federal 
States  
• Quality of TB treatment in Germany using Insight Health data 
• Sexually transmitted infections among Female Sex Workers in Germany 
• Measles vaccination coverage among 20-35 year old in Rhineland-Palatinate 
• Determinants of vaccination coverage among preschool children in Germany: Results from 
three cross-sectional surveys 
2.4.  Additional work and methods for investigations  
New training tools and evaluation tools are continuously being developed and implemented in 
cooperation with the EPIET coordination team. The EPIET team is presently undertaking a new 
quality assurance project based on the core competencies for public health officials developed by 
ECDC and the European member states. 
At present, the MSAE is participating in the accreditation of all medical study courses of the Charité 
performed by the Accreditation Agency for Study Programmes in Health and Social Sciences 
(AHPGS).  
The training course for public health officials organised by the department since 1995 is currently 
being evaluated in respect to its usefulness to improve the management of outbreaks at the local 
level. For this purpose the training programme team is participating in the evaluation of the course 
by conducting a survey among former participants to the course and planning focus group 
discussions among stakeholders. An expert in adult education is being consulted to assist in this 
process. 
2.5.  Scientific advice and consulting services 
As an EPIET associated programme the PAE is regularly involved in the quality assurance and 
planning for the EPIET curriculum.  
Scientists of the department of infectious disease epidemiology are regularly involved in the 
specialisation courses for public health physicians by planning and conducting training units at the 
academies for specialisation in public health in Southern Germany (Akademie für Gesundheit und 
Lebensmittelsicherheit, AGL) and Western Germany (Akademie für den Öffentlichen 
Gesundheitsdienst, AfÖG) as well as the newly established specialisation course at the Berlin 
School of Public Health (BSPH). 
2.6  Training and teaching activities 
The major goal of the unit “training programmes in infectious disease epidemiology” is service-
oriented training of experts in infectious disease control and prevention. Members of the unit 
participate in the following training and teaching activities: 
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• Two year training programme postgraduate training for applied epidemiology (PAE) with 
integrated Master of Science in Applied Epidemiology (MSAE) 
• Short courses for public health officials in Germany 
• Teaching in university courses for public health and epidemiology 
• Teaching at the German academies for specialisation of public health officials 
• Participation in international training activities (e.g. ECDC train the trainer courses) 
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3. Cooperation with other scientists or research institutions 
3.1. Internal (within RKI) 
PAE fellows conduct their scientific projects under supervision from scientists in the units 32 to 37 
at the department for infectious disease epidemiology, projects are also conducted in cooperation 
with various units in the RKI department 1, 2 and ZBS. 
PAE/EPIET also closely cooperates with the fellows and supervisors of the European Programme 
for Public Health Microbiology Training (EUPHEM) based at ZBS and RKI department 1. An actual 
example is the project “A systematic overview of laboratory diagnosis of paediatric tuberculosis in 
the European Union”.This international study is conducted within the framework of the EUPHEM 
programme and under the supervision of the Department for Infectious Disease Epidemiology. The 
aim of the study is to attain a systematic overview of the range of diagnostic tests and their success 
in different specimens used to diagnose active tuberculosis in children across European Union 
(EU) countries. Primary scientific partner and the main project site is the Health Protection Agency 
National Mycobacterium Reference Laboratory (HPA NMRL), London, UK. Routinely collected 
laboratory data (within the period of 2007-2011) on conventional and molecular laboratory tests 
used in children are analysed across several other partner sites: German National Mycobacterium 
Reference Laboratory; Lithuanian National Tuberculosis Reference Laboratory; Latvian National 
Tuberculosis Reference Laboratory, Croatian National Reference Laboratory. Additionally 22 
national tuberculosis reference laboratories in the EU took part in a complementary survey aiming 
to identify the commonalities and differences between the countries in the workload related to 
paediatric specimens, types of specimens obtained from children and diagnostic methods applied.  
3.2.  External / National 
Since 2006, a proportion of each cohort of PAE-fellows is placed at some selected public health 
offices of the Federal States. Scientists from these institutions are involved in the design and 
supervision of their projects and contribute to the network of trainers. 
Since 2009 in collaboration with the Berlin school of Public Health (BSPH) and the Charité Medical 
University in Berlin a Master of Science degree in Applied Epidemiology (MSAE) has been 
integrated in the PAE-programme. The study regulations have been published in the “Amtliches 
Mitteilungsblatt” Nr. 055 dated 16.11.2009 
(www.charite.de/charite/presse/publikationen/amtliche_mitteilungsblaetter/?no_cache=1&cid=313
53&did=23136&sechash=98f7bcf7) 
Katharina Alpers is member of EPIET Alumni network (EAN) 
3.3.  External / International 
As an EPIET associated programme the PAE is part of this important EU training network and 
regularly contributes to the organisation and further development of theoretical and practical 
aspects of the programme (Krause G et al., Euro Surveill 2009). 
PAE is also member of the Training Programmes in Epidemiology and Public Health Interventions 
NETwork (TEPHINET) which was founded in 1997 and aims to improve networking between the 
FETP in different countries (www.tephinet.org). Today 56 FETP world-wide are officially members of 
TEPHINET.  
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4.  Appendix 
4.1 Overview on achievements of the unit, 2009-2012 
4.1.1.  Scientific publications, 2009 – 2012 
Number of peer-review publications co-authored by trainings programmes: 86 





Cumulative 2009-12: 366.5 
A) Original research articles in peer-review journals 
2012 (until Sept.) 
Adlhoch C, Wadl M, Behnke M, Pena Diaz L A, Clausmeyer J, Eckmanns T: Pandemic influenza 
A(H1)pdm09 in hospitals and intensive care units - results from a new hospital surveillance, 
Germany 2009/2010. Influenza Other Respi Viruses 2012; 6(6):e162-e168 
Adlhoch C, Hoehne M, Littmann M, Mas Marques A, Lerche A, Dehnert M, Eckmanns T, 
Wichmann O, Koch J. Rotavirus Vaccine Effectiveness and Case-Contol Study on Risk Factors for 
Breakthrough Infections in Germany, 2010-2011. Pediatr Infect Dis J 2012,  
Altmann M, Fiebig L, Buda S, von Kries R, Dehnert M, and Haas W: Unchanged severity of 
Influenza a(H1n1)Pdm09 infection in children during first postpandemic season. Emerg Infect Dis 
2012; 18:1755-1762. 
Altmann M, an der Heiden M., Scheufele R., Hartmann K., Houareau C., Bartmeyer B., Hamouda 
O., for the German HIV-1 Seroconverter Cohort. The risk of AIDS-defining events is decreasing over 
time in the German HIV-1 Seroconverter Cohort. BMC Infect Dis 2012, 12:94. 
Askar M, Mohr O, Eckmanns T, Krause G, Poggensee G: Quantitative assessment of passenger 
flows in Europe and its implications for tracing contacts of infectious passengers. Euro Surveill 
2012; 17:pii=20195 
Dehnert M, Fingerle V, Klier C, Talaska T, Schlaud M, Krause G, Wilking H, Poggensee G: 
Seropositivity of Lyme borreliosis and associated risk factors: a population-based study in children 
and adolescents in Germany (Kiggs). PLoS One 2012; 7:e41321. 
Ducomble T, Wilking H, Stark K, Takla A, Askar M, Schaade L, Nitsche A, Kurth A: Lack of 
evidence for Schmallenberg virus infection in highly exposed persons, Germany, 2012. Emerg Infect 
Dis 2012, 18(8):1333-1335. 
Geis S, Prifert C, Weissbrich B, Lehners N, Egerer G, Eisenbach C, Buchholz U, Aichinger E, Dreger 
P, Neben K, Burkhardt U, Ho AD, Krausslich HG, Heeg K, Schnitzler P. Molecular characterization 
of a respiratory syncytial virus (RSV) outbreak in a hematology unit, Heidelberg, Germany. J Clin 
Microbiol. 2012.  
Hellenbrand W, Elias J, Wichmann O, Dehnert M, Frosch M, Vogel U: Epidemiology of Invasive 
Meningococcal Disease in Germany, 2002-2010, and Impact of Vaccination with Meningococcal C 
Conjugate Vaccine, J Infect (2012). 
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Rosner B, Buchholz U, Stark K, Krause G, HUS Investigation Team. Epidemic profile of 
Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Eng J Med 2011; 
365(19): 1771-80. 
2. Poggensee G, Gilsdorf A, Buda S, Eckmanns T, Claus H, Altmann D; RKI Working Group 
Pandemic Influenza, Krause G, Haas W . The first wave of pandemic influenza (H1N1) 
2009 in Germany: from initiation to acceleration. BMC Infect Dis 2010, 10:155. 
3. Williams CJ, Schweiger B, Diner G, Gerlach F, Haaman F, Krause G, Nienhaus A, 
Buchholz. Seasonal influenza risk in hospital healthcare workers is more strongly 
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associated with household than occupational exposures: results from a prospective cohort 
study in Berlin, Germany, 2006/07. BMC Infect Dis 2010, 10 (1): 8.  
4. Williams CJ, Schenkel K, Eckmanns T, Altmann D, Krause G. FIFA World Cup 2006 in 
Germany: Enhanced surveillance improved timeless and detection. Epidemiol Infect 2009, 
139 (4): 597-605. 
5. Krause G, Aavitsland P, Alpers K, Barrasa A, Bremer V, Helynck B, Perra A. Differences and 
Commonalities of National Field Epidemiology Training Programmes in Europe. Euro 
Surveill 2009;14(43) 
Five important publications for the public 2009–2012 
1. Studienordnungen Weiterbildender Masterstudiengang „Applied Epidemiology“ der Charite 
- Universitätsmedizin Berlin, Amtliches Mitteilungsblatte der Charité Nr.55, vom 16.11.2009  
4.1.3. Overview on collaborations in networks 
• EPIET Scientific Coordination Team 
• EPIET Training Site Forum 
• TEPHINET (Training Programs in Epidemiology and Public Health Interventions Network)  
4.1.4. Memberships and participation in Advisory Boards 
Dr. Katharina Alpers 
• Participation in TEPHINET Board (representative for the European Region) 
4.1.5. List of completed dissertation or master theses in the unit, 2009 – 2012 




Statistical modelling of dynamic 
systems for infectious disease 
epidemiology 
F. Weidemann Dr. rer. 
nat.  
PD Dr. M. Höhle (RKI),  
Dr. M. Dehnert (RKI) 
2012 Beispiele für das Public Health 
Management von Infektions-
krankheiten bei gefährdeten 
Personengruppen durch lokale, 
nationale und internationale 
Gesundheitsbehörden 
E. Aichinger M.Sc. Dr. K. Alpers (RKI), Dr. 
G. Pfaff (Ffederal Health 
Authority Baden-
Wuerttemberg) 
2012 Die Identifizierung von Risiko-




M. Askar M.Sc. Prof. K. Stark (RKI), Dr. 
Bettina Rosner (RKI) 
2012 Das Landesgesundheitsamt als 
Schnittstelle zwischen Gesund-
heitsämtern und Robert Koch 
Institute im öffentlichen 
Gesundheitsdienst in Deutsch-
land. Ausgewählte Aufgaben des 
niedersächsischen Landesgesund-
heitsamt (NLGA) am Beispiel von 
wissenschaftlichen Studien im 
Bereich der angewandten 
Epidemiologie 
M. Diercke M.Sc. Prof. G. Krause (RKI), Dr. 
J. Dreesmann (Federal 
Health Authority Lower 
Saxony) 
2012 Importance of data quality for 
surveillance, outbreak detection 
and epidemiological studies 
- a regional perspective on the 
H. Englund M.Sc. Dr. I. Karagiannis (RKI), 
Dr. Wolfgang Hautmann 
(Federal Health Authority 
Bavaria) 
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German surveillance system for 
infectious diseases 
2012 Challenges in surveillance and 
importance of laboratory 
collaboration in intervention 
epidemiology - examples of 
tuberculosis, rubella, measles and 
EHEC 
S. Lassen M.Sc. Dr. I. Karagiannis (RKI), 
Dr. B. Hauer (RKI) 
2012 Die Bedeutung von Prävention und 
früher Intervention bei impfpräven-
tablen Erkrankungen – am Beispiel 
von Projekten zu Mumps und 
Masern (The importance of 
prevention and early intervention 
in vaccine preventable diseases – 
projects on mumps and measles) 
A. Takla M.Sc. K. Tolksdorf (RKI), Dr. J. 
Koch (RKI) 
2011 Das Erkennen, Bekämpfen und 
Verhüten von Infektions-
krankheiten 
C. Adlhoch M.Sc. Prof. Dr. G. Krause (RKI), 
Dr. T. Eckmanns (RKI) 
2011 Identifying risk factors and 
formulating public health 
recommendations using 
surveillance data 
A. Altmann M.Sc. Dr. I. Karagiannis (RKI),  
Dr. O. Hamouda (RKI) 
2011 Analysis and interpretation of 
surveillance and research data - 
four examples how to address 
public health relevant questions 
S. Dudareva M. Sc. Dr. I. Karagiannis (RKI), 
Dr. C. Frank (RKI) 
2011 Pandemische Influenza und 
Gastroenteritis-Ausbrüche – 
epidemiologische Studien im 
Rahmen des Masterstudiengangs 
„Applied Epidemiology“ (MSAE) 
der Charité - Universitätsmedizin 
Berlin 
B. Greutélaers M. Sc. Dr. I. Karagiannis (RKI), 
Dr. Anette Siedler (RKI) 
2011 Angewandte Infektions-
epidemiologie - Prospektive 
Erfassung der Influenza-Inzidenz 
in einer sensitiven Subpopulation 
und Auswertung von Routinedaten 
des öffentlichen Gesundheits-
dienstes 
E. Mertens M.Sc. Dr. K. Alpers (RKI), 
Florian Burckhardt 
(Federal Health Authority 
Rhineland-Palatinate) 
2011 Infektionsepidemiologische 
Synopsis aus den Erfahrungen mit 
SARI-Surveillance in Berlin, STI-
Surveillance in vier europäischen 
Ländern, einem MRSA-Ausbruch 
sowie einer Meningokokken-
Zeitreihenanalyse 
M. Nachtnebel M.Sc. Dr. M. Dehnert (RKI), Dr. 
Sabine Reiter (RKI) 
2011 Angewandte Infektionsepide-
miologie - Praktische Datener-
hebung und -analyse sowie public 
value ausgewählter Infektions-
geschehen als Baustein des 
Infektionsschutzes in Deutschland 
P. Stöcker M.Sc. Dr. M. Dehnert (RKI), Dr. 
Y. Déleré (RKI) 
2011 Analyse und Interpretation von 
Surveillance-Daten – Drei Beispiele 
zur Erkennung von Risikofaktoren 
und der Formulierung von Public-
H. Wilking M.Sc. Prof. K. Stark (RKI), Dr. T. 
Eckmanns (RKI) 
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Health-Empfehlungen 




M.Sc. Dr. K. Alpers (RKI), Dr. 
Wolfgang Hautmann 
(Federal Health Authority 
Bavaria) 
2010 Mathematische Modellierung der 
Auswirkung von Impfungen auf die 
Dynamik des Rotavirus 
S. Werner Dipl. 
Math. 
PD Dr. G. Jetschke 
(Friedrich-Schiller-
Universität Jena) / Dr. M. 
Dehnert (RKI) 
     
4.1.6. Presentations as invited speaker, 2009 – 2012 
Staff from the Unit PAE were invited to speak at 7 conferences. 
4.1.7. Reports and written scientific advice to the Ministry of Health, 2009-2012 
There were 3 reports and written scientific advice to the Ministry of Health between 2009 and 
30.09.2012. 
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1. General information - Unit 31 
Head:  Dr. Hermann Claus 
Deputy:  Dr. Göran Kirchner 
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2. Tasks and goals of the unit 
2.1. Summary  
The Data Management unit is responsible for design, development and management of IT-
projects within the Department for Infectious Disease Epidemiology at RKI and moreover provides 
scientific services and consultancies for other units at RKI as well as external partners and in the 
general public. The main project is the national reporting system for surveillance of notifiable 
infectious diseases (SurvNet@RKI) according to the infection protection act (IfSG). In the field of 
surveillance applications the most notables are those for Influenza (‘Arbeitsgemeinschaft 
Influenza’ -AGI), sexual transmitted diseases (in particular HIV) and antibiotic resistance. Other 
applications are laboratory information management programs for laboratories at RKI. Additionally 
there are a lot of smaller projects.  
All these projects include the joint conceptual design with experts and potential users as well as 
the development of all required IT components (databases, Windows applications, Web 
applications). Furthermore the unit does the whole management and technical support, allocation 
of required tools to analyse the data, and the creation of official data for publishing. This includes 
the statistical analysis for users at RKI and external users (see 3.2., Unit 31). The aim is to use 
automated solutions for all data processing steps (routine import/export of data files and regular 
reports). 
During the reporting period the unit realised a project on epidemiologic modelling of infectious 
diseases and co-initiated an EU-funded project to use natural language processing and other data 
mining methods to make web 2.0 contents usable for public health topics. 
2.2. Current status of the work and summary of relevant results 
2.2.1. National Reporting System for surveillance of notifiable infectious diseases 
Since 2001, Germany has an electronic reporting system for communicable diseases. Cases are 
notified by medical practitioners, hospitals and laboratories via fax, mail or telephone to the local 
health authorities, where they are assessed and then electronically reported via the regional to the 
national level. Since then many local health departments and all regional ones use a tool developed 
by Unit 31 for data collection and analysis (SurvNet@RKI). 
A complete redesign of this software for data collection and transport of case reports from local 
health departments via state health departments to RKI was done and SurvNet@RKI was rolled out 
during the reporting period. Besides RKI and all 16 state health departments over 100 of about 400 
local health departments in Germany and the German armed forces use this software. Various 
training courses for the software SurvNet@RKI were hold (see. 2.6., Unit 31). 
To publish the data the unit operates the web application SurvStat@RKI (http://www3.survstat.de). 
Moreover, the notification data are also periodically published in several other formats, such as 
weekly in ‘Epidemiologisches Bulletin’, yearly in ‘Infektionsepidemiologisches Jahrbuch’, report on 
tuberculosis, and map of risk areas for tick-borne encephalitis, reports to ECDC according the 
TESSy-system, to the Federal Statistical Office, and to health reporting of the states.  
Using a special service-tool the unit 31 supports the external users with installation and 
configuration of the software. Definitions used in the software are provided to other software 
producers working on the same subject. So these companies can integrate a SurvNet@RKI 
compatible module into their products. The unit develops and applies several small applications 
and tools for running the reporting system and integration of additionally data. 
2.2.2.  Deutsches Elektronisches Meldesystems für Infektionsschutz (DEMIS) 
After the pandemic 2009 and the HUS/EHEC outbreak 2011, an assessment is underway, to advice 
whether the German system for communicable diseases can be improved by introducing an 
electronic notification, in order to reduce delays and enhance data quality.  
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Part of this process is the development of secure and trustworthy infrastructure which can be used 
by medical practitioners, hospitals, laboratories as well as schools, kindergartens and residential 
care homes for the elderly, to seamlessly integrate their systems into an electronic one. The 
main goal is to avoid media interruptions as far as possible and allow a flexible adaption of 
contents and distribution paths to be well prepared for future challenges. 
Modern instruments of sharing information will be used, e.g. apps, interactive data mining tools, 
personalised information etc. Many of the recommended changes would require a variation of the 
classical notification cascade from local over regional to national public health authorities. The 
suggested functionalities will be considered in the revision of the German notification system for 
communicable diseases. The role of unit 31 in this process is to contribute their experience in 
requirements engineering, technology and process knowledge and software architectural skills. 
2.2.3. Working Group on Infectious Disease Control (AGI) 
All existing applications for the surveillance of influenza and other respiratory diseases (since 
2002) have been new designed and developed in the reporting period. During this process former 
tasks of ‘Deutsches Grünes Kreuz’ where adopted. For example the following projects were 
implemented: Digitalisation of fax reports (with commercial software ‘Teleform’) and data 
migration of the AGI file, migration of SEED-ARE data (automated import of attached files in email 
massages), migration of laboratory data from the national reference centre of influenza (unit 12 
RKI) and some states, data presentation inclusively graphs and maps on RKI website 
(http://influenza.rki.de) with the opportunity to recall personal data for participating physicians, 
and a variety of tools for data analysis in RKI. Furthermore unit 31 supports unit 36 within the 
projects ‘Shedding’ and ‘GrippeWeb’ (https://grippeweb.rki.de/).  
2.2.4. Projects for unit 34 (unit responsible for sexually transmitted diseases) 
A new application for data collection according §7.3 IfSG (particularly HIV and syphilis) was 
designed. The aim of this application which is still under development is to simplify the data entry 
explicitly (yearly ca. 6000 reports each) as well as to structure the complex evaluation and analysis 
of the data. Another project (‘ClinSurv’) is also still in development; it is a system for physicians to 
report important information on HIV surveillance of their patients to RKI. Within another project, 
supported by the ministry of health (‘applications with additional benefit of the electronic health 
insurance card’) a special technique of electronic data transfer was designed. This technique was 
adapted to the project ‘Chlamydia-Sentinel’ and is already used by some laboratories to transmit 
data to RKI automatically. Furthermore a complex interface was developed to use the 
epidemiological HIV-database of unit 34 and the laboratory database of unit 18 for data exchange in 
joint projects. 
2.2.5. Applications for laboratories within the RKI 
Since 1996 laboratories at RKI have been supported by special laboratory information systems. 
Most of the currently used systems were developed and are supported by unit 31. Because of the 
very specific tasks of the laboratories this in-house-solution is well-proven. There are applications in 
unit 11, unit 12, unit 13, unit 15, unit 16, unit 17, and unit 18. In the reporting period unit 31 works on 
the following subjects: required extensions for accreditation of the laboratories were embedded, an 
interface to web services of Stanford-University to evaluate resistance of HIV-gene sequences 
automatically was established, and a tool to transmit diagnostic findings and reports was 
implemented. Unit3 1 realises currently adaption of the applications because of frequently changing 
workflows and tasks in the laboratories. To support the activities in the laboratories interfaces to 
commercial software products like ‘GelCompar’ were established, and data exports to cooperation 
partners like WHO were realised. 
2.2.6. Antibiotic resistance 
The basic activities of the IT-projects in this field are done by a member of unit 32 staff. Unit 31 
gives support if it is needed. Detailed information on the project can be found in the report of unit 
32. This applies to the administration of the sentinel data from the National Association of 
Statutory Health Insurance Physicians too. Within these projects data-mining techniques were used 
for the first time. 
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2.2.7. Mathematical modelling 
The project ‘Modelling of the spread of infectious diseases’ was funded by the Federal Ministry 
of Health and finished in June 2009. Within this project a mathematical model was developed that 
simulates the spatial spread of an infectious disease like influenza in Germany. The model allowed 
simulations stratified by county, age, and risk groups. It is a common SEIR-model based on 
ordinary differential equations and implemented in ‘MatLab’. Several strategies of prevention like 
Immunisation, the use of antiviral drugs, and contact reduction by restraint of public transport or 
closing schools can be considered. Disease-specific parameters as well as information like 
population size, contact behaviour, and dynamic data were used in the model. In 2009 the model 
was used to find recommendations for optimal Immunisation strategies against pandemic 
influenza. 
Figure 5: Spread of influenza in Germany according to SEIR model at days 100, 130, and 160 of an example 
epidemic 
 
2.2.8. M-Eco – Using Web 2.0 resources for event detection 
Unit 31 realised a substantial part in the architectural design and management of data and dataflow 
within the EU-funded project ‘M-Eco’ (http://www.meco-project.eu). These results can be used to 
supplement the data of notifiable infectious diseases with data from the Web. An early warning 
system for potential disease outbreaks that uses information from media and social networks 
was prototyped and evaluated regarding the quality, timeliness, usability and usefulness. Many new 
insights in the handling of unstructured text through natural language technologies (computational 
linguistics) were gained. 
2.2.9. Other projects 
Unit 31 developed a special application to support the study group varicella (AGV) which contains 
the opportunity to adopt the data administration from German green cross. 
With the transfer of the project enterovirus-surveillance from NLGA Hannover (Governmental 
Institute of Public Health of Lower Saxony) to unit 15 at RKI unit 31 takes care about data 
management of the project. A new application for collecting and processing the data and a website 
to publish these data was developed. 
Unit 31 offers a special ‘zip-code-tool’ (http://tools.rki.de/plztool) to support the reporting system 
of notifiable infectious diseases, currently with maintenance of the underlying data. 
A special concept for data encryption was developed to secure confidentiality in the human 
resources management system at RKI. The implementation can start when the organisational 
requirements will be established. The invented methods can be used for other project with need to 
secure confidentiality like data transport via internet. 
In several projects run in unit 31 we use special data from other firms (like ‘Insight Health’), to use 
these information special preparation of the data is necessary.  
Another task is the administration of web- and database servers and the IT support within 
Department for Infectious Disease Epidemiology. 
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2.3. Major goals and contribution to the goals of the department  
The Data Management Unit is responsible for national reporting system for surveillance of 
notifiable infectious diseases (SurvNet@RKI) according to the infection protection act (IfSG). It is 
also responsible for the design, development and management of IT-projects within the 
Department. All details are listed in the chapter 2.2. 
2.4. Additional work and methods for investigations 
One main emphasis of unit 31 is the maintenance of applications for on-going projects, the 
adaption to new software methodologies, and to open up new technologies. During the reporting 
period the development platform for several projects has changed from Microsoft-Access to 
C#.Net (C#, XAML) under Visual-Studio (Microsoft) together with MS SQL Server technologies. 
We introduced Team-Foundation-Server (Microsoft) for project management and collaboration. 
The functionalities developed are made available through web services for reuse. Many processes 
were automatized. XSL-transformations are used to process huge amount of XML-formatted data. 
The Analysis Services component of MS SQL Server is becoming the standard tool to analyse large 
amounts of data efficiently. In particular, using these technologies (Online Analytical Processing 
(OLAP)) for data mining and multidimensional data processing, the unit can support the users 
of all current projects by providing means to handle the data fast and easily even if the analysis is 
very complex. This requires an improved storage of master data to ensure the integrity of 
information and consistency of data across different applications. First steps in this direction have 
already been taken by using MS SQL Master Data Services. 
2.5. Scientific advice and consulting services 
Unit 31 provides support in generating special data files and statistical analysis for scientific 
projects within the Department for Infectious Disease Epidemiology. One important area of 
investigation is the improvement of outbreak detection algorithms. In joint work with other units 
of the department these algorithms were implemented and are subject to continuous further 
development. 
As already mentioned above the field of data mining is the most active area of research. Nearly all 
the above mentioned projects either already have implemented or will implement new tools for the 
profound analysis of the vast amount of data collected within the department.  
The knowledge gained during the modelling project provides the unit with elaborated means to 
understand the spread of diseases and to test conjectures for interventions thereof. Further 
improvements are expected through the collaboration with the newly established professorship of 
mathematical modelling at RKI, especially in the field of complex networks. 
Part of the services developed within M-eco project mentioned above will be continued to improve 
the capabilities in text mining and to extend the resources to build epidemiologic knowledge 
through the assessment of raw and unstructured text. Here the field of natural language 
processing is touched. 
A minor but still important area is the development of domain specific languages (DSL) to 
describe and conserve ideas, concepts and models within the domain of epidemiology. First steps 
were done during the redesign of SurvNet@RKI to generate (and thereby to automate the build) a 
good portion of the system. Further work will bridge the gap from special queries to completely 
free-form input. The long-term goal is to make epidemiologic knowledge computable and 
accessible. 
Many of the above mentioned technologies are not developed separately. It is especially their 
interaction and skilful orchestration which helps to reduce the complexity of problems and to 
improve the knowledge acquired. 
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 2.6. Training and teaching activities 
• For the software SurvNet@RKI thirty training courses for staff members at local and state 
health departments were hold. Additional there were in-house-courses for the Department for 
Infectious Disease Epidemiology at RKI.  
• Since 2005 in each year one or two apprentices started their 3-year apprenticeship as 
Computer Specialist for Applications Development (‘Fachinformatiker für 
Anwendungsentwicklung’) in unit 31. Five of them successfully completed their training and 
two more will finish it in 2013. Two of them gained a permanent position at RKI. 
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3. Cooperation with other scientists or research institutions 
3.1. Internal (within RKI) 
Data-driven applications developed and managed in Unit 31: 
• AGI - Unit 36 
• AGV - Unit 33 
• BSD (Data management solution for blood donor data) - Unit 34 
• Cdiff (Data management solution for C. difficile lab) - Unit 13 
• EARSS (Data management solution for hospital-based data of the antimicrobial resistance 
project) - Unit 32 
• Entero (Data management solution for Enterococcus lab) - Unit 11 
• EVSurv (Data management solution for Enterovirus surveillance project) - Unit 15 
• EVSurvWeb (Web site for Enterovirus surveillance project) - Unit 15 
• FSME (Data management solution for FSME-virus lab) - ZBS1 
• Gastro (Data management solution for for Noro- and Rotavirus lab) - Unit 15 
• Giardia (Data management solution for Gardia lab) - Unit 16 
• GrippeWeb (Webapplication and data management for GrippeWeb-project) - Unit 36 
• HCV (Data management solution for HCV lab) - Unit 15 
• HIV (Data management solution for HIV lab) - Unit 18 
• HIVInzidenz (Data management solution for HIV-incidence project) - Unit 34 
• HIVReg (Data management solution for ClinSurv-project) - Unit 34 
• Influenza (Data management solution for Influenza lab) - Unit 12 
• MaMuRoe (Data management solution for Measles Mumps Rubella lab) - Unit 12 
• MortSurv (Data management solution for mortality surveillance project) - Unit 32 
• Myko (Data management solution for mycology lab) - Unit 16 
• Pneumo (Data management solution for Pneumococcus surveillance) - Unit 33 
• Polio (Data management solution for Polio- and Enterovirus lab) - Unit 15 
• Problag (Management application for specimen storage) - Dept. 1, ZBS 
• Salmo (Data management solution for Salmonella lab) - Unit 13 
• Shedding (Data management solution for the shedding project) - Unit 36 
• SpezErreger (Data management solution for biohazardious agents) - ZBS1 
• SurvNet@RKI (Reporting system for infectious diseases) - Dept. 3 
• STD (Data management solution for sexually transmitted diseases project) - Unit 34 
• WNV (Data management solution for West Nile virus lab) - ZBS1 
• Ticks (Data management solution for viral tick-borne diseases lab) - ZBS1 
3.2. External / National 
• SurvNet@RKI 
• Local and state health departments 
• Bundeswehr 
• Software vendors (easysoft GmbH Dresden, Computerzentrum Strausberg GmbH, 
software.house informationstechnik AG Kiel, mikroprojekt GmbH Kaiserslautern, UniSoft 
Gesellschaft für Software Engineering mbH Roth) 
3.3. External / International 
• ECDC Stockholm - TESSy 
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4. Appendix 
4.1 Overview on achievements of the unit, 2009-2012 
4.1.1. Scientific publications, 2009 – 2012 
Number of peer-review publications co-authored by members of the unit: 21 
Impact factor (IF) according to JCR (of 2012 publications: according to 2011 IF) 
2009:  13.9 
2010:  8.5 
2011:  26.7 
2012:  2.8 
Cumulative 2009-2012: 51.9 
A) Original research articles in peer-review journals 
2011 
Altmann M, Wadl M, Altmann D, Benzler J, Eckmanns T, Krause G, Spode A, an der Heiden M: 
Timeliness of Surveillance during Outbreak of Shiga Toxin–producing Escherichia coli Infection, 
Germany, 2011 Emerg Infect Dis 2011; 17(10):1906-1909. 
Denecke K, Kirchner G, Dolog P, Smrz P, Linge J, Backfried G, Dreesman J: Event-driven 
Architecture for Health Event Detection from Multiple Sources. In: Proceedings of the XXIII 
International Conference of the European Federation for Medical Informatics (MIE 2011), 28-
31.August, 2011, Oslo, Norway. 
Hauri AM, Westbrock HJ, Claus H, Geis S, Giernat S, Forßbohm M, Uphoff H: Electronic outbreak 
surveillance in Germany: A first evaluation for nosocomial norovirus outbreaks PLoS One  2011 
Mette A, Reuss A, Feig M, Kappelmayer L, Siedler A, Eckmanns T, Poggensee G: Under-reporting of 
measles - An evaluation based on data from North Rhine-Westphalia, [Untererfassung von Masern 
- Eine Evaluation basierend auf Daten aus Nordrhein-Westfalen]. Dtsch Ärztebl 2011 
Uphoff H, an der Heiden M, Schweiger B, Campe H, Beier D, Helmeke C, Littmann M, Haas W, 
Buda S, Faensen D, Feig M, Altmann D, Wichmann O, Eckmanns T, Buchholz U: Effectiveness of 
the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 - A Comparison of 
Two Methods; Germany, 2009/10. PLoS One 2011; 6(7):1-9. 
Wadl M, Rieck T, Nachtnebel M, Greutélaers B, an der Heiden M, Altmann D, Hellenbrand W, 
Faber M, Frank C, Schweickert B, Krause G, Benzler J, Eckmanns T: Enhanced surveillance during a 
large outbreak of bloody diarrhoea and haemolytic uraemic syndrome caused by Shiga 
toxin/verotoxin-producing Escherichia coli in Germany, May to June 2011 Euro Surveill 2011; 
16(24):1-5. 
2010 
Buchholz U, Brockmann S, Duwe S, Schweiger B, an der Heiden M, Reinhardt B, Buda S: 
Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza 
a(H1N1) viruses, Germany, 2007-8. Euro Surveill 2010 
Poggensee G, Gilsdorf A, Buda S, Eckmanns T, Claus H, Altmann D, Krause G, Haas W: The first 
wave of pandemic influenza (H1N1) 2009 in Germany: From initiation to acceleration BMC Infect 
Dis 2010; 10(155): 1-12. 
Reuss A, Feig M, Kappelmayer L, Eckmanns T, Poggensee G: Determination of vaccination 
coverage and disease incidence using statutory health insurance data , [Bestimmung von 
Impfquoten und Inzidenzen von Erkrankungen anhand von Daten der kassenärztlichen 
Vereinigungen] Gesundheitswesen 2010 
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Reuss AM, Feig M, Kappelmayer L, Siedler A, Eckmanns T:, Poggensee G: Varicella vaccination 
coverage of children under two years of age in Germany. BMC Public Health 2010; 10:502. 
Reuss AM, Walter D, Feig M, Kappelmayer L, Buchholz U, Eckmanns T, Poggensee G: Influenza 
vaccination coverage in the 2004/05, 2005/06, and 2006/07 seasons: A secondary data analysis 
based on billing data of the German associations of statutory health insurance physicians, 
[Influenzaimpfquoten der Saisons 2004/05, 2005/06 und 2006/07: Eine Sekundärdatenanalyse 
von Abrechnungsdaten der kassenärztlichen Vereinigungen]. Dtsch Ärztebl 2010 
Spackova M, Altmann D, Eckmanns,T, Koch J, Krause G: High Level of Gastrointestinal 
Nosocomial Infections in the German Surveillance System, 2002–2008. Infect Control Hosp 
Epidemiol 2010; 31 (12): 1273-1278. 
Wichmann O, Stöcker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, 
Eckmanns T: Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine 
effectiveness in Germany 2009-2010 Euro Surveill 2010; 15(18):1-4 
Wilking H., Buda S., von der Lippe E., Altmann D., Krause G., Eckmanns T., Haas W. Mortality of 
2009 pandemic influenza A(H1N1) in Germany Euro Surveill 2010; 15(49): 
2009 
Alpers K, Altmann D, an der Heiden M, Bartels C, Bätzing-Feigenbaum J, Becker A, Behnke S, 
Bergholz A, Bernard H, Bielecke J, Biere B, Böhmer M: Description of the early stage of pandemic 
(H1N1) 2009 in Germany, 27 April-16 June 2009 Euro Surveill 2009; 14(31). 
an der Heiden M, Buchholz U, Krause G, Kirchner G, Claus H, Haas W: Breaking the waves: 
Modelling the potential impact of public health measures to defer the epidemic peak of novel 
influenza A/H1N1. PLoS One  2009; 4(12):e8356. 
Cuny C, Nathaus R, Layer F, Strommenger B, Witte W, Altmann D: Nasal Colonization of Humans 
with Methicillin-Resistant Staphylococcus aureus (MRSA) CC398 with and without Exposure to Pigs 
PLoS One 2009; 4(8): :e6800. 
Dettmann M , Poggensee G, Buda S, Claus H, Krause G: Demographic characteristics of influenza 
A (H1N1) cases in Germany: From April to the end of August 2009. MMW Fortschr Med 2009; 
151(40):35-37. 
Reuss AM, Wiese-Posselt M, Weißmann B, Siedler A, Zuschneid I, an Der Heiden M, Claus H, von 
Kries R, Haas WH: Incidence rate of nontuberculous mycobacterial disease in immunocompetent 
children a prospective nationwide surveillance study in Germany Pediatr Infect Dis J 2009; 
28(7):642-644. 
Ritter S, Willand L, Reinhardt B, Hamouda O: Blutspenderpopulationen in Deutschland: 
Demographie und Spendeaktivität – Ergänzung zum Bericht des Robert Koch Institutes zu den 
Meldungen nach § 22 Transfusionsgesetz. Bundesgesundheitsbl-Gesundheitsforsch-
Gesundheitsschutz 2009;  
Williams C J, Schenkel K, Eckmanns T, Altmann D, Krause G: FIFA World Cup 2006 in Germany: 
enhanced surveillance improved timeliness and detection Epidem Infect 2009; 137: 597-605. 
4.1.2. List of reports and written scientific advice to the Ministry of Health, 2009-
09/2012 




Evaluation Report (Public Version) Unit 32: Surveillance 
63 
Unit 32: Surveillance 




1. General information - Unit 32 ..................................................................................................... 63 
2.  Tasks and goals of the unit .......................................................................................................... 64 
2.1.  Summary ................................................................................................................................ 64 
2.2.  Current status of the work and summary of relevant results ............................................... 64 
2.3.  Major goals and contribution to the goals of the department .............................................. 71 
2.4.  Additional work and methods for investigations .................................................................. 72 
2.5. Scientific advice and consulting services ............................................................................... 72 
2.6 Training and teaching activities ............................................................................................. 73 
3.  Cooperation with other scientists or research institutions ........................................................ 74 
3.1. Internal (within RKI) ............................................................................................................... 74 
3.2. External / National ..................................................................................................................... 74 
3.3.  External / International .......................................................................................................... 74 
4. Appendix ..................................................................................................................................... 75 





1. General information - Unit 32 
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2.  Tasks and goals of the Unit 
2.1.  Summary 
Unit 32 “Surveillance” was responsible for the infectious disease surveillance and co-ordinated the 
epidemiological and organisational aspects of the surveillance system within the framework of the 
Protection against Infection Act (IfSG). Since 2006 the unit was responsible for the surveillance of 
antimicrobial resistance and antibiotic consumption. The unit was characterised by an 
interdisciplinary approach with expertise in social and infectious disease epidemiology, veterinary 
medicine, information technology, medicine, microbiology, virology, infection control, and hospital 
epidemiology. The following description of the unit refers to the period till Sept 2012, before the 
reorganisation described in 2.3.1. and 2.3.3, AL3. 
2.2.  Current status of the work and summary of relevant results 
The character of the unit was generic. The unit supported the other more disease specific units in 
general questions of surveillance and international reporting. Important goals were improvement 
of early warning and early detection of outbreaks, as well as the development, implementation and 
evaluation of new surveillance systems especially during extraordinary events like mass gathering 
and severe epidemics (Takla A et al., BMC Public Health 2012, Adlhoch C et al. Influenza Other 
Respi Viruses 2012, Wadl M et al., Euro Surveill 2011, Williams C et al., Epidemiol Infect 2009). 
Also international reporting with a special focus in investigating the need for contact tracing (Mohr 
O et al., Euro Surveill 2012, Askar M et al., Euro Surveill 2012, Leitmeyer K, Euro Surveill 2011), 
close cooperation with public health authorities on the one side and hospitals and ambulatory 
medicine on the other side, and continuously improving surveillance of healthcare associated 
infections/outbreaks, antimicrobial resistance (Schweickert et al., Eur J Clin Microbiol Infect Dis 
2012), and antibiotic consumption were further important goals. Surveillance of antimicrobial 
resistance and antibiotic consumption was a new area and was for the first time dealt with in a 
wider range in the department.  
The main tasks are 
• Continuous epidemiological analysis of notifiable diseases and entities/events in the 
framework of the IfSG 
• Quality management of surveillance data  
• Development of case definitions  
• Development of recommendations on procedures for the surveillance of infectious 
diseases and events 
• Early detection of epidemics and communicable diseases with the potential of threatening 
public health  
• Development and implementation of the antibiotic resistance surveillance system (ARS), 
including an early warning system as a tool for data quality check for participating 
laboratories  
• Development of a surveillance system for antibiotic consumption 
• Development, implementation and evaluation of novel surveillance methods especially 
during extraordinary events 
• Coordination of a working group comprised of health departments from government and 
the federal states on surveillance (“Bund-Länder-Arbeitsgruppe”)and the weekly 
epidemiological situation telephone conference “EpiLag” with federal states  
• Support for investigating healthcare associated outbreaks and severe outbreaks/epidemics  
• Implementation of targets of the German strategy to combat antibiotic resistance (DART)  
• Establishment of a centre for the prevention and control of antibiotic resistance  
• Hosting of the executive secretary of the German Committee on Antimicrobials Resistance 
and Therapy (ART)  
• Implementation of the International Health Regulation (IHR) 
Evaluation Report (Public Version) Unit 32: Surveillance 
65 
• Reporting to the ECDC, WHO and to European Networks 
Figure 6: Tasks of the Surveillance Unit 
 
  
(BLAG: Bund Länder Arbeitsgruppe Surveillance, DART: Deutsche Antibiotikaresistenz Strategie, 
ART: Antiinfektiva Resistenz und Therapie, EBPH: Evidence Based Public Health, M-Eco: Medical 
Ecosystem, EpilLag: epidemiologische Lagekonferenz, SBD: Surveillance Blutige Durchfälle, PIKS: 
Pandemische Influenza Krankenhaus Surveillance, REACT: Response to Emerging infectious 
disease: assessment and development of core Capacities and Tools, CDAD-KISS: Clostridium 
difficiel associated infection Krankenhausinfektionen Surveillancesystem, DEMIS: Deutsches 
Elektronisches Meldesystem für Infektionsschutz, KV: Kassenärztliche Vereinigung, IHR: 
International Health Regulation, EWRS: Early Warning and Response System, RAGIDA: risk 
assessment guidelines for infectious diseases transmitted on aircraft, AIRSAN: Coordinated action 
in the aviation sector to control public health threats (granted in 2012, starting 2013)) 
2.2.1. Surveillance  
The main task of the unit was surveillance with all the other tasks grouping around this subject 
(Figure 6). General tasks were quality management of surveillance of notifiable diseases and events 
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as imposed by the IfSG, continuous epidemiological analysis of the surveillance data, and further 
development of case definitions and criteria for transmission and interpretation. Additionally, 
recommendations on procedures for the surveillance of infectious diseases were prepared in 
cooperation with the disease specific units. From 2009 to 2012 18 informational briefs 
(“Infobriefe”) were developed and distributed to local health departments. In addition handling of § 
7 (3) notifications (malaria, connate toxoplasmosis and connate rubella, and Echinococci infection) 
was part of the tasks of the unit. These data as well as all other diseases to be notified are 
published weekly in the weekly epidemiological bulletin (Epid Bull), SurvStat@RKI (a public 
useable interactive program), and the annual report of infectious diseases (“Jahrbuch 
Infektionsepidemiologie”), the epidemiological part of these publications was always organised in 
the unit. The annual report is written by the whole department. The editorial responsibility is in the 
Surveillance Unit. The first part of the reports is an actual description with recent amendments of 
the IfSG further the reports included a part with general information for each notifiable disease 
(regional distribution, sex distribution, outbreaks, hospitalisation), followed by a more extensive 
and detailed information for each notifiable disease (short description, actual data, comparison to 
former data). 
2.2.2. Development of novel surveillance approaches and methods 
An important task of the unit was to develop new surveillance methods.  
One very important area in this field in event based surveillance (see 2.2.5., Unit 32). 
In cooperation with all 17 Associations of Statutory Health Insurance Physicians (KVen) in Germany 
(covering approximately 85% of the German population, i.e. 70 Million people) insurance refund 
claim data are transmitted to RKI and analysed continuously for the epidemiological assessment of 
vaccine preventable diseases and estimation of vaccination coverage. The project was initiated, 
implemented and evaluated in Unit 32 (Siedler A et al., Euro Surveill 2012, Reuss A et al., 
Gesundheitswesen 2010, Reuss A et al, BMC Public Health 2010, Reuss A et al., Dtsch Arztebl Int 
2010). In August 2012, it was transferred to the Immunisation Unit to be used as a routine tool for 
the monitoring of vaccination coverage especially in children before school entry and in 
adolescents.  
Together with the national reference centre for surveillance of nosocomial infections, a hospital 
based surveillance system for hospital acquired C. difficile infections was developed (CDAD KISS, 
now situated at the NRZ) (Gastmeier P et al., Int J Antimicrob Agents 2009).  
In the year the 2009 MRSA in bloodstream and liquor had become a pathogen to be notified. The 
unit developed together with unit 31 the reporting system (Schweickert B et al., Eur J Clin Microbiol 
Infect Dis 2012). 
The unit is responsible for the surveillance of healthcare associated outbreaks. Since August 2011 
health-care associated outbreaks are reported mandatory via the federal state public health 
authorities to the RKI. In the first year data were collected by faxed or e-mailed standardised 
questionnaires and line lists; currently an electronic version is developed together with unit 31 and 
will be fully implemented soon. For the first time systematic data of hospital acquired outbreaks are 
available. 
Further, a working group engaged in social epidemiology within the unit has since 2009 examined 
health disparities as increased risk of acquiring infections and accordingly has developed methods 
for the surveillance of socio-behavioural factors of infectious disease. The aim of one study was to 
describe in an ecological analysis the impact of different social factors on the risk of acquiring 
infectious diseases in an urban setting (Wilking H et al., Int J Health Geogr 2012). The specific 
outcome of interest was the spatial distribution of hospitalised patients with Rotavirus infections in 
Berlin, which are a leading cause of acute gastroenteritis among infants and also a burden in the 
elderly in Germany. A spatial Bayesian Poisson regression model was used for the statistical 
analysis of incidences at neighbourhood level in relation to socio-demographic variables. The 
results may help to generate more specific hypothesis for infectious disease transmission in this 
urban area. The field of social epidemiology should gain more importance, and closing the gap 
should be a prioritised goal. 
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2.2.3. Surveillance during severe epidemics and during mass gathering 
The development of surveillance systems in extraordinary situations is a challenge, and during 
epidemics the introduction of these systems must be very fast; even still, it must include the 
consideration of needs and expenditure assessments (especially during mass gathering). 
In recent major outbreaks of community-acquired diseases (Pandemic Influenza 2009/2010 and 
the outbreak of entero-haemorrhagic Escherichia coli (EHEC) and haemolytic-uremic syndrome 
(HUS) in 2011), the Surveillance Unit complemented the existing reporting system with additional 
event-related surveillance systems in hospitals. The Pandemic Influenza A/H1N1 hospital 
surveillance (PIKS, Adlhoch C et al., Influenza Other Respi Viruses 2012) and the surveillance of 
bloody diarrhoea (SBD) were quickly implemented and able to capture data timely and effectively 
both to the severity and course of the pandemic influenza of 2009/2010 and the outbreak of EHEC 
and HUS in spring and summer of 2011. As the structures and especially contacts to German 
hospitals still exist, a hospital surveillance system can easily be set up and implemented again, in 
case of an occurring severe outbreak. 
Mass gatherings often require a temporarily intensified surveillance. Unit 32 was responsible for 
national coordination of intensified surveillance measures during the 2011 FIFA Women’s World 
Cup (Takla A et al., BMC Public Health 2012). Based on previous experience with intensified 
surveillance during the 2006 FIFA Men’s World Cup (Williams C et al., Epidemiol Infect 2009), we 
conducted a needs assessment with the district health authorities in the 9 host cities in March 
2011. Specific measures with majority consent were implemented. During the event, we surveyed 
the 9 district and their corresponding 7 state health authorities to evaluate the implemented 
measures. Implemented measures, including moving from weekly to daily (Monday - Friday) 
reporting within the routine infectious disease surveillance system, regular feedback on those 
notification reports and summaries of national and international World Cup-relevant 
epidemiological incidents, were rated as adequate. Involvement of the participating stakeholders 
early-on in the planning phase secured ownership of and guaranteed support for the chosen 
strategy. The enhanced surveillance for this event resulted as a low-level surveillance. However, we 
included mechanisms for rapid upscaling if the situation would require adaptations. 
2.2.4. Surveillance of entities which are not notifiable 
Furthermore the Surveillance Unit has established a timely monitoring of all-cause mortality in the 
state of Berlin to be able to identify an unusual increase in mortality and a possible underlying 
public health threat. The Surveillance Unit is an active partner of The European Mortality 
Monitoring Project and delivers weekly the mortality data of Berlin, which are published on the 
project´s website (www.euromomo.eu). Efforts are underway to develop a timely German national 
mortality monitoring as it already exists in many other countries worldwide. 
In October 2009 the third interdisciplinary expert workshop on Lyme borreliosis was organised by 
Unit 32. Main objective were to identify research deficits and to prioritise areas which need to be 
addressed. Among the research areas which have to be prioritised are the standardisation of 
diagnostic tests, the development of markers to detect an active infection, the improvement of the 
epidemiological data and the analysis of the burden of disease (Freitag M et al., Int J Med Microbiol 
2009). 
On the latter issue, initiatives have been taken to analyse the sera of children and adolescents for 
antibody seroprevalence of Borrelia burgdorferi in the nationwide and representative KiGGS-study 
herewith sound data on the distribution and on risk factors in Germany could have been obtained 
(Dehnert et al., PLoS ONE 2012). 
The responsibility for Lyme borreliosis changed to Unit 35 in August 2011. 
Typical hospital pathogens are not notifiable in Germany that means special surveillance systems 
have to be developed.  
“Antibiotika-Resistenz-Surveillance in Deutschland (ARS)” is the National Antimicrobial Resistance 
Surveillance System. It is a major component of the German Strategy for Detection, Prevention and 
Control of Antimicrobial Resistance (DART) and its implementation was funded by the Ministry of 
Health from January 2007 to June 2010. ARS operates as a network of laboratories participating on 
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a voluntary basis submitting data from routine susceptibility testing of clinical samples from 
hospitals as well as from outpatient care settings in a standardised format via an electronic 
interface to the RKI for central processing. The main objective is to provide reference data for 
antimicrobial resistance of the most important pathogens in inpatient and outpatient care on 
national and regional level (Noll I et al., Bundesgesundheitsbl-Gesundheitsforsch-
Gesundheitsschutz 2012, Schweickert B et al., Eur J Clin Microbiol Infect Dis 2012, Wadl M et al., 
Infection 2010). These data are accessible through an interactive database on the ARS website 
(https://ars.rki.de/). Participating laboratories receive hospital reports as feedback as well as alerts 
in case of rare resistance events. ARS provides data on trends in resistance as well as for 
comparisons by region (yet limited) or by structural characteristics such as ward type or specialties 
thus allowing for identification of resistance problems that can be used for developing 
recommendations and strategies for the containment of antimicrobial resistance. ARS is part of the 
European Antimicrobial Resistance Surveillance Network (EARS-Net); by submitting resistance 
data according to the EARS-Net protocol as well as denominator data once a year it contributes to 
EARS-Net reports and publications. Running and developing the national antimicrobial resistance 
surveillance system needs good service for participating laboratories and recruitment of new 
participants to obtain a nationwide coverage. Maintenance of the ARS database and ARS website 
and further development of tools and algorithms for data analysis such as for multi-resistance and 
notifiable resistance phenotypes are major IT-requirements. In the field of resistance the unit paid 
special attention to multiresistant pathogens especially MRSA, VRE, ESBL and carbapenem-
resistant gram negative pathogens, and C. difficile. 
Another task is antibiotic consumption in the ambulatory sector. In Germany, antibiotics are only 
available on prescription and the surveillance of antibiotic consumption primarily relies on 
reimbursement data of the legal insurance systems, which cover around 85% of the German 
population. There are two institutions which bring together data on antibiotic consumption from 
the different associations of Statutory Health Insurance Physicians (Kassenärztlichen 
Vereinigungen): the Central Institution for statutory health care provision (Zentralinstitut für 
kassenärztliche Versorgung, ZI) and the Scientific Institution of the AOK, one of the statutory 
health insurance funds (Wissenschaftliches Institut der AOK, WiDO). The RKI took the initiative for 
collaboration with the ZI in order to acquire data on antibiotic consumption in the ambulatory 
sector and to cooperate in the field of data evaluation and the provision of feedback and advice to 
the medical practitioners. So far, a realisation of this project was not successful for technical 
reasons (an appropriate certification for the transfer of data according to current data protection 
rules can currently not be realised by the RKI). Currently, the WiDO provides data on antibiotic 
consumption in aggregated form to GERMAP (Report on antibiotic consumption and resistance in 
human and veterinary medicine) and, in collaboration with the RKI, provides data to the European 
Surveillance System of Antibiotic Consumption –Network (ESAC-Net). 
The surveillance of antibiotic consumption in hospital care requires a different methodological 
approach. The sources of data for the acquisition of antibiotic consumption are pharmacies. 
Several years ago, a project for the monitoring of antibiotic consumption in hospitals was initiated 
and established by the University Hospital of Infectiology, Freiburg and the Society of German 
hospital pharmacists (Bundesverband deutscher Krankenhausapotheker, ADKA). This project has 
initially been funded by the BMBF and since 2010 is continued with the support of the RKI 
(financial and technical support) with the aim to extend the project over the regional boarders in 
order to obtain nationally representative data and provide reference data. This surveillance system 
is conceived as a sentinel system and does currently not provide comprehensive coverage of all 
German hospitals. Awaiting the new “Deutsches Elektronisches Meldesystem für Infektionsschutz 
(DEMIS)”, the RKI has abstained from developing innovating IT-technical tools for the automated 
collection of antibiotic consumption data in hospitals. 
In 2011, §23 of the IfSG has been supplemented by a new regulation, which obliges hospitals to 
monitor antibiotic consumption. In order to support the hospitals in the implementation of an 
appropriate surveillance system and in order to promote the connection of the results of other 
established surveillance systems with data on antibiotic consumption, the RKI, in cooperation with 
the NRZ of Nosocomial Infections, intends to initiate a new project: the establishment of a unit on 
antibiotic consumption that will be associated with the existing KISS-System. The technical and 
financial requirements have been determined according to the detailed project specifications.  
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Together with the UK HPA (Leader), the unit also developed a surveillance system for monitoring 
infectious disease outbreaks among Health Care Workers. This was part of the REACT project (see 
2.2.7., Unit 32). 
2.2.5. Early detection of epidemics 
In 2010, the RKI joined a consortium of computer scientists to address novel methods for event-
based and syndromic surveillance. The objective of the project - called the Medical Ecosystem (M-
Eco), was to create an accessible technology for the early detection of public health incidents 
(potentially indicating outbreaks) that occur in news and social media. During the duration of the 
project, computer scientists developed detection mechanisms with the aim to continuously scan 
the Internet for these media types, based on the simple semantic (disease names and symptoms) 
and statistically relevant (varying search algorithms) epidemiological requirements deemed critical 
for the surveillance of different infectious diseases. Development of these functionalities resulted in 
a “search function” on a Web-based user interface that enables epidemiologists to monitor 
“mentions” of diseases and symptoms occurring in Twitter and news media (fed via a news 
aggregate technology) over time, and geo-located to enable comparison with other sources of 
epidemiological information, including standard governmental infectious disease surveillance and 
monitoring. The project was closed in 2012. 
In January 2009, a weekly telephone conference with all competent authorities of the German 
federal states and the RKI was established to identify, discuss and respond to infectious disease 
events in real-time (Mohr O et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 
2010). The topics of the conferences focused on national events involving more than one federal 
state, on events at regional level, and on international events with potential relevance for Germany. 
In this sense, the teleconference is part of early warning. Further, these conferences are used for 
the exchange of scientific and organisational information and serve as a platform to provide IT 
support for the surveillance software SurvNet. 
2.2.6. Outbreak investigation 
A multidisciplinary team with expertise in clinical medicine, microbiology, infection control and 
epidemiology supports upon request from the responsible state authorities local public health 
authorities in investigating and managing healthcare associated outbreaks. Over the past years the 
unit was increasingly involved in several outbreak investigations in different hospital settings (alone 
2012 official involvement in 5 outbreaks) (Hermes J et al., Gesundheitswesen 2011, Weiss B et al. 
Infect Control Hosp Epidemiol 2009. Strong collaboration with national reference laboratories and 
laboratories within the RKI is well established to combine epidemiological as well as 
microbiological and molecular typing and sequencing expertise to investigate healthcare associated 
outbreaks.  
Multiresistant pathogens in animals and the potential transmission of these pathogens to human 
have large outbreak potential (Walther B et al. PLoS ONE 2012). In response, the MedVet-Staph 
research network including veterinarians, biologists, human physicians, epidemiologists, 
bioinformaticians and experts for risk assessment and simulation was established. In summary, the 
interdisciplinary network analyses the mechanisms facilitating the spread of Staphylococcus 
aureus/MRSA within one species and across species barriers. The project aims to provide robust 
data on transmission of livestock associated MRSA (LA-MRSA) to humans exposed to animals 
(farmers, veterinarians) and further transmission to their non-exposed contact persons. A cohort of 
MRSA-positive veterinarians (including their families) from all over Germany and a control group 
have been established in order to study dynamics, risk factors for and clinical significance of 
colonisation with MRSA.  
In another project, C. difficile and potential transmission between human and domestic animals is 
investigated. 
2.2.7. International reporting and contact tracing 
Reporting to the WHO and to the European Networks especially the EWRS (Early Warning and 
Response System) and assessment of the necessity of contact tracing are important; however there 
are still many questions which need to be addressed systematically.  
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The unit started to work in a scientific way in this area with a tender of the ECDC (RAGIDA risk 
assessment guidelines for infectious diseases transmitted on aircraft, Mohr O et al., Euro Surveill 
2012, Askar M et al., Euro Surveill 2012). The guiding principle behind RAGIDA was the 
development of algorithms to enable efficient disease control and prevention for a range of 
infectious diseases. For a total of 12 diseases, ranging from anthrax to SARS, the authors 
systematically reviewed and summarised the scientific literature and, if available, related air 
transportation guidelines. Then the evidence retrieved from the literature was combined with expert 
knowledge. The resulting paper provides a host of viable options for decision makers, particularly 
when faced with the decision whether to contact trace air travellers and crew that were exposed to 
infectious diseases during a flight. 
The REACT (Response to Emerging infectious disease: assessment and development of core 
Capacities and Tools) project (EU financed, RKI scientific lead) was created to support an improved 
and better coordinated response to the outbreak of infectious diseases – especially newly emerging 
infections -within the European Union. The project was organised in subject-specific work 
packages: "Enhanced surveillance during international mass gatherings", "Surveillance of 
infectious disease outbreaks among Health Care Workers" "Tools for local implementation of the 
International Health Regulations (IHR)" and "International contact tracing after exposure to 
infectious diseases". The choice of the four areas of interest was inspired by the observation that in 
these areas little is known or done and that existing international regulations for surveillance 
urgently need reinforcement for effective implementation. The general objective of the project has 
been to provide evidence and tools towards a common European standard for the response to 
emerging public health threats. In order to use the available expertise in all areas of interest four 
European public health institutions from Poland, UK, Norway and Germany took over responsibility 
each for one area of response. In all four areas all planned products and tools – training modules, 
education and information material, guidelines and protocols - have been elaborated and tested. 
The React tools are now available for dissemination and application. 
Another important point in this area was the implementation of the International Health Regulation 
(IHR). According to the Act on the International Health Regulations (2005) (IHR) of 23 May 2005, 
dated 20 July 2007 (Federal Law Gazette II, p. 930), the Robert Koch Institute is the responsible 
point of contact for the German IHR focal point in the field of prevention and control of 
communicable diseases. In the Robert Koch Institute, currently the department for infectious 
disease epidemiology is the responsible point of contact and also ensures the capacity to detect, 
assess, notify and report events in accordance with the IHR, as specified in Annex 1. 
Furthermore, the Surveillance Unit was asked by the German Federal Ministry of Health to develop 
recommendations on the core capacities of German airports and ports that were designated in 
accordance with paragraph 1 of Article 20 of the IHR. The purpose of these already developed 
recommendations was to define the core capacity requirements according to Annex 1 B of the IHR 
in more detail, thus to create a manageable instrument to develop and maintain these core 
capacities at designated German airports and ports.  
Within the scope of the implementation of the IHR (2005) the Surveillance Unit was recently 
awarded a grant by the EU (DG SANCO) in the framework of the “Second Programme of 
Community action in the field of health (2008-2013)”. The project, named AIRSAN (Coordinated 
action in the aviation sector to control public health threats) aims to support European Member 
States in IHR implementation by creating a functioning Network of stakeholders in the aviation and 
public health sector across the EU and by reviewing existing and developing new SOPs, regulations 
and guidelines in the area of response to public health threats on aircraft. In addition the unit is 
involved in the SHIPSAN project which is the corresponding project for ports. 
2.2.8. Policy and Committee 
A further important task was the coordination of the working group of the government and federal 
states on the IfSG (“Bund-Länder-Arbeitsgruppe”). Three to four times per year, one- or two-day 
conferences with representatives of the competent authorities of the German federal states, the 
German armed forces and the RKI. During the conferences, developments of the surveillance 
system, planned and on-going studies on infectious diseases involving the participation of more 
than one federal state, and outstanding public-health events were presented and discussed. The 
most frequently discussed topics were developments of the electronic surveillance software 
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SurvNet, case definitions, reporting and transmission issues and outbreak investigations. 
Tuberculosis, influenza, and Norovirus infections were the most frequently discussed diseases.  
A further task was the realisation of the German strategy to combat antibiotic resistance (DART, 
Noll I, Eckmanns T, Hyg Med 2011). Since 2008, the unit has initiated a number of different studies 
to investigate underlying socio-behavioural factors of influence for antibiotic prescribing and 
antibiotic resistance in Germany to get background information for DART (Velasco E et al. BMJ 
Open 2012, Velasco et al., Infection 2011, Faber et al., Euro Surveill 2010). The studies comprising 
this research area included a literature review, focus group discussions with medical professionals, 
a national representative cross-sectional study of physicians and a Web-based survey of the general 
population. Further components to realise DART were first steps to establish a centre for the 
prevention and control of antibiotic resistance, and the preparation of hosting the executive 
secretary of the German Standing Committee on Antimicrobials Resistance and Therapy (ART) in 
the unit (according to The German Protection against Infection Act (Infektionsschutzgesetz) (§23)). 
One of the main tasks of the Committee will be the development of state-of-the art guidelines for 
diagnostic and therapeutic principles in the context of multiresistant pathogens.  
Principles of evidence based public health (EBPH) will hereby be applied. In this field strong 
cooperation with Unit 33 is planned. Experiences with the principals of EBPH were gathered in the 
RAGIDA and REACT projects. In both projects guideline development was one aim and systematic 
reviews on infectious disease transmission on airplanes and other vehicles were conducted. 
In the PRECEPT (tender of ECDC lead by RKI) project the application of EBPH for guideline 
development will be investigated further with a focus on antimicrobial resistance. 
2.3.  Major goals and contribution to the goals of the department 
International reporting was one of the major goals of the department. This was done in a regular 
and reliable manner by the unit and RKI is a confidential partner for the WHO and the EU / ECDC. 
Implementation of the IHR was another important goal in the last years. RKI was not only 
successful in this task but in addition RKI is established as a leading research institute in this area 
in Europe. It started with the RAGIDA tender, followed by the REACT project and now continued by 
the AIRSAN project - all 3 projects were or are coordinated by RKI. 
In the field of surveillance during severe epidemics and mass gathering the unit implemented and 
evaluated successfully surveillance systems as shown in several publications. 
One goal of the unit was to integrate social epidemiology as part of infectious disease 
epidemiology. Nowadays no epidemiological studies should be conducted without considering 
social factors as risk factors and no measures should be implemented without investigation how 
the social gap is influenced as consequence of the introduced measures.  
Especially in the area of healthcare associated infections, antibiotic resistance and antibiotic use 
public health and the clinical medicine are getting closer. In the revised German Protection against 
Infection Act the legal responsibilities for hospitals concerning healthcare associated infections and 
antibiotic resistance and use increase. With surveillance of infection control and hospital 
epidemiology issues like antibiotic resistance, antibiotic consumption, hospital acquired infections 
/ outbreaks was for the first time dealt with in a wider range in the department. Only two (MRSA in 
blood culture and liquor and severe cases of C. difficile) of the typical hospital pathogens are 
notifiable. These two pathogens are responsible for more than 50 % of reports of death notification 
(Fig. 7). Analysis of reporting data of severe cases of C. difficile is complicated as compliance with 
notification is low, as it is a rather complicated notification algorithms which is not very known 
among physicians. More work has to be done on this pathogen and in the area of multi-resistant 
pathogens.  
In future there will be a specific unit for this field established in the Department of Infectious 
Diseases Epidemiology. The reorganisation of the department will be a huge task for the units, the 
department, and the whole institute. Until recently surveillance of antibiotic resistance and 
antibiotic consumption was an integrated part of the Surveillance Unit. Now there are two new 
units and new strategies and goals have to be developed. For the area of antibiotic resistance, 
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antibiotic consumption, and healthcare associated infections reorganisation within the RKI will be 
necessary affecting not only the Department of Infectious Diseases Epidemiology.  
Figure 7: Percentage of deceased (n = 1,115) of diseases to be notified (excluding IfSG §7.3 notifications) in 
the year 2012 (until 31st of October) 
 
2.4.  Additional work and methods for investigations  
Evidence based public health 
Event based surveillance (EpiLag, M-Eco) 
Social epidemiology in infectious diseases 
2.5. Scientific advice and consulting services 
1) Scientific advice to the German MoH:  
In 2009–2012, under the lead of the Surveillance Unit a total of reports have been written upon 
the request of the MoH. Details are listed in the appendix of the department report.  
2) Scientific advice or guidance to healthcare professionals: 
- Yearly workshop for laboratories participating in ARS, 20 to 30 participants, certified as a 
training course by the Chamber of Physicians; 
- 1. and 2. Antibiotic Resistance Workshop at the RKI (in cooperation with the DGHM, DGI 
and EURSAFETY) 2010 and 2012, 2 days with ca. 90 participants (microbiologist, infection 
control physicians, public health physicians, clinicians), certified as a training course by the 
Chamber of Physicians 
- Telephone support or email support for interpretation of The German Protection against 
Infection Act (about 800 calls per year) 
3) Consulting service for state and local Public Health authorities on best practice for implementing 
and putting into practice of IHR and IfSG 
4) Support of the local public health authorities concerning outbreak investigation especially 
healthcare associated outbreaks 
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5) 18 informational briefs (“Infobriefe”) were developed and distributed to local health 
departments. 
2.6 Training and teaching activities 
• Participation as facilitators in bi-annual 1-week courses on field epidemiology for public 
health workers in Germany hosted by the department. 
• Project supervisors for fellows of the German Postgraduate program for Applied 
Epidemiology (PAE) and the European Intervention Epidemiology Training program 
(EPIET)  
• Activities as lecturers and supervisors in the Masters Program in International Health 
(Charité University Medicine, Berlin), Masters Program in Public Health (Berlin School of 
Public Health), and the Masters Program in Applied Epidemiology (Robert Koch Institute), 
and within the programme of the International Research Training Group GRK1673 
“Functional Molecular Infection Epidemiology”. 
• Supervisors for dissertations and master theses (currently 2 master thesis projects). 
• Participation as facilitators in teaching modules of the EPIET program 
• Lecturer in the DGHM infection control course, in the training course for infection control 
link physicians, in the education of infection control nurses, and for medical students in 
infection control and hospital epidemiology (University, Charité) 
• Lecturer in the trainings course for antibiotic stewardship (University, Freiburg) 
• Trainings for the local health departments and the states in the international health 
regulation (IHR) and the IfSG 
• Lecturer in the training course for medical officers (Akademie für öffentliches 
Gesundheitswesen, Düsseldorf) 
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3.  Cooperation with other scientists or research institutions 
3.1. Internal (within RKI) 
Department 1 (Unit 13, NRC for S. aureus: G. Werner; Unit 11: A. Flieger, Unit 17: Schweiger) 
• Abu Sin et al. 2012  
• Dudareva et al.2011  
• Wichmann et al.2010  
• Jansen et al. 2010  
• Kola et al. 2009 
3.2. External / National 
National Reference Laboratory for surveillance of nosocomial infections (P. Gastmeier) 
• Adlhoch et al. 2012  
• Schweickert et al.2011  
• Kola et al. 2009 
• Gastmeier et al. 2009 
Institute of Microbiology and Epizootics, Veterinary Faculty, Freie Universität Berlin (L.H. 
Wieler)  
• Walther et al. 2012 
German state health departments 
• Abu Sin et al. 2012, Wilking et al.2012, Uphoff et al. 2011, Adlhoch et al. 2010, Mohr et al. 
2010 
3.3.  External / International 
Health Protection Agency, London, UK (M. Catchpole) 
• Aghaizu et al. 2011 
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4. Appendix 
4.1  Overview on achievements of the Unit, 2009-2012 
4.1.1.  Scientific publications, 2009-2012 
Number of peer-review publications co-authored by members of unit: 82 





Cumulative 2009-2012: 352,8 
A) Original research articles in peer-review journals 
2012 (until Sept.) 
Abu Sin M, Takla A, Flieger A, Prager R, Fruth A, Tietze E, Fink E, Korte J, Schink S, Höhle M, 
Eckmanns T: Carrier prevalence, secondary household transmission and long-term shedding in 
two districts during the Escherichia coli O104:H4 outbreak in Germany, 2011. J Infect Dis 2012. 
Adlhoch C, Wadl M, Behnke M, Pena Diaz L A, Clausmeyer J, Eckmanns T: Pandemic influenza 
A(H1)pdm09 in hospitals and intensive care units - results from a new hospital surveillance, 
Germany 2009/2010. Influenza Other Respi Viruses 2012; 6(6):e162-e168. 
Adlhoch C, Kaiser M, Loewa A, Ulrich M, Forbrig C, Adjogoua E V, et al.: Diversity of Parvovirus 4-
like Viruses in Humans, Chimpanzees, and Monkeys in Hunter-Prey Relationships. Emerg Infect 
Dis 2012; 18(5):859-862. 
Askar M, Mohr O, Eckmanns T, Krause G, Poggensee G: Quantitative assessment of passenger 
flows in Europe and its implications for tracing contacts of infectious passengers. Euro Surveill 
2012; 17:pii=20195. 
Dehnert M, Fingerle V, Klier C, Talaska T, Schlaud M, Krause G, Wilking H, Poggensee G: 
Seropositivity of Lyme Borreliosis and Associated Risk Factors: A Population-Based Study in 
Children and Adolescents in Germany (KiGGS). PLoS ONE 2012; 7(8):e41321. 
Klein S, Schöneberg I, Krause G: Vom Zwang zur Pockenschutzimpfung zum Nationalen Impfplan 
- Die Entwicklung des Impfwesens vom Deutschen Kaiserreich bis heute [The historical 
development of immunization in Germany : From compulsory smallpox vaccination to a National 
Action Plan on Immunization]. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2012, 
55(11-12):1512-1523. 
Mohr O, Askar M, Schink S, Eckmanns T, Krause G, Poggensee G: Evidence for airborne 
infectious disease transmission in public ground transport - a literature review. Euro Surveill 2012; 
17:pii=20255. 
Müller I, Freitag MH, Poggensee G, Scharnetzky E, Straube E, Schoerner C, et al.: Evaluating 
frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany: a retrospective 
model analysis. Clin Dev Immunol 2012; 2012:595427. 
Nachtnebel M, Greutélaers B, Falkenhorst G, Jorgensen P, Dehnert M, Schweiger B, Trader C, 
Buda S, Eckmanns T, Wichmann O, Hellenbrand W: Lessons from a one-year hospital-based 
surveillance of acute respiratory infections in Berlin- comparing case definitions to monitor 
influenza. BMC Public Health 2012; 12:245. 
Noll I, Schweickert B, Abu Sin M, Feig M, Claus H, Eckmanns T.: Daten zur 
Antibiotikaresistenzlage in Deutschland [Antimicrobial Resistance in Germany : Four years of 
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Antimicrobial Resistance Surveillance (ARS)]. Bundesgesundheitsbl-Gesundheitsforsch-
Gesundheitsschutz 2012, 55 (11-12):1370-6.  
Schweickert B, Noll I, Feig M, Claus H, Krause G, Velasco E, Eckmanns T: MRSA-surveillance in 
Germany: data from the Antibiotic Resistance Surveillance System (ARS) and the mandatory 
surveillance of MRSA in blood. Eur J Clin Microbiol Infect Dis 2012; 31(8):1855-1865. 
Siedler A, Rieck T, Reuss A, Walter D, Poggensee G, Poethko-Muller C, et al.: Estimating 
vaccination coverage in the absence of immunisation registers - the German experience. Euro 
Surveill 2012; 17:pii=20152. 
STEC Workshop Reporting Group: Experiences from the Shiga toxin-producing Escherichia coli 
O104:H4 outbreak in Germany and research needs in the field, Berlin, 28-29 November 2011. Euro 
Surveill 2012, 17(7):pii=20091. 
Takla A, Velasco E, Benzler J: The FIFA Women's World Cup in Germany 2011--a practical example 
for tailoring an event-specific enhanced infectious disease surveillance system. BMC Public Health 
2012; 12:576. 
Velasco E, Ziegelmann A, Eckmanns T, Krause G: Eliciting views on antibiotic prescribing and 
resistance among hospital and outpatient care physicians in Berlin, Germany: results of a 
qualitative study. BMJ Open 2012; 2(1):e000398. 
Walther B, Hermes J, Cuny C, Wieler LH, Vincze S, Abou Elnaga Y, Stamm I, Kopp PA, Kohn B, 
Witte W, Jansen A, Conraths FJ, Semmler T, Eckmanns T, Lübke-Becker A: Sharing More than 
Friendship - Nasal Colonization with Coagulase-Positive Staphylococci (CPS) and Co-Habitation 
Aspects of Dogs and Their Owners. PLoS ONE 2012; 7(4):e35197. 
Wilking H, Höhle M, Velasco E, Suckau M, Eckmanns T: Ecological analysis of social risk factors 
for Rotavirus infections in Berlin, Germany, 2007-2009. Int J Health Geogr 2012; 11(1):37. 
2011 
Aghaizu A, Elam G, Ncube F, Thomson G, Szilagyi E, Eckmanns T, et al.: Preventing the next 
'SARS' - European healthcare workers' attitudes towards monitoring their health for the 
surveillance of newly emerging infections: qualitative study. BMC Public Health 2011; 11:541. 
Altmann M, Wadl M, Altmann D, Benzler J, Eckmanns T, Krause G, et al.: Timeliness of 
surveillance during outbreak of Shiga Toxin-producing Escherichia coli infection, Germany, 2011. 
Emerg Infect Dis 2011; 17(10):1906-1909. 
Amato-Gauci A, Zucs P, Snacken R, Ciancio B, Lopez V, Broberg E, Penttinen P, Nicoll A, European 
Influenza Surveillance Network EISN: Surveillance trends of the 2009 influenza A(H1N1) 
pandemic in Europe. Euro Surveill 2011, 16(26):pii:19903. 
Askar M, Faber M, Frank C, Bernard H, Gilsdorf A, Fruth A, Prager R, Höhle M, Suess T, Wadl M, 
Krause G, Stark K, Werber D: Update on the ongoing outbreak of haemolytic uraemic syndrome 
due to Shiga toxin-producing Escherichia coli (STEC) serotype O104, Germany, May 2011. Euro 
Surveill 2011; 16:pii=19883. 
Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gartner B, et al.: Communicable 
diseases prioritized for surveillance and epidemiological research: results of a standardized 
prioritization procedure in Germany, 2011. PLoS ONE 2011; 6(10):e25691. 
Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van 
Dissel JT, Kuijper EJ, ECDIS Study Group: Clostridium difficile infection in Europe: a hospital-
based survey. Lancet 2011; 377:63-73. 
Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, RKI HUS 
investigation team: German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl 
J Med 2011; 365(19):1763-1770. 
Dudareva S, Barth A, Paeth K, Krenz-Weinreich A, Layer F, Delere Y, Eckmanns T: Cases of 
community-acquired meticillin-resistant Staphylococcus aureus in an asylum seekers centre in 
Germany, November 2010. Euro Surveill 2011; 16:pii=19777. 
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Eckmanns T: Ausbruchsvehikel multiresistenter Enterobacter cloacae: neue Erkenntnisse durch 
eine Fall-Kontroll-Studie [Multi-dose packaging of drugs as the causative vehicle for multidrug-
resistant Enterobacter cloacae: new results from a case-control study]. Gesundheitswesen 2011; 
73(11):778-783. 
Hermes J, Bernard H, Buchholz U, Spackova M, Löw J, Loytved G, et al.: Lack of evidence for pre-
symptomatic transmission of pandemic influenza virus A(H1N1) 2009 in an outbreak among 
teenagers; Germany, 2009. Influenza Other Respi Viruses 2011; 5(6):e499-503. 
Frank C, Faber M, Askar M, Bernard H, Fruth A, Gilsdorf A, RKI HUS investigation team: Large 
and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011. Euro Surveill 2011; 
16:pii=19878. 
Frank C, Schöneberg I, Stark K: Trends in imported Chikungunya virus infections in Germany, 
2006-2009. Vector Borne Zoonotic Dis 2011; 11(6):631-636. 
Frank C, Werber D, Cramer JP, Askar M, Faber M, Heiden MA, RKI HUS investigation team: 
Epidemic profile of Shiga-Toxin-producing Escherichia coli O104:H4 outbreak in Germany - 
preliminary report. N Engl J Med 2011; 365(19):1771-1780. 
Hermes J, Jansen A, Geipel U, Herrmann M, von Müller L, Haber M, Jung W, Thomé-Granz S,  
Jourdan PM, Roald B, Poggensee G, Gundersen SG, Kjetland EF: Increased Vascularity in 
Cervicovaginal Mucosa with Schistosoma haematobium Infection. PLoS Negl Trop Dis 2011; 
5(6):e1170. 
Leitmeyer K: European Risk Assessment Guidance for Infectious Diseases transmitted on Aircraft - 
the RAGIDA project. Euro Surveill 2011; 16:pii=19845. 
Mette A, Reuss A, Feig M, Kappelmayer L, Siedler A, Eckmanns T, Poggensee G: Untererfassung 
von Masern - Eine Evaluation basierend auf Daten aus Nordrhein-Westfalen. Dtsch Arztebl Int 
2011; 108(12):191-196. 
Mombo-Ngoma G, Oyakhirome S, Ord R, Gabor JJ, Greutelaers KC, Profanter K, Greutelaers B, 
Kurth F, Lell B, Kun JF, Issifou S, Roper C, Kremsner PG, Grobusch MP. High prevalence of dhfr 
triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in 
vivo in Gabonese children. Malaria J 2011;10:123. 
Noll I, Eckmanns T: DART - gemeinsam Antibiotikaresistenzen verhüten und bekämpfen. 
Deutsche Antibiotika-Resistenzstrategie - eine Zwischenbilanz des RKI. Hyg Med 2011; 36(4):150. 
Schweickert B, Geffers C, Farragher T, Gastmeier P, Behnke M, Eckmanns T, et al.: The MRSA-
import in ICUs is an important predictor for the occurrence of nosocomial MRSA cases. Clin 
Microbiol Infect 2011; 17:901-906. 
Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany. 
Quantifying the burden of disease. BMC Infect Dis 2011; 11:173. 
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Buda S, Faensen D, Feig M, Altmann D, Wichmann O, Eckmanns T, Buchholz U: Effectiveness of 
the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of 
two methods; Germany, 2009/10. PLoS ONE 2011; 6(7):e19932. 
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sectional study on socio-behavioural factors that influence physicians' decisions to begin 
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Faber M, Frank C, Schweickert B, Krause G, Benzler J, Eckmanns T: Enhanced surveillance during 
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toxin/verotoxin-producing Escherichia coli in Germany, May to June 2011. Euro Surveill 2011; 
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2009 in Germany, 27 April-16 June 2009. Euro Surveill 2009; 14(31):pii=19295. 
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Oh DY, Baumann K, Hamouda O, Eckert JK, Neumann K, Kücherer C, Bartmeyer B, Poggensee G, 
Oh N, Pruss A, Jessen H, Schumann RR: A frequent functional toll-like receptor 7 polymorphism is 
associated with accelerated HIV-1 disease progression. AIDS 2009; 23(3):297-307. 
Poggensee G, Reuss A, Reiter S, Siedler A: Überblick und Bewertung der verfügbaren 
Datenquellen zur Inzidenz impfpräventabler Krankheiten, zum Durchimpfungsgrad und zum 
Immunstatus in Deutschland [Overview and assessment of available data sources to determine 
incidence of vaccine preventable diseases, vaccination coverage, and immune status in Germany.]. 
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009; 52:1019-1028. 
Reuss AM, Wiese-Posselt M, Weimann B, Siedler A, Zuschneid I, an der Heiden M, Claus H, von 
Kries R, Haas WH: Incidence rate of nontuberculous mycobacterial disease in immunocompetent 
children: a prospective nationwide surveillance study in Germany. Pediatr Infect Dis J 2009; 
28(7):642-644. 
Schmid S, Chiodini P, Legros F, D'Amato S, Schöneberg I, Liu C, Janzon R, Schlagenhauf P: The 
risk of malaria in travelers to India. J Travel Med 2009; 16(3):194-199. 
Wadl M, Pölzler T, Flekna G, Thompson L, Slaghuis J, Köfer J, Hein I, Wagner M: Easy-to-use rapid 
test for direct detection of Campylobacter spp. in chicken feces. J Food Prot 2009; 72(12):2483-
2484. 
Weiss B, Kleinkauf N, Eckmanns T, an der Heiden M, Neumann M, Michels H, Jansen A: Risk 
factors related to a hospital-associated cluster of Clostridium difficile PCR ribotype 027 infections in 
Germany During 2007. Infect Control Hosp Epidemiol 2009; 30(3):282-284. 
Williams CJ, Schenkel K, Eckmanns T, Altmann D, Krause G: FIFA World Cup 2006 in Germany: 
enhanced surveillance improved timeliness and detection. Epidemiol Infect 2009; 137(04):597-605. 
B) Overview articles or systematic reviews (incl. non peer-review articles) 
Adlhoch C, Schöneberg I, Benzler J, Fell G, Brandau D: Das Erkennen, Bekämpfen und Verhüten 
von Infektionskrankheiten. Der Landkreis 2011; 2:76-78. 
Adlhoch C, Poggensee G: Lyme-Borreliose: Ein Situationsbericht aus den sechs östlichen 
Bundesländern 2007-2009 [Lyme Borreliosis: Situation report from the Federal States of Berlin, 
Brandenburg, Mecklenburg-West-Pomerania, Saxony, Saxony-Anhalt and Thuringia, 2007-2009]. 
UMID 2010; 2:5-8. 
Eckmanns T: Die Rolle von Einmalhandschuhen in der Krankenhaushygiene. Krankenhaushygiene 
up2date 2012; 7:147. 
Eckmanns T: Elf Jahre Infektionsschutzgesetz - Rück- und Ausblick. Krankenhaushygiene up2date 
2012; 7:107-118. 
Eckmanns T: Die häusliche Quarantäne bei der Neuen Influenza AH1N1. Der Hygieneinspektor 
2009, 02:53. 
Hollmeyer H, Eckmanns T, Krause G: Surveillance gemäß den Internationalen 
Gesundheitsvorschriften (2005). Der Hygieneinspektor 2009; 11(01/2009):29-175. 
Hügler S, Eckmanns T: Häusliche Quarantäne: Brötchenkaufen ist erlaubt. Dtsch Med 
Wochenschr 2009; 37:1800. 
C) Books 
Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2008, Berlin, 2009 
Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2009, Berlin, 2010 
Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2010, Berlin, 2011 
Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2011, Berlin, 2012 
Schenkel K, Amorosa R, Mücke I, Dias-Ferrao V, Diercke M, Leitmeyer K, Krause G, Eckmanns 
T: Technical Report: Risk assessment guidelines for infectious diseases transmitted on aircraft. 
Report, Stockholm; 2009. Available from: 
http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=464 
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D) Book chapters 
ECDC: Risk assessment guidelines for diseases transmitted on aircraft. Part 2: Operational 
guidelines for assisting in the evaluation of risk for transmission by disease. ECDC Guidance, 2nd 
edition, Stockholm 2010. Available from: 
http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=596 
ECDC: Risk assessment guidelines for diseases transmitted on aircraft. Part 2: Operational 
guidelines for assisting in the evaluation of risk for transmission by disease. ECDC Guidance, 
Stockholm 2009. Available from: 
http://www.ecdc.europa.eu/en/publications/Publications/1012_GUI_RAGIDA_2.pdf 
Eckmanns T, Schweickert B: Clostridium difficile. In: Handbuch der Infektionskrankheiten 2010 
Hofmann F (ed.). ecomed Medizin, Landsberg/Lech. pp 1-13 
GERMAP 2010 - Antibiotika-Resistenz und -Verbrauch. In. Rheinbach: Antiinfectives Intelligence 
Gesellschaft für klinisch-mikrobiologische Forschung und Kommunikation mbH; 2011. 
www.bvl.bund.de/SharedDocs/Downloads/08_PresseInfothek/Germap_2010.pdf?__blob=publicati
onFile&v=2 
E) Articles in the Epidemiological Bulletin 
Reiseassoziierte Infektionskrankheiten 2010. Epid Bull 2011;41:372-378. 
Zum Auftreten multiresistenter Erreger bei in EU-Ländern behandelten libyschen Patienten. Epid 
Bull 2011;41:379. 
Intensivierte Surveillance während eines großen EHEC-/HUS-Ausbruchs in Deutschland, Mai-Juni 
2011. Epid Bull 2011;25:225-229. 
Zur Entwicklung der Erkrankungszahlen im aktuellen EHEC/HUS-Ausbruch in Deutschland - 
Update. Epid Bull 2011;24:215-217. 
Zum Weltgesundheitstag 2011: DART - gemeinsam Antibiotikaresistenzen verhüten und 
bekämpfen. Epid Bull 2011;13:97-99. 
Deutsche Antibiotikaresistenzstrategie – eine Zwischenbilanz des RKI. Epid Bull 2011;13:98-99. 
Bericht zum 1. Workshop "Antibiotikaresistenz". Epid Bull 2011;13:99-101. 
Überarbeitete Falldefinitionen zur Übermittlung von Nachweisen von Denguevirus und Norovirus 
und Erkrankungs- oder Todesfällen an Denguefieber und an Norovirus-Gastroenteritis. Epid Bull 
2010;49:494-495. 
Evaluation des Infektionsepidemiologischen Jahrbuchs meldepflichtiger Krankheiten für 2009 - 
Eine Umfrage unter Lesern des Jahrbuchs. Epid Bull 2010;47:472-475. 
Ratgeber Clostridium difficile; Epid Bull 24/ 2010 
Clostridium-difficile-Infektionen: Übermittlungen gemäß IfSG von 01/2008 bis 12/2009; Epid Bull 
10/2010 
Bundesweite Häufung von Erkrankungen durch S. Panama 2010. Epid Bull 2010;40:399-400. 
Reiseassoziierte Infektionskrankheiten 2009. Epid Bull 2010;38:379-387. 
Auswertung der bundesweit übermittelten Meldedaten zu Adenovirus-Konjunktivitiden. Epid Bull 
2010;37:369-272. 
Meldepflicht gemäß Infektionsschutzgesetz (IfSG): Hinweise zur Meldepflicht für Labore. Epid Bull 
2010;29:275. 
Creutzfeldt-Jakob-Erkrankungen in den Jahren 2008 und 2009. Epid Bull 2010;27:253-259. 
Lyme-Borreliose: Analyse der gemeldeten Erkrankungsfälle der Jahre 2007 bis 2009 aus den sechs 
östlichen Bundesländern. Epid Bull 2010;12:101-07. 
Pandemische Influenza A/H1N1 Krankenhaus-Surveillance (PIKS): Erste Ergebnisse. Epid Bull 
2010;4:31-34. 
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Reiseassoziierte Infektionskrankheiten. Epid Bull 2009;39:385-393. 
Krankheiten, für die gemäß LVO eine erweiterte Meldepflicht zusätzlich zum IfSG besteht (Stand 
2009). Epid Bull 2009;5:33-49. 
Falldefinitionen übertragbarer Krankheiten für den ÖGD: Krankheiten, für die gemäß LVO eine 
erweiterte Meldepflicht zusätzlich zum IfSG besteht (Stand 2009). Epid Bull 2009;5:33-49. 
4.1.2. Appendix with selected relevant publications  
Five important publications for the scientific community 2009–2012 
1. Abu Sin M, Takla A, Flieger A, Prager R, Fruth A, Tietze E, Fink E, Korte J, Schink S, Höhle 
M, Eckmanns T: Carrier prevalence, secondary household transmission and long-term 
shedding in two districts during the Escherichia coli O104:H4 outbreak in Germany, 2011. J 
Infect Dis 2012. Published online 21 Nov 2012. 
2. Schweickert B, Noll I, Feig M, Claus H, Krause G, Velasco E, Eckmanns T: MRSA-
surveillance in Germany: data from the Antibiotic Resistance Surveillance System (ARS) 
and the mandatory surveillance of MRSA in blood. Eur J Clin Microbiol Infect Dis 2012; 
31(8):1855-1865. 
3. Mohr O, Askar M, Schink S, Eckmanns T, Krause G, Poggensee G: Evidence for airborne 
infectious disease transmission in public ground transport - a literature review. Euro 
Surveill 2012; 17:pii=20255. 
4. Adlhoch C, Wadl M, Behnke M, Pena Diaz L A, Clausmeyer J, Eckmanns T: Pandemic 
influenza A(H1)pdm09 in hospitals and intensive care units - results from a new hospital 
surveillance, Germany 2009/2010. Influenza Other Respi Viruses 2012; 6(6):e162-e168. 
5. Weiss B, Kleinkauf N, Eckmanns T, an der Heiden M, Neumann M, Michels H, Jansen A: 
Risk factors related to a hospital-associated cluster of Clostridium difficile PCR ribotype 027 
infections in Germany During 2007. Infect Control Hosp Epidemiol 2009; 30(3):282-284. 
Five important publications for the public 2009–2012 
1. Abu Sin M, Takla A, Flieger A, Prager R, Fruth A, Tietze E, Fink E, Korte J, Schink S, Höhle 
M, Eckmanns T: Carrier prevalence, secondary household transmission and long-term 
shedding in two districts during the Escherichia coli O104:H4 outbreak in Germany, 2011. J 
Infect Dis 2012. Published online 21 Nov 2012. 
2. Wilking H, Höhle M, Velasco E, Suckau M, Eckmanns T: Ecological analysis of social risk 
factors for Rotavirus infections in Berlin, Germany, 2007-2009. Int J Health Geogr 2012; 
11(1):37. 
3. Velasco E, Espelage W, Faber M, Noll I, Ziegelmann A, Krause G, Eckmanns T: A national 
cross-sectional study on socio-behavioural factors that influence physicians' decisions to 
begin antimicrobial therapy. Infection 2011; 39:289-297. 
4. Adlhoch C, Wadl M, Behnke M, Pena Diaz L A, Clausmeyer J, Eckmanns T: Pandemic 
influenza A(H1)pdm09 in hospitals and intensive care units - results from a new hospital 
surveillance, Germany 2009/2010. Influenza Other Respi Viruses 2012; 6(6):e162-e168. 
5. Faber MS, Heckenbach K, Velasco E, Eckmanns T: Antibiotics for the common cold: 
expectations of Germany's general population. Euro Surveill 2010; 15(35):pii=19655. 
4.1.3. List of reports and written scientific advice to the Ministry of Health, 2009-2012 
There were 138 reports and written scientific advice to the Ministry of Health between 2009 and 
30.09.2012. 
4.1.4. Overview on collaborations in networks 
ECDC:  
• National Epidemiology Contact Point for EARS-Net: Ines Noll 
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• National Epidemiology Contact Point for ESAC-Net: Britta Schweickert 
• National Focal Point Surveillance: Tim Eckmanns 
WHO 
• IHR Expert Roster:  Tim Eckmanns 
4.1.5. Memberships and participation in Advisory Boards 
Dr. Tim Eckmanns 
• Member of „Ständige Arbeitsgemeinschaft Allgemeine und Krankenhaushygiene“ since 
2009 (DGHM)  
• Schriftführer „Fachgruppe Infektionsprävention und Antibiotikaresistenz in der 
Krankenhaushygiene“ since 2009 (DGHM)  
• Member ECCMID 2006  
• From 2006 to 2009 deputy of the “Working Group Infectious Disease Epidemiology of 
the DGEPI” 
• Editor of “Krankenhaushygiene Prävention nosokomialer Infektionen up2date” since 
2011 
4.1.6. List of completed dissertation or master theses in the Unit, 2009 – 2012 
Year Title Name Title University/ 
Supervisor 
RKI 
2009 Epidemiological situation of Lyme borre-
liosis in Germany: Surveillance data from 
six Eastern German States, 2002 to 2006 
Balazs Fülöp Dr. med Charité / 
G. Poggensee 
2012 Bestimmung von Impfquoten und 
Inzidenzen impfpräventabler 




Dr. rer. medic. Charité / 
G. Poggensee 
2012 Socio-behavioural determinants for 
antimicrobial prescribing and 
antimicrobial resistance in hospital and 
outpatient care practice in Germany 
Edward 
Velasco 
Dr. rer. medic. Charité / 
G. Krause 
2009 Bestimmung von Risikofaktoren für 
Antibiotikaresistenzen in Escherichia coli 
Auswertung eines laborgestützten 
Surveillance Systems in Deutschland 
Kirsten 
Heckenbach 
MSE Charité / 
T. Eckmanns 
2011 Systematic literature review on event-
based public health surveillance 
Tumacha 
Agheneza 
MPH Hamburg / 
T. Eckmanns 
2012 Prävalenz bakterieller Erreger in 
Blutkulturen – Daten aus Antibiotika-
Resistenz-Surveillance Eine retrospektive 
Analyse der Erreger von Bakteriämien 
der Jahre 2008 bis 2010 
Franziska 
Krüger 
M.A. Bremen / 
T. Eckmanns 
2012 Auswertung der an das Robert Koch 
Institute übermittelten Datensätze zu 
weiteren bedrohlichen Krankheiten, 
2002-2011 
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4.1.7. Presentations as invited speaker, 2009 - 2012 
Staff from the Surveillance Unit were invited to speak at 54 conferences. 
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2. Tasks and goals of the Unit 
2.1. Summary 
The Immunisation Unit is responsible for a wide range of activities related to the development and 
evaluation of evidence-based vaccination recommendations (Figure 8). According to The German 
Protection against Infection Act (IfSG §20), the unit hosts the executive secretariat of the German 
Standing Committee on Vaccination (STIKO), which is responsible for developing national 
vaccination recommendations. These recommendations serve as a basis for the federal states’ 
vaccination guidance, for the inclusion in the Immunisation guidelines of the Federal Joint 
Committee (which is linked to the reimbursement of vaccines: G-BA), and as a “best-practice” 
guidance to clinicians. Focus of the unit’s activities is therefore the generation of evidence and 
review of scientific literature, but also the communication of new recommendations as well as 
monitoring their implementation and impact (Figure 8). 
As a tool for the estimation of baseline disease burden and assessment of vaccination impact, the 
unit monitors the epidemiology of vaccine-preventable diseases (VPD) in Germany. In addition to 
routine national disease surveillance, the unit currently operates enhanced sentinel surveillance 
systems for varicella/herpes zoster and for invasive pneumococcal diseases. The unit is also 
responsible for the collection, analysis, and publication of vaccination coverage data for Germany, 
and conducts research on the barriers and facilitating factors of vaccine uptake in specific target 
groups. The unit also conducts epidemiological research on disease burden, the effectiveness of 
vaccines in the post-licensure phase, and the impact of vaccination on a population level, as well as 
projects on disease transmission modelling, health economic evaluations of vaccines, and cost of 
illness studies. Since the end of 2012, the unit also hosts the executive secretariat of the National 
Verification Committee (NVC) for measles and rubella elimination. 
Figure 8: Major activities / tasks of the Immunisation Unit 
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2.2. Current status of the work and summary of relevant results 
2.2.1. Health economic evaluations and transmission modelling 
Besides data on the efficacy and safety of vaccines (available from published literature) and local 
disease burden, transmission modelling and health economic evaluations provide important 
information to guide decisions whether to adopt a vaccination into the national Immunisation plan 
or not (Figure 9). Until recently, such models were not available or considered for vaccination 
decisions in Germany, mainly due to the lack of expertise in the RKI and in the STIKO.  
Since 2010, projects on transmission modelling and health economic evaluations (e.g. cost-
effectiveness analyses (CEA) or cost-utility analyses (CUA)) of vaccinations have been conducted by 
external research groups with funds provided by RKI and in close cooperation with the 
Immunisation Unit. The following evaluations have been completed or are currently in process: 
CEA, CUA and impact of HPV vaccination (completed in 2011, manuscripts submitted), CEA and 
CUA of rotavirus vaccination (completed in 2012, manuscript in preparation), CEA, CUA and 
transmission modelling of varicella vaccination (project started in 2012), and CEA and CUA of 
meningococcal B vaccination (project will start in 2013). Furthermore, the unit applied successfully 
for internal funding of two PhD-positions: A 3-year PhD-position for a health economic project 
(2011-13, CEA and CUA of herpes zoster vaccination) and a 3-year PhD-position for a transmission 
modelling project (2012-14, rotavirus transmission). 
2.2.2. Communication 
Healthcare professionals and local/state health authorities are the main target groups of the 
health-communication activities of the Unit, with the aim of improving knowledge and advising on 
appropriate procedures concerning vaccinations. The Immunisation Unit operates a telephone 
hotline twice a week, where healthcare professionals can obtain information on questions regarding 
the implementation of STIKO recommendations. This enables the Unit also to identify 
misperceptions in the healthcare community and requirements for further online information (two-
way communication approach). 
With the development of newly designed RKI web pages, the Immunisation Unit also updated and 
expanded its online information services, including FAQ that provide a broad overview on 
questions related to Immunisation and vaccines, also for the general public. A new link provides 
rapid access to this information: www.rki.de/impfen  
To increase its visibility and the communication capacity, a separate web page was created for 
STIKO: www.stiko.de. With this easy-to-remember link, healthcare providers now have quicker 
access to all STIKO recommendations and the scientific background papers. STIKO-
recommendations were translated into English in 2011 to support the international exchange with 
other Immunisation technical advisory groups and experts: www.stiko.de/en  
Within a Ministry of Health (MoH) funded project on “Immunisation and migration” a new web 
module was created in 2012, available under www.rki.de/impfen. Here, the current 2012 national 
Immunisation plan and information sheets for measles, mumps, rubella and varicella vaccination 
are available in 15 languages. 
2.2.3. Monitoring of vaccination coverage and barriers to vaccine uptake  
One of the tasks of the Immunisation Unit is to collect, analyse and publish national vaccination 
coverage data that are routinely collected by local health authorities at school entry (age 5-6 years). 
In the absence of an Immunisation register in Germany, these data are the only representative 
national coverage data available on an annual basis. These data are also reported to the World 
Health Organization. However, no routine data are available for children below 5 years of age and 
for adolescents or adults. Therefore, only limited information exists in Germany e.g. on the uptake 
of HPV vaccines, of newly introduced vaccines in infants (e.g. against pneumococci) or of vaccines 
recommended for adults. To close some of these data gaps, the Immunisation Unit utilises two 
important data sources: 
a) Assessment of vaccination coverage through billing data: Within a MoH-funded project in 
cooperation with all 17 Associations of Statutory Health Insurance Physicians in Germany (covering 
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approximately 85% of the German population, i.e. 70 Million people) insurance refund claim data 
are transmitted to RKI and analysed continuously for the epidemiological assessment of VPD and 
estimation of vaccination coverage. The project was initiated, implemented and evaluated by the 
surveillance unit (Unit 32), and was transferred to the Immunisation Unit in 2012 to be used as a 
routine tool for the monitoring of vaccination coverage especially in children before school entry 
and in adolescents. This tool also allows analysis of vaccination coverage at district level in 
Germany and for 24-months-old children, which is the standard age for vaccination coverage 
figures reported to the World Health Organization and the United Nations. If this project can be 
maintained, it will be used as a routine tool for the assessment of coverage data reported to these 
international authorities in the future.  
b) GEDA: The Immunisation Unit has contributed to the development of questions on vaccinations 
in the “German Health Update” (GEDA) telephone survey, which is conducted annually by RKI 
Department 2. Based on the survey data, the Immunisation Unit in collaboration with Department 
2 calculated coverage estimates for influenza, pertussis and tetanus vaccinations in adults and 
analysed socio-demographic determinants for vaccine uptake in adults living in Germany. Results 
were published in various papers (e.g. Böhmer et al., BMC Public Health 2012; Böhmer et al., 
Vaccine 2011; Böhmer et al. Human vaccines 2011). 
2.2.4. Research on the impact and effectiveness of vaccines 
a) Varicella/Zoster sentinel surveillance: Until 2010, RKI was the scientific coordinator of a 
public-private partnership project to monitor the impact of measles and varicella vaccination in a 
network of approximately 1,000 private physician offices (paediatricians and family doctors) 
(Siedler & Arndt, Euro Surveill 2010). In 2011 the project was transferred to the sole responsibility 
of the RKI Immunisation Unit, with funds provided by MoH (project planned for 2011-2014). Since 
measles incidence was decreasing in recent years and only rarely reported from this sentinel, the 
project’s focus is now on the surveillance of varicella disease, varicella breakthrough infections, and 
herpes zoster. Mathematical modelling suggests that a shift in the age-distribution of varicella 
cases or an increase in zoster incidence might occur in the decades following the implementation 
of routine varicella vaccination (in Germany since 2004). So far, no such epidemiological changes 
have been observed in the sentinel. Based on these sentinel data, the effectiveness of 1-dose 
varicella vaccination was estimated (Höhle et al., Epidem Infect 2011). 
b) Impact analyses: Analyses to evaluate the impact of vaccination on the disease incidence at the 
population level were performed and published in collaboration with external partners. Before-and-
after analyses, regression analyses, and time-series analyses were conducted and published for 
rotavirus, meningococcal and varicella disease (Dudareva-Vizule et al., Human vaccines & 
immunother 2012; Hellenbrand et al., J infect 2012; Höhle et al., Epidem Infect 2011). 
c) Assessment of vaccine effectiveness: There are several study designs that can be applied to 
assess vaccine effectiveness. In contrast to vaccine efficacy, which is assessed in the pre-licensure 
phase in randomised-controlled trials by usually including only healthy participants and 
administrating the vaccine according to a standard protocol, vaccine effectiveness is measured in 
the post-licensure phase after widespread use of the vaccine in the general population under “real-
life” conditions. During the 2009/10 H1N1 influenza pandemic, the Immunisation Unit assessed 
H1N1 vaccine effectiveness against medically-attended laboratory-confirmed H1N1-influenza by 
applying the screening method, and against H1N1-associated hospitalisation by conducting a 
hospital-based case-control study in a network of 9 clinics in Berlin (in collaboration with the 
Vivantes Clinic Network) (Wichmann et al., Euro Surveill 2010; Hellenbrand et al., BMC Infect Dis 
2012). In cooperation with the state health authority in Mecklenburg Western-Pomerania the 
effectiveness of rotavirus vaccination and risk factors for breakthrough infections were investigated 
in 2011(Adlhoch et al., Ped Infect Dis J 2012, in press). In collaboration with federal/local health 
authorities, the effectiveness of vaccines against measles (in Berlin), mumps (in Bavaria), and 
varicella (in seven day-care centres) was assessed during outbreaks in 2009-12 (Spackova et al., 
Vaccine 2010; additional papers submitted or in preparation). Results from such studies can 
confirm the effectiveness of these vaccines (excellent for measles, less effective for mumps), 
demonstrate differences between vaccine products (varicella), and suggest waning of vaccine-
induced immunity (rotavirus). 
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2.2.5. Methods for the development of evidence-based vaccination recommendations 
In 2010 and 2011, the Immunisation Unit organised two international workshops on procedures for 
the development of evidence-based vaccination recommendations in Berlin, which were funded by 
the German Ministry of Health (MoH). Members of national and international Immunisation 
technical advisory groups or their executive secretariats (e.g. from the US and Canada, other 
European countries, and the World Health Organization’s SAGE) as well as experts from ECDC and 
the GRADE working group participated in this meetings. The main results of the first meeting were 
published in an international journal (Matysiak-Klose et al. Vaccine 2012). Based on this exchange 
and following intensive discussions within the “STIKO Methods working-group”, a new Standard 
Operating Procedure (SOP) for the development of vaccination recommendations was developed 
and endorsed by STIKO in 2011 (www.stiko.de/en). The framework of this new methodology is 
presented in Figure 9. 
Figure 9: Current framework of the STIKO / executive secretariat in Unit 33 for the development of evidence-
based vaccination recommendation (based on GRADE) 
 
2.3. Major goals and contribution to the goals of the department  
2.3.1. Short-term goals 
a. Support the implementation and conduct communication activities after the parliament’s 
decision to make mumps, postnatal rubella, pertussis, and varicella notifiable in 
Germany. A parliament decision for the commensurate amendment of the German 
Protection against Infection Act (IfSG) is expected by the end of 2012 or beginning of 2013. 
The Immunisation Unit has already developed and finalised case definitions for these four 
diseases, in collaboration with Unit 31/Unit 32 and by formal consultations of the federal 
states. 
b. According to a request of the World Health Organization Regional Office for Europe to 
establish a National Verification Committee for measles and rubella elimination (NVC), the 
German MoH asked the RKI Immunisation Unit in 2012 to host the executive secretariat 
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of the NVC. With the constitutive meeting of the NVC, which is expected to take place in 
the beginning of 2013, the secretariat will start its work with the preparation of the first NVC 
report and will support the development of a national action plan. 
c. Publication of the rotavirus vaccination recommendation and the scientific background 
paper, the first STIKO recommendation developed according to the new SOP, by mid-2013. 
d. Release an interim report on varicella vaccination: In 2009, STIKO committed to 
evaluating the recommendation to vaccinate all children against varicella with 2 vaccine 
doses. A publication of preliminary results on the impact of the varicella vaccination and on 
open questions for further research is planned for 2013. 
e. Continue the systematic review, grading of evidence, and preparation of background 
papers required for STIKO’s decisions on vaccination recommendations related to high 
priority topics (i.e. vaccination against meningococcal B disease, update of the hepatitis B 
vaccination recommendation, and adult pneumococcal conjugate vaccination) in 2013/14. 
f. Start preparations for STIKO’s decisions on vaccination recommendations related to the 
medium priority topics (i.e. reassessment of the influenza vaccination recommendation, 
HPV vaccination for boys, and infant vaccination schedule 2+1 vs. 3+1). 
2.3.2. Medium- to long-term goals 
a) Continue the process of implementation and evaluation of the new STIKO methodology 
for the development of evidence-based vaccination recommendations (Figure 9). This 
process will be supported by a continued exchange with other national and international 
Immunisation technical advisory groups and by an ECDC-funded project on methods for 
evidence-based public health. 
b) Develop a standard methodology for the conduct of health economic evaluations of 
vaccines/vaccinations in Germany and the integration of the results of such analyses into 
the decision-making process of STIKO and other relevant stakeholders. Resources need to 
be identified to build on this recently developed expertise in the Immunisation Unit and to 
continue this important process in close cooperation with other relevant stakeholders in 
Germany. 
c) Increase the capacity and expertise in the unit to conduct systematic reviews. The new 
methodology for the development of evidence-based vaccination recommendation has led 
to a dramatic increase in work load. However, the resources of the executive secretariat 
have not grown accordingly. Therefore, STIKO was compelled to undertake a prioritisation 
of current relevant topics. This means that certain tasks like the re-evaluation of current 
STIKO recommendations had to be postponed and new STIKO recommendations may be 
delayed in the future. 
d) Increase research capacity and expertise in the unit related to the evaluation of 
vaccination recommendations and vaccination strategies. This includes the conduct of data 
analyses and epidemiological studies for the assessment of vaccine effectiveness and 
impact of vaccination after introduction in the population. 
e) Integrate continuous vaccination coverage assessment through health insurance 
refund claim data into the routine tasks of the Unit. Currently, this is a MoH-funded 
research project. Funding will end in 2013 and resources will be required to continue this 
important activity. 
f) Expand and improve information resources on vaccines and on the benefit/risk of 
vaccinations on the webpages of RKI and STIKO. Foster the collaboration with the German 
Federal Centre for Health Education (BZgA) to improve two-way communication activities 
with the professional community and the general public, including the utilisation of new 
media and new technologies. 
g) Create an understanding among stakeholders/policymakers that the introduction of 
new vaccines requires a well-functioning system. Such a system includes the systematic 
review of evidence as a basis for national vaccination recommendations, implementation of 
vaccinations supported by two-way communication activities, the monitoring of vaccine 
uptake in all target groups, and the systematic evaluation of the risks and benefits of 
vaccination after introduction in the population.  
Such a system helps  
i) to identify the most efficient use of vaccines and to avoid the waste of public resources, 
ii) to identify effects of vaccinations in a timely manner and adapt recommendations if 
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needed, and  
iii) to better inform the public about the benefits/risks of vaccinations to counteract 
increasing vaccination scepticism in the population and support equal access to the 
benefits of vaccination. 
2.3.3. Contributions to the goals of the department 
a) One of the main goals of the department is the protection of the population from infectious 
disease. The unit contributes substantially to this goal through:  
a. the continuous surveillance and evaluation of the epidemiologic situation of 
vaccine preventable diseases (VPD); 
b. targeted research activities on the impact of widespread vaccination on the 
epidemiology of specific VPDs in the German population and on vaccine 
effectiveness;  
c. the development of scientific background papers, the publication of STIKO 
recommendations, and the communication of vaccination-related issues to 
healthcare professionals (Figure 9); 
d. scientific advice and guidance of public health authorities on state and local level in 
implementing prevention and containment strategies and decisions with regard to 
VPD, including support in VPD outbreaks and publication of best practice; 
e. constant dialogue with vaccinating health care professionals and local public health 
authorities through a telephone hotline twice a week.  
f. Exchange of experiences gained in the development and implementation of 
methods for evidence-based public health decisions. 
b) Support of other RKI-units during large outbreaks and in public health crises. 
2.4. Additional work and methodologies for investigations 
2.4.1. Surveillance activities  
a) Routine surveillance of notifiable VPD in close co-operation with Unit 31 and Unit 32 as well 
as with national reference laboratories and with the state public health institutes: Analysis 
of serotype distribution, outbreak detection, trend analysis etc.  
b) Sentinel surveillance for VPD, which are not notifiable: 
• PneumoWeb: laboratory-based sentinel reporting system on invasive pneumococcal 
disease (IPD) to evaluate the impact of infant vaccination with pneumococcal 
conjugate vaccines on IPD-incidence and serotype distribution in children and adults 
(herd protection) 
• Varicella/zoster sentinel: see 2.2.4, Unit 33 
c) Supportive research projects if no routine population-based or sentinel surveillance 
systems are available: For HPV, a population-based representative cross-sectional study 
with cervical self-sampling was conducted in 2011/12 among unvaccinated women aged 20-
25 years to assess a baseline HPV genotype prevalence (shortly after vaccine introduction). 
Results of the pilot phase have been published (Deleré et al. J Clin Microbiol 2011), an 
interim analysis was presented at EUROGIN 2012, and a paper with the results of the 
cross-sectional study is in preparation. Such a cross-sectional study should be repeated in 
4-8 years. 
d) Identification of TBE risk areas in Germany in cooperation with unit 31 based on district 
incidences. Results are published annually together with a TBE surveillance summary. 
2.4.2. Methods for evidence-based public health 
In an ECDC-funded project, a comprehensive methodology will be developed for the appraisal of 
evidence in the field of public health, with a particular focus on infectious disease epidemiology, 
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prevention and control. Within a consortium (led by the RKI Immunisation Unit) between 
European public health agencies, academic institutions and the GRADE working group, the 
framework will cover interventional as well as non-interventional study designs.  
2.4.3. Workshops organised by the Immunisation unit 
Between 2009 and 2012, the Immunisation unit has organised a number of scientific workshops to 
support the exchange with national and international experts. 
a) Workshop on methods for the assessment of vaccination coverage. National workshop 
with the federal states and other experts in the field in 2012 (responsible: S. Reiter, D. 
Walter); 
b) Workshop on methods for defining TBE risk areas. National workshop with federal states 
and other experts in the field in 2011 (responsible: W. Hellenbrand); 
c) International workshops on methods for the development of evidence-based vaccination 
recommendations. Two MoH-funded workshops in 2010 & 2011 (see also 2.2.1, Unit 33) 
(responsible: D. Matysiak-Klose). The agenda, presentations, and meeting reports of the 
two workshops are published on the RKI web pages: www.stiko.de/en/methods 
d) Challenges after introduction of HPV vaccines – Experiences and results from HPV post-
licensure monitoring in industrial countries. Satellite Symposium to the 27th International 
Papillomavirus Conference in 2011 (responsible: Y. Deleré); 
e) Workshop on vaccination and migration. National workshop with experts in the field in 
2011 (responsible: K. Atzpodien). A meeting report was published in the Epid Bull 48/2011; 
f) Workshop with experts in the field of Immunisation, public health or health communication 
on “Challenges in a complex media environment” in 2011 (responsible: S. Reiter, D. Walter) 
g) Workshop on rotavirus vaccination. National workshop with experts in the field in 2010 
(responsible: J. Koch). 
2.5. Scientific advice and consulting services 
a) Scientific advice to the German MoH. In 2009–2012, the Immunisation Unit wrote a total 
of 192 ad-hoc reports requested by the MoH.  
b) Scientific advice or guidance to healthcare professionals: 
• Publication of STIKO-recommendations which include beside the routine vaccinations 
(Figure 10) also recommendations for specific indications like health status or 
occupation (see www.stiko.de/en).  
• Development and publications of FAQ and other information resources on vaccination-
related issues online. From January to October 2012, there were a total 2.37 million 
clicks on the webpages of STIKO and www.rki.de/impfen;   
• Response to written inquiries (email, fax or letters). In 2009–2012, there were a total  
3,802 written inquiries (as of 30. October 2012); 
• Answering inquiries by telephone. In 2009-2012, an estimated total 8,000 telephone 
requests were answered (as of 30 October 2012); 
• Contributions to the “epidemiological year book” of the department and the “guide for  
physicians” (“Ratgeber für Ärzte”);  
• Preparation of detailed surveillance reports for publication in the Epidemiologisches  
Bulletin at regular intervals. 
c) Participation in scientific advisory boards (see 4.1.5., Unit 33). 
d) Scientific advice for state (and on special demand for local) public health authorities on 
best practice for VPD control and supplemental vaccination activities, i.e. in case of 
vaccination campaigns or outbreaks of VPD, or for the development of the National 
Vaccine Plan (published by the federal states in 2012).  
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Figure 10: Routine vaccination calendar according to current STIKO recommendations 
 
2.6. Training and teaching activities 
• Participation as facilitators in biannual 1-week courses on field epidemiology for public 
health workers in Germany hosted by the department. 
• Project supervision and hosting of fellows attending the German Postgraduate Program 
for Applied Epidemiology (PAE) and the European Intervention Epidemiology Training 
Program (EPIET): 9 fellows were trained within the Immunisation Unit from 2009-2012.  
• Activities as lecturers and supervisors in the Masters Program in International Health 
(Charité University Medicine, Berlin), Masters Program in Public Health (Berlin School 
of Public Health), and the Masters Program in Applied Epidemiology (Robert Koch 
Institute). 
• Supervisors for PhD/dissertations and master theses (currently 5 PhD/dissertation 
projects in the unit and 2 master thesis projects). 
• Participation as facilitators in teaching modules of the EPIET program. 
• Supervisors of international guests of the unit (like Fulbright scholars) working on 
scientific questions concerning vaccinations  
• Lecturer in the RKI-coordinated teaching module "Infectious Diseases Epidemiology" at 
the Charité University Medicine, Berlin. 
• Teaching at midwives colleges (Charité University Medicine, Berlin). 
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3. Cooperation with other scientists or research institutions 
3.1. Internal (within RKI) 
Department 1, FG12 (NRC for Measles/Mumps/Rubella: A. Mankertz) 
• Siedler A et al., J Infect Dis 2011 
• Bätzing-Feigenbaum J et al., Euro Surveill 2010 
• Wichmann O et al., Bulletin of the World Health Organisation 2009 
Department 1, FG15 (National Certification Committee Poliomyelitis: S. Dietrich;  
and German consultant laboratory for rotavirus: A. Mas Marques) 
• Participation in the meetings of the National Certification Committee (NCC) 
Poliomyelitis and provision of poliomyelitis vaccination coverage data for the NCC 
report to the World Health Organization. 
• Adlhoch C et al., Ped Infect Dis J 2012 
Department 1, FG17 (NRC for influenza: B. Schweiger) 
• Nachtnebel M et al., BMC Pub Health 2012 
• Hellenbrand WJ et al., BMC Infect Dis 2012 
Department 2, FG23 (M. Schlaud)  
• Siedler A et al., Euro Surveill 2012 
• Schmitz R et al., Dtsch Arztebl Int 2011 
• Jorgensen P et al., Epidem Infect 2010 
Department 2, FG25 (C. Lange) 
• Böhmer MM et al., BMC Pub Health 2012 
• Böhmer MM et al., Vaccine 2011 
• Böhmer MM et al., Human Vaccines 2011 
3.2. External / National 
National Reference Laboratory for Meningococci, Würzburg (M. Frosch) 
• Hellenbrand W et al., J Infect 2012. Epub ahead of print Oct 5 
• Vogel U et al., Kinderarztl Prax 2010 
National Reference Laboratory for Pneumococci, Aachen (M. van der Linden) 
• van der Linden M et al., Vaccine 2012 
• Rückinger S et al., Klin Padiatr 2011 
• Rückinger S et al., Pediatr Infect Dis J 2009 
• Rückinger S et al., Vaccine 2009 
National Consultation Laboratory for Rabies, Essen (R.S. Ross) and National and OIE 
Reference Laboratory for Rabies, WHO Collaborating Centre for Rabies Surveillance and 
Research, Wusterhausen/Dosse (C.M. Freuling, T. Müller) 
• Ross RS et al., Berl Munch Tierarztl Wochenschr 2012 
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Vivantes Clinic Network, Berlin (C. Träder) 
• Nachtnebel M et al., BMC Public Health 2012 
• Hellenbrand WJ et al., BMC Infect Dis 2012 
Clinic for Gynecology, Charité University Medicine Berlin (A. Kaufmann) 
• Deleré Y et al., J Clin Microbiol 2011 
Institute for Social Medicine, Epidemiology and Health Economic, Charité University  
Medicine Berlin (T. Reinhold) 
• Ultsch B et al., BMC Infect Dis 2011 
Paul-Ehrlich-Institute, PEI (B. Keller-Stanislawski) 
• Dudareva-Vizule S et al., Hum Vaccin Immunother 2012 
Federal Centre for Health Education, BZgA (S. Wortberg) 
• Wortberg S et al., Dtsch Med Wochenschr 2010 
• Wortberg S et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009 
Institute of Social Pediatrics and Adolescent Medicine, University of Munich (R. v. Kries) 
• von Kries R et al., PLoS One 2011 
• Höhle M et al., Epidemiol Infect 2011 
University of Bielefeld (W. Greiner/O. Damm) and Helmholtzzentrum für Infektiologie  
Braunschweig (R. Mikolajczyk) 
• Publication submitted on HPV vaccination impact and cost effectiveness.  
• Project on varicella transmission modeling and cost-effectiveness ongoing 
University of Cologne and Düsseldorf (I. Schubert and A. Icks) 
• Publication submitted on herpes zoster cost-of-illness 
3.3. External / International 
VENICE network (see also 4.2.5): 
• Haverkate MDA et al., Euro Surveill 2012 
• Dorleans F et al., Euro Surveill 2010 
Dutch National Institute for Public Health and the Environment, RIVM (M. Kretzschmar) 
• Bonacic-Marinovic AAS et al., Emerg Infect Dis 2012 
• van Boven M et al., J R Soc Interface 2010 
National Institute of Public Health, Warsaw, Poland (P. Stefanoff) 
• Stefanoff P et al., Zoonoses Public Health 2012  
• Hellenbrand W et al., Epidemiol Infect 2011 
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4. Appendix 
4.1. Overview on output achievements of the unit 2009-2012 
4.1.1. Scientific publications 2009–2012 
Number of peer-review publications co-authored by members of the unit: 81 
Impact factor (IF) according to JCR (for 2012 according to 2011) 
2009: 62.9 
2010:  26.3 
2011: 207.1 
2012.  72.5 
Cumulative 2009-12:  368.8 
A) Original research articles in peer-review journals 
2012 
Adlhoch C, Hoehne M, Littmann M, Mas Marques A, Lerche A, Dehnert M, Eckmanns T, 
Wichmann O, Koch J. Rotavirus Vaccine Effectiveness and Case-Contol Study on Risk Factors for 
Breakthrough Infections in Germany, 2010-2011. Pediatr Infect Dis J 2012, epub ahead of print. 
Böhmer MM, Walter D, Falkenhorst G, Müters S, Krause G, Wichmann O: Barriers to pandemic 
influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in 
Germany. BMC Public Health 2012, 12(1):938.  
Bonacic-Marinovic AAS, Swaan C, Wichmann O, van Steenbergen J, Kretzschmar M. Effectiveness 
and Timing of Vaccination during School Measles Outbreak. Emerg Infect Dis 2012; 18(9):1405-
1413. 
Cramer JPM, Mac T, Hogan B, Stauga S, Eberhardt S, Wichmann O, Mertens T, Burchard GD. 
Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination 
as well as natural infection in November 2010 in Hamburg, Germany. Euro Surveill 2012; 17: 
pii=20052. 
Dudareva-Vizule S, Koch J, An der Heiden M, Oberle D, Keller-Stanislawski B, Wichmann O. 
Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. Hum 
Vaccin Immunother 2012; 8(10): 1407-15. 
Haverkate MDA, D'Ancona F, Giambi C, Johansen K, Lopalco P, Cozza V, Appelgren E, VENICE 
project gatekeepers and contact points (including Reiter S). Mandatory and recommended 
vaccination in the EU, Iceland and Norway: results of the VENICE 2010 survey on the ways of 
implementing national vaccination programmes. Euro Surveill 2012; 17: pii=20183. 
Hellenbrand W, Jorgensen P, Schweiger B, Falkenhorst G, Nachtnebel M, Greutelaers B, Traeder 
C, Wichmann O. Prospective hospital-based case-control study to assess the effectiveness of 
pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009- 2010 
using matched hospital and test-negative controls. BMC Infect Dis 2012; 12:doi:10.1186/471-2334-
12-127. 
Hellenbrand W, Elias J, Wichmann O, Dehnert M, Frosch M, Vogel U. Epidemiology of invasive 
meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal c 
conjugate vaccine. J Infect 2012; Oct 5: pii: S0163-4453(12)00259-9.  
Kurkela S, Pebody R, Kafatos G, Andrews N, Barbara C, Bruzzone B, Butur D, Caplinskas S, 
Davidkin I, Hatzakis A, Hellenbrand W, Hesketh LM, Nardone A, Nemecek V, Pistol A, Sobotova 
Z, Vranckx R, Anastassopoulou CG. Comparative hepatitis A seroepidemiology in 10 European 
countries. Epidemiol Infect 2012; 140(12): 2172-81. 
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Mereckiene JC, Cotter S, Weber JT, Nicoll A, D'Ancona F, Lopalco PL, Johansen K, Wasley AM, 
Jorgensen P, Lévy-Bruhl D, Glambi C, Stefanoff P, Dematte L, O'Flanagan D, VENICE project 
gatekeepers group (including Reiter S). Influenza A(H1N1)pdm09 vaccination policies and 
coverage in Europe. Euro Surveill 2012; 17: pii=20064. 
Muscat M, Zimmerman L, Bacci S, Bang H, Glismann S, Mølbak K, Reef S; EUVAC.NET group 
(including Siedler A). Toward rubella elimination in Europe: an epidemiological assessment. 
Vaccine 2012; 30:1999-2007.  
Nachtnebel M, Greutelaers B, Falkenhorst G, Jorgensen P, Dehnert M, Schweiger B, Traeder C, 
Buda S, Eckmanns T, Wichmann O, Hellenbrand W. Lessons from a one-year hospital-based 
surveillance of acute respiratory infections in Berlin- comparing case definitions to monitor 
influenza. BMC Public Health 2012; 12: 245. 
Ross RS, Freuling CM, Deleré Y, Thomas Müller T. Assessment of the human medical significance 
of the rabies zoonosis in Germany – analysis of available data and desiderata. Berl Munch Tierarztl 
Wochenschr 2012; 125: 272–277. 
Siedler A, Rieck T, Reuss A, Walter D, Poggensee G, Poethko-Müller C, Reiter S. Estimating 
vaccination coverage in the absence of immunisation registers – the German experience. Euro 
Surveill 2012; 17:pii=20152. 
Stefanoff P, Pfeffer M, Hellenbrand W, et al. Virus Detection in Questing Ticks is not a Sensitive 
Indicator for Risk Assessment of Tick-Borne Encephalitis in Humans. Zoonoses Public Health 
2012. epub ahead of print 
Stöcker P, Dehnert M, Schuster M, Wichmann O, Deleré Y. Human papillomavirus vaccine 
uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010. Hum Vaccin 
Immunother 2012; 9, epub ahead of print. 
Takla A, Barth A, Siedler A, Stocker P, Wichmann O, Deleré Y. Measles outbreak in an asylum-
seekers' shelter in Germany: comparison of the implemented with a hypothetical containment 
strategy. Epidemiol Infect 2012; 140(9):1589-98. 
van der Linden M, Weiss S, Falkenhorst G, Siedler A, Imohl M, von Kries R. Four years of 
universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive 
pneumococcal disease and serotype distribution in children. Vaccine 2012; 30: 5880-5. 
Vong S, Goyet S, Ly S, Ngan C, Huy R, Duong V, Wichmann O, Letson GW, Margolis HS, Buchy P. 
Under-recognition and reporting of dengue in Cambodia: a capture-recapture analysis of the 
National Dengue Surveillance System. Epidemiol Infect 2012; 140(3): 491-9. 
Walter D, Böhmer MM, Reiter S, Krause G, Wichmann O. Risk perception and information-
seeking behaviour during the 2009/10 influenza A(H1N1)pdm09 pandemic in Germany. Euro 
Surveill 2012; 17:pii=20131. 
2011 
Bätzing-Feigenbaum J, Kollan C, Kühne A, Matysiak-Klose D, Gunsenheimer-Bartmeyer B, 
Hamouda O. Cohort profile: the German ClinSurv HIV project – a multicentre open clinical cohort 
study supplementing national HIV surveillance. HIV Med 2011; 12: 269-78. 
Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gartner B, Gross U, Haas W, Hamouda 
O, Hubner J, Janisch T, Kist M, Kramer MH, Ledig T, Mielke M, Pulz M, Stark K, Suttorp N, Ulbrich 
U, Wichmann O, Krause G. Communicable Diseases Prioritized for Surveillance and 
Epidemiological Research: Results of a Standardized Prioritization Procedure in Germany, 2011. 
PLoS One 2011; 6(10): e25691. 
Böhmer MM, Walter D, Krause G, Muters S, Gosswald A, Wichmann O. Determinants of tetanus 
and seasonal influenza vaccine uptake in adults living in Germany. Hum Vaccin 2011; 7: 1317-25. 
Böhmer MM, Walter D, Muters S, Krause G, Wichmann O. Seasonal influenza vaccine uptake in 
Germany 2007/2008 and 2008/2009: Results from a national health update survey. Vaccine 2011; 
29: 4492-8. 
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Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, Deleré Y, et al. 
German outbreak of Escherichia coli O104:H4 associated with sprouts. N Eng J Med 2011; 365(19): 
1763-70. 
Deleré Y, Schuster M, Vartazarowa E, Hansel T, Hagemann I, Borchardt S, Perlitz H, Schneider A, 
Reiter S, Kaufmann Am. Cervicovaginal self-sampling is a reliable method for determination of 
prevalence of human papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol 
2011; 49(10): 3519-22. 
Domingo C, Niedrig M, Gascon J, Palacios G, Reyes N, Malo MJ, Wichmann O, et al. Molecular 
Surveillance of Circulating Dengue Genotypes Through European Travelers. J Travel Med 2011; 
18(3): 183-90. 
Fluegge K, Wons J, Spellerberg B, Swoboda S, Siedler A, Hufnagel M, Berner R. Genetic differences 
between invasive and noninvasive neonatal group B streptococcal isolates. Pediatr Infect Dis J 2011; 
30(12): 1027-31. 
Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, 
Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Muller L, King LA, Rosner B, Buchholz 
U, Stark K, Krause G, HUS Investigation Team (incl. Reiter S, Böhmer MM, Deleré Y, Falkenhorst 
G, Hellenbrand W, Koch J, Schuster M, Ultsch B, Wlater D). Epidemic profile of Shiga-toxin-
producing Escherichia coli O104:H4 outbreak in Germany. N Eng J Med 2011; 365(19): 1771-80. 
Frank C, Faber MS, Askar M, Bernard H, Fruth A, Gilsdorf A, Hohle M, Karch H, Krause G, Prager 
R, Spode A, Stark K, Werber D; HUS investigation team (incl. Atzpodien K, Böhmer MM, Ultsch 
B). Large and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011. Euro 
Surveill 2011; 16. 
Höhle M, Siedler A, Bader HM, et al. Assessment of varicella vaccine effectiveness in Germany: a 
time-series approach. Epidemiol Infect 2011; 139: 1710-9. 
Koch J, Wiese-Posselt M. Epidemiology of Rotavirus Infection in Children Less Than 5 Years of 
Age: Germany, 2001-2008. Pediatr Infect Dis J 2011; 30: 112-117. 
Mette A, Reuss AM, Feig M, Kappelmayer L, Siedler A, Eckmanns T, Poggensee G. Under-reporting 
of measles: an evaluation based on data from north rhine-westphalia. Dtsch Arztebl Int 2011; 
108(12): 191-6.  
Rückinger S, van der Linden M, Siedler A, von Kries R. Potential Benefits From Currently Available 
Three Pneumococcal Vaccines for Children - Population-Based Evaluation. Klin Padiatr 2011; 223: 
61-4. 
Schmitz R, Poethko-Müller C, Reiter S, Schlaud M. Vaccination status and health in children and 
adolescents: findings of the German Health Interview and Examination Survey for Children and 
Adolescents (KiGGS). Dtsch Arztebl Int 2011; 108(7): 99-104. 
Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: 
Quantifying the burden of disease. BMC Infect Dis 2011; 11: 173. 
Uphoff H, an der HM, Schweiger B, Campe H, Beier D, Helmeke, C, Littmann, M, Haas W, Buda S, 
Faensen D, Feig M, Altmann D, Wichmann O, et al. Effectiveness of the AS03-adjuvanted vaccine 
against pandemic influenza virus A/(H1N1) 2009- a comparison of two methods; Germany, 
2009/10. PLoS One 2011; 6: e19932. 
von Kries R, Weiss S, Falkenhorst G, et al. Post-Pandemic Seroprevalence of Pandemic Influenza A 
(H1N1) 2009 Infection (Swine Flu) among Children <18 Years in Germany. PLoS One 2011; 6: 
e23955. 
Wadl M, Siedler A, Kramer W, et al. Measles transmission from an anthroposophic community to 
the general population, Germany 2008. BMC Public Health 2011; 11: 474. 
Wadl M, Rieck T, Nachtnebel M, et al. Enhanced surveillance during a large outbreak of bloody 
diarrhoea and haemolytic uraemic syndrome caused by Shiga toxin/verotoxin-producing 
Escherichia coli in Germany, May to June 2011. Euro Surveill 2011; 16: pii=19893. 
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Walter D, Böhmer MM, Heiden M, Reiter S, Krause G, Wichmann O. Monitoring pandemic 
influenza A(H1N1) vaccination coverage in Germany 2009/10 - results from thirteen consecutive 
cross-sectional surveys. Vaccine 2011; 29: 4008-12. 
Wichmann O, Yoon I-K, Vong S, et al. Dengue in Thailand and Cambodia: An Assessment of the 
Degree of Underrecognized Disease Burden Based on Reported Cases. PLoS Negl Trop Dis 2011; 
3:e996. 
2010 
Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. Forecasting dengue vaccine demand in 
disease endemic and non-endemic countries. Human Vaccines 2010; 6(9): 745-53. 
Bätzing-Feigenbaum J, Pruckner U, Beyer A, Sinn G, Dinter A, Mankertz A, Siedler A, Suckau M. 
Spotlight on measles 2010: Preliminary report of an ongoing measles outbreak in a subpopulation 
with low vaccination coverage in Berlin, Germany, January-March 2010. Euro Surveill 2010; 15(13): 
pii=19527. 
Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O'Flanagan D, Lopalco PL, 
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2. Deleré Y, Schuster M, Vartazarowa E, Hansel T, Hagemann I, Borchardt S, Perlitz H, 
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years. JClin Microbiol 2011; 49(10): 3519-22. 
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4. Spackova M, Wiese-Posselt M, Dehnert M, Matysiak-Klose D, Heininger U, Siedler A. 
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5. Muscat M, Bang H, Wohlfahrt J, Glismann S, Molbak K, EUVAC.Net Group (for Germany 
Siedler A). Measles in Europe: an epidemiological assessment. Lancet 2009; 373(9661): 
383-9. 
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1. Annual STIKO recommendations 
2. Webpage of the STIKO and the RKI Immunisation Unit: www.stiko.de and 
www.rki.de/impfen  
3. Vaccination - 20 objections and responses (In German: „Schutzimpfungen – 20 Einwände 
und Antworten des Robert Koch Institutes und des Paul-Ehrlich-Instituts“). Available online 
at www.rki.de/impfen 
4. Annual publication of geographic areas at risk for tick-borne encephalitis in Germany 
5. Annual publications of vaccination coverage data  
4.1.3. Awards and honours, 2009–2012 
• Detlef Petzoldt-Award 2012 (German Society for Sexually-Transmitted Diseases) in 
recognition of the study/publication on cervico-vaginal self-sampling as a method to 
determine HPV genotype prevalence in Women: Yvonne Deleré 
4.1.4. Overview on collaborations in networks 
a) ECDC: National Epidemiology Contact Point for vaccine-preventable diseases 
• Measles: Dorothea Matysiak-Klose 
• Mumps: Judith Koch 
• Varicella: Anette Siedler 
• Pertussis: Wiebke Hellenbrand 
• Meningococcal Disease: Wiebke Hellenbrand 
• Haemophilus influenzae b: Yvonne Deleré 
b) VENICE: ECDC-funded project “Vaccine European New Integrated Collaboration Effort” 
(VENICE). In the network all 27 EU member states and two EEA/EFTA countries (Iceland and 
Norway) participate with the aim to collect and share information on the national vaccination 
programs through a network of professionals and to build up a knowledge base endeavoring to 
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improve the overall performance of the Immunisation systems. 
National Gatekeeper: Until 2012 Sabine Reiter; since end of 2012 Ole Wichmann. 
c) PRECEPT: ECDC-funded “project on a Framework for Rating Evidence in Public Health”. 
Consortium partners are the Health Protection Agency Scotland, NICE, SIGN, University of 
Rotterdam, Liverpool School of Tropical Medicine, Dutch Tropical Institute, GRADE working group, 
University of Munich, and German Cochrane Center Freiburg. 
Project Coordinator: Thomas Harder 
4.1.5. Memberships and participation in Advisory Boards 
Ole Wichmann 
• Member of the Advisory Board of the German Surveillance System for Rare Pediatric 
Diseases (ESPED) 
• Member of the Expert Committee “Influenza” of the German Association for the Control of 
Viral Diseases (DVV)  
• Member of the Advisory Board for the “Study on the association of pH1N1-vaccination and 
Guillain-Barré Syndrome in Germany” conducted by the Paul Ehrlich Institute 2009/10:  
Wiebke Hellenbrand 
• Member of the Advisory Board for the “Study on the association of pH1N1-vaccination and 
Guillain-Barré Syndrome in Germany” conducted by the Paul Ehrlich Institute 2009/10  
• Member of the Extended Board of the European Meningococcal Disease Society (EMGM) 
4.1.6. List of completed dissertation or master theses in the Unit, 2009 – 2012 
Year Title Name Title of thesis University / 
RKI Supervisor 




The importance of prevention and early 
intervention in vaccine preventable 
diseases – projects on mumps and 
measles 
J. Koch and K. 
Alpers 




Angewandte Infektionsepidemiologie – 
praktische Datenerhebung und –Analyse 
sowie public value ausgewählter 
Infektionsgeschehen als Baustein des 
Infektionsschutzes in Deutschland 
Y. Deleré and K. 
Alpers 





Attitude and practice of private 
physicians related to seasonal and 
pandemic influenza vaccination in 
Germany: Analysis of a telephone survey 
conducted in 2010 
Hannover /  
M. Böhmer,  
D. Walter 
2011 Dr. med. Thomas 
Hänsel 
Assessment of HPV prevalence in 
women aged 20-30 years by using a self-
sampling device  
Y. Deleré and G. 
Krause 




Communication of preventive measures 
during measles outbreak in populations 
with inadequate vaccination coverage  
A. Siedler and G. 
Krause 
4.1.7. Presentations as invited speaker, 2009 - 2012 
Staff from the Immunisation Unit were invited to speak at 66 conferences. 
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4.1.8. Reports and written scientific advice to the Ministry of Health, 2009 - 2012 
There were 192 reports and written scientific advice to the Ministry of Health between 2009 and 
30.9.2012. Total number under the responsibility of the Immunisation Unit: 185 
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1. General information - Unit 34 
Head:  Dr. Osamah Hamouda 
Deputy:  Dr. Viviane Bremer 
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2. Tasks and goals of the Unit 
2.1. Summary 
The unit for HIV/AIDS, STI and Bloodborne Infections (unit 34) is in charge of the control of 
HIV/AIDS, sexually transmitted infections (STI), blood-borne infections such as hepatitis B and C, 
Creutzfeldt-Jakob disease as well as the safety of blood donations. Unit 34 staff collects reports of 
infection with HIV and syphilis that are directly reported anonymously to the RKI. Furthermore, the 
unit is responsible for the laboratory notifications of viral hepatitis B and C and Creutzfeldt-Jakob 
disease. Staff members collect data on blood donations and the number of infections detected in 
blood donors through for the blood donor surveillance.  
Unit 34 maintains additional surveillance systems: The voluntary AIDS registry, the “HIV 1-
Serokonverter” study for HIV-patients with known date of HIV-seroconversion, “InzSurvHIV”, to 
measure the proportion of recent HIV diagnoses, “ClinSurv HIV” cohort study to follow up the 
clinical course of HIV patients. Also, data on HIV resistance data is routinely collected. A laboratory 
sentinel system for the detection of chlamydia has been set up to monitor chlamydia screening 
programme. Chlamydia prevalence has been measured using material from the national survey in 
children (KIGGS) and adults (DEGS).  
Unit 34 has carried out integrated behavioural and biological surveillance in targeted populations, 
such as men who have sex with men, sex workers and i.v. drug users.  
Unit 34 is in charge of the investigation of outbreaks of STI and hepatitis B and C. The unit 
participates in the design and the realisation of national, European and international surveillance 
and research networks. The unit participates in the further development of prevention concepts for 
HIV, STI and hepatitis B and C in close cooperation with the Federal Centre for Health Education 
(Bundeszentrale für gesundheitliche Aufklärung), expert societies and non-governmental 
organisations (e.g. Deutsche AIDS-Hilfe)). Unit staff is involved in setting up guidelines both for 
treatment and for prophylaxis of HIV, STI and Blood-borne infections. 
2.2. Current status of the work and summary of relevant results 
The activities of Unit 34 are divided in basic (statutory) surveillance, additional surveillance and 
cohort studies, integrated behavioural and biological studies and behavioural studies. An overview 
is given in Figure 11. 
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Figure 11: Overview over current and planned activities of Unit 34: Basic surveillance, additional surveillance 
and cohort studies, integrated biological and behavioural surveillance and behavioural studies 
 
2.2.1. Statutory surveillance systems  
Unit 34 staff collects reports of infection with HIV and syphilis that are directly reported 
anonymously to the RKI according to §7.3 of the Infection Protection Act. Laboratory reports are 
completed by physician’s information on symptoms and possible way of transmission. In 2011, 
2911 newly diagnosed HIV-infections were reported, most of them in MSM. The number of syphilis 
diagnoses has increased by 22% from 2010 to 2011 to 3698 cases. Of these, 94% have been 
reported in men.  
Unit 34 is responsible for the laboratory notifications of viral hepatitis B, C and D and 
Creutzfeldt-Jakob disease. Hepatitis B and C are reported through physicians and laboratories to 
the local health units. These reports are forwarded anonymously to the RKI via the state-level health 
authorities. Trends for notified cases of acute hepatitis B with clinical symptoms and laboratory 
confirmation show a decrease since 2001 and have stabilised at a level of 800 cases per year since 
2008. Incidence of newly diagnosed acute or chronic hepatitis C cases is decreasing continuously 
since 2004 from 9,000 cases to 5,000 cases in 2011. New diagnoses are mainly reported in 
persons who inject drugs. Laboratory confirmed hepatitis D cases as super infection or 
simultaneous infection with hepatitis B are rare in Germany. Annual notifications of cases are in 
the range of 7 to 21 cases. 
All sites in Germany collecting blood or blood products are requested to report on a quarterly base 
aggregated data on blood donations and the number of infections by HIV, hepatitis B, hepatitis C 
and syphilis detected in blood donors through for the blood donor surveillance according to the 
Transfusion Act. Since 2001 the prevalence and incidence of HBV and HCV among blood has 
declined whereas incident HIV-infections reached a peak in 2008 and 2010 and show an increasing 
trend. Also, the proportion of syphilis infections among first time donors was highest in 2010. 
From 2008 to 2010, the prevalence for HIV ranged from 6.6 to 7.0/100.000, for HCV from 68.9 to 
81.6/100.000, for HBV from 116.2 to 136.6/100.000 and for syphilis from 31.0 to 42.1/100,000 
donations. The proportion of incident infections/100,000 donations ranged from 0,8-0,9 for HIV, 
0,8-1,0 for HCV, 0,3-0,5 for HBV and 1,4-1,6 for syphilis. 
Surveillance data are regularly analysed and fed back to national and regional stakeholders through 
yearly reports and presentations at national and international conferences.  
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2.2.2. Additional surveillance systems and cohort studies 
The voluntary AIDS registry collects data on AIDS cases and deaths since 1982. These data provide 
information on the HIV/AIDS epidemic, demographic characteristics of AIDS patients and AIDS-
related opportunistic infections, medical care and treatment. Completeness of the system has 
decreased from 85% in the mid-90ies to 50%.  
The HIV 1-Serokonverter Study aims to collect epidemiological and laboratory information on 
newly infected HIV-patients with known date of HIV-seroconversion. These data are used to 
estimate the time between HIV seroconversion and Aids or other important clinical endpoints, to 
monitor the spread of HIV subtypes and the dynamic of HIV resistance in Germany in order to 
optimise treatment. Overall prevalence of transmitted drug resistance is stable at 11% in this study 
population. NRTI resistance was observed most frequently (6%), followed by NNRTI associated 
resistance (2.4%) and PI resistance (2%). HIV subtype B is predominantly reported in the study 
cohort (subtype B: 92% vs. non B-subtype 8%). Currently samples of patients co-infected with HIV 
and hepatitis B and C viruses were analysed serologically as well as bio-molecularly by using 
phylogenetic analysis. To investigate influences by host on the HIV disease progression genome 
wide association studies are performed by exome sequencing in patients with rapid disease 
progression as well as in elite controllers to identify host polymorphisms influencing the course of 
the HIV disease.  
The German Incidence Study (2008-2010) aimed to monitor recent HIV infections in a 
representative study sample in Germany for the first time. A nationwide cross-sectional study was 
initiated to estimate the proportions of recent infections (RIs) among newly diagnosed HIV cases 
in Germany. The overall proportion of RI in the study sample was 29.2%. Men were found to be 
recently infected in 30.8% (793/2575), whereas the proportion of RI in women was 21.4% (107/499) 
(OR=1.6; 95%CI [1.3;2.1]). In order to detect trends the “Study for Surveillance of recent HIV 
infections in Germany (InzSurvHIV)” was launched in December of 2010.  
The “InzSurvHIV ” (2010-2013) aims to measure the proportion of recent HIV diagnoses among 
reported HIV diagnoses in Germany and to identify populations at risk, time trends and regional 
differences among patients with recent HIV infections. The study also explores whether incidence 
testing can be implemented into routine HIV surveillance. In 2011 the proportion of recent 
infections overall was 26%. Highest proportions were found in MSM, indicating frequent testing 
and on-going HIV transmission in that group. Proportion of RI among migrants, especially from 
sub-Saharan Africa are lower (<15%) which might be attributed to limited access to HIV testing. 
The implementation of HIV-incidence testing into routine HIV-surveillance seems to be possible 
and practicable and is planned for 2014. 
The “ClinSurvHIV” multicentre cohort study has been established in 1999 to follow up the clinical 
course of HIV patients. Data on demographics, HIV-associated and Aids-defining diseases as well 
as detailed information on antiretroviral treatment are regularly collected from centres specialised 
in HIV-care. The Clinical Surveillance of HIV Disease in Germany (ClinSurv HIV) was initiated in 
1999 as collaboration between major HIV treatment centres and the Robert Koch Institute (RKI). 
The ClinSurv Cohort is a national multi centre prospective observational open cohort. The study 
design allows assessing the associations between demographic and clinical characteristics, 
different treatment regimens and trends of disease progression over time under routine clinical 
care conditions. The cohort represents the clinical reality of HIV treatment and care for a large 
proportion of HIV-infected patients in Germany (21% of all patients under care in Germany). 
Currently 16,751 patients were enrolled into the cohort (113.825 person years of observation; 
31.12.2011). Follow-up of clinical care of patients infected with HIV in Germany requires additional 
surveillance systems. Thus the study design of the ClinSurv HIV study complements the cross 
sectional mandatory HIV surveillance in Germany. Antiretroviral treatment success in the study 
population is high (more than 80% under the viral detection limit <50 copies/ml). Time on 
treatment interruption declined in this study collective during the period of observation to currently 
2%. 
Following the establishment of a national chlamydia screening programme offered to women less 
than 25 years of age, a chlamydia laboratory sentinel system for the detection of chlamydia has 
been set up. The aim of the sentinel system is to monitor the proportion of positive chlamydia 
tests. Current data set provides information on approximately 19% (433.622) of all Chlamydia tests 
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performed in Germany in years 2008 to 2012 (August). Among all tests performed in women 20% 
were screening tests for women less than 25 years of age, 38% screening for pregnant women, and 
33% were diagnostic tests. Positivity rates were 5.5%, 2.5% and 3.7%, respectively. 
2.2.3. Integrated behavioural and biological studies 
Chlamydia prevalence studies (2007-10): Prevalence of Chlamydia trachomatis has been 
measured using urines from the representative national survey in children and teenagers (KIGGS) 
and adults (DEGS). Prevalence among 1925 teenagers was highest in 17-year old girls with 3.3%. 
Risk factors for chlamydia infection were smoking, marihuana and alcohol consumption and low 
social status. Prevalence among 6800 tested adults was 0.7%. Highest prevalence among women 
was in the group aged 18-20 year (4.5%) and among men in the group aged 25-30 years (4.9%). 
Risk factors were smoking and social status.  
STD-Sentinel surveillance (2003-2009) was a multicentre sentinel system to collect data on STI 
diagnoses in different clinical settings. STI patients were also asked to fill in a questionnaire on 
their sexual behaviour and social status. Chlamydia trachomatis was the most frequently diagnosed 
STI. The sentinel system was not able to provide representative data on STI trends nor prevalences.  
Pharyngeal and Rectal Infection Screening Study (PARIS) (2009-10): A total of 2247 MSM was 
screened for gonorrhoea and chlamydia using urethral, rectal and pharyngeal swabs. Laboratory 
results were combined with information on sexual behaviour, sexual practices and medical history. 
The aim was to measure gonorrhoea and chlamydia prevalence and co-infection in different sites 
and to describe factors associated with the infection in order to better understand the need for a 
routine screening. PARIS has been the first multicentre study in Germany measuring the infection 
burden of rectal and pharyngeal infections with gonococci and chlamydia in MSM. In addition, 
most Chlamydia-positive samples have been subtyped to determine the proportion of L-subtypes 
(causing LGV) among Chlamydia-positive MSM in Germany. Chlamydia prevalence was 1.5% in 
pharyngeal, 8.0% in rectal, and 3.3% in urethral specimen. Gonorrhoea prevalence was 5.5% in 
pharyngeal, 4.6% in rectal, and 1.9% in urethral specimens. Rectal and pharyngeal infection was 
significantly more likely in men reporting multiple partners and men diagnosed with HIV. Rectal 
infection was more likely in men practising receptive anal intercourse without condom. In a 
subsample of Chlamydia positive specimens LGV prevalence was 16.5% in rectal and 15.4% in 
pharyngeal specimens. Two publications have been submitted to peer review journals and are 
currently under review. 
STI Prevalence and Behaviour in female sex workers (KAP-Surv-STI) (2010-11): Information on 
STI diagnoses, sexual behaviour and social status were collected from female sex workers attending 
STI testing sites. Among 1425 recruited sex workers, 3% were diagnosed with an STI. Three quarters 
of sex workers were of non-German origin and 44% had a valid health insurance. Risk factors for 
STI were young age, street work, lack of German language skills and unprotected sex.  
KABP-survey as part of the German HIV-Incidence Study (2008-2010): Clinical and socio-
demographic data and dried blood spots (DBS) of 348 persons newly diagnosed with HIV and 320 
HIV negative controls, matched for age, gender, and HIV-transmission route were collected by 
physicians in six sentinel regions in Germany. Cases and controls completed a KABP-questionnaire. 
To distinguish recent (<5 months) from longstanding (>5 months) infection, the BED IgG-capture 
EIA was performed from DBS. Reported risk behaviour of cases with recent infection was compared 
with controls. Among MSM controls were more often in a relationship of >6 months. Controls also 
more often used condoms with acquaintances, with partners met online and with partners of 
unknown serostatus, whereas cases more often had unprotected anal sex with partners of unknown 
serostatus. Having a conversation about serostatus was protective.  
Serobehavioural survey in injecting drug users (DRUCK study) (2012-15): This survey aims to 
determine HIV, hepatitis C and hepatitis B prevalence and risk profiles among injecting drug users 
in selected German cities to improve prevention of HIV and Hepatitis among this population in 
Germany. Blood samples and behavioural data are collected of 2,000 IDUs recruited via 
respondent driven sampling. Results of a pilot study in 2011 showed high prevalence for antibodies 
against hepatitis C (in Berlin (n=337) 52.5%, in Essen (n=197) 79.7% and hepatitis C RNA (Berlin: 
36.9%; Essen: 58.0%). HIV prevalence was 3.9% in Berlin and 3% in Essen. In the coming years six 
others cities in Germany will be explored. 
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2.2.4. Behavioural studies 
European MSM Internet Survey (EMIS)(2009-11): EMIS was an EU-funded study coordinated by 
Unit 34. The aim of the survey was to harmonise indicators to measure sexual health in MSM and 
contribute to set up an European HIV/STI-second generation surveillance among MSM. Data on 
sexual health, sexual behaviour, HIV- and STI-testing patterns and potential prevention factors were 
collected online. Over 55,000 participants were recruited from Germany. EMIS was the first 
European-wide MSM survey, and is so far the largest scientific behaviour survey among MSM 
worldwide with more than 180,000 participants. A final report of the project will be published by 
the European Centre for Disease Control and Prevention (ECDC) in the first quarter of 2013. Several 
publications in international peer review journals are currently in preparation. EMIS collected 
comparable data for MSM to be used for Global AIDS Response Progress (GARP – WHO/UNAIDS) 
and Dublin Declaration Monitoring (EU) Reporting. 
HIV-Surveillance with migrants from sub-Saharan Africa (2012): Using a participatory research 
approach this project aims to develop a study design and recruitment strategy with community 
members and other partners (e.g. NGOs) in order to gain understanding of the HIV prevention 
needs in African communities in Germany.  
2.2.5 Other studies 
Estimation of the HIV prevalence and incidence: We established a unified back calculation 
model based on the AIDS case register and the HIV diagnoses from the national mandatory 
surveillance system. Recent estimates show that 78.000 people are living with HIV (PLWH) in 
Germany in 2012 and 3.400 new HIV infections must be expected for the same year. The estimated 
number of PLWH who are on antiretroviral treatment has increased to 50.000 or 85% of those 
diagnosed with HIV, but at the same time the number of undiagnosed HIV infections has risen to 
14.000 in 2012. 
Demographic studies on blood donors: The demographic characteristics of blood donors were 
analysed to estimate whether aging of the general population would lead to a lack of blood donors 
in future years. Although the general population eligible to donate blood is on the decline since 
2003, with a loss of 2 % between 2006 and 2010, this has not led to a decrease in number of blood 
donors and donations. Instead, the number of new and repeat whole blood donors increased by 
8 % and 7 %, respectively. At the same time, the number of new plasma donors grew by 23 %, that 
of repeat plasma donors by 41 %. In 2010, more than 4.3 % of the population aged 18 to 68 years 
were active as repeat whole blood donors; 0.4% repeatedly donated plasma or platelets. Since 
2006 the percentage of donors among the general population increased significantly, especially 
among the youngest age group (18 to 24 years). 
2.3. Major goals and contribution to the goals of the department  
The unit has a complementary approach to cover its broad public health mission in the field of HIV 
and other STI, Hepatitis and other blood born infections and therewith of the department for 
infectious disease epidemiology. By maintaining the statutory surveillance systems for HIV, 
Syphilis, Hepatitis B, C and D, for infection markers in blood donors and for Creutzfeld-Jacob 
disease, it takes part in one of the main tasks of the department, the collection analysis and 
interpretation of data communicated to the RKI as a result of the Protection against Infection Act 
(Infektionsschutzgesetz, IfSG). 
As an important complement, the unit conducts numerous and partly extensive additional 
surveillance systems and cohort studies to improve the health status of the German population in 
the fields of interest of the unit.  
On basis of two large cohort studies in the scope of HIV research (ClinSurv und HIV 1-
Seroconverter study), Unit 34 analyses real-life factors influencing the spread and course of HIV 
infection, dynamics of and influencing factors for HIV therapy resistance in Germany, and 
outcomes of antiviral therapy. Therewith, the unit compiles data for evidence based prevention 
approaches and therapy optimisation. 
The additional surveillance systems in the field of HIV/AIDS, the voluntary AIDS registry and the 
InzSurv-HIV study, collect data important to monitor and evaluate the dynamics of the disease 
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complementing the statutory surveillance and allowing for giving in-depth information and advice 
to the MoH and the public health authorities on federal and communal level as a main task of the 
department. Regarding research on the dynamics of other STI, this is supplemented by the 
laboratory based Chlamydia sentinel, and by collaborating with other departments of the RKI in the 
scope of the general national health surveys in children (KIGGS) and adults (DEGS) regarding STI 
prevalence. 
As another methodological complement to specify the knowledge regarding the infections covered 
by the unit, several large surveys on knowledge, attitude and behaviour (KAB) as well as integrated 
behavioural and biological surveillance studies (IBBS) in main groups at risk such as men who 
have sex with men (MSM), injecting drug users (IDU), and sex workers were or are conducted. In 
collaboration with national, federal and communal partners in Germany, these studies are used as 
the basis to tailor prevention strategies targeting specifically these groups. 
The unit was concerned with several outbreak investigations (e.g. a hepatitis B outbreak in a 
nursing home in Thüringen in 2011, and an outbreak of anthrax among injecting drug users in 
several federal states of Germany and other European countries in 2009, 2010 and 2012). 
Through its cooperation in networks on scientific level and with public health authorities on 
international, national, federal and communal level, the unit supports another important public 
health task of the department. The unit collaborates and gives its advice in setting up guidelines, in 
compiling public health approaches, in conducting outbreak investigations etc. On methodological 
level, the unit takes part in improving methods, such as for estimating HIV incidences and 
prevalence on country and federal state level. Existing surveillance instruments are improved 
constantly in terms of second generation surveillance approaches, to ameliorate quality and validity 
of epidemiological data. Concerning all these issues, the unit represents the department in 
numerous national and international political and scientific committees (, Unit 34) 
As part of the communication tasks of the department and in addition to numerous workshops of 
the particular projects of the unit, the unit invented a bi-annual meeting of the epidemiological 
HIV/STI-projects of the RKI. On October 28th and 29th 2011, nineteen lectures on RKI-projects were 
held; the auditorium consisted of about 200 participants from partnering research institutions, 
public health authorities, physicians and the interested public. 
2.4. Additional work and methods for investigations  
Statistical methods  
• Survival analysis (e.g. to describe the risk of AIDS-defining events over time in the German 
HIV-1 Seroconverter Cohort., to analyse the association of cumulative viremia and AIDS-
related lymphoma in the ClinSurv cohort)  
• Back calculation methods (to estimate HIV-prevalence and –incidence in different risk 
groups) 
• Time series analysis (to analyse time trends of syphilis and HSV-2 co-infection among men 
who have sex with men in the German HIV-1 seroconverter cohort from 1996-2007)  
• Multiple imputation for missing values (e.g. to estimate the HIV-prevalence and –
incidence, to analyse late presentation for HIV diagnosis and care in Germany 
Respondent driven sampling 
Since 2011, unit 34 has been implementing respondent-driven sampling (RDS) as part of the 
integrated behavioural and biological study (“DRUCK-study”) among people who inject drugs. RDS 
is a method of data collection based on peer-to-peer recruitment (similar to snowball-sampling) as 
well as a statistical method (“RDS inference”) to adjust for biases in the recruitment. In 2012, staff 
of unit 34 participated in the RDS training organised by the “Respondent WHO Collaborating 
Centre for HIV Surveillance” (Zagreb, Croatia). 
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2.5.  Scientific advice and consulting services 
Unit 34 is directly involved in advising the MOH in issues regarding epidemiology, prevention and 
provision of health services in the field of HIV/AIDS, STI and blood borne infections. The head of 
the unit represents the RKI in the National AIDS Board (Nationaler AIDS Beirat) as well as the Joint 
Bund-Länder Coordination Board for AIDS prevention (Bund-Länder Koordinierungsgremium 
AIDS). Advice in the above mentioned field is also provided for the supreme health authorities 
(Landesgesundheitsämter) of the 16 German federal states as well as the numerous local health 
offices (Gesundheitsämter). Consulting services are made available for health care providers as 
well as the scientific expert audience providing up-to-date information on issues like post exposure 
prophylaxis or antiretroviral treatment guidelines within the 24/7 on call duty and beyond. On 
request of the supreme health authorities of the federal states we advise and support local health 
authorities in conducting outbreak investigations or other epidemiological research. In addition 
unit 34 staff participates in the work of several medical associations developing guidelines (e.g. 
Recommendations for HIV positive health care providers, STI-treatment guidelines, antiretroviral 
treatment guidelines, Revision of the vaccination guidelines for hepatitis B).  
Within the department statistical advice is provided for other units:  
• Multivariable Analysis (e.g. in household studies to investigate risk factors for influenza 
transmission – Unit 36) 
• Estimation of secular trends (e.g. to describe the impact of rotavirus vaccination – Unit 33) 
• Capture-recapture methods (e.g. to estimate the incidence rate of nontuberculous 
mycobacterial disease in immunocompetent children – Unit 36, to estimate the total 
number of cases of human alveolar echinococcosis in Germany from 2003 through 2005, 
Unit 32) 
• Estimation of excess consultations to estimate the number of consultations due to 
influenza – Unit 36  
• Now-casting during outbreaks (e.g. during the big EHEC outbreak in Germany 2011 – Unit 
35) 
• Imputation of missing values (e.g. for data from emergency units during the STEC outbreak 
in Germany 2011, Unit 32) (see also list of publications) 
2.6. Training and teaching activities 
• Participation as facilitators in biannual 1-week courses on field epidemiology for public 
health workers in Germany hosted by the department (an der Heiden, Scheufele, Jansen, 
Dudareva-Vizule). 
• Project supervision and hosting of fellows attending the German Postgraduate Program for 
Applied Epidemiology (PAE) and the European Intervention Epidemiology Training 
Program (EPIET): 6 fellows were trained in projects within Unit 34 from 2009-2012.  
• Activities as lecturers and supervisors in the Master’s Program in Public Health (Berlin 
School of Public Health), and the Master’s Program in Applied Epidemiology (Robert Koch 
Institute) (Hamouda, Nielsen). 
• Supervisors for PhD/dissertations and master theses (currently 2 master thesis projects). 
• Participation as facilitators in teaching modules of the EPIET program: Computer Tools in 
Outbreak Investigations, multivariable Analysis, Time Series Analysis (an der Heiden, 
Bremer) 
• Supervisors of international guests of the unit working on scientific questions concerning 
HIV and STI 
• Lecturer in the RKI-coordinated teaching module "Infectious Diseases Epidemiology" at the 
Charité University Medicine, Berlin.  
• Training of physicians applying for a board certification in transfusion medicine (Offergeld) 
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3.  Cooperation with other scientists or research institutions 
3.1. Internal (within RKI) 
FG15 Molecular Epidemiology of Viral Pathogens 
1. DRUCK study: validation of hepatitis B (HBV) and C (HCV) serology and molecular biology 
from filter-dried capillary blood spots in 2012, since October 2012 testing for HBV and HCV 
of the DRUCK study samples (ongoing) 
2. HIV 1-Seroconverter study: HBV- and HCV-genom associated studies, e.g. resistance 
patterns and phylogenetic studies 
FG18 Centre of HIV and other Retroviruses and Unit 34  
1. Surveillance of transmitted drug resistance in patients recently infected with HIV (HIV 1-
Seroconverter study) 
2. Genome wide association studies within HIV-1 seroconverters (HIV 1-Seroconverter study) 
3. Surveillance of incident HIV infections: Validation of resistance testing and subtype 
determination from dried plasma spots  
4. DRUCK study: validation of HIV serology and molecular biology from filter-dried capillary 
blood spots in 2012, since October 2012 testing for HIV of the DRUCK study samples 
(ongoing) 
• Bartmeyer B et al., PLoS One 2010 
• Bätzing-Feigenbaum J et al., HIV Med 2009 
• Bätzing-Feigenbaum J, Loschen S, Gohlke-Micknis S, Zimmermann R, Kücherer C; 
Hamouda O: Piloting second generation HIV surveillance in Berlin, Germany, 2005 - 2007: 
Risk profile of recently acquired HIV infections in MSM. J AIDS HIV Res 2009 
Unit 26 Central Epidemiological Laboratory 
Longitudinal serological screening for HBV, HCV and syphilis of samples of HIV1 seroconverters 
(HIV 1-Serokonverter study) 
Unit 36 respiratory diseases/tuberculosis and Unit 34 ClinSurv HIV 
Tuberculosis as AIDS-defining disease in Germany: occurrence, case characteristics, course of 
disease and treatment 
• Fiebig L et al, PLoS One 2012 
Department 2 Epidemiology and Health Reporting 
1. Prevalence of Chlamydia trachomatis among youth (KIGGS) in Germany 
2. Prevalence of Chlamydia trachomatis among in adult population in Germany 
3. Hepatitis B immunogenicity and hepatitis B seroprevalence in children and teenagers 
4. HIV-denominator study: Together with unit 24 an online survey was launched that was sent 
to all HIV-diagnostic laboratories in Germany to gain understanding of the number of HIV-
tests conducted in 2011.  
• Desai S et al., Sex Health 2011 
• Haar K et al., J US–China Med Sci 2011 
• Jorgensen P et al., Epidemiol Infect 2010 
• Cai W et al., Pediatr Infect Dis J 2011 
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Department 1, (ZBS), Unit 35 and Unit 34: 
Collaboration concerning the Anthrax outbreak among injecting drug users in Germany and Europe 
in 2009/10 and 2012 
• Radun D et al., Euro Surveill 2010 
Department 3 
Unit 34 staff was intensely involved in supporting the department wide effort to manage the large 
EHEC outbreak (2011) as well as the Influenza2009 pandemic. This included lead management of 
the situation room, participation of on-site outbreak investigations, data management and 
statistical analyses.  
3.2 External / National 
Unit 34 and the ClinSurv HIV Study Group 
The ClinSurv-study is part of the German centre for Infection research (DZIF). Collaborating clinical 
centres are: Berlin: PD Dr K. Arastéh, D. Hampf: Auguste-Viktoria-Klinikum; Dr. F. Bergmann, M. 
Warncke: Charité Campus Virchow; Bonn: Prof. Dr. J. Rockstroh, Dr. J. Wasmuth, S. Hass: 
Universitätsklinikum Bonn; Düsseldorf: PD Dr. S. Reuter, L. Rollmann: Universitätsklinik 
Düsseldorf; Essen: Dr. S. Esser, P. Schenk-Westkamp: Universitätsklinikum Essen; Hamburg: Prof. 
Dr. A. Plettenberg, T. Lorenzen, I. Walther: ifi; Drs. A. Adam/ L. Weitner/ K. Schewe, H. Goey, Drs. 
S. Fenske/ T. Buhk/ HJ. Stellbrink, PD Dr. C. Hoffmann: IPM Studycenter; PD. Dr. J. van Lunzen, K. 
Wassmus; Universitätsklinikum Eppendorf; Hannover: Prof. Dr. M. Stoll, S. Gerschmann: 
Medizinische Hochschule Hannover; Frankfurt: Dr. A. Haberl, Dr. P. Kaikhin, Universitätsklinikum 
der Johann Wolfgang-Goethe-Universität Frankfurt Kiel: Prof. Dr. H. Horst, S. Trautmann: 
Universitätsklinikum Schleswig Holstein W Campus Kiel; Köln: Prof. Dr. G. Fätkenheuer, T. 
Kümmerle, D. Gillor: Universitätsklinik Köln; München: Prof. Dr. J. Bogner, B. Sonntag: 
Universitätsklinikum München; Regensburg: Prof. Dr. B. Salzberger: Universitätsklinik Regensburg; 
Rostock: Dr. C. Fritzsche: Universitätsklinik Rostock 
• Bätzing-Feigenbaum J et al., HIV Med 2011 
• Brunner J et al., Dtsch Med Wochenschr 2010 
• Kastenbauer U et al., Eur J Med Res 2009 
• Stoll M et al., PLoS One 2011 
• Zoufaly A et al., J Infect Dis 2009 
• Zoufaly A et al., HIV Med 2012 
• Zoufaly A et al., J Infect Dis 2011 
Unit 34 and the HIV-1 Seroconverter study group 
The HIV 1-Serokonverterstudie collaborates with the RESINA study network and with the (former) 
national reference centre for HIV in Erlangen as well as with the Institute for Microbiology of the 
Charité, Berlin. Collaborating clinical centres are: Aachen: Dres. Habets and Knechten; Augsburg: 
Dr. Hammond (Klinikum Augsburg); Berlin: Dres. Mayr, Schmidt, Speidel, and Strohbach 
(Medizinisches Versorgungszentrum, Ärzteforum Seestraße), PD Dr. Arastéh (Auguste-Viktoria-
Krankenhaus/Vivantes), Dres. Bieniek and Cordes, Dr. Claus, Dres. Baumgarten, Carganico, and 
Dupke, Dres. Freiwald and Rausch, Dres. Gölz, Klausen, Moll, and Schleehauf, Dr. Hintsche, Dres. 
Jessen and Jessen, Dres. Köppe and Krauthausen, Dr. Reuter; Bielefeld: Dr. Pfaff (Krankenhaus 
MARA II); Bochum: Prof. Dr. Brockmeyer (St. Joseph-Hospital); Bonn: Prof. Dr. Rockstroh 
(Universitätsklinik Bonn); Dortmund: Prof. Dr. Gehring and Dr. Schmalöer and Dr. Hower 
(Klinikum Dortmund, ID27 Ambulanz); Dresden: Prof. Dr. Spornraft-Ragaller (Universitätsklinikum 
Dresden); Duisburg: Dr. Becker-Boost, Dr. Kwirant; Düsseldorf: Prof. Dr. Häussinger and PD Dr. 
Reuter (Universitätsklinik Düsseldorf); Frankfurt/Main: Prof. Dr. Helm (Universitätsklinik Johann-
Wolfgang-Goethe-Universität); Frankfurt/Oder: Dr. Markus; Halle/Saale: Dr. Kreft 
(Universitätsklinik Martin-Luther-Universität); Hamburg: Prof. Dr. Plettenberg, Dr. Stoehr, Dr. 
Graefe, and Dr. Lorenzen (Institut für Infektionsmedizin, ifi, Allgemeines Krankenhaus St. Georg); 
Dres. Adam, Schewe, and Weitner, Dr. Fenske, DrHansen, Prof. Dr. Stellbrink 
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(Infektionsmedizinisches Zentrum Hamburg, ICH); Hannover: Prof. Dr. Schmidt (Medizinische 
Hochschule Hannover), Dres. Buck and Leugner; Koblenz: Prof. Dr. Eisenhauer and Dr. Rieke 
(Krankenhaus Kemperhof); Köln: Dr. Bihari, Dr. Ferdinand, Prof. Dr. Fätkenheuer 
(Universitätsklinik Köln); Prof. Dr. Oette, Krankenhaus der Augustinerinnen, Köln; Leipzig: Dr. Pfeil 
(Universitätsklinik Leipzig); Magdeburg: Prof. Dr. Malfertheiner and Dr. Wolle (Universitätsklinik 
Otto-v.-Guericke-Universität); Mainz: Prof. Dr. Galle (Klinikum der Joh.-Gutenberg-Universität); 
München: Dres. Jäger and Jägel-Guedes, Dr. Malm, Dr. Rieger, Städtisches Krankenhaus 12 
München-Schwabing, Prof. Dr. Fröschl (Technische Universität München); Münster: Prof. Dr. 
Rahn, (Universitätsklinik Münster); Norderstedt: Dr. Soldan; Nürnberg: Dr. Brockhaus (Klinikum 
Nürnberg); Osnabrück: Dr. Mutz (Städtische Klinik Natruper Holz); Regensburg: Prof. Dr. 
Salzberger, Prof. Dr. Schölmerich, and Dr. Schneidewind (Universitätsklinik Regensburg); 
Remscheid: Dr. Steege; Rostock: Dr. Kreft, Prof. Dr. Ziegler and Prof. Dr. Reisinger 
(Universitätsklinik Rostock); Stuttgart: Dres. Ißler, Schaffert, Schnaitmann, and Trein, Dres. 
Frietsch, Müller, and Ulmer; Dr. Wagner-Wiening (Landesgesundheitsamt Stuttgart); Ulm: Prof. Dr. 
Kern and Prof. Dr. Dr. Kreidler (Universitätsklinik Ulm); Viernheim: Dr. van Treek; Wiesbaden: Dr. 
Starke. 
• Oh DY et al., AIDS 2009 
• Bartmeyer B et al., PLoS One 2010 
• Spielmann N et al., Sex Transm Infect 2010 
• Altmann M et al., BMC Infect Dis 2012 
InzSurv-HIV 
Cooperation partners of this study are HIV-diagnostic laboratories that send dried plasma or serum 
spots of newly diagnosed and reported HIV-cases. Abteilung Mikrobiologie, Krankenhaushygiene, 
Infektionsschutz, Infektionsepidemiologie, Hannover; Landesgesundheitsamt Baden-Württemberg, 
Stuttgart; Institut für Medizinische Virologie, Frankfurt (Main); Institut für Laboratoriumsmedizin 
Hygiene-Institut des Ruhrgebiets, Gelsenkirchen; Bayerisches Landesamt für Gesundheit und 
Lebensmittelsicherheit, Oberschleißheim; Institut für Medizinische Mikrobiologie, Virologie und 
Hygiene, Hamburg; Labor Prof. Gisela Enders & Partner, Stuttgart; Landeslabor Berlin-
Brandenburg, Fb-III-4 Infektionsdiagnostik, Berlin; Institut für Virologie, Universitätsklinikum 
Heinrich-Heine-Universität, Düsseldorf; Institut für Virologie, Klinikum der Universität zu Köln; 
Institut für Virologie - Klinische und Molekulare Virologie, Universitätsklinikum Erlangen; MVZ für 
Labordiagnostik Köln GbR, Synlab Köln; Medizinisch-Diagnostisches Labor Kempten; Labor Dr. 
Limbach & Kollegen, Abteilung für Immunologie, Infektionsserologie und Genetik, Heidelberg; 
Abteilung für medizinische Mikrobiologie, Institut für Hygiene und Umwelt, Hamburg; 
Medizinisches Versorgungszentrum Dortmund ; Dr. Eberhard & Partner, Medizinisches 
Versorgungszentrum ; Laboratoriumsmedizin & Mikrobiologie Kassel; Gemeinschaftspraxis für 
Laboratoriumsmedizin, Mikrobiologie und Humangenetik Dr. Stein & Kollegen, Mönchengladbach; 
Gemeinschaftspraxis für Laboratoriumsmedizin, Mikrobiologie und Infektionsepidemiologie, 
Medizinische Laboratorien Düsseldorf; Medizinisches Labor Prof. Seelig und Kollegen, Karlsruhe; 
Labor Ingelheim mit Zentrum für Humangenetik, Bioscientia Institut für Medizinische Diagnostik 
GmbH, Ingelheim am Rhein ; Institut f. Transfusions- und Laboratoriumsmedizin, Rhön-Klinikum, 
Klinikum Pforzheim; Laboratoriumsmedizin Köln, Dres. med. Wisplinghoff & Kollegen, Köln; Labor 
Krone, Bad Salzuflen; Laborärztliche Gemeinschaftspraxis Lübeck; Hygiene-Institut, Abt. Virologie, 
Universitätsklinikum Heidelberg; Labor Becker, Olgemöller & Kollegen, München; Labor Schottdorf 
MVZ GmbH, Augsburg; Labormedizinisches Versorgungszentrum, LADR GmbH, Geesthacht; 
Labor-Zentralinstitut Springe, DRK Blutspendedienst NSTOB, Springe; Labor Dr. A.v. Froreich und 
Kollegen GmbH, Hamburg; Laborärzte Sindelfingen; MVZ Wagnerstibbe für med. Mikrobiologie, 
Göttingen; Institut für Laboratoriumsmedizin Berlin (IFLB), Berlin; Medizinisches 
Versorgungszentrum für Laboratoriumsmedizin und Mikrobiologie, Synlab München, Dachau; 
Institut für Laboratoriumsmedizin, Klinik am Eichert, Kliniken des Landkreises Göppingen gGmbH; 
Abt. Med. Mikrobiologie und Hygiene, Landesuntersuchungsanstalt für das Gesundheits- und 
Veterinärwesen Sachsen, Dresden ; Gemeinschaftspraxis Labor 28, Berlin ; Landesamt für 
Verbraucherschutz des Landes Sachsen-Anhalt, Fachbereich 2 – Hygiene, Magdeburg; IMD - 
Institut für Medizinische Diagnostik, Gemeinschaftspraxis für Labormedizin, Mikrobiologie, 
Transfusionsmedizin, Berlin; Labor Lademannbogen, Hamburg; Institut für Medizinische 
Mikrobiologie & Hygiene, Universität Regensburg; Gemeinschaftspraxis für Laboratoriumsmedizin 
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Köln; MVZ für Laboratoriumsdiagnostik GbR, Synlab Augsburg; MVZ für Laboratoriumsmedizin 
Koblenz-Mittelrhein, Labor Koblenz; Centrum für Laboratoriumsmedizin, Universitätsklinikum 
Münster; Institut für Transfusionsmedizin, Universitätsklinikum Schleswig-Holstein, Lübeck; 
Institut Lütjensee, DRK-Blutspendedienst Nord gGmbH, Lütjensee; Zentrallabor Hagen, DRK-
Blutspendedienst West, Hagen; Medizinisches Labor Dres. Brunner-Zillikens & Kommerell, 
Konstanz; Institut für medizinische Mikrobiologie, Otto-von-Guericke-Universität Magdeburg; 
Institut für Transfusionsmedizin Cottbus, DRK-Blutspendedienst Ost Gmbh, Cottbus; 
Medizinisches Labor Dr. Berg, Berlin; Institut für Laboratoriumsmedizin & Mikrobiologie, 
Evangelisches Krankenhaus Oberhausen; Institut für Transfusionsmedizin Suhl gGmbH, Suhl; 
Laborarztpraxis Dres. med. Jochem, Walther und Kollegen, Bad Homburg; Institut für 
Transfusionsmedizin, Universitätsklinikum Münster; Universitätsklinikum Essen Institut für 
Virologie, Essen; Institut für Infektionsmedizin mit Medizinaluntersuchungsamt, 
Universitätsklinikum Schleswig-Holstein, Kiel; Justus-Liebig-Universität Gießen, Institut für 
Medizinische Virologie, Gießen; Universität Tübingen, Hygiene-Institut / Abt. Virologie, Tübingen; 
Institut für Virologie und Immunologie, der Universität Würzburg; Max-von-Pettenkofer-Institut, 
Virologie, München ; Katharinenhospital, Zentralinstitut für klin. Chemie und 
Laboratoriumsmedizin, Stuttgart; Klinikum der LMU, Dermatologische Klinik, Serologisches Labor, 
München; Medizinische Hochschule, Abt.Virologie u. Seuchenhygiene, Hannover; Institut für 
Klinische Chemie, Laboratoriumsmed. & Transfusionsmed., Klinikum Nürnberg –
Zentrallaboratorium, Nürnberg; Staatliches Untersuchungsamt Hessen, Standort Dillenburg; 
Universitätsklinikum Homburg, Institut f. Med. Mikrobiologie u. Hygiene, Homburg (Saar); 
Landesuntersuchungsamt Koblenz, Institut für Hygiene und Infektionsschutz, Koblenz; 
Universitätsklinikum Charité, Inst. für Mediz. Virologie, Berlin; Arztpraxis für med. Mikrobiologie 
und Labordiagnostik, Dessau; Medizinisch-Diagnostische Institute, Berlin; Fachärzte für 
Laboratoriumsmedizin, Dr. Hermann & Dr. Holzer, Würzburg; Laborpraxis in Kooperatin mit 
Bioscientia, Dres. Lorenz und Kollegen, Berlin; CSL Plasma GmbH, Labor Göttingen; 
Medizinisches Versorgungszentrum, AescuLabor - Karlsruhe GmbH; Labor Dr. Latza und Partner, 
St. Ingbert/Rohrbach; MEDILYS Institut für Labormedizin, Mikrobiologie und Krankenhaushygiene, 
Zentrallabor c/o Asklepios Klinik Altona, Hamburg; Klinikum Dortmund gGmbH, Institut für 
Transfusionsmedizin, Laboratoriumsmedizin und medizinische Mikrobiologie, Dortmund 
Unit 34 STI-HIT and STI-Outreach 
Cooperation partners of these ongoing prevalence studies of STI in persons asking for anonymous 
HIV tests and sex workers in North Rhine-Westphalia are Dres Münstermann, Tiemann, Lucht 
(Labor Krone), and public health authorities of Aachen, Bielefeld, Bonn, Bochum, Disburg, 
Düsseldorf, Essen, Euskirchen, Hochsauerlandkreis, Grevenbroich, Gütersloh, Köln, Leverkusen, 
Wesel/Moers, Münster, Recklinghausen, Siegen-Wittgenstein, Soest, Warendorf, Wuppertal. The 
study is ongoing.  
DRUCK-pilot study (Unit 34) and National reference Centre for Hepatitis C (Department of 
Virology, University of Essen; Prof. Stefan Ross): 
Validation of HIV, HBC and HCV serology and molecular biology from filter-dried capillary blood 
spots in 2010/11, testing for HIV, HBV and HCV including genotyping of HCV of 534 specimens of 
the DRUCK pilot study in 2011 
• Ross RS et al., Virol J (submitted for publication) 
DRUCK-pilot study (Unit 34) and co-operating partners (2011): 
Fixpunkt e.V. Berlin (Kerstin Dettmer, Astrid Leicht), Suchthilfe direkt Essen (Bärbel Marrziniak, 
Johannes Bombeck), Local Health Department of Essen (Brigitte Menze) and Department of 
Psychiatrics, University hospital Essen (Prof. Norbert Scherbaum); Deutsche AIDS Hilfe (Dirk 
Schaeffer) 
Euro-GASP 
Cooperation partner consiliary laboratory for gonococci and ECDC.  
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• Annual epidemiological report 2011 - Reporting on 2009 surveillance data and 2010 
epidemic intelligence data. 
http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?I
D=767  
Unit 34 Blutspendersurveillance 
Bundesärztekammer (Federführung G. Bein)/Paul-Ehrlich-Institut (M. Heiden, R. Seitz): 
gemeinsamen Arbeitsgruppe „Blutspendeausschluss von Personen mit sexuellem Risikoverhalten 
(RKI: R. Offergeld, R. Burger, Gast: O. Hamouda).  
• blood donor management’ at 
http://www.edqm.eu/medias/fichiers/paphts_11_28_2r_european_committee_partial_agre
eme.pdf 
3.3. External / International 
Annecy Group 
The Annecy Group was founded in 1996 as a network of leading epidemiologist in the field of HIV 
from Canada, the US, Australia, UK, France, Italy, Spain and Germany to discuss state of the art 
HIV surveilance in industrialised countries. Recent topics cover surveillance of HIV incidence, 
modeling of HIV incidence and prevalence for national estimates, HIV/STI co-infection 
• Sullivan PS et al., Ann Epidemiol 2009  
CHAIN  
ClinSurv collaborates with EU funded project “Collaboration on HIV and anti-HIV drug resistance 
network, CHAIN.  
EUROCOORD-COHERE 
ClinSurv Cohort takes part in the Collaboration of Observational HIV Epidemiological Research in 
Europe (EUROCOORD-COHERE).  
EUROCOORD-CASCADE 
The HIV 1-Seroconverter study is member of the Concerted Action on SeroConversion to AIDS 
and Death in Europe (EUROCOORD-CASCADE). 
• van der Helm JJ et al., AIDS 2011 
• Zugna D et al., Antivir Ther 2012  
• Jarrin I et al., Clin Infect Dis 2012  
• Pantazis N et al., PLoS One 2012  
• Madec Y et al., AIDS submitted  
ESAR 
The HIV 1-Seroconverter study is member of the European Society for antiviral resistance (ESAR). 
• Theys K et al., Retrovirology. 2012 
BEST HOPE 
On basis of the HIV 1-Seroconverter study, the unit is project coordinator for the project Bio-
Molecular and Epidemiological Surveillance of HIV Transmitted Drug Resistance, Hepatitis Co-
Infections and Ongoing Transmission Patterns in Europe (BEST HOPE), collaborating with 
partners in Portugal (Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de 
Lisboa; Lisbon) and Romania (National Institute for Infectious Diseases “Prof. Dr. Matei Bals” 
(NIID), Bucharest) in the time frame 7/2012-6/2015. 
Evaluation Report (Public Version) Unit 34: HIV/AIDS, STI and other Blood-borne Infections 
122 
EMIS 
The EMIS Network consists of Associated Researchers: Rigmor A. Berg (Norwegian Knowledge 
Centre for the Health Services, Oslo); Michele Breveglieri (Regione del Veneto, Verona); Laia Ferrer 
(CEEISCat, Barcelona); Percy Fernández-Davila (CEEISCat, Barcelona); Cinta Folch (CEEISCat, 
Barcelona); Martina Furegato (Regione del Veneto, Verona); Ford Hickson (Sigma Research, 
London); Harm J. Hospers (University College Maastricht); Ulrich Marcus (Robert Koch Institute, 
Berlin) ; David Reid (Sigma Research, London) ; Axel J. Schmidt (Robert Koch Institute, Berlin) ; 
Todd Sekuler (Robert Koch Institute, Berlin); Peter Weatherburn (Sigma Research, London). 
National collaborating partners of the EMIS Network: AIDS-Hilfe Wien (Austria); Facultés 
Universitaires Saint-Louis, Institute of Tropical Medicine, Ex Aequo, Sensoa, Arc-en-ciel (Belgium); 
Vstrecha (Belarus); National Centre of Infectious and Parasitic Diseases, Queer Bulgaria 
Foundation (Bulgaria); Charles University, Institute of Sexology (Czech Republic); Research Unit in 
Behaviour & Social Issues (Cyprus); University of Zagreb, Faculty of Humanities and Social 
Sciences (Croatia); Statens Serum Institut, Department of Epidemiology, stopaids (Denmark); 
National Institute for Health Development (Estonia); University of Tampere, Department of 
Nursing Science, Finnish AIDS council (Finland); Institut de veille sanitaire (InVS), AIDeS, Act UP 
Paris, Sida Info Service, Le kiosque, The Warning (France); Berlin Social Science Research Center 
(WZB), Deutsche AIDS-Hilfe (DAH), Federal Centre for Health Education, Cologne (BZgA) 
(Germany); Positive Voice (Greece); Hungarian Civil Liberties Union, Háttér (Hungary); Gay Men's 
Health Service, Health Services Executive (Ireland); University of Bologna, Italian Lesbian and Gay 
Association (Arcigay), Instituto Superiore di Sanità (National AIDS Unit)(Italy); The Infectiology 
Center of Latvia, Mozaika (Latvia); Center for Communicable Diseases and AIDS (Lithuania); 
GenderDoc-M (Moldova); schorer (Netherlands); Norwegian Knowledge Centre for the Health 
Services, The Norwegian Institute of Public Health (Norway); National AIDS Centre, Lamda 
Warszawa (Poland); GAT Portugal, University of Porto, Medical School, Inst. of Hygiene and 
Tropical Med. (Portugal); PSI Romania (Romania); PSI Russia (Russia); Safe Pulse of Youth 
(Serbia); OZ Odyseus (Slovakia); National Institute of Public Health, SKUC-Magnus, Legebitra, 
DIH (Slovenia); National Centre of Epidemiology, stopsida, Ministerio de Sanidad, Política Social e 
Igualdad (Spain); Malmö University, Health and Society, RFSL, National Board of Health and 
Welfare (Sweden); Institut universitaire de médecine sociale et preventive, AIDS-Hilfe Schweiz 
(Switzerland); Turkish Public Health Association, Siyah Pembe Üçgen İzmir, KAOS-GL, Istanbul-
LGBTT (Turkey); Gay Alliance, Nash Mir, LiGA, Nikolaev (Ukraine); City University London, 
Department for Public Health, Terrence Higgins Trust and the CHAPS partners including GMFA, 
The Eddystone Trust, Healthy Gay Life, The Lesbian and Gay Foundation, The Metro Centre 
London, NAM, Trade Sexual Health, Yorkshire, MESMAC (United Kingdom). 
European Collaborating Partners: International Gay and Lesbian Organization (ILGA); European 
AIDS Treatment Group (EATG); PlanetRomeo.com; Manhunt and Manhunt Cares 
• Marcus U et al., BMC Public Health 2012 
SIALON II 
The unit takes part in the SIALON II study, collaborating with the following partners: Institute of 
Tropical Medicine (Antwerp, Belgium); NCIPD, National Reference Laboratory of HIV (Bulgaria); 
Azienda Universitaria Ospedaliera Integrata (Regione Veneto, Verona, Italy); Istituto Superiore di 
Sanità (Rome, Italy); Istituto Nazionale Malattie Infettive (Italy); Centre for Communicable 
Diseases and AIDS (Lithuania); National Institute of Public Health – National Institute of Hygiene 
(Poland); Instituto Higiene e Medicina Tropical (Lisbon, Portugal); National Institute of Infectious 
Diseases “M. Bals” (Bucharest, Romania); Slovak Medical University (Bratislava, Slovak Republic); 
National Institute of Public Health (Ljubljana, Slovenia);Centre d'Estudis Epidemiològics sobre la 
Sida de Catalunya (CEEISCAT)(Barcelona, Spain); Swedish Institute for Communicable Disease 
Control (Sweden); Centre for Health Research, University of Brighton (UK). 
Unit 34 Blutspendersurveillance 
European Directorate for the Quality in Medicines and healthcare (EDQM). Working group TS057 
“Sexual risk behavior having an impact on blood donor management”. Chair: Rut Norda (Sweden) 
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Vice Chair M. Heiden (Geramny). Publication of the Technical memorandum at 
http://www.edqm.eu/medias/fichiers/paphts_11_28_2r_european_committee_partial_agreeme.pdf 
Bordernetwork 
Budget Holder: SPI-Forschung Berlin 
Austria: Coordinator: Aids-Hilfe Wien.  
SMZ Süd/Kaiser Franz Josef Spital, 4. Med. Abt. (Infektiologie u. Tropenmedizin) Vienna; 
Allgemeines Krankenhaus der Stadt Wien, Univ.Klinik f. Dermatologie; STD-Ambulanz, Vienna; KA 
Rudolfstiftung, Abt. für Allgemeine Dermatologie, Vienna; STD-Ambulatorium der Stadt Wien 
(MA15) Vienna; Pilzambulatorium Floridsdorf; Pilzambulatorium Schlösselgasse GmbH, Vienna; 
Pilzambulatorium Hietzing GmbH, Vienna; Praxisgemeinschaft Wien9 (GP specialised in HIV-
care), Vienna; Aids Hilfe Wien, Vienna; Dr. Bernd Gmeinhart (dermatologist, GP), Vienna; 
Medizinische Universität Graz, Klin. Abt. f. Umweltdermatologie u. Venerologie, Graz; Aids Hilfe 
Steiermark, Graz; Aids Hilfe Oberösterreich, Linz.  
Bulgaria: Coordinator: HESED (Health and Social Development Foundation) 
District Dispensary for Dermato-Venereal Diseases, Plovdiv; Department of Dermatology and 
Venereology, Medical University, Plovdiv; Multiprofile Hospital for Active Treatment "St. Ana " Unit 
203 Dermato-Venerology, Varna; District Dispensary for Dermato- Venereal Diseases, Sofia; 
Department of Dermatology and Venereology, Medical University, Sofia.  
Romania: Coordinator: ARAS (Romanian Association against Aids) 
Dermato-Venerological Unit, Clinical Hospital “Prof.Dr. Scarlat Longhin”, Bucharest; Dermato-
Venerological Clinic in Hospital Constanta, Constanta; Baylor Marea Neagra Foundation, 
Constanta; ARAS – Titan drop-in clinic, Bucharest; ARAS Bucuresti – ARENA drop-in clinic and 
mobile unit, Bucharest; Public Health Department Brasov, Brasov; Hospital of Infectious Diseases 
"Str. Memorandului, Brasov; ARAS - VCT Community Centre Brasov; ARAS, Constanta; ARAS, 
Timisoara;, VCT Community Centre ARAS, Neamt; ARAS, Iasi; 2nd Dermatological Clinic "Carol 
Davila" University of Medicine and Pharmacy Colentina Clinical Hospital Sos., Bucharest.  
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• Bridging research on HIV/STI prevalence and risks to evidence-based effective practice. 
Final Report: HIV/STI Sentinel-Surveillance.  
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Willkommen H mit besonderer Unterstützung von Beekes M. (2012): Sicherheit von Blut und 
Blutprodukten angesichts aktueller Berichte über die Übertragbarkeit der Alzheimer-Krankheit im 
Tierexperiment. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz; in press 
2011 
Arbeitskreis Blut, Untergruppe „Bewertung Blutassoziierter Krankheitserreger“. Dengue Virus. 
Transfus Med Hemother 2011, in press 
Haar K, Marcus U, Ehrhard I, Nielsen S, Jansen K, Hamouda O, Kohl P. Therapieversagen durch 
Cefixim-Resistenz von Neisseria gonorrhoeae in Österreich, Situation in Deutschland. HIV & more 
2011- 4. 
Evaluation Report (Public Version) Unit 34: HIV/AIDS, STI and other Blood-borne Infections 
130 
Marcus U: Bericht zur Entwicklung der HIV-Epidemie in Deutschland im Jahr 2010 aus dem Robert 
Koch Institute. HIV&more 2/2011: 56-59 
Marcus U: HIV-Test zur Prävention. HIV&more 1/2011: 21-25. 
Marcus U: Entwicklung des „Late Presenter“-Anteils im Zusammenhang mit Veränderungen der 
HIV-Inzidenz und Testbereitschaft - Späte Diagnose von HIV in Deutschland. MedReview 13/2011  
Marcus U: Postexpositionsprophylaxe - ja oder nein? MMW-Fortschr Med 2011, 153 (18): 35-37. 
Offergeld R, Heiden M, Stötzer F, Northoff H. Der einheitliche Blutspenderfragebogen. 
Hämotherapie 2011, 16:23-27  
2010 
Arbeitskreis Blut, Untergruppe «Bewertung Blutassoziierter Krankheitserreger» (für das RKI Burger 
R, Pauli G, Offergeld R). Parvovirus B19 – revised. Transfus Med Hemother 2010;37:339-350.  
Arbeitskreis Blut, Untergruppe «Bewertung Blutassoziierter Krankheitserreger» (für das RKI Burger 
R, Pauli G, Offergeld R). Orthopox Viruses: Infections in Humans. Transfus Med Hemother 
2010;37:351–364. 
Arbeitskreis Blut, Untergruppe «Bewertung Blutassoziierter Krankheitserreger» (für das RKI Burger 
R, Offergeld R). Human Cytomegalovirus (HCMV) – Revised. Transfus Med Hemother 
2010;37:365-375. 
Marcus, U; Rockstroh, J; Schmidt, R; für den Expertenworkshop GWB und DAIG: HIV-Testung: 
Empfehlungen zur Verbesserung der aktuellen Situation. DMW 2010: 1201  
Marcus U, Nassauer A: Erschweren Hygienerichtlinien für Zahnarztpraxen eine normale 
zahnärztliche Versorgung von HIV-Patienten? HIV&more 2/2010: 21-22. 
Marcus U: HIV-Infektionen und AIDS-Erkrankungen - Bericht zur Entwicklung im Jahr 2009 aus 
dem Robert Koch Institute. HIV&more 2/2010: 44-48. 
Neue antiretrovirale Therapien mit Integrase-Inhibitoren, CCR5-Antagonisten und Second-
generation –NNRTI. Bartmeyer B. und die Studiengruppe Klinische Surveillance von HIV, ClinSurv. 
MedReview 10/2009 
Offergeld R, Burger R. Die Rolle des Robert Koch Institutes im Transfus Med Hemother 2010; 
14:74-78 
Schmidt RE, Rockstroh J, Marcus U: HIV-Diagnostik – Zu wenige Tests bei Risikopersonen. Dtsch 
Ärztebl 2010 
2009 
Arbeitskreis Blut, Untergruppe „Bewertung Blutassoziierter Krankheitserreger“. Arboprotozoae (für 
das FG 34 Offergeld R). Transfus Med Hemother 2009;36:8-31 
Arbeitskreis Blut, Untergruppe „Bewertung Blutassoziierter Krankheitserreger“ (für das FG 34 
Offergeld R). Malaria. Transfus Med Hemother 2009;36:48-60  
Arbeitskreis Blut, Untergruppe „Bewertung Blutassoziierter Krankheitserreger“ (für das FG 34 
Offergeld R). Influenza Virus. Transfus Med Hemother 2009;36:32-39 
Arbeitskreis Blut, Untergruppe „Bewertung Blutassoziierter Krankheitserreger“ (für das FG 34 
Offergeld R). Hepatitis E Virus. Transfus Med Hemother 2009;36:40-47 
Arbeitskreis Blut, Untergruppe „Bewertung Blutassoziierter Krankheitserreger“ (für das FG 34 
Offergeld R). Arbobacteria – Pathogens Transmittable by Arthropods. Transfus Med 
Hemother 2009;36:62-78  
Bartmeyer B., Kollan C., Kühne H., Die klinische Surveillance von HIV in Deutschland. 
Beobachtungen aus der ClinSurv Kohorte (2005-2009). Retrovirus Bulletin 3, 2009. 
Marcus U: HIV bei Migranten in Deutschland. HIV&more 1/2009: 52-55 
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Marcus U: Bericht zur Entwicklung der HIV/AIDS-Epidemie in Deutschland im Jahr 2008 aus dem 
Robert Koch Institute. HIV&more 2/2009: 36-38 
Marcus U, Hamouda O: Späte HIV-Diagnose und später Behandlungsbeginn in Deutschland. 
HIV&more 4/2009: 58-62 
Seitz R, Heiden M, Offergeld R, Burger R. Still in Focus: Assessment of Blood-Borne Pathogens. 
Transfus Med Hemother 2009:36:5–6:32(3-4),110-111. 
C) Book chapters 
2011 
Hamouda O: Global Epidemiology of HIV. In: Gross G, Tyring S.K. (Hrsg.) Sexually Transmitted 
Infections and Sexually Transmitted Diseases. Springer Verlag Berlin Heidelberg 2011, S. 249-270 
2010 
Bartmeyer B: Beobachtungsbeginn und Art der Erstbehandlung unter zusätzlicher 
Berücksichtigung der Behandlungskosten. Beobachtungen aus der ClinSurv Kohorte 2005-2009. 
HIV/AIDS besiegen: Visionen der Heilung. Hofmann/Jäger (Hrsg) 13 AIDS und HIV Infektionen in 
Klinik und Praxis Monographiereihe 2010 
Marcus U: Medizinische und strukturelle Prävention von HIV-Infektionen und Aids-Erkrankungen. 
In Strukturelle Prävention, AIDS-Forum DAH, 2010, S. 170-183 
Offergeld R, Burger R: The role of the Robert Koch Institute in Transfusion Medicine. Transfusion 
medicine in Germany: Current Status and Perspectives, Frankfurt, :22-25 
E) Articles in the Epidemiological Bulletin 
Erneuter Anstieg der Syphilis-Meldungen in 2011. Epid Bull 2012; 24: 221-223. 
HIV bei Migranten in Deutschland. Epid Bull 2012; 3: 19-21. 
DRUCK-Studie – Drogen und chronosche Infektionskrankheiten in Deutschland. Epid Bull 2012; 33: 
335-339. 
Virushepatitis B, C und D im Jahr 2011. Epid Bull 2012; 38: 371-385 . 
Zur Situation bei wichtigen Infektionskrankheiten in Deutschland. Virushepatitis B, C und D im Jahr 
2010. Epid Bull 2011; 29: 261-271. 
Gonorrhö: Erster Cefixim-resistenter Stamm führt in Österreich zu Therapieversagen; Situation in 
Deutschland(für das FG 34 Haar K). Epid Bull 2011 (47):429-30 
Sechs Jahre STD-Sentinel-Surveillance in Deutschland – Zahlen und Fakten (für das FG 34 Haar K). 
Epid Bull 2010 (3), 20-27 
Zur Situation bei wichtigen Infektionskrankheiten in Deutschland. Virushepatitis B, C und D im Jahr 
2009. Epid Bull 2010; 20: 177-187 
Webbasierte Erhebung zur HIV-Diagnostik in Deutschland 2009. Epid Bull 2010; 39: 391-395 
Zur Analyse der HIV-Meldedaten 2000 - 2007 zu Migranten aus Hochprävalenzländern im Rahmen 
der HIV-Inzidenzstudie am RKI Epid Bull 2009 (1), 1-5 
Zur Situation bei wichtigen Infektionskrankheiten in Deutschland Virushepatitis B, C und D im Jahr 
2008. Epid Bull 2009 (20), 189-199  
4.1.2. Selected relevant publications  
Five important publications for the scientific community 2009–2012 
1. Zoufaly A, Stellbrink HJ, an der Heiden M, Kollan C, Hoffmann C, van Lunzen J, Hamouda O; 
ClinSurv Study Group. Cumulative HIV viremia during highly active antiretroviral therapy is a 
strong predictor of AIDS-related lymphoma. J Infect Dis 2009; 200(1):79-87. 
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2. Schmidt AJ, Rockstroh JK, Vogel M, an der Heiden M, Baillot A, Krznaric I, Radun D. Trouble 
with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a 
case-control study. PLoS One 2011; 6(3):e17781. 
3. Marcus U, Schmidt AJ, Hamouda O (2011): HIV serosorting among HIV-positive men who 
have sex with men is associated with increased self-reported incidence of bacterial sexually 
transmissible infections. Sexual Health 2011, 8: 184–193. 
4. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, Somogyi S, Kollan C, Jessen H, 
Dupke S, Hamouda O, on behalf of the German HIV-1: Prevalence of Transmitted Drug 
Resistance and Impact of Transmitted Resistance on Treatment Success in the German HIV-1 
Seroconverter Cohort. PLoS One 2010; 5(10): e12718.  
5. Desai S, Meyer T, Thamm M, Hamouda O , Bremer V. Prevalence of Chlamydia trachomatis 
among young German adolescents, 200506. Sexual Health 2011; 8(1):120-122. 
Five important publications for the public 2009–2012 
1. Rabenau HF, Gottschalk R, Gürtler L, Haberl AE, Hamouda O, et al: Prävention der 
nosokomialen Übertragung von humanem Immunschwächevirus (HIV) durch HIV-positive 
Mitarbeiterinnen und Mitarbeiter im Gesundheitswesen. Bundesgesundheitsbl-
Gesundheitsforsch-Gesundheitsschutz 2012, (55):937-943. 
2. Stoll M, Kollan C, Bergmann F, Bogner J, Faetkenheuer G, Fritzsche C, Hoeper K, Horst H.-
A, van Lunzen J, Plettenberg A, Reuter S, Rockstroh J, Stellbrink H.-J, Hamouda O, 
Bartmeyer B: Calculation of direct antiretroviral treatment costs and potential cost savings 
by using generics in the German HIV ClinSurv Cohort,PLoS One, 2011; 6(9). 
3. Bremer V, Brockmeyer N, Hagedorn H, Knoell A, Marcus U, Meyer T, Nitschke H, Nick S, 
Ross, Straube E: Gemeinsame Stellungnahme des RKI, PEI und der DSTIG: Schnelltests in 
der Diagnostik sexuell übertragbarer Infektionen. Epid Bull 2012 (5): 38-41 
4. Haar K, Marcus U, Ehrhard I, Nielsen S, Jansen K, Hamouda O, Kohl P: Therapieversagen 
durch Cefixim-Resistenz von Neisseria gonorrhoeae in Österreich, Situation in 
Deutschland. HIV & More 2011; 4. 
5. Bremer V, Marcus U, Hamouda O: Syphilis on the rise again in Germany - results from 
surveillance data for 2011. Euro Surveill 2012; 17(2). 
4.1.3. Awards and honours, 2009 – 2012 
2010  
Dr. Barbara Gunsenheimer-Bartmeyer, Dr. Osamah Hamouda: Deutsche Medizinische 
Wochenschrift Walter Siegenthaler Preis 2010:Langristig wirksame Zweit Therapie der HIV 
Infektion bei Klassenwechsel nach virologischem Versagen unter Protease Inhibitoren: Brunner J., 
Seybold U., Gunsenheimer-Bartmeyer B., Hamouda O., Bogner J. DMW 2010; 135 
2012  
Dr. Karin Haar: Detlef-Petzold Award of the DSTIG (Deutsche STI-Gesellschaft - German STI-
Society) for the original scientific work "Low Sensitivity of Chlamydia Testing in a Pooled Sample of 
the Young German General Population" 
4.1.4. Overview on collaborations in networks 
Dr. Bartmeyer 
HIV 
EUROCoord HIV, EuroCoord-CASCADE Network European network of HIV/AIDS cohort studies to 
coordinate at European and International level clinical research on HIV/AIDS 
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CHAIN Network CHAIN is a large scale integrating project aimed to effectively and durably combat 
new and existing anti-HIV drug resistance in clinical settings, with a special emphasis on Eastern 
Europe and in heavily affected resource-poor regions in Africa. 
 CJD 
National expert of surveillance of transmissible spongiforme encephalitis infections in the 
European network 
Dr. Zimmermann 
National expert for the indicator “drug related infectious diseases” at the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) 
Member of Deutsche Gesellschaft für Suchtmedizin (DGS) 
C. Santos-Hövener 
Working Group HIV Prevention and Migration: LABAS Berlin (Statewide Association Berlin of 
organisations working in the field of Hepatitis, HIV and STIs 
K. Jansen 
Member for „Methodology & Standards“ of Steering Committee of the German Competence 
Network for HIV/AIDS 
Member of the Section Sexual Health of the German STI Society 
4.1.5. Memberships and participation in Advisory Boards 
Dr. Hamouda 
• Representative of the RKI in the National AIDS Board (Nationaler AIDS Beirat) 
• Representative of the RKI in the Joint Bund-Länder Coordination Board for AIDS prevention 
(Bund-Länder Koordinierungsgremium AIDS) 
• Chairman of the ECDC Coordination Group for HIV/AIDS surveillance 
• Chairman of the ECDC Coordination Group for STI surveillance 
• Member of the ECDC Coordination Group for Hepatitis B and -C surveillance 
• Member of the Board and Council of the European Society for Antiviral Resistance (ESAR) 
Dr. Bremer 
• Member of the Executive Board of the German STI Society (treasurer) 
• Spokeswoman of the Section Sexual Health of the German STI Society 
Dr. Offergeld 
• Managing director of the National Advisory Committee “Blood” (Arbeitskreis Blut) 
• Member of the epidemiology group of the European Medicines Agency (EMA) 
• Expert, EDQM, TS 057 
• Member of the German Society of Transfusion Medicine and Imnunhaematology (DGTI) 
Dr. Marcus 
• Member of the Northern Dimension Partnership in Public Health and Social Wellbeing 
(NDPHS) Expert Group on HIV/AIDS and Associated Infections 
4.1.6. List of completed dissertation or master theses in the Unit, 2009 – 2012 
Year Title Name Titel University/Supervisor 
RKI 
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2012 Untersuchung infektionsepidemio-
logischer Meldedaten von Anti-HBc-
positiven und HBsAg-negativen 




MSc Epi Berlin School of Public 
Health / G. Krause, 
O. Hamouda 
2012 HIV-Surveillance among sub-Saharan 
African migrants in Germany. How 






Berlin School of Public 
Health/C. Santos-
Hövener  
2012 Die Capture-Recapture Methode zur 
Bestimmung verborgener 
Populationsgrößen – Im Rahmen des 
Sero- und Verhaltenssurvey bei 
injizierenden Drogengebrauchern des 






Charité Berlin / U. 
Marcus 
2012 Prävalenz von urogenitalen 
Chlamydia trachomatis- Infektionen 
bei Teilnehmern des bundesweiten 
Kinder- und Jugendgesundheits-
surveys (KiGGS) 
Karin Haar MSc 
Public 
Health 
Berlin School of Public 
Health/ O. Hamouda 
2012 Risikoprofil von injizierenden Drogen-
gebraucherInnen im Rahmen der 
DRUCK - Studie (Drogen und 







Hochschule Fulda/ R. 
Zimmermann/ O. 
Hamouda 
2012 Erhebung der regionalen Abdeckung 
der Chlamydia trachomatis 
Diagnostik in Deutschland sowie 







Beuth Hochschule für 
Technik Berlin 
Haar/Hamouda 
2012 Prävalenz übertragener HIV-Resistenz 
und Einfluss übertragener HIV-Resis-
tenz auf den Therapieerfolg der First-
Line-Therapie in der HIV-1 Serokon-








2012 Risk factors for Chlamydia, Gonorr-
hoea, and Trichomonas infections for 









2011 Prävalenz von urogenitalen 
Chlamydia trachomatis-Infektionen 
bei Teilnehmern des bundesweiten 
Kinder- und Jugendgesundheits-
surveys (KIGGS) 
Karin Haar MPH Charité - Berlin School of 
Public Health/ Dr. 
Osamah Hamouda 
2011 Identifying risk factors and formulat-
ing public health recommendations 
using surveillance data 
Mathias 
Altmann 
MPH Charité - Berlin School of 
Public Health/ Dr. 
Osamah Hamouda 
2009 Wer testet was und wen in Köln? – 
Versorgungssituation von HIV-und 
STD-Testungen am Beispiel Köln 
Alexandra 
Hofmann 
MPH Freie Univerität Berlin 
Prof. Dieter Kleiber 
Dr. Osamah Hamouda 
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4.1.7. Presentations as invited speaker, 2009 - 2012 
Staff from the HIV/AIDS, STI and other Blood-borne Infections Unit were invited to speak at 67 
conferences. 
4.1.8. List of reports and written scientific advice to the Ministry of Health, 2009-
2012 
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1. General information - unit 35 
Head:  Prof. Dr. Klaus Stark  
Deputy:  Christina Frank, PhD  
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2.  Tasks and goals of the unit 
2.1.  Summary 
The unit is responsible for infections with a wide range of gastrointestinal and zoonotic pathogens - 
about two thirds of all pathogens notifiable in Germany. The spectrum includes the classical 
gastrointestinal and food-borne pathogens such as salmonellae, campylobacter, Shiga toxin-
producing E. coli, listeria, Norovirus, hepatitis A virus, other zoonotic agents such as hepatitis E 
virus, hantavirus, leptospirosis, and vector-borne pathogens (e.g., Borrelia burgdorferi, 
Plasmodium species, Dengue virus, West Nile virus). One major focus is placed on outbreak 
investigations. Since 2009 Unit 35 has coordinated and managed various large outbreak 
investigations. It also has supported public health authorities in many local and regional outbreaks. 
Additional important work areas are disease surveillance and research (especially epidemiological 
studies regarding burden of disease, risk factors for infection, importance of emerging pathogens 
for human health in Germany), development of epidemiological and statistical methods, training of 
German public health service staff (especially in how to investigate food borne outbreaks), and the 
formulation of preventive schemes and public health recommendations based on epidemiological 
findings. Aside from food borne, vector-borne and zoonotic infections, the unit focuses on the 
topics of climate change and infectious diseases, emerging infections, and molecular 
epidemiology. 
Figure 12: Major activities / tasks of Unit 35 
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2.2.  Current status of the work and summary of relevant results 
2.2.1.  Outbreak investigations 
Outbreak investigations are a major work focus. In recent years they concerned food-borne 
outbreaks as well as outbreaks due to zoonotic pathogens transmitted via other routes (e.g. 
hantavirus, leptospirosis, or anthrax among injecting drug users).  
In large multistate or international outbreaks the unit is prepared to assume a leading role in 
coordination and investigations into the scope and dynamics of the outbreak and to identify the 
vehicle of infection. Since 2009 the unit has participated in or coordinated many outbreak 
investigations. Prime examples are the large outbreak of STEC O104:H4 caused by sprouts in 2011, 
generating the largest number of HUS cases in an outbreak worldwide (Figure 13), the Norovirus 
outbreak of more than 10,000 cases caused by frozen strawberries in 2012, and an outbreak caused 
by S. Newport in 2011, again associated with sprouts. The unit’s work was pivotal for identifying the 
vehicles of infection in these outbreaks. 
Unit 35 leads the communication and cooperation with the federal food safety authorities 
(Bundesinstitut für Risikobewertung, Bundesamt für Verbraucherschutz und 
Lebensmittelsicherheit), and with the state health departments. In such outbreaks the unit has also 
a major role in the communication of the epidemiological findings and management issues to the 
scientific and medical community and the public. 
In international outbreaks where the German population is affected (but not the centre of the 
outbreak), we collaborate intensively with partner institutions abroad, e.g., within the framework of 
ECDC’s Food and water borne diseases network. 
In local or regional outbreaks (involving only one federal state), Unit 35 assists responsible public 
health authorities. The assistance activities range from telephone consultations regarding strategy 
and study design, supply of data collection tools (e.g., specific questionnaires, templates for 
analytic studies) and supporting staff, to coordinating the local outbreak investigation on behalf of 
the local health department.  
Cooperating with our partners, the local and state health and food safety authorities, laboratories 
and hospitals, outbreaks frequently could be “solved” (identification of the vehicle/source of 
infection). Results are routinely published in international scientific journals (see publication list). 
In addition, outbreak reports are produced and made accessible to the scientific and the general 
population via the RKI website and the Epidemiological Bulletin. 
Figure 13: Outbreak of HUS and STEC gastroenteritis caused by STEC O104:H4 in Germany, 2011 – 
Epidemiologic curve and back projection of the exposure phase 
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2.2.2.  Surveillance 
Surveillance data (infections notifiable by law) are analysed weekly in order to detect changing 
trends or disease clusters (outbreak algorithms). These activities form the basis for outbreak 
detection and for scientific in-depth analyses of spatio-temporal trends of relevant pathogens. 
Timely detection of multistate food-borne outbreak is challenging. Molecular subtyping surveillance 
is a useful tool for this purpose, but currently subtyping is not routinely conducted in Germany. 
Therefore, a concept for a systematic subtyping surveillance of selected food-borne enteric 
pathogens (e.g., EHEC, Listeria monocytogenes, non-typhoidal Salmonella serotypes) is being 
developed in collaboration with the Department for Infectious Diseases (Dept. 1). 
Germany has experienced several outbreaks of infection with a rare sorbitol-fermenting clone of 
EHEC O157. Outbreaks are characterised by a predominance of paediatric patients with HUS, a life-
threatening post infectious sequelae of EHEC infection, and only very few cases of diarrhoea-only 
cases. Consequently, we have established active surveillance for paediatric “enteropathic” (i.e., 
diarrhoea-associated) HUS in collaboration with the German Society of paediatric nephrology. 
If we notice conspicuous changes in the incidence or distribution of notified infections, we assess 
the reasons for such trends (e.g., changes in epidemiologic patterns and risk factors, or changes in 
diagnostic procedures). This may trigger in-depth epidemiological studies (e.g., hepatitis E, Giardia 
lamblia).  
We routinely assess the surveillance data (notifiable infections) regarding their validity and 
completeness. Since 2004, for example, every death marked on a notified infectious disease report 
falling into the responsibility of Unit 35, is subject to quality control. An email is sent to the local 
health department with the purpose of verifying the death notice and the assessment of a (co-
)causal contribution of the infectious disease. The data are compared with the cause-of-death 
census statistic in irregular intervals to assess completeness of the passive surveillance system and 
to more accurately assess the burden these pathogens cause.  
2.2.3. Research 
Studies are being conducted in the following fields: 
Burden of disease, frequency and trends in gastroenteric and zoonotic diseases 
These include telephone surveys on the frequency of acute gastroenteritis in a representative 
population subsample (n=22,000), as well as analyses on burden of disease (case-fatality, years-of-
life-lost) based on surveillance data of important gastrointestinal infections. The survey showed 
that acute gastroenteritis is very common (incidence 0.9 per person-year) and is associated with 
variables such as body mass index or diabetes. Time series analyses provide important findings 
regarding temporal trends, geographic and demographic distribution of infectious diseases. We 
have performed and published such analyses for yersiniosis, salmonellosis, Norovirus enteritis, 
and leptospirosis providing important clues for prevention and further epidemiological 
investigations. Serosurveys on markers of infection in representative population subsamples (Lyme 
borreliosis and hepatitis E) and in special-risk populations (Coxiella burnetii in veterinarians) were 
also conducted. Surprisingly high seroprevalences were found. About 20% of the adult population 
showed antibodies against HEV. Borrelia burgdorferi seroprevalence was 6% among children and 
increased significantly with age. In the veterinarians, the seroprevalence of Coxiella burnetii was 
about 40% and associated with cattle obstetrics. Another topic of interest is the spatio-temporal 
variation of hantavirus infection and its determinants. In an externally funded project, burden of 
disease of non-cholera vibrio infections in Germany (diarrheal disease, wound infections) is being 
studied (Figure 14). 
Evaluation Report (Public Version) Unit 35: Gastrointestinal Infections, Zoonoses and Tropical Infections 
141 
Figure 14: Mean annual incidence of notified hantavirus infections by place of infection (county) and serotype 
(Puumala or Dobrava), Germany 2004-10 (n=4412) 
 
Risk factor studies are essential for targeted public health measures 
They supply new scientific knowledge which leads to new or improved public health 
recommendations. In this context we conducted a large multi-state case-control study on risk 
factors for sporadic Yersinia enterocolitica infection in conjunction with the public health service, 
yielding the somewhat surprising finding that even in (very young) children, consumption of raw 
ground pork is the main risk factor for infection. In other case-control studies, risk factors for 
sporadic infection with hantaviruses and Giardia lamblia were studied. Currently we are conducting 
large nation-wide or multi-state case-control studies on sporadic campylobacteriosis, listeriosis and 
on specific risk factors for hepatitis E virus infections. 
Figure 15: Case control study on the risk factors for yersiniosis in Germany: Consumption of raw minced pork 
by age group in cases and controls 
 
Molecular Epidemiology 
There is growing awareness of the importance of molecular epidemiology at the cross roads 
between classic infectious disease epidemiology and microbiology/virology. Linkage of 
epidemiological and molecular data (regarding human, food, and environmental samples) allows 
dynamic monitoring of specific pathogens (and their subtypes) in various populations, as well as a 
better quantification of the importance of various source and vehicles of infection in Germany. For 
example, the unit conducted and published studies regarding hepatitis A and E in collaboration 
jointly with the respective expert laboratories (Dr. Schreier/Dr. Höhne, RKI and Prof. Jilg, 
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conducted in cooperation with Prof. Suerbaum, Hannover (Medical School, Institute of Medical 
Microbiology and Hospital Hygiene). The study results should enable us to quantify the impact of 
different groups of food items on the campylobacter incidence in Germany, the most common 
bacterial gastrointestinal infection (annually 70,000 notified cases). 
Figure 16: Molecular epidemiology of hepatitis A in Germany: Neighbor-joining phylogenetic tree of a 348-bp 




Emerging and re-emerging infectious diseases/zoonoses 
In recent years Lyme borreliosis has been a focus of attention. Notification data available only from 
5 eastern German states are of variable quality and thus allow very limited conclusions on the 
epidemiology of the disease in Germany as a whole. Consequently population-based studies on 
antibody seroprevalence are paramount and are being done in collaboration with Department 2 on 
sera collected for the national “Kids and youths” (KiGGS) and the “Adult health” surveys (DEGS) 
(see above). For pathogens newly emerging in Germany, it is important to determine possible 
threats for humans. A good example is Schmallenberg virus (SBV), discovered in November 2011 
by the Friedrich-Loeffler-Institut (federal institute for veterinary health) in sick dairy cows in North 
Rhine-Westphalia. In view of the German and international public health interest (this was also 
recommended by ECDC), it had to be quickly determined whether these animal infections posed a 
risk for human health. In conjunction with our colleagues in the laboratory (ZBS1), Unit 35 assessed 
A: Place of infection  
B: Migration background and 
C: age of case-patients  
■, 0–9 y; 
■■, 10–19 y; 
■■■, 20–39 y; 
■■■■, 40– 59 y; 
■■■■■, >60 y)  
are shown for each HAV isolate 
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the risks based on quickly developed laboratory assays and a rapidly organised epidemiological 
study among exposed shepherds. We were able to conclude and publish in a timely manner, that 
the human health risk of SBV is negligible. Unit 35 has the appropriate expertise and cooperation 
links to replicate such rapid risk assessments in similar situations in the future. 
Imported infections 
Surveillance data on imported mosquito borne diseases (malaria, dengue fever, chikungunya fever) 
are constantly monitored and analysed for trends. This enables the unit to issue pertinent 
information for travel medicine experts and the public. Based on mathematical modelling, potential 
autochthonous transmission of relevant pathogens is addressed. Unit 35 collaborates closely with 
the Bernhard-Nocht-Institut for Tropical Medicine. To promote entomological monitoring, Unit 35 
has initiated an external project (funded by RKI) on the systematic monitoring of potential 
mosquito vectors in Germany and is curating the project, which is carried out by the Friedrich-
Loeffler-Institut. 
Climate Change 
The risk of changes in the occurrence of climate sensitive infections during times of climate change 
are being assessed (publication in Bundesgesundheitsbl-Bundesgesundheitsforsch-
Bundesgesundheitsschutz, Climate Assessment Report). Studies are being conducted, e.g., on the 
importance of ecological and climatic factors on the incidence of hantavirus infections in Germany, 
on scenarios for potential autochthonous transmission of dengue virus in South West Germany, on 
the impact of extreme weather events like rain storms on outbreaks of climate sensitive pathogens, 
and on the correlation of very warm summers with the incidence of wound infections with marine 
non-cholera vibrio. 
Statistical-epidemiological Methods 
The unit (with its full-time biostatistician) is also involved in interdisciplinary research on the 
boundary between biostatistical methods and infectious disease epidemiology. This ranges from 
statistical consulting within the unit and department to interfacing with statistical research 
environments at universities. As a consequence, state-of-the art methods are readily applied in the 
unit’s projects or, where necessary, extended to address RKI specific needs. Examples are: real-time 
tracking of epidemic curves during outbreaks, exposure estimation using back-projection methods 
in foodborne outbreaks, outbreak detection algorithms and model selection for case-control and 
cohort studies in light of missing data and exposure misclassification. Furthermore, when 
combining notification data with additional geo-referenced information (e.g., variables on 
demographics, socio-economics, climate or land use) spatial and spatio-temporal ecological 
regression is performed. Open-source software is provided whenever possible, which contains an 
implementation of the methodological extensions.  
2.2.4. Training 
Training of staff in public health institutions is another major area of work. In various federal states, 
we carried out training workshops for public health service staff on how to investigate food-borne 
outbreaks epidemiologically. To this end, we developed a simple tool based on Excel, which can be 
efficiently used by (local) public health authorities in outbreak investigations to timely record 
relevant epidemiological data (demographics, exposures) from patients and control persons. The 
tool is programmed to automatically calculate bivariable measures of association (e.g., odds ratios, 
relative risks).  
2.3. Major goals and contribution to the goals of the department  
The major goals for the coming years are: 
• To timely detect outbreaks, particularly multistate outbreaks. Improved statistical 
algorithms are being developed, as well as concepts for systematically integrating 
subtyping information for specific pathogens (e.g., STEC, Listeria, non-typhoidal 
Salmonella serotypes) (in collaboration with the Department for Infectious Diseases, Abt. 
1). 
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• To further develop and refine methods and tools to identify more timely and more 
frequently the vehicles and sources of infection in food-borne outbreaks. 
• To carry out research into the burden of disease of the major gastrointestinal infectious and 
vector-borne diseases. 
• To investigate the distribution, risk factors and the clinical outcome of relevant 
gastrointestinal and zoonotic pathogens in Germany in large multistate epidemiological 
studies. When appropriate, classical epidemiological and molecular methods (molecular 
epidemiology) are being combined. 
• To assess the effectiveness of intervention measures for relevant gastrointestinal and 
zoonotic infections. 
• To investigate the impact of travel-associated infections and to assess the potential of 
autochthonous transmission of selected pathogens in Germany. 
• To analyse the effects of climate patterns on the occurrence and distribution of climate-
sensitive infectious diseases. 
• To intensify the work on statistical-methodological methods (e.g., outbreak detection, 
spatio-temporal models). 
• To provide tools, training and practical support for public health authorities to investigate 
outbreaks. 
• To provide sound scientific evidence for consumer advice and public health 
recommendations. 
2.4. Additional work and methods for investigations  
In addition to the scientific and training activities, which are described in the respective chapters, 
we regularly inform the public and the scientific community not only by peer-reviewed publications 
but also by a substantial number of reports written for the Epidemiological Bulletin of the RKI and 
we produce the Fact Sheets (Ratgeber) for Physicians on selected gastrointestinal and zoonotic 
pathogens. We have also coordinated the interim and final reports on the large food-borne 
outbreaks in 2011 (STEC O104:H4) and 2012 (Norovirus due to contaminated frozen strawberries), 
and we contributed to Assessment Reports (e.g., on Climate Change and Health). We published (in 
collaboration with other authorities and institutes such as the Friedrich-Loeffler-Institut and 
National Reference Laboratories) recommendations on prevention of selected gastrointestinal and 
zoonotic pathogens (e.g., hantavirus) or contributed to consumers’ advice (e.g., by the Federal 
Institute of Risk Assessment on consumption of raw minced pork or sprouts).  
We are developing innovative methods especially in the field of statistical-epidemiological methods 
(See 2.2, Unit 35).  
2.5. Scientific advice and consulting services 
Unit 35 provides (scientific) advice to a range of national and international authorities and bodies: 
Federal Ministry of Health 
Advice on trends in food-borne and zoonotic infections (e.g., emerging and re-emerging 
pathogens), on climate change and infectious diseases, and on priority setting. Assessment of risk 
to the general population in foodborne or other outbreak situations. 
Public Health and Food Safety authorities 
Advice concerning strategies and tools (e.g., questionnaires) in outbreak investigations, hygienic 
measures in the context of food-borne and zoonotic outbreaks. 
Advice concerning interpretation of case definitions, surveillance data, epidemiologic findings etc. 
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Federal Environment Agency, and Federal Ministry for the Environment, Nature Conversation 
and Nuclear Safety 
Advice on vector-borne pathogens and on climate change and infectious diseases.  
Clinicians, scientists from other institutes etc. 
Advice on interpretation of surveillance data and epidemiological findings. Provision of data, 
figures, presentations, etc. 
Advice on epidemiological methods (study design, data collection, data analysis). 
Public 
Telephone and written advice regarding risks from food-borne and zoonotic pathogens (routes of 
transmission etc.). 
Berlin School of Public Health 
Advice and collaboration concerning training in infectious disease epidemiology and on PhD 
programme (epidemiology). 
European Food Safety Authority (EFSA)  
• Working Group on Food-borne outbreak reporting, 2008/10 (D. Werber) 
• Working Group on Epidemiological Criteria on Meat Inspection 2010/11 (C. Frank) 
European Center for Disease Prevention and Control (ECDC) 
Advice on surveillance, epidemiology and control of food-borne, zoonotic, and travel-associated 
infections in Germany (and cross-border). 
Advice and collaboration concerning molecular typing for public health surveillance (K. Stark). 
2.6.  Training and teaching activities 
• Coordination of the module Infectious Diseases Epidemiology within the master 
programmes (Public Health, Epidemiology) at the Berlin School of Public Health (BSPH), 
Charité Medical School, Berlin 
• Mentoring of fellows of the training Programme Applied Epidemiology (PAE) and the 
European Programme for Intervention Epidemiology Training (EPIET) 
• Contribution to EPIET training modules 
• Lectures at the Charité for medical students, in the Master Programme International Health 
(Module Epidemiology), and at the University of Bonn (Medical Geography) 
• Teaching on “Statistical Methods for Infectious Diseases” in various Biostatistics 
programmes (University of Munich, University of Zurich) or as short courses 
• Supervision of master’s and doctoral theses 
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3.  Cooperation with other scientists or research institutions 
3.1.  Internal (within RKI) 
Department of Infectious Diseases (Dept. 1), Division 11 Bacterial Infections 
• Outbreak investigations, epidemiological studies (STEC, salmonellae, listeria), molecular 
surveillance 
• Frank C et al., Euro Surveill 2011 
• Frank C et al., N Eng J Med 2011 
• Stöcker P et al., Euro Surveill 2011 
• Koch J et al., Foodborne Pathog Dis 2010 
• Nielsen S et al., Zoonoses public health 2011 
• Weiss B et al., Vector Borne Zoonotic Dis 2011 
Department of Infectious Diseases (Dept. 1), Division 15 Molecular Epidemiology of Viral 
Pathogens 
• Molecular epidemiological studies (hepatitis A, norovirus). 
• Faber MS et al., Emerg Infect Dis 2009 
• Wadl M et al., BMC Infect Dis 2010 
Department of Epidemiology and Health Reporting (Dept. 2), Divisions 21, 22, 23, 24, 25, 26 
• Studies on seroprevalence of various pathogens in the general population in Germany. 
Case-control studies (control populations). 
• Faber MS et al., Emerg Infect Dis 2012 
• Dehnert M et al., PloS One 2012 
Centre for Biological Security, ZBS1 Highly Pathogenic Viruses 
• Studies on emerging viruses. 
• Ducomble T et al., Emerg Infect Dis 2012 
Centre for Biological Security, ZBS2 Highly Pathogenic Microorganisms 
• Studies on emerging bacteria. 
• Holzmann T, et al. Euro Surveill 2012. 
3.2. External / National 
University of Regensburg, Institute of Microbiology, Dept. of Virology (Prof. Jilg) 
• Hepatitis E (Studies on seroprevalence in the general population, risk factors, molecular 
epidemiology) 
• Faber MS, et al. Emerg Infect Dis 2012 (see also under Internal Cooperation) 
University hospitals, clinical departments of other hospitals 
• Frank C et al., N Eng J Med 2011 
• Holzmann T et al., Euro Surveill 2012 
Consiliar Laboratory for Coxiella burnetii, Stuttgart (Landesgesundheitsamt, Dr. Wagner-
Wiening) 
• Bernard H et al., Vector Borne Zoonotic Dis 2012 
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Consiliar Laboratory for Hantavirus, Berlin (Charité, Institute of Virology, Prof. Krüger) 
• Faber MS et al., Euro Surveill 2010 
Consiliar Laboratory for Leptospirae, Berlin (Federal Institute for Risk Assessment, Dr. 
Nöckler) 
• Desai S et al., Clin Infect Dis 2009 
National Reference Centre for Borrelia burgdorferi, München (Landesamt für Gesundheit und 
Lebensmittel, Dr. Fingerle) 
• Dehnert M et al., PloS One 2012 
Consiliar Laboratory for Haemolytic-Uraemic Syndrome, Münster (University Münster, 
Institute of Hygiene, Prof. Karch), and Research Network Food-borne zoonotic bacterial 
infections (FBI-Zoo) 
• Werber D et al., Lancet 2011 
• Frank C et al., Euro Surveill 2011 
• Mellmann A et al., Emerg Infect Dis 2009 
• Alpers K et al., Epidemiol Inf 2009 
German Society of pediatric nephrology 
• Active Surveillance of Pediatric HUS 
Hannover Medical School, Institute for Medical Microbiology and Hospital Hygiene (Prof. 
Suerbaum) 
• Vonberg R et al., Clin Infect Dis; in press. 
National and Federal State Food Safety Authorities (e.g., Federal Institute of Risk 
Assessment, Federal Authority for Consumer Protection and Food) 
• Buchholz U et al., N Eng J Med 2011 
• Kamga Wambo GO et al., Euro Surveill 2011 
• Frank C et al., Euro Surveill 2009 
• Pires SM et al., Foodborne Pathog Dis 2009 
Friedrich-Loeffler-Institute for Veterinary Health, Riems 
• Faber MS et al., Euro Surveill 2010 
VibrioNet (BfR, Alfred-Wegener-Institut, FU Berlin, LAVES, TU Dresden, Q-Bioanalytic) 
• Alter T et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2011 
Bernhard-Nocht-Institute for Tropical Medicine, Hamburg 
• Schmidt-Chanasit J et al., Infection 2012 
• Schmidt-Chanasit J et al., Euro Surveill 2010 
Federal State Authorities for Infectious Disease Epidemiology 
• Bernard H et al., Vector Borne Zoonotic Dis 2012 
• Holzmann T et al., Euro Surveill 2012 
• Kamga Wambo GO et al., Euro Surveill 2011 
• Brockmann S et al., BMC Infect Dis 2010 
• Faber MS et al., Euro Surveill 2010 
• Alpers K et al., Epidemiol Inf 2009 
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• Schroeter M et al., Epidemiol Inf 2009 
• Winter CH et al., Epidemiol Inf 2009 
District Public Health Authorities (various) 
• Wilking H et al., Emerg Infect Dis 2012 
• Frank C et al., N Eng J Med 2011 
Institute of Tropical Medicine, Berlin 
• Zoller T et al., Malaria J 2009 
Ludwig-Maximilians-Universität München (Institute of Statistics) 
• Meyer S et al., Biometrics 2012 
German Armed Forces/Bundeswehr (Institute for Microbiology, Medical Service Kiel, and 
other units) 
• Holzmann T et al., Euro Surveill 2012 
• Wadl M et al., BMC Infect Dis 2010 
3.3.  External / International 
European Centre for Disease Prevention and Control 
• Contributions to various rapid risk assessments 
National Institute for Public Health and the Environment (RIVM), The Netherlands 
• Haagsma JA et al., Epidemiol Infect 2012 
• Verhoef L et al., Epidemiol and Infect 2012:1-11. 
• Verhoef L et al., Emerg Infect Dis 2011 
• Pires SM et al., Foodborne Pathog Dis 2009 
Statens Serum Institut, Denmark 
• Kuhn K et al., Euro Surveill 2011 
• Buchholz U et al., N Eng J Med 2011 
Smittskyddsinstitutet (Swedish Institute for Communicable Disease Control), Sweden 
• Buchholz U et al. N Eng J Med 2011 
Austrian Agency for Health and Food Safety (AGES), Austria 
• Fretz R et al., Euro Surveill 2010 
National Public Health Institutes in Poland, Romania and Slovakia 
• Desai S et al., Clin Infect Dis 2009 
WHO-Europe, Health Authorities Montenegro and United Kingdom (HPA) 
• Werber D et al., Epidemiol Infect 2009 
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4.  Appendix 
4.1  Overview on achievements of the unit, 2009-2012 
4.1.1.  Scientific publications, 2009 – 2012 
Number of peer-review publications co-authored by members of the unit: 76 





Cumulative 2009-2012: 413.4 
Original research articles in peer-review journals 
2012 (until Sept.) 
Bernard H, Brockmann SO, Kleinkauf N, Klinc C, Wagner-Wiening C, Stark K, Jansen A. High 
seroprevalence of Coxiella burnetii antibodies in veterinarians associated with cattle obstetrics, 
Bavaria, 2009. Vector Borne Zoonotic Dis 2012;12(7):552-557. 
Dehnert M, Fingerle V, Klier C, Talaska T, Schlaud M, Krause G, Wilking H, Poggensee G. 
Seropositivity of Lyme borreliosis and associated risk factors: a population-based study in Children 
and Adolescents in Germany (KiGGS). PloS One 2012;7(8):e41321. 
Ducomble T, Wilking H, Stark K, Takla A, Askar M, Schaade L, Nitsche A, Kurth A. Lack of 
evidence for Schmallenberg virus infection in highly exposed persons, Germany, 2012. Emerg Infect 
Dis 2012;18(8):1333-1335. 
Faber MS, Wenzel JJ, Jilg W, Thamm M, Höhle M, Stark K. Hepatitis E Virus Seroprevalence 
among Adults, Germany. Emerg Infect Dis 2012;18(10):1654-167. 
Haagsma JA, Geenen PL, Ethelberg S, Fetsch A, Hansdotter F, Jansen A, Korsgaard H, O'Brien SJ, 
Scavia G, Spitznagel H, Stefanoff P, Tam CC, Havelaar AH. Community incidence of pathogen-
specific gastroenteritis: reconstructing the surveillance pyramid for seven pathogens in seven 
European Union member states. Epidemiol Inf 2012;27:1-15. 
Holzmann T, Frangoulidis D, Simon M, Noll P, Schmoldt S, Hanczaruk M, Grass G, Pregler M, 
Sing A, Hormansdorfer S, Bernard H, Grunow R, Zimmermann R, Schneider-Brachert W, Gessner 
A, Reischl U. Fatal anthrax infection in a heroin user from southern Germany, June 2012. Euro 
Surveill 2012;17(26). 
Johne R, Dremsek P, Kindler E, Schielke A, Plenge-Bonig A, Gregersen H, Wessels U, Schmidt K, 
Rietschel W, Groschup MH, Guenther S, Heckel G, Ulrich RG. Rat hepatitis E virus: geographical 
clustering within Germany and serological detection in wild Norway rats (Rattus norvegicus). Infect 
Genet Evol 2012;12(5):947-956. 
Meyer S, Elias J, Höhle M. A space-time conditional intensity model for invasive meningococcal 
disease occurrence. Biometrics 2012;68(2):607-16. 
Rosner BM, Stark K, Höhle M, Werber D. Risk factors for sporadic Yersinia enterocolitica 
infections, Germany 2009-2010. Epidemiol Inf 2012;140(10):1738-47. 
Schmidt-Chanasit J, Tenner-Racz K, Poppert D, Emmerich P, Frank C, Dinges C, Penning R, Nerlich 
A, Racz P, Gunther S. Fatal dengue hemorrhagic fever imported into Germany. Infection 
2012;40(4):441-3. 
Schoene CU, Staubach C, Grund C, Globig A, Kramer M, Wilking H, Beer M, Conraths FJ, Harder 
TC; the BL Monitoring Group. Towards a new, ecologically targeted approach to monitoring wild 
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bird populations for avian influenza viruses. Epidemiol Infect 2012 Aug 24:1-11. 
Schrader C, Schielke A, Ellerbroek L, Johne R. PCR inhibitors - occurrence, properties and removal. 
J Appl Microbiol 2012;113(5):1014-26. 
Verhoef L, Koopmans M, Van Pelt W, Duizer E, Haagsma J, Werber D, Van Asten L, Havelaar A. 
The estimated disease burden of norovirus in The Netherlands. Epidemiol Inf 2012:1-11. 
Werber D, Hille K, Frank C, Dehnert M, Altmann D, Müller-Nordhorn J, Koch J, Stark K. Years of 
potential life lost for six major enteric pathogens, Germany, 2004-2008. Epidemiol Inf 2012:1-8.  
Wilking H, Gotsch U, Meier H, Thiele D, Askar M, Dehnert M, Frank C, Fruth A, Krause G, Prager 
R, Stark K, Boddinghaus B, Bellinger O, Gottschalk R. Identifying risk factors for shiga toxin-
producing Escherichia coli by payment information. Emerg Infect Dis 2012;18(1):169-70. 
Wilking H, Höhle M, Velasco E, Suckau M, Eckmanns T. Ecological analysis of social risk factors 
for Rotavirus infections in Berlin, Germany, 2007 - 2009. Int J Health Geogr 2012;11:37. 
2011 
Abbas T, Wilking H, Staubach C, Ziller M, Conraths FJ. Priority areas for surveillance and 
prevention of avian influenza during the water-bird migration season in Pakistan. Geospatial 
Health 2011 Nov;6(1):107-16. 
Askar M, Faber MS, Frank C, Bernard H, Gilsdorf A, Fruth A, Prager R, Höhle M, Suess T, Wadl 
M, Krause G, Stark K, Werber D. Update on the ongoing outbreak of haemolytic uraemic 
syndrome due to Shiga toxin-producing Escherichia coli (STEC) serotype O104, Germany, May 
2011. Euro Surveill 2011;16(22). 
Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gartner B, Gross U, Haas W, Hamouda 
O, Hubner J, Janisch T, Kist M, Kramer MH, Ledig T, Mielke M, Pulz M, Stark K, Suttorp N, Ulbrich 
U, Wichmann O, Krause G. Communicable diseases prioritized for surveillance and 
epidemiological research: results of a standardized prioritization procedure in Germany, 2011. PloS 
One 2011;6(10):e25691. 
Buchholz U, Bernard H, Werber D, Bohmer MM, Remschmidt C, Wilking H, Delere Y, Heiden 
MA, Adlhoch C, Dreesman J, Ehlers J, Ethelberg S, Faber MS, Frank C, Fricke G, Greiner M, Höhle 
M, Ivarsson S, Jark U, Kirchner M, Koch J, Krause G, Luber P, Rosner BM, Stark K, Kuhne M, the 
HUS investigation team. German Outbreak of Escherichia coli O104:H4 Associated with Sprouts. 
N Eng J Med 2011;365(19):1763-1770. 
Du Y, Rosner BM, Knopf H, Schwarz S, Doren M, Scheidt-Nave C. Hormonal contraceptive use 
among adolescent girls in Germany in relation to health behavior and biological cardiovascular risk 
factors. The Journal of adolescent health : official publication of the Society for Adolescent 
Medicine. 2011;48(4):331-7. 
Dudareva S, Schweiger B, Thamm M, Höhle M, Stark K, Krause G, Buda S, Haas W. Prevalence of 
antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and 
post-pandemic period. PloS One 2011;6(6):e21340. 
Frank C, Faber MS, Askar M, Bernard H, Fruth A, Gilsdorf A, Höhle M, Karch H, Krause G, 
Prager R, Spode A, Stark K, Werber D. Large and ongoing outbreak of haemolytic uraemic 
syndrome, Germany, May 2011. Euro Surveill 2011;16(21). 
Frank C, Schöneberg I, Stark K. Trends in Imported Chikungunya Virus Infections in Germany, 
2006-2009. Vector Borne Zoonotic Dis 2011;11(6):631-6. 
Frank C, Werber D, Cramer JP, Askar M, Faber MS, Heiden MA, Bernard H, Fruth A, Prager R, 
Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Muller L, King LA, Rosner BM, 
Buchholz U, Stark K, Krause G, the HUS investigation team. Epidemic Profile of Shiga-Toxin-
Producing Escherichia coli O104:H4 Outbreak in Germany. N Eng J Med 2011;365(19):1771-1780. 
Hermes J, Bernard H, Buchholz U, Spackova M, Low J, Loytved G, Suess T, Hautmann W, Werber 
D. Lack of evidence for pre-symptomatic transmission of pandemic influenza virus A(H1N1) 2009 
in an outbreak among teenagers; Germany, 2009. Influenza Other Respi Viruses 2011;5(6):e499-
503. 
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Höhle M, Siedler A, Bader HM, Ludwig M, Heininger U, Von Kries R. Assessment of varicella 
vaccine effectiveness in Germany: a time-series approach. Epidemiol Infect 2011;139(11):1710-9. 
Kamga Wambo GO, Burckhardt F, Frank C, Hiller P, Wichmann-Schauer H, Zuschneid I, 
Hentschke J, Hitzbleck T, Contzen M, Suckau M, Stark K. The proof of the pudding is in the eating: 
an outbreak of emetic syndrome after a kindergarten excursion, Berlin, Germany, December 2007. 
Euro Surveill 2011;16(15). 
Koch J, Wiese-Posselt M. Epidemiology of rotavirus infections in children less than 5 years of age: 
Germany, 2001-2008. The Pediatric infectious disease journal. 2011;30(2):112-7. 
Kuhn K, Torpdahl M, Frank C, Sigsgaard K, Ethelberg S. An outbreak of Salmonella Typhimurium 
traced back to salami, Denmark, April to June 2010. Euro Surveill 2011;16(19). 
Nielsen S, Frank C, Fruth A, Spode A, Prager R, Graff A, Plenge-Bonig A, Loos S, Lutgehetmann M, 
Kemper MJ, Muller-Wiefel DE, Werber D. Desperately seeking diarrhoea: outbreak of haemolytic 
uraemic syndrome caused by emerging sorbitol-fermenting shiga toxin-producing Escherichia coli 
O157:H-, Germany, 2009. Zoonoses and public health. 2011;58(8):567-72. 
Schielke A, Filter M, Appel B, Johne R. Thermal stability of hepatitis E virus assessed by a 
molecular biological approach. Virology journal. 2011;8:487. 
Stöcker P, Rosner BM, Werber D, Kirchner M, Reinecke A, Wichmann-Schauer H, Prager R, 
Rabsch W, Frank C. Outbreak of Salmonella Montevideo associated with a dietary food 
supplement flagged in the Rapid Alert System for Food and Feed (RASFF) in Germany, 2010. Euro 
Surveill 2011;16(50):20040. 
Velasco E, Espelage W, Faber MS, Noll I, Ziegelmann A, Krause G, Eckmanns T. A national cross-
sectional study on socio-behavioural factors that influence physicians' decisions to begin 
antimicrobial therapy. Infection. 2011;39(4):289-97. 
Verhoef L, Kouyos RD, Vennema H, Kroneman A, Siebenga J, van Pelt W, Koopmans M, 
Foodborne Viruses in Europe Network. An integrated approach to identifying international 
foodborne norovirus outbreaks. Emerg Infect Dis 2011;17(3):412-8. 
Wadl M, Rieck T, Nachtnebel M, Greutelaers B, An der Heiden M, Altmann D, Hellenbrand W, 
Faber MS, Frank C, Schweickert B, Krause G, Benzler J, Eckmanns T. Enhanced surveillance during 
a large outbreak of bloody diarrhoea and haemolytic uraemic syndrome caused by Shiga 
toxin/verotoxin-producing Escherichia coli in Germany, May to June 2011. Euro Surveill 2011;16(24). 
Weiss B, Rabsch W, Prager R, Tietze E, Koch J, Mutschmann F, Roggentin P, Frank C. Babies and 
Bearded Dragons: Sudden Increase in Reptile-Associated Salmonella enterica Serovar Tennessee 
Infections, Germany 2008. Vector Borne Zoonotic Dis. 2011;11(9):1299-301. 
2010 
Brockmann S, Piechotowski I, Bock-Hensley O, Winter C, Oehme R, Zimmermann S, Hartelt K, 
Luge E, Nockler K, Schneider T, Stark K, Jansen A. Outbreak of leptospirosis among triathlon 
participants in Germany, 2006. BMC Infect Dis 2010;10:91. 
Espelage W, an der Heiden M, Stark K, Alpers K. Characteristics and risk factors for symptomatic 
Giardia lamblia infections in Germany. BMC Public Health 2010;10:41. 
Faber MS, Heckenbach K, Velasco E, Eckmanns T. Antibiotics for the common cold: expectations 
of Germany's general population. Euro Surveill 2010;15(35). 
Faber MS, Ulrich RG, Frank C, Brockmann SO, Pfaff GM, Jacob J, Kruger DH, Stark K. Steep rise 
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evidence for Schmallenberg virus infection in highly exposed persons, Germany, 2012. 
Emerg Infect Dis 2012;18(8):1333-5. 
2. Faber MS, Wenzel JJ, Jilg W, Thamm M, Höhle M, Stark K. Hepatitis E Virus 
Seroprevalence among Adults, Germany. Emerg Infect Dis 2012;18(10):1654-7. 
3. Frank C, Werber D, Cramer JP, Askar M, Faber MS, Heiden MA, Bernard H, Fruth A, 
Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Muller L, King LA, 
Rosner BM, Buchholz U, Stark K, Krause G, the HUS investigation team. Epidemic Profile 
of Shiga-Toxin-Producing Escherichia coli O104:H4 Outbreak in Germany. N Eng J Med 
2011;365(19):1771-80. 
4. Buchholz U, Bernard H, Werber D, Bohmer MM, Remschmidt C, Wilking H, Delere Y, 
Heiden MA, Adlhoch C, Dreesman J, Ehlers J, Ethelberg S, Faber MS, Frank C, Fricke G, 
Greiner M, Höhle M, Ivarsson S, Jark U, Kirchner M, Koch J, Krause G, Luber P, Rosner 
BM, Stark K, Kuhne M, the HUS investigation team. German Outbreak of Escherichia coli 
O104:H4 Associated with Sprouts. N Eng J Med 2011;365(19):1763-70. 
5. Faber MS, Stark K, Behnke SC, Schreier E, Frank C. Epidemiology of hepatitis a virus 
infections, Germany, 2007-2008. Emerg Infect Dis 2009;15(11):1760-8. 
Five important publications for the public 2009–2012 
1. Final Report on the epidemiology of the Norovirus outbreak due to frozen strawberries, 
Germany 2012 (in German, Abschlussbericht) (Also see Report in the Epidemiological 
Bulletin 41/2012) 
2. Yersiniosis – Risk factors in Germany. Epidemiological Bulletin 6/2012 (German)(based on 
Rosner BM, et al. Epidemiol Infect 2012;140(10):1738-47.) 
3. Final presentation and evaluation of epidemiological findings in the EHEC O104:H4 
outbreak, Germany 2011 (Abschlussbericht, in German and English) 
4. Merkblatt: Informationen zur Vermeidung von Hantavirus-Infektionen (joint information 
sheet by RKI, Consiliar Laboratory for Hantaviruses, Friedrich-Loeffler-Institut, Bernhard-
Nocht-Institut für Tropenmedizin) 
5. Eis D, Helm D, Laußmann D, Stark K. Klimawandel und Gesundheit – Ein 
Sachstandsbericht. Robert Koch Institute, Berlin, 2010 (244 Seiten). 
4.1.3.  Awards and honours, 2009 - 2012 
2010 
Michael Höhle, 2nd Gustav-Adolf-Lienert-Preis 2010, German Region of the International Biometric 
Society (IBS), for his habilitation thesis "Statistical Modeling and Monitoring of Infectious 
Diseases". 
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4.1.4.  Overview on collaborations in networks 
Food-Borne Zoonotic Infections (Research Network FBI-Zoo, Germany): 
Interdisciplinary research on the microbiology, clinical aspects and the epidemiology of food-borne 
bacterial zoonotic infections in humans and animals in Germany (Campylobacter, Salmonella, 
STEC, Yersinia enterocolitica). 
VibrioNet 
The research network VibrioNet connects different disciplines of human and veterinary medicine, 
ecology, molecular biology and epidemiology to evaluate the risk of climate change and the 
emergence of seafood- and waterborne infections with non-cholera-vibrio in Germany. 
Food- and Waterborne Diseases Network (European Network, ECDC) 
European network on surveillance, outbreak investigations, epidemiological research and control of 
food- and waterborne infections. 
Network Rodent-Borne Pathogens (Germany) 
Network (coordinated by Friedrich-Loeffler-Institut, Dr. Ulrich) on microbiology/virology, 
epidemiology and control of rodent-borne infections in Germany. 
Food-borne viruses in Europe (coordinated by RIVM, The Netherlands) 
European network on surveillance, outbreak investigations, epidemiological research and control of 
food- and waterborne infections. 
Med-Vet-Net (European Network on Zoonoses Research, 2006-2010) 
Interdisciplinary network involving institutes of veterinary health, public health institutes and 
university departments from many European countries (microbiology, virology, parasitology, 
epidemiological and clinical aspects, prevention and control). 
4.1.5.  Memberships and participation in Advisory Boards 
Prof. Dr. Klaus Stark 
• German Society of Epidemi0logy 
(also: Member of the commission for the certificate in 
epidemiology) 
• German Society of Medical Informatics, Biometrics and Epidemiology 
Christina Frank, PhD 
• ECDC: Member of FWD (Food- and Waterborne Diseases) Coordination Group 
Dr. Bettina Rosner 
• German Society of Epidemi0logy (DGEpi) 
• Association for General and Applied Microbiology - VAAM 
Dr. Helen Bernard 
• EPIET Alumni Network (EAN) – Treasurer from 2009-2012 
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4.1.6.  List of completed habilitation, dissertation or master theses in the Unit, 2009 - 
2012 
2012 
Habilitation: PD Dirk Werber, Charité, Berlin School of Public Health 
Year Titel / 
Degree 
Name Title of thesis University /  
Supervisor RKI 
2010 MSc Epi Katja Hille "Years of life lost" ausgewählter 
Infektionskrankheiten anhand der 
Meldedaten nach Infektions-
schutzgesetz 
Charité / BSPH 
PD Dr. D. Werber 
2010 BSc Franca 
Kirchberg 
Die Backcalculation-Methode und 
deren Anwendung zur Schätzung 
der HIV-Infektionsrate 
Department of Statistics, 
University of Munich 
PD Dr. M. Höhle 
2010 Diplom Juliane Manitz Automated detection of infectious 
disease outbreaks  
Department of Statistics, 
University of Munich 
PD Dr. M. Höhle 
2011 MSAE Sandra 
Dudareva 
Analysis and interpretation of 
surveillance and research data - 
four examples how to address 
public health relevant questions 
Charité / BSPH 
C. Frank, PhD 
2011 Diplom Annika Witt Count data time series modelling 
of diseases covered by the German 
Infection Protection Act 
Department of Statistics, 
University of Munich 
PD Dr. M. Höhle 
2011 Diplom Mirjam Rehr Statistische Methoden zur 
räumlichen und zeitlich-
räumlichen Clusterdetektion 
Department of Statistics, 
University of Munich 






Statistical Modelling of Dynamic 
Systems for Infectious Disease 
Epidemiology 
Department of Statistics, 
University of Munich 
PD Dr. M. Höhle 
2012 MSc Epi Karina Preußel Vergleich der Virulenz gastroin-
testinaler Infektionserreger in 
Deutschland 
Charité / BSPH 
PD Dr. D. Werber 
2012 MSc Epi Katrin 
Neubauer 
Polio eradication - analysis of the 
Enterovirus surveillance in 
Germany 
Charité / BSPH 
Prof. Dr. K. Stark 
2012 MSAE Mona Askar Die Identifizierung von Risiko-




Charité / BSPH 






Stochastic differential equations 
and their parameter inference for 
the susceptible-infected-recovered 
model 
Department of Statistics, 
University of Munich 






Modern algorithms for the 
automatic detection of outbreaks 
Enrolment ongoing 
PD Dr. M. Höhle 
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4.1.7. Presentations as invited speaker, 2009 – 2012 
Staff from the Gastrointestinal Infections, Zoonoses and Tropical Infection Unit were invited to 
speak at 79 conferences. 
4.1.8. Reports and written scientific advice to the Ministry of Health, 2009-2012 
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1. Unit 36: Respiratory Infections 
Head:  PD Dr. Walter Haas 
Deputy:  Dr. Silke Buda 
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2.  Tasks and goals of the Unit 
Respiratory infections are the leading cause of death among infectious diseases and pneumonia is 
the leading single cause of death in children younger than five years of age - killing every year about 
1.2 million children and accounting for approximately 18% of mortality in this age group worldwide 
(http://www.who.int/mediacentre/factsheets/fs331/en/index.html). In Germany, it is estimated that 
approximately 400,000-600,000 outpatient visits and 230,000 hospital admissions per year are 
caused by community-acquired pneumonia alone with 13% of these dying in the hospital 
(http://www.sqg.de/ergebnisse/leistungsbereiche/ambulant-erworbene-pneumonie.html). 
In 2002, within the Centre for Infectious Disease Epidemiology at the Robert Koch Institute (RKI), a 
team was formed to work on the epidemiology of respiratory infections. With the establishment of 
the Department for Infectious Disease Epidemiology in 2003, this work was assigned to the Unit 
for Respiratory transmitted Diseases and Vaccine Prevention. With the recognition of the huge 
burden of respiratory infections, the need to prepare for the pandemic threat of influenza, and the 
opportunity to reorganise the Department with resources provided by RKI 2010 the Respiratory 
Infections Unit was established, in 2006.  
2.1.  Summary  
Assessing the epidemiology of respiratory infections in the German population, the development 
and evaluation of strategies to reduce disease burden represent the main tasks of the Unit of 
Respiratory Infections. For this purpose the systematic analyses of data from the notification 
system, from the virological and syndromic sentinel surveillance is complemented by surveillance 
in collaboration with specific networks (e.g. paediatric hospitals, ICUs), outbreak investigations, 
and clinical epidemiological studies. A special focus is put on diseases with high priority for public 
health: Influenza, tuberculosis, and legionellosis. The results are regularly reported to the medical 
community and the public. Specific studies address the burden of Influenza (and other acute 
respiratory diseases), the risk of infection, factors facilitating transmission, and the efficacy of 
vaccination and nonpharmaceutical interventions. Since 2003 the Unit is in charge for scientific 
advice on pandemic influenza preparedness and the Influenza Task Force at RKI. Following in the 
tracks of Robert Koch, the unit is responsible for surveillance, epidemiology, and control of 
tuberculosis. A stagnating trend in case numbers and increasing incidence in children demonstrate 
the need of scientifically based strategies to prevent a resurgence of tuberculosis. In this context, 
we work to introduce new indicators for rapid assessment of the epidemiological situation and 
longer-term trends, as well as molecular epidemiological tools for the detection of clusters and the 
interruption of chains of infections. Vulnerable groups such as children, the elderly, migrants, 
prisoners, and people living with HIV/AIDS that suffer from active TB are addressed by different 
projects in collaboration with national and international partners. Only recently, we could extend 
our work to include travel associated cases of legionellosis within the European network. 
2.2.  Current status of the work and summary of relevant results 
2.2.1 Surveillance of influenza and other acute respiratory infections 
Syndromic surveillance of acute respiratory infections 
The Working Group Influenza is a physician-based sentinel surveillance system of acute respiratory 
infections (ARI) with special focus on influenza that has been fully implemented by Unit 36 in 
2009. It consists of two complementary systems, the syndromic and the virological surveillance. 
The syndromic surveillance system relies on voluntarily participating physicians in primary care 
(general practitioners, internists in primary care and paediatricians) who report on consultations 
because of ARI among their patients (Buda et al., Bericht zur Epidemiologie der Influenza in 
Deutschland Saison 2011/12). Virological surveillance is done with a subsample of about twenty per 
cent of AGI physicians who were instructed to take samples of the upper respiratory tract, e.g. nasal 
swabs, of a weekly number of 3-5 patients with influenza-like illness (ILI) and send them to the 
National Reference Center for Influenza (NRCI). 
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The surveillance is carried-out year-round and we have developed a modelling approach to allow 
estimation of the burden of influenza that is attended to by the primary care sector. 
Surveillance results are reported online and in a weekly (April to September monthly) bulletin that 
also includes notification data from the mandatory reporting of laboratory confirmed influenza, 
virological data by state reference laboratories of Baden-Württemberg, Bavaria, Mecklenburg-
Western Pomerania, Saxony, Saxony-Anhalt and Thuringia, and a summary of the international 
situation based on reports published by the World Health Organization (WHO) and the European 
Centre for Disease Prevention and Control (ECDC). In Addition, the assessment of the 
epidemiological situation is transmitted to ECDC, WHO, and the Pandemic Influenza Working 
Group (PIWG) at the Global Health Security Action Group (GHSAG) thus contributing to their 
international reports. 
Figure 17: Working Group on Influenza (AGI): Schematic flow of work and information 
 
ICD10-based electronic surveillance 
A new surveillance system easy to use for the physicians and affording automatic fast data 
processing has been developed by Unit 36, based on a pilot project in cooperation with Hessisches 
Landesprüfungs- und Untersuchungsamt im Gesundheitswesen starting in 2007. SEEDARE is a 
surveillance instrument to monitor burden of acute respiratory diseases – especially of influenza – 
in the German population based on electronic patient records in physician information systems for 
primary care providers. At this time approximately one hundred primary care practices including 
general practitioners, paediatricians, and internists are taking an active part in the sentinel. The 
software interface was developed at the RKI and a corresponding software tool was integrated in 
five physician information systems which are in widespread use in Germany (approx. 25% of 
primary care practices). The software tool captures case based anonymized data such as 
consultation date, age, gender, ICD-10 codes of patients with acute respiratory diseases (defined by 
ICD-10 codes out of following blocks: J00-J06, J09-J18, J20-J22 and additionally, J44.0 and B34.9) 
for each patient consultation as well as aggregated data such as the number of all patients visiting 
the doctor(s) in the sentinel practice per day (stratified by 7 age groups). The physicians send an 
encrypted data file to the RKI once a week, where the data are automatically imported in a RKI 
database and analysed with validity and plausibility checks. First results of detailed data analyses 
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were published in annual reports of AGI for the influenza seasons 2009/10, 2010/11, and 2011/12. 
Beginning with the winter season 2012/13 the data of SEEDARE are included in the weekly reports of 
AGI to strengthen the AGI surveillance system. In principle, the approach developed by our group 
can be extended to as surveillance instrument for monitoring of other diseases and interventions in 
primary care. 
Web-based surveillance of ARI at the population level 
As recently as 2011, with third-party research funding, an online surveillance system has been 
developed by Unit 36 to estimate the disease burden in the general population (i.e. independent of 
physician visits). This system, named GrippeWeb, is an online tool that enables RKI to 
"communicate" directly with the public. It allows the monitoring of the incidence of acute 
respiratory illnesses, including influenza-like illness. It was designed with the successful Dutch 
example in mind (De Grote Griepmeting) which has motivated also other countries to set up a 
similar system. Registered participants receive an e-mail once a week with the weblink to the results 
of the surveillance, which are published online, and a reminder to report symptoms of acute 
respiratory illness. The system is now running since 1.5 years and has attracted more than 4000 
participants. It has generated interesting data, for example the frequency of consulting a physician 
in case of an acute respiratory illness in general (approx. 15-25%) or an influenza-like illness (40-
50%) or the frequency of an acute respiratory illness throughout the year (children: 3-4 times/year, 
adults: (1-)2 times per year). It is envisaged to co-operate with the Helmholtz Zentrum für 
Infektiologie to stimulate participants to self-collect samples for virological validation of the 
syndromic results. So far, this system is unique in Germany and has also the potential to be 
extended to monitor other infectious disease syndromes. 
Monitoring of published human cases of highly pathogenic avian influenza A(H5N1) 
In addition, given the threat of avian influenza (AI) viruses to humans in Europe, a routine 
monitoring instrument was established in 2005 by Unit 36, condensing information on all human 
AI and other zoonotic influenza cases worldwide reported from the WHO and other sources into a 
single line list. This line list was maintained until March 2011 and made available online 
(http://www.rki.de/Prevention/Avian_Influenza/Avian_Influenza_node_en.html). 
An epidemiological evaluation of the instrument (09/2006 to 08/2010) showed that these data 
from the public domain yield important epidemiological information on the global AI situation, 
which was not evident from single case reports. E.g., a longer delay from symptom onset to 
hospital admission and belonging to older age groups were associated with higher mortality in AI 
patients. There were independent country-specific effects such as a rather low CFR in Egypt which 
were not explained by the patients’ young age and early hospital admission. Given these 
advantages, the placing of a publicly accessible line list of anonymised human AI cases, e.g. directly 
by WHO, was suggested (Fiebig et al., Euro Surveill 2011). 
2.2.2 Burden of disease caused by influenza and other acute respiratory infections 
Modelling the excess burden of influenza at the level of primary care 
In the context of the course of the influenza pandemic (H1N1) 2009 it became clear, that the 
availability of estimates of the burden of disease in the population and the severity are of 
paramount importance. The number of patients seeking health care is a central indicator: (1) as a 
proxy for the impact on the burden of the primary care system; (2) as a starting point to estimate 
the number of persons ill with influenza (number seeking health care divided by the proportion of 
diseased seeking health care = total ill); (3) as the denominator data for the calculation of case 
fatality rate and the proportion hospitalised (severity indicators); (4) for economic calculations. 
Using data of the syndromic surveillance system, we developed a statistical model to estimate the 
excess of outpatient visits caused by ARI (manuscript submitted). For estimating the number of 
outpatient visits we used a regression model for counts and for the baseline a cyclic regression 
model. Using this approach, we estimated the highest ARI burden within the last 10 years for the 
influenza season 2004/05 with an excess of 7.5 mill outpatient visits (CI95% 6.8-8.0). In contrast, 
the pandemic wave 2009 accounted for one third of this burden with an excess of 2.4 mill (CI95% 
1.9-2.8); we could show that during the pandemic school children in the age group 5-14 years were 
most affected with 9.6% (95%-CI 7.4%-12.0%), whereas in most years the age group of infants (0-4 
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years) was most frequently seen by a primary care physician. In addition to age specific analysis, 
the developed method allows separate estimates for 4 different geographic regions in Germany. 
Estimates can be produced also real time during the influenza waves, piloted for the first time for 
the 2012/13 influenza season. 
Figure 18: Observed excess outpatient visits for acute respiratory infections (green) during periods of 
influenza virus circulation (light blue) influenza seasons 2006/07 to 2011/12 for the age group 0-4 years; 
modelled baseline and confidence intervals (dotted line) in red. (an der Heiden et al., submitted) 
 
Modelling excess mortality associated with influenza 
Modelling of excess mortality due to influenza is the standard method to calculate the magnitude 
of the most severe outcome of influenza in populations. Different methods exist, however, and 
methods can only use the data that are available. Recently, detailed historic mortality data (from 
1999-2009) have become available which require to develop a new model and re-estimation of 
influenza-attributed mortality in those years (co-operation with statisticians in the department). 
Unit 36 also co-operates with two WHO supported teams on the global mortality of the pandemic 
A(H1N1)pdm09 virus. Both teams have presented estimates on the global mortality of pandemic 
influenza 2009 (partially published), already. 
2.2.3 Transmission and risk of infection with influenza 
Clinical epidemiological studies in households during seasonal and pandemic influenza 
Over 4 seasons between 2007/08 and 2010/2011, spanning the pandemic wave 2009, our unit 
carried-out clinical epidemiological household studies on the virus shedding and transmission 
(and its prevention) of influenza. Primary care practices collaborating in these studies recruited 
index cases with laboratory confirmed influenza. For one week after onset of symptoms, the index 
case and members of the household were systematically monitored for symptoms and daily 
samples of nasal secretion were taken. In the seasons 2009/10 and 2010/11 a cluster-randomised 
intervention study was embedded in the investigation (ClinicalTrials.gov Identifier: NCT00833885). 
Households with an identified index case of influenza were randomised into one of three 
intervention arms: 1. group, where the household received general information about transmission 
of influenza virus and means to prevent it (Controls); 2. group, which received surgical masks and 
was asked to wear them whenever they are in close contact with the index case or other persons of 
the household that became ill during the observation period; 3. group, which was given and asked 
to wear surgical masks as well as to execute intensified hand hygiene. In addition to assessing the 
secondary attack rate as primary outcome measure, the compliance to those interventions was 
evaluated by questionnaires (Süss et al., BMC Infect Dis 2012). 
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Results of the intervention study demonstrated tolerability of wearing surgical facemasks also for 
(sick) children, which is most important for policy decisions concerning the choice of interventions. 
In addition, the non-pharmaceutical interventions tested most likely are effective to prevent 
transmission of the virus,: the odds of developing influenza were reduced by 86% (adjusted 
OR=0,16, 95%KI=0,03-0,92), if the measures were implemented within 36 hours after the onset of 
symptoms in the index case or by 70% (adjusted OR=0,30, 95%KI=0,10-0,94), if they were applied 
stringently. 
Analysis of virus shedding showed similar patterns for seasonal influenza and the pandemic virus 
that correlated well with the severity and course of symptoms. In symptomatic patients virus 
shedding started in 30% before onset of symptoms and was influenced little by antiviral treatment. 
Serological surveillance 
Due to the highly variable manifestation of clinical disease caused by acute viral infections, the 
serological measurement remains the standard approach to measure infections rates and 
transmission. With the 2009 pandemic, a revival of the need for population based studies on 
influenza infection was identified. In order to collect information on potential pre-existing immunity 
to the new virus and to measure age specific infection rates of the influenza A (H1N1) 2009 
pandemic in Germany, we conducted a seroprevalence study based on samples from an on-going 
representative nationwide interview and examination survey for adults that had started 6 months 
prior to the first registered case of influenza A (H1N1)pdm09 in Germany (Dudareva et al, Plos 
One 2011). The highest proportions of cross-reactive antibodies at titre ≥40 before the pandemic 
were observed among 18–29 year olds, 12.5% (95% CI 7.3–19.5%). Despite this finding, the same 
age group showed also the highest increase in seroprevalence between pre- and post-pandemic of 
29.9% (95% CI 16.7–43.2%). 
Risk factors and complications of influenza and pneumonia 
In 2011 a third-party funded project started to identify risk, concomitant, and secondary diseases of 
influenza and community-acquired pneumonia in Germany. The advantage of SEEDARE technology 
for collecting anonymised patient data including ICD-10 diagnosis codes on a computerised basis 
should be exploited in this project. Therefore, based on the experience with the software interface 
of SEEDARE the requirements for a new interface were developed at RKI suitable to collect over 
several months surrounding the event of acute illness the pertinent data from electronic patient 
records of physician information systems in 200 primary care practices for this study. A public 
tender was published Germany-wide in July 2012 for external programming of the new interface. 
The pilot phase will start in November 2012 and it is planned to roll-out the software to the 200 
practices before start of the seasonal influenza wave 2012/13. Currently an extensive review of 
literature on complications of viral seasonal and the 2009 pandemic influenza is carried-out and a 
systematic literature-review is being prepared to prepare and guide the analysis of the data 
retrieved in the course of the project. 
2.2.4 Outbreak investigations and interventions to prevent infection and severe 
disease 
Information on nosocomial spread from SARI surveillance in paediatric hospitals 
The potential of outbreaks of respiratory infections, especially in institutional settings (e.g. elderly 
homes, hospitals) is frequently underestimated. In collaboration with the paediatric network for 
rare diseases (ESPED) We conducted a nationwide hospital-based prospective study in Germany of 
influenza A(H1N1)pdm09 cases among children <15 years of age. Children admitted to paediatric 
intensive care units and related deaths during the 2009–10 pandemic and the 2010–11 post 
pandemic influenza seasons were included into the study. One striking result was, that 14% of 
these most severe cases represented hospital-acquired infections (Altmann et al, EID 2011; 
Altmann et al, EID 2012). 
RSV-outbreak investigation in a haematology unit 
In January 2012 RKI was invited to assist in the investigation of a large nosocomial RSV outbreak 
among adult haematology patients in a university hospital. It became clear that the outbreak was 
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the largest ever recorded in the literature among haematology patients and had started already in 
November 2011 (three months before the RSV wave in the community) and lasted until the end of 
January 2012. The outbreak was detected late because RSV (and other respiratory agents) was not 
tested for. Our analytic studies revealed that (mostly unrecognised) RSV patients had been placed 
in one room together with a susceptible, other patient; furthermore, patients who socialised more 
seemed to be at higher risk for infection. Due to the intervention-measures taken by the end of 
January a second wave of hospitalised cases admitted to the hospital with community acquired 
infections in February 2012 from the community did not lead to another nosocomial outbreak. The 
investigation was carried-out in collaboration with the University Hospital Heidelberg, the local 
health and state health authorities. A report agreed upon with all stakeholders has been finalised 
and currently a manuscript is being written up. 
Monitoring of influenza vaccine effectiveness using surveillance data 
Influenza viruses evolve constantly, therefore the influenza vaccine antigen composition needs to 
be adapted every year. The vaccine strains (containing one antigen of an A(H1N1), one of an 
A(H3N2) and one of a B reference strain) are recommended each year by the WHO. The protection 
of the vaccine against disease needs to be assessed through observational studies during the 
season. However, estimates of influenza vaccine effectiveness from previous years cannot be 
simply carried over to the next year. During the pandemic wave 2009 Unit 36 applied a test-
negative case-control-study using national influenza data (n=2.002) of the Arbeitsgemeinschaft 
Influenza (AGI) to estimate vaccine effectiveness and established this approach for routine 
monitoring the seasonal vaccine effectiveness against influenza A (H3N2) during the season 
2011/12. The influenza vaccine effectiveness adjusted for age group and week of disease onset was 
49% (95% KI: 17 – 69 %). Point estimates of the influenza vaccine effectiveness were higher in 
younger age groups than in older age groups. Using this method, influenza vaccine effectiveness 
can be monitored during subsequent seasons. Results for the season 2011/12 are published in Epid 
Bull 41/2012.  
Evaluation of the use of antivirals during the 2009 pandemic 
The 2009 influenza pandemic provided a unique opportunity to investigate factors associated with 
severe clinical disease and the impact of pharmaceutical interventions. International and national 
guidelines recommend early antiviral treatment for patients with severe influenza or those at 
increased risk of severe illness. However, little was known about the use of antivirals in Germany. 
Using national notification data (n=170,856) we determined that the proportion of cases with 
laboratory confirmed A(H1N1)pdm09 infection that had been treated with antivirals during the 
pandemic in Germany was 21%. Multivariable analysis showed that the chance for being treated 
with antivirals was between one half to two thirds for children in comparison to adults, 
independent of underlying medical conditions and severity of disease. The underlying reasons 
leading to the observed differences in patient management of children remain to be investigated. 
The results were presented at 4. German Influenzakongress 2012 (Erfurt) and the 4. ESWI Influenza 
Conference 2011 (Malta). The publication is in progress 
2.2.5 Pandemic influenza preparedness 
In Germany, a National Pandemic Preparedness Plan was written by the Federal level and the 
Federal States level in 2005 and updated in 2007. During the recent H1N1-pandemic Unit 36 served 
as a think tank for the Institute and led the field-investigations of the first outbreaks in Germany, in 
Spring 2009. Within the first 13 weeks of the pandemic, 16 outbreak investigations were carried-out 
to investigate virus transmission and clinical presentation of the initial cases. These studies had 
been prepared and tested by our unit in the preceding two years. 
Evaluation of the response to the 2009 pandemic 
Immediately following the pandemic, evaluations of Germanys’ pandemic preparedness and 
response were carried-out by different institutions in the public health sector at the national, 
regional and local level. In March 2010, a national evaluation workshop was organised by RKI with 
representatives from different professions involved in the pandemic response. Furthermore, Unit 
36 reviewed international and national reports and articles regarding the evaluation of national 
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pandemic preparedness activities and the response to the pandemic (H1N1) 2009 in Germany in 
order to identify key lessons. 
Key findings of the evaluations were: optimise concepts for vaccine logistics, distribution and cost 
coverage, define a clearer role of medical and public health professionals in immunisation and aim 
for more flexible contracts. Influenza surveillance could benefit from strengthening the instruments 
for timely monitoring of severe disease (hospital and mortality surveillance) and of vaccination 
coverage. Risk and crisis communication have been identified as important areas for the planning 
process. These results were presented at 4. German Influenzakongress 2012 (Erfurt) and the 4. 
ESWI Influenza Conference 2011 (Malta). 
Updating of pandemic preparedness plans 
Unit 36 coordinates the update of the scientific part of the national pandemic preparedness plan. 
During this process, a new expert committee is being established (Expertenbeirat Influenza) 
consisting of public health experts of Federal institutes and of professional medical societies. These 
experts will support RKI. Furthermore, RKI advises the Federal States in which epidemiological 
situations during a pandemic which measures are appropriate. 
RKI has an internal plan where the main tasks and responsibilities of the institute in case of a 
pandemic are described. Unit 36 coordinates the work of the RKI Task Force Influenza and the 
update of the influenza module in the crisis plan of the institute. In 2012, a meeting with all 
persons responsible for pandemic preparedness planning and general crisis planning took place. 
Focus of the discussions was the differentiation between general and disease specific planning. 
2.2.6 Tuberculosis surveillance and control 
Monitoring progress of TB control in Germany 
130 years after the first demonstration of the tubercle bacillus by Robert Koch in March 24th 1882 
tuberculosis (TB) remains at the top of public health priorities among communicable diseases 
identified by RKI, shared only by HIV (Balabanova et al., Plos One 2011). The Berlin Declaration on 
Tuberculosis signed by the Ministers of Member States of the WHO European Region at a meeting 
with the WHO Regional Director for Europe and high-level partners at the WHO European 
Ministerial Forum on Tuberculosis “All against Tuberculosis”, held in Berlin on 22nd October 
2007, shows that the importance of TB control has also been recognised at the political level. 
Member States also committed themselves to closely monitor and evaluate the implementation of 
the actions and commitments outlined in this Declaration. For this purpose, the M&E  (Monitoring 
and Evaluation) Framework was developed by WHO Euro. Unit 36 participated in the development 
of this framework and tested this approach by selecting a set of indicators from the surveillance 
point of view, demonstrating that there were no specific gaps in Germanys TB surveillance and 
control. Furthermore, to assess trends, epidemiological indicators of the follow-up to the 
Framework TB Action Plan by ECDC were applied to Germany. All but one indicator fulfilled the 
defined targets. This suggests an overall decreasing TB trend and thus rather successful TB control 
in Germany. However, a potential increase in notification rates in children stresses the need for a 
close monitoring of childhood TB – including its possible determinants – and to implement 
countermeasures at best. 
Multi and extensively drug resistant TB (M/XDR-TB), recognised as a major public health threat to 
the WHO Europe an region, has been recently addressed by WHO Euro with the ”Roadmap to 
prevent and combat drug-resistant tuberculosis”, where Unit 36 participated as a member of the 
steering group as well as member of the task force for the development of a respective M&E 
framework. 
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Figure 19: Proportions of any and multidrug-resistant tuberculosis by country of birth, Germany 2002-2009 
(pooled data) 
 
Surveillance of tuberculosis in Germany 
Case-based electronic notification of tuberculosis has been introduced in Germany with the 
Communicable Disease Law Reform Act in 2001. The TB surveillance system was updated in 
agreement with international standards. The data allow detailed analysis of the TB epidemiology. 
Results of this analysis are compiled in a comprehensive yearly report that is presented to the 
public at World TB day in March each year, usually in the context of a scientific TB conference in 
Berlin. In addition, data are reported to the European level and to WHO Euro as requested. 
A major benefit of the surveillance system implemented in 2001 has been the inclusion of 
information about drug resistance against first line anti-TB drugs. Effective treatment of drug 
resistant TB is crucial to avoid relapse or further development of drug resistance. A stratified 
analysis (covering 2002-2004) of drug resistance patterns observed in tuberculosis patients 
notified in Germany showed that only four drug resistance patterns contribute ¾ of resistant TB 
cases (>60% to Isoniazid/Streptomycin). MDR-TB equals resistance to at least four drugs in ⅔ of 
cases. An on-going study builds upon the previous findings extending the data set on the recent 
notification years. This study is expected to highly contribute to improve the clinical management 
of TB patients in Germany by informing on the optimal initial treatment regimen of TB patients 
suspected of having drug resistant TB.  
Assessing and improving treatment outcome of TB 
A major achievement of the introduction of the new notification system is the availability of 
treatment outcome results as indicator for successful TB control and case management. However, 
definitions of treatment outcome differ between WHO, ECDC and the national level in Germany. 
Therefore a study evaluating what matters in tuberculosis treatment outcome monitoring was set-
up using German 2002-2008 notification data.  
Differences in case inclusion for treatment success rate (TSR) calculations were found to highly 
impact TSR: 80.6% were found for the RKI approach, statistically significantly (P<0.001) higher 
than applying WHO (75.7%) or ECDC (76.6%) case inclusions, however still not reaching the 
European TSR target of 85%. In multivariable models, factors associated with treatment success 
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were investigated. Irrespective of ECDC, WHO and RKI case inclusion criteria, being male, of older 
age, having multi-drug resistance and living in an Eastern Federal State of Germany were negatively 
associated with treatment success. A third-party follow-up and extension of this study on a 
European level is planned for 2013. 
Although up-to-date national guidance documents on TB treatment are available, little is known 
about adherence to recommendations and the overall quality of TB treatment (to note: all TB 
guidance documents are developed by the German Central Committee against Tuberculosis [DZK] 
in close collaboration with Unit 36). We currently perform an evaluation of TB therapy quality in 
Germany based on TB drug prescription data provided by Insight Health® for the years 2006-
2009.  
Surveillance of extrapulmonary TB 
Gaps have also been identified for the surveillance of different TB forms. As TB surveillance 
commonly focuses on the main organ affected, which by definition is pulmonary whenever lungs 
are involved, we suspected an underestimation of extrapulmonary TB (EPTB) forms in routine 
analyses. We thus conducted a study to estimate the frequency of all individual EPTB forms 
(classified as main or secondary site), describe demographic and clinical characteristics of patients 
affected by specific extrapulmonary sites of disease, and identify factors associated with meningitis 
TB in order to illustrate the real EPTB burden. 
We found that analysing solely the main site of disease ignored one third of extrapulmonary 
manifestations reported as the secondary site. Using of all available information, meningitis TB – 
involving a 25% case fatality ratio – accounted for 0.9% of TB patients. It was more likely among 
children younger than 10 years old, female patients and individuals born in the South-East Asia and 
the Eastern Mediterranean WHO regions. We concluded that EPTB manifestations were indeed 
more widespread in Germany than previously shown. A manuscript with these findings has been 
published (Ducombe T et al., Eurosurveillance 2013).  
Molecular surveillance of TB 
Molecular typing of TB strains has contributed significantly to a better understanding of 
transmission and populations at risk. However, the public health impact of molecular surveillance 
embedded in routine TB surveillance and control needs still to be determined. In collaboration with 
the public health offices (PHO) in Baden-Wuerttemberg and the National Reference Laboratory for 
mycobacteria in Borstel, Unit 36 has initiated a pilot project investigating the linkage of molecular 
typing and TB notification data (2008-2010). Among 860 notified TB patients from Baden-
Wuerttemberg with available molecular typing information, 208 (24%) were cluster-associated (80 
clusters). About 60% of these cluster involved two or more PHOs. About 52% of clusters, 
especially those involving two or more PHOs, were not confirmed by epidemiological links 
identified through conventional contact investigation. Molecular typing may thus complement 
classical contact tracing in uncovering transmission chains. The practical and public health 
relevance of molecular typing for the investigative work of PHOs remains to be further explored. In-
depths analyses and interpretation of results are on-going. 
2.2.7 Tuberculosis among vulnerable groups 
Additional studies are carried-out based on the collected notification data to describe the 
epidemiology in specific groups at risk for TB or specific disease manifestations. 
Improved diagnostics and surveillance of TB in children 
Only recently, children have been internationally recognised as a neglected group for TB control 
and case management. Specific studies to enhance diagnostics and surveillance of childhood TB 
are specifically addressed by an investigation of diagnostic (PCR, culture) findings by use of gastric 
aspirate, embedded in a European study in the context of the EUPHEM fellowship program. At this, 
in collaboration with European NRLs a survey is performed to gain a systematic overview of 
laboratory diagnosis of paediatric TB in the EU/EEA member states; 20/30 member States 
participated in the survey; 4 provided 5-year raw data sets. The analysis is on-going. In addition 
Unit 36 contributes actively in the development of national and international recommendations for 
diagnostic and treatment of TB in children. 
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TB in the elderly 
To address the impact and challenges in TB control for an aging population, demographic, clinical 
and bacteriological characteristics between elderly and younger adult TB patients among all TB 
cases notified in Germany between 2002 and 2006 were compared and published (Hauer et al., 
Eur Respir J 2011). The study identified several specific epidemiological features of TB in the elderly, 
such as a high proportion of genitourinary TB (predominantly among males), a considerable 
fraction of culture-confirmed TB cases, a relatively small contribution of active case finding, 
comparatively low drug-resistance rates except for pyrazinamide, low treatment success and high 
mortality rates. The study provided substantial new evidence that elderly adults present a 
vulnerable group for TB in Germany. 
TB in big cities 
In low incidence countries TB control increasingly focuses on populations at risk, with urban risk 
groups being one of the most relevant targets. Unit 36 initiated a survey on the TB situation in 
European Big Cities in 2008, which prompted the establishment of a Wolfheze European 
Consensus working group including members from Unit 36, the Health Protection Agency/UK, 
KNCV Tuberculosis Foundation/The Netherlands, ECDC, and other members from EU Member 
States. A Workshop was held at the RKI to work on a consensus document in 2011. The group is in 
the state of drafting several manuscripts in regard to TB control recommendations and the 
epidemiological situation in EU Big Cities.  
TB in prisons 
One specific population at risk is the prison population, although little is known in low incidence 
high resource settingsIn collaboration with the prison hospital (Justizvollzugskrankenhaus) Berlin 
in the context of a BSPH master thesis we performed a retrospective case series of tuberculosis 
patients in prisons in Berlin from 2007 to 2010, hereby following up on an investigation covering 
1996-1998. 
It was shown, that the case detection rate (CDR) for definite pulmonary TB based on X-ray entry 
screening had nearly halved between the two study periods in the Berlin prison system (208 in 
1996-1998 vs 111 cases/100,000 X-ray examinations in 2007-2010). CDRs were particularly high 
among patients older than 60 years and those originating from the Former Soviet Union countries 
(estimate of 3,396 cases/100,000 population) .  
The series of 62 TB cases documented from 2007-2010 was characterised by high proportions of 
male (94%) and foreign citizens (61%), as well as high levels of MDR-Tb (12%, N=34). It revealed 
Hepatitis B or C/TB and HIV/TB co-infections (18% vs 3%) at systematic screening. Entry screening 
remains hence important to avoid (potentially MDR)-TB transmission in prison. Approaches 
targeted to specific subpopulations and infection screening remains to be evaluated. Together with 
the German Committee to fight against Tuberculosis a best practices workshop bringing together 
local health authorities and physicians in charge of the health in prisons is planned for 2013. 
TB in migrants and the population with migration background 
Many Western European countries observe a significant impact on their epidemiological situation 
by TB occurring in persons originating from high TB prevalence countries or with other migration 
background. In an in depth 2002-2009 surveillance data analysis we found that declines in the 
incidence were higher in German than in foreign nationals (43.3% vs. 35.2%). In 2009, TB 
incidence in foreign nationals was 5.5-times higher than in Germans. The majority of patients born 
outside Germany originated from a Newly Independent State (NIS) of the former Soviet Union with 
18.9% (362/1,918), followed by Turkey. The proportion of drug resistant TB was higher in foreign 
borns – particularly in patients from the NIS, but not from Turkey. Foreign born patients showed an 
almost two-times higher proportion of treatment interruption or defaulting.  
In conclusion, in Germany TB increasingly concentrates in specific populations with migration 
background that differ according to proportions of drug resistance and treatment success. To 
assure effective TB-control and case management more detailed knowledge on different migration 
groups and their specific risks is necessary.  
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To investigate of the TB risk of second generation migrants, Unit 36 is performing a prospective 
cross-sectional study in Berlin in collaboration with Charité, the Tuberculosis Centre at the Local 
Health, Office Berlin-Lichtenberg, and DZK. Of 182 patients, 98 (54%) were first generation 
migrants, 20 (11%) were second generation migrants with the remainder being native residents. TB 
notification rates per 100,000 people were 4.1 for native residents, 28.8 for first generation (relative 
risk (RR): 7.0) and 13.1 for second generation migrants (RR: 3.2). These preliminary data suggest 
that two-thirds of all TB cases in Berlin occur among individuals with migration background. Both, 
first and second generation migrants are at increased risk of TB compared to native residents and 
should be considered for preventive measures.  
2.2.8 HIV/TB comorbidity in Germany 
Tuberculosis (TB) and HIV comorbidity is, together with M/XDR-TB, considered a leading cause 
impairing success in TB control: TB as an AIDS-defining disease is a major cause of morbidity and 
mortality in people living with HIV; HIV-positive individuals infected with M. tuberculosis complex 
bacteria are placed at a 20 to 30 times greater risk of developing active TB. 
However, the HIV/TB burden is difficult to assess in Germany (and other European countries) as 
data confidentiality precludes notifying the HIV status of TB patients in the national surveillance 
system. To still address this issue, we investigated the long-term observational open multicentre 
cohort ClinSurv HIV, which systematically captures TB diagnoses. Our aim was to first estimate the 
HIV-prevalence in TB patients, and second, to determine the occurrence of TB as AIDS-defining 
disease in Germany.  
On average, the estimated HIV-prevalence in TB patients average was 4.5% from 2002-2009, 
without significant trend. This level approximates available surveillance data from neighbouring 
countries and indicates a non-negligible HIV/TB burden in Germany. Our estimation approach is 
valuable for epidemiological monitoring of HIV/TB within the current legal frameworks. 
As to the occurrence of TB as AIDS-defining disease, we found that 2.7% (252/9,437) of the 
individuals enrolled in ClinSurv HIV from 2002-2011 were diagnosed with active TB. These HIV/TB 
patients were predominantly male, aged between 30-39 years and originating from Sub-Sahara 
Africa. The TB incidence density rate was 0.8 cases per 100 person-years (PY) overall. Highest rates 
were observed among female and male patients originating from Sub-Sahara Africa (2.2 vs. 3.4 per 
100PY, respectively). These results help to target prevention and control strategies on risk groups 
and to consider them in HIV/TB monitoring. 
Figure 20: Estimated HIV-prevalence in TB patients in Germany, 2002 to 2009. (Fiebig et al., Plos One 2012) 
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2.2.9 Disease caused by non-tuberculous Mycobacteria 
Several industrialised countries have reported an increase of non-tuberculous mycobacterial (NTM) 
diseases in children. Worldwide, information on the therapeutic management and treatment 
outcomes in children are scarce. In a prospective nationwide study including all paediatric 
hospitals in Germany between October 2002 and September 2005, 102 immune-competent 
children with incident NTM disease had been identified and the epidemiology of NTM disease 
described. A follow-up study in 2011 on the long term course of disease, treatment regimens and 
outcomes in these children showed that children with NTM lymphadenitis are not treated in line 
with international and national guidelines in Germany and the cure rate was not satisfying. The 
Publication of the results is in progress.  
In order to investigate treatment strategies and outcomes in-depth, a prospective nationwide study 
including all paediatric hospitals in Germany is carried out 2011 to 2013. During the course of the 
study, physicians fill in a questionnaire when children with new NTM diagnosis are admitted to 
hospital and a second questionnaire after six months of treatment. 
2.2.10 Legionnaire’s disease (LD) 
Risk of LD and cut off values of the Drinking Water Ordinance (TrinkwV) and LD 
The network for community-acquired pneumonia disease estimates that there are 20,000 cases per 
year in Germany (www.capnetz.de/). Although much is known about Legionella and the illness they 
cause, the relationship between their concentration in water and the risk of infection remains 
unclear. A workshop was held in 2009 co-organised by and supported by epidemiological data from 
Unit 36. This workshop brought together a comprehensive body of evidence and experience 
showing that the growth of Legionella in heated water distribution systems can be effectively 
controlled by following the preventive measures described in the generally acknowledged codes of 
practice. As orientation to trigger action, a technical action level of 100 colony-forming units in 100 
ml water has been found  
As a result of the scientific exchange facilitated by RKI and Unit 36 research questions were defined 
(Schäfer et al., Bundesgesundheitsbl-Gesundheitsforsch Gesundheitsschutz. For the future, further 
research concerning the reported source of infection and exposition is planned based on the 
collected notification data. The epidemiology of legionnaires´ disease (LD) in specific settings 
(especially nosocomial and travel associated LD) will be analysed in more detail. For this reason a 
number new algorithms have been created and a special dataset will be constructed by our Unit in 
cooperation with Unit 31. 
Travel associated LD – international surveillance by EWGLI/ELDSNet 
In April 2010, the European Surveillance Scheme for Travel Associated Legionnaires’ Disease 
(EWGLINET) located at the UK´s Health Protection Agency (HPA) in London was transferred to 
ECDC being continued as ELDSNet (European Legionnaires´Disease Surveillance Network). The 
aim of the network is the early detection of clusters of travel-associated Legionnaires’ disease 
(TALD) in Europe in order to identify and eliminate the source of infection.  
Until September 2012 Germany did not participate in these networks because of uncertainties 
concerning the legal situation especially regarding the publication of accommodations for which a 
cluster of legionnaires´ disease has been reported. Based on a report from ECDC in September 
2011 Unit 36 together with the legal office at RKI reassessed the possibility of participation in 
ELDSNet and Germany will now fully participate in the network.  
Currently in cooperation with Unit 31 the technical requirements will be implemented in the 
German electronic surveillance system in order to include the necessary travel details (e g. hotel 
Name, address, travel dates etc.) and report them weekly via the European Surveillance System 
(TESSy) to ELDSNet. 
2.3.  Major goals and contribution to the goals of the department  
The major goals for the coming years are: 
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• Expanding the work on burden of acute respiratory infections to other viral and bacterial 
pathogens 
• Development of systems and analytical tools to rapidly assess the severity of (new) 
respiratory infections 
• Serological and immunological studies for estimating cross-protection against new 
influenza viruses and age-specific infection rates in the population (e.g. Influenza 
A(H3N2)v) 
• Enhanced capacity for outbreak investigations of respiratory infections 
• Investigation of epidemiology of community acquired pneumonia and its complications 
• Population-based studies on the respiratory infections and the role of concomitant 
pathogens using self-sampling 
• Establishing and evaluation of molecular surveillance of tuberculosis at the national level 
and development of indicators to estimate probability of true clusters 
• Building an evidence-base for management and control of tuberculosis in vulnerable 
groups 
• Cohort studies on latent tuberculosis infection (LTBI) in the German population 
(Helmholtz Cohort). To embark on the work on LTBI, a Knowledge-Attitude-Practice study 
is being prepared together with the Pediatric Pneumology Unit of Hannover Medical 
University  
Surveillance of respiratory infections, the assessment of the burden of disease in the population 
and the identification of groups at risk for severe disease and complications by Unit 36 provide a 
clear picture of the epidemiology of respiratory infections in Germany. This is crucial for setting 
priorities in public health, devise and evaluate prevention strategies, early recognise changing 
disease trends and emergence of new diseases – all of which are central aims of the department. In 
a prioritisation exercise in 2011, respiratory infections, namely tuberculosis, influenza, RSV, and 
Legionellosis, were all in the group with the highest priority for public health (Balabanova et al., 
PloS One 2011). 
Our unit has developed and provides unique expertise for the department in syndromic 
surveillance, ICD10-based as well as web-based surveillance, and in the use of molecular tools for 
epidemiologic purposes. Specifically, the development of clinical epidemiological studies has been 
an important asset for early analysis of the risk of transmission in the 2009 influenza pandemic. 
Work on influenza mortality is carried-out in close collaboration with Unit 32 (surveillance unit) and 
has been instrumental in establishing the setting-up of modelling tools for excess mortality by 
infectious diseases and the effect of interventions on the spread of disease. Naturally, a close 
collaboration exists with Unit 33 (vaccine prevention) by providing disease-specific expertise and 
data for development of recommendations for vaccination.  
Through the work on pandemic influenza preparedness, Unit 36 has gained important experience 
in planning for critical situations for the health of the population. In recent years, our unit 
developed or participated in several large national and international exercises on pandemic 
influenza. This has resulted in very practical expertise on organisation and setting-up a crisis 
centre, that has also been used in other situations, such as the EHEC outbreak 2011. The 
investigation on protective measures in the outbreak of influenza A(H5N1) and work on monitoring 
of human cases has led to additional attributes in the notification software and to a closer linkage 
of the Department with the Friedrich-Löffler-Institute on animal health.  
2.4.  Additional work and methods for investigations  
One key element of tuberculosis control is treatment quality and adherence. To address this issue, 
we currently work on the development of methods to estimate the number of treatment courses for 
tuberculosis by using prescription data. Additional applications of this approach are the 
investigation of co-treatment for underlying chronic diseases, e.g. diabetes, or other infectious 
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diseases such as hepatitis C or B and HIV. This work is also expanded to other respiratory 
infections. 
In 2011 a pilot study was started to investigate the feasibility of noninvasive diagnostics of 
pneumococcal pneumonia in children from stools. This proof of principle study was carried out in 
collaboration with the Junior Group on Novel Zoonoses at RKI and the Department of Pediatric 
Pneumology at Charité, Berlin. The approach was based on the field studies of the Junior Group to 
detect severe pneumococcal disease in great apes in Africa. A joint research proposal is under 
consideration. 
Starting in 2010 a new lecture series on “Infectious Disease Epidemiology” has been developed by 
members of Unit 36 in collaboration with other units. The lectures function as an introduction into 
the topic to familiarise students with the wide area of infectious disease epidemiology. 
Methodological issues and practical issues of designing a study protocol are also included. The 
series serves as obligatory teaching module for the ZIBI Graduate School Berlin and the Graduate 
School “Functional Molecular Infection Epidemiology” at the Free University Berlin. It has also 
been well received by students of the RKI PhD-Programme. 
2.5.  Scientific advice and consulting services 
Unit 36 is directly involved in advising the Ministries of Health at the national and state level on all 
questions concerning respiratory transmitted diseases and their prevention. An important 
counterpart at the state level is the Working Group on Protection against Infection 
(Arbeitsgemeinschaft Infektionsschutz). A specific area of expertise is the scientific basis of 
influenza pandemic preparedness. Unit 36 is in charge of working out and updating the scientific 
part of the National Influenza Pandemic Preparedness Plan. 
The Unit supports and advises local health authorities in regard to tuberculosis contact 
investigations and identification of sources of legionellosis outbreaks. 
A seasonal recurring task is the advice to the public on individual as well as on generic strategies to 
prevent influenza infection and transmission. 
In addition to active media work, including giving interviews for print media, radio as well as 
regional and national TV, our Unit continuously updates the disease-specific institutional internet 
pages. Areas covered are influenza (seasonal, pandemic, human cases of avian and swine 
influenza), tuberculosis, legionellosis, and RSV, but also rare or emerging pathogens, such as SARS 
or novel Coronavirus (hCoV-ECM). Hereby, the medical community as well as the public is 
addressed, providing comprehensive information on the epidemiologic situation in Germany, 
diagnostics, prevention, management and control, including response to frequently asked 
questions. Online access statistics reveal a highly frequent utilisation of these pages: e.g. the 
influenza pages are accessed more than 6 million per year, with more than 2 million per month 
during the season, and also the tuberculosis sites are very often accessed, and documents have 
been downloaded between April and September 2012 about 10.000 times. 
Members of our Unit serve as scientific advisors for various scientific or professional associations, 
e.g. the Pediatric Infectious Disease Society, the German Central Committee against Tuberculosis, 
the Tuberculosis Working Group of the Protection of Infection Committee of the Federal 
Association of Public Health Service Physicians, or the Committee for Biological Agents. They are 
invited to participate in scientific Programme Committees of national scientific conferences, e.g. 
the 5th National Influenza Kongress in Erfurt 2012 or the TB symposia of the Koch.Metschnikow-
Forum 
At the international level, Unit 36 members serve as national epidemiological contact points, and 
are invited to participate in or facilitate international Workshops and Meetings at the European or 
WHO level. Recent examples are the WHO consultation on public health measures during the 
influenza A(H1N1)2009 pandemic (26–28 October 2010, Gammarth, Tunisia), the meeting of the 
WHO STOP TB childhood subgroup, which was co-organised in December 2011 at the RKI, a 
Workshop of the Consensus Group on TB control in Big Cities and urban risk groups in the EU in 
November 2011 hosted by RKI, and the tuberculosis Wolfheze Workshop in The Hague in May 
2011. Unit 36 participated also on the WHO Technical Consultation on Global Tools and Manual 
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for Influenza Surveillance (WHO HQ) and the Working group to review regional guidance for 
influenza surveillance (WHO Euro) 
Members of Unit 36 are frequently asked for scientific advice (sometimes `behind the scene´) on 
ECDC risk assessments, to participate in expert panels for the development of scientific guidance 
documents, e.g. the ECDC IGRA guidance 2011, to peer review recommendations and action plans, 
or to contribute to the future development of the work. Two current examples are the peer review of 
the second edition of the WHO Guidance for national tuberculosis programmes on the 
management of tuberculosis in children and the request for input and annotations in the WHO 
Childhood Tuberculosis Roadmap (both to be published in spring 2013). 
Advice is further provided as peer reviewers for several national and international scientific journals 
and the head of the unit serves also as Assistant Editor of BMC Public Health 
2.6.  Training and teaching activities 
In addition to the supervision and mentoring of fellows of the PAE- and EPIET- programme and of 
postgraduate Master students of the Berlin School of Public Health, members of Unit 36 are 
involved in regular teaching activities, represented in the following list of short term and 
continuous teaching activities: 
• Lecture on Tuberculosis and Gender, Module 6 Health and Society: Gender and Diversity 
Studies, BSPH, Charité, Medical University Berlin 
• Bed-side Teaching of clinical skills in paediatric respiratory infections, Department of 
Pediatric Pneumology, Charité, Medical University Berlin 
• Training for German public health professionals (ÖGD-Kurs), one week course, organised 
by RKI (2x/ year) 
• Lectures on control of infectious diseases within the module Infectious Disease 
Epidemiology at Charité, Medical University Berlin 
• Excursion “Tuberculosis epidemiology and analysis of notification data”, Institute of Social 
Medicine, Epidemiology and Health Economics, Medical University Berlin  
• Presentation on influenza epidemiology during a two-day seminar for continuing education 
for medical professionals (Fortbildung des Berufsverbands der Ärzte für Mikrobiologie, 
Virologie und Infektionsepidemiologie e. V. (BÄMI)) 
• Two-day seminar on basic principles of epidemiology at Apollon, University of Applied 
Sciences Health Economics (Apollon Hochschule der Gesundheitswirtschaft) 
• EPIET/PAE-Module Computer tools in outbreak analysis, one week course (1x/year) 
• Lecture within the Master in Epidemiology program at the Swiss Tropical and Public Health 
Institute (SwissTPH) 
• Lecture Series on “Infectious Disease Epidemiology”. ZIBI Graduate School Berlin and the 
Graduate School “Functional Molecular Infection Epidemiology” at the Free University 
Berlin. 
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3.  Cooperation with other scientists or research institutions 
3.1.  Internal (within RKI) 
Department 1, FG14 (M. Mielke, N. Wischnewski) 
• Schaefer B et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 20111  
• Ziegler R et al., Gesundheitswesen 2012  
Department 1, FG17 (NRC for Influenza: B. Schweiger) 
• Working Group Influenza (AGI): AGI-Homepage, Seasonal reports, weekly reports 
http://influenza.rki.de/  
• Haas W et al., Dtsch Arztebl 2009 
• Buchholz U et al., Euro Surveill 2010 
• Buda S et al., Epid Bull 2011  
• Dudareva S et al.; PLoS One 2011 
• Uphoff H et al., PLoS One 2011 
Department 2, FG26 (M. Thamm) 
• Dudareva S et al., PLoS One 2011  
Centre for Biological Security (L. Schaade, R. Grunow) 
• Suess T et al., Am J Epidem 2010  
• Schaade L et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2010 
3.2.  External / National 
Friedrich-Loeffler-Institute (Federal Research Institute for Animal Health: T Harder, 
National reference laboratory for avian influenza and reference laboratory of the World 
Organisation for Animal Health (O.I.E.) for avian influenza) 
• Harder, Reuß, Buda: Seasonal influenza report 2011/12, Chap. 9: Influenza a zoonosis (Kap. 
9: Influenza als Zoonose, Bericht zur Epidemiologie der Influenza in Deutschland, Saison 
2011/12). http://influenza.rki.de/Saisonberichte/2011.pdf 
• Humane Fälle mit Infektion durch Schweineinfluenzaviren. Epid Bull 2011 
Public health authorities of Federal States  
• Mecklenburg-Western Pomerania: 
Cai W et al., BMC Infect Dis 2009 
• Lower Saxony: 
Humane Fälle mit Infektion durch Schweineinfluenzaviren. Epid Bull 2011 
State laboratories of Baden-Württemberg, Bavaria, Mecklenburg-Western Pomerania, 
Saxonia, Saxony-Anhalt and Thuringia (Partner of the Working Group Influenza) 
• Uphoff H et al., PLoS OnE 2011 
• Wirksamkeit der Influenza-Impfung gegen saisonale Influenza A(H3N2) in der Saison 
2011/2012. Epid Bull 2012 
                                                     
1 For full reference see Appendix 4.1.1 
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Ludwig-Maximilians-Universität, Munich/ESPED (Rüdiger von Kries) 
• Altmann M et al., Emerg Infect Dis 2011  
• Altmann M et al., Emerg Infect Dis 2012 
• Reuss A et al., Pediatr Infect Dis J 2009 
German Central Committee against Tuberculosis (DZK) 
• Hauer et al. Tuberculosis in the elderly in Germany.Eur Respir J 2011 
• Castell S et al., Pneumologie 2011 
• Diel R et al., Pneumologie 2011. 
• Ziegler R et al., Pneumologie 2012 und Gesundheitswesen 2012  
• Schaberg T et al., Pneumologie 2012 
National Reference Center for Mycobacteria (S. Rüsch-Gerdes; Linkage of Molecular 
Typing data and Epidemological data) 
• Devaux I et al., Euro Surveill 2010  
• Ziegler R et al., Pneumologie 2012  
German Society for Pneumology and Respiration Medicine (DGP, T. Schaberg) 
• Schaberg T et al., Pneumologie 2012. 
Tuberculosis working group of the Protection of Infection Committee of the Federal 
Association of Public Health Service Physicians (Arbeitsgruppe Tuberkulose beim 
Fachausschuss Infektionsschutz des BVÖGD) 
• Arbeitskreis Tuberkulose im Fachausschuss Infektionsschutz des Berufsverbandes der 
Arztinnen und Arzte des OGD. Epid Bull 2012 
Federal Enviromental Agency (Umweltbundesamt) (B. Schaefer) 
• Schaefer B et al., Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2011  
Paul-Ehrlich-Society for Chemotherapy (GERMAP) 
• Brodhun BH et al.: Mycobacterium tuberculosis. In: (BVL) BfVuL, editor. Germap 2010, 
Antibiotika-Resistenz und -Verbrauch 2011 
German Society for Paediatric Infectious Diseases 
• Bialek R et al.: Tuberkulose und nicht tuberkulöse mykobakterielle Krankheiten. In: DPGI 
Handbuch Infektionen bei Kindern und Jugendlichen 2009 
• Johannes F et al.: Influenza (nicht aviär). In: (DPGI Handbuch Infektionen bei Kindern und 
Jugendlichen. Stuttgart 2009 
German Social Accident Insurance Institution for the health and welfare services 
(Berufsgenossenschaft für Gesundheitsdienst und Wohlfahrtspflege, A. Nienhaus) 
• Hauer B et al.: Die Tuberkulose als Berufskrankheit- ein historischer Abriss. In: Tuberkulose 
als Berufskrankheit, Ein Leitfaden zur Begutachtung und Vorsorge 2012 
• Brodhun B et al.: Die Bedeutung der Tuberkulose-Aktuelle Trends und Entwicklung. B et al.: 
Die Tuberkulose als Berufskrankheit- ein historischer Abriss. In: Tuberkulose als 
Berufskrankheit, Ein Leitfaden zur Begutachtung und Vorsorge 2012 
• Haas W: Tuberkulose-Meldeverfahren nach Einführung des Infektionsschutzgesetzes 
(IfSG). B et al.: Die Tuberkulose als Berufskrankheit- ein historischer Abriss. In: 
Tuberkulose als Berufskrankheit, Ein Leitfaden zur Begutachtung und Vorsorge 2012 
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University of Heidelberg (Department of Infectious Diseases, Virology and Department of 
Internal Medicine V) 
• Geis S et al., J Clin Microbiol 2012 
3.3.  External / International 
ECDC 
• European Influenza Surveillance Network (EISN): 
Devaux I et al., Euro Surveill 2010 
• Ciancio BC et al., Euro Surveill 2009 
• European Tuberculosis Surveillance Network: 
Devaux I et al., Euro Surveill 2010 
WHO-EURO  
• EuroFlu (Brown, CS, Jorgensen): 
Martirosyan L et al., BMC Infect Dis 2012  
• WHO Euro: Recommendations for good practice in pandemic preparedness: identified 
through evaluation of the response to pandemic (H1N1) 2009); Key changes to pandemic 
plans by Member States of the WHO European Region based on lessons learnt from the 
2009 pandemic. 
• WHO Europe: Roadmap to prevent and combat drug resistant tuberculosis. The 
Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-
Resistant Tuberculosis in the WHO European Region, 2011-2015. WHO 2012 ISBN 978 92 
890 0246 2 
WHO Head Quarter, Geneva  
• Hollmeyer HG et al., Vaccine 2009 
• Van Kerkhove MD et al., PLoS Med 2011 
• Hollmeyer H et al., Influenza Other Respi Viruses 2012 
• WHO GLaMOR project: estimation of the global pandemic (H1N1)pdm09 mortality; 
publication pending. 
Centers for Disease Control and Prevention, USA (Widdowson MA) 
• Dawood FS et al., Lancet Infect Dis 2012 
L'Istituto cantonale di microbiologia, Bellinzona, Schweiz 
• Gandolfi-Decristophoris et al., Am J Infect Control 2011 
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4.  Appendix 
4.1  Overview on achievements of the Unit, 2009-2012 
4.1.1.  Scientific publications, 2009 – 2012 
Number of peer-review publications co-authored by members of the unit: 67 
Impact factor (IF) according to JCR (of 2012 publications: according to 2011 IF) 
2009:  26,3 
2010:   34,8 
2011:  188,0 
2012:   42,1 
Cumulative 2009-12: 291,2 
A) Original research articles in peer-review journals 
2012 (until Sept.) 
Altmann M, Fiebig L, Buda S, von Kries R, Dehnert M, Haas W. Unchanged severity of influenza 
A(H1N1)pdm09 infection in children during first postpandemic season. Emerg Infect Dis 2012; 
18(11).  
Fiebig L, Kollan C, Hauer B, Gunsenheimer-Bartmeyer B, An der Heiden M, Hamouda O, Haas W. 
HIV-Prevalence in Tuberculosis Patients in Germany, 2002-2009: An Estimation Based on HIV and 
Tuberculosis Surveillance Data. PLoS One 2012; 7(11):e49111. 
Geis S, Prifert C, Weissbrich B, Lehners N, Egerer G, Eisenbach C, Buchholz U, Aichinger E, Dreger 
P, Neben K, Burkhardt U, Ho AD, Krausslich HG, Heeg K, Schnitzler P. Molecular Characterization 
of a Respiratory Syncytial Virus (RSV) Outbreak in a Hematology Unit, Heidelberg, Germany. J Clin 
Microbiol 2012. Epub 2012/10/27. 
Hollmeyer H, Hayden F, Mounts A, Buchholz U. Review: interventions to increase influenza 
vaccination among healthcare workers in hospitals. Influenza Other Respi Viruses 2012.  
Martirosyan L, Paget WJ, Jorgensen P, Brown CS, Meerhoff TJ, Pereyaslov D, Mott JA, EuroFlu 
group (for Germany: Buda S, Schweiger B)The community impact of the 2009 influenza pandemic 
in the WHO European region: a comparison with historical seasonal data from 28 countries. BMC 
Infect Dis 2012; 12:36. 
Nachtnebel M, Greutelaers B, Falkenhorst G, Jorgensen P, Dehnert M, Schweiger B, Trader C, Buda 
S, Eckmanns T, Wichmann O, Hellenbrand W. Lessons from a one-year hospital-based surveillance 
of acute respiratory infections in Berlin- comparing case definitions to monitor influenza. BMC 
Public Health 2012; 12:245. 
Remschmidt C, Stocker P, An der Heiden M, Suess T, Luchtenberg M, Schink S, Schweiger B, 
Haas W, Buchholz U. Preventable and non-preventable risk factors for influenza transmission and 
hygiene behavior in German influenza households, pandemic season (H1N1) 2009/2010. Influenza 
Other Respi Viruses 2012.  
Siedler A, Rieck T, Reuss A, Walter D, Poggensee G, Poethko-Muller C, Reiter S. Estimating 
vaccination coverage in the absence of immunisation registers--the German experience. Euro 
Surveill 2012; 17(17).  
Suess T, Remschmidt C, Schink S, Schweiger B, Heider A, Milde J, Nitsche A, Schroeder K, 
Doellinger J, Braun C, Haas W, Krause G, Buchholz U. Comparison of shedding characteristics of 
seasonal influenza virus (sub)types and influenza A(H1N1)pdm09; Germany, 2007-2011. PLoS One 
2012. 
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Suess T, Remschmidt C, Schink S, Schweiger B, Nitsche A, Schroeder K, Doellinger J, Milde J, 
Haas W, Koehler I, Krause G, Buchholz U. The role of facemasks and hand hygiene in the 
prevention of influenza transmission in households: results from a cluster randomised trial; Berlin, 
Germany, 2009-2011. BMC Infect Dis 2012; 12(1):26.  
2011 
Altmann M, Fiebig L, Soyka J, von Kries R, Dehnert M, Haas W. Severe cases of pandemic (H1N1) 
2009 in children, Germany. Emerg Infect Dis 2011;17(2):186-192.  
Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gartner B, Gross U, Haas W, Hamouda 
O, Hubner J, Janisch T, Kist M, Kramer MH, Ledig T, Mielke M, Pulz M, Stark K, Suttorp N, Ulbrich 
U, Wichmann O, Krause G. Communicable diseases prioritized for surveillance and 
epidemiological research: results of a standardized prioritization procedure in Germany, 2011. PLoS 
One 2011; 6(10):e25691. 
Brodhun B, Buchholz U. Epidemiologie der Legionarskrankheit in Deutschland [Epidemiology of 
Legionnaires' disease in Germany]. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 
2011;54(6):680-687. 
Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, Deleré Y, an der 
Heiden M, Adlhoch C, Dreesman J, Ehlers J, Ethelberg S, Faber M, Frank C, Fricke G, Greiner M, 
Höhle M, Ivarsson S, Jark U, Kirchner M, Koch J, Krause G, Luber P, Rosner B, Stark K, Kühne M. 
German Outbreak of Escherichia coli O104:H4 Associated with Sprouts. N Engl J Med 
2011;365(19):1763-1770. 
Castell S, Hauer B, Brodhun B, Haas W. Epidemiology of tuberculosis: The current situation in 
Germany and worldwide [Epidemiologie der Tuberkulose: Aktuelle Situation in Deutschland und 
weltweit]. Pneumologe. 2011;8(1):9-16. 
Dudareva S, Schweiger B, Thamm M, Hohle M, Stark K, Krause G, Buda S, Haas W. Prevalence of 
antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and 
post-pandemic period. PLoS One 2011;6(6):e21340. 
Fiebig L, Soyka J, Buda S, Buchholz U, Dehnert M, Haas W. Avian influenza A(H5N1) in humans: 
new insights from a line list of World Health Organization confirmed cases, September 2006 to 
August 2010. Euro Surveill 2011;16(32). 
Frank C, Faber MS, Askar M, Bernard H, Fruth A, Gilsdorf A, Hohle M, Karch H, Krause G, Prager 
R, Spode A, Stark K, Werber D, team HUSi. Large and ongoing outbreak of haemolytic uraemic 
syndrome, Germany, May 2011. Euro Surveill 2011;16(21). 
Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, 
Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Muller L, King LA, Rosner B, Buchholz 
U, Stark K, Krause G, Team HUSI. Epidemic profile of Shiga-toxin-producing Escherichia coli 
O104:H4 outbreak in Germany. N Eng J Med 2011; 365(19):1771-1780. 
Gandolfi-Decristophoris P, De Benedetti A, Petignat C, Attinger M, Guillaume J, Fiebig L, 
Hattendorf J, Cernela N, Regula G, Petrini O, Zinsstag J, Schelling E. Evaluation of pet contact as a 
risk factor for carriage of multidrug-resistant staphylococci in nursing home residents. Am J Infect 
Control 2011(0). 
Hauer B, Brodhun B, Altmann D, Fiebig L, Loddenkemper R, Haas W. Tuberculosis in the elderly 
in Germany. Eur Respir J 2011;38(2):467-470. 
Hauer B, Castell S, Loddenkemper R. Drug-resistant tuberculosis: Growing problems and solutions 
[Resistente Tuberkulose: Zunehmende Probleme und Lösungsansätze]. Pneumologe. 2011;8(1):25-
31. 
Hermes J, Bernard H, Buchholz U, Spackova M, Low J, Loytved G, Suess T, Hautmann W, Werber 
D. Lack of evidence for pre-symptomatic transmission of pandemic influenza virus A(H1N1) 2009 
in an outbreak among teenagers; Germany, 2009. Influenza Other Respi Viruses 2011; 5(6):e499-
503. 
Houben RMGJ, Crampin AC, Ndhlovu R, Sonnenberg P, Godfrey-Faussett P, Haas W, Engelmann 
G, Lombard CJ, Wilkinson D, Bruchfeld J, Lockman S, Tappero J, Glynn JR. Human 
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immunodeficiency virus associated tuberculosis more often due to recent infection than 
reactivation of latent infection. Int J Tuberc Lung Dis 2011;15(1):24-31. 
Mall S, Buchholz U, Tibussek D, Jurke A, An der Heiden M, Diedrich S, Schweiger B, Alpers K. A 
Large Outbreak of Influenza B-associated Benign Acute Childhood Myositis in Germany, 
2007/2008. Pediatr Infect Dis J 2011;30(oxj, 8701858):e142-e6.  
Mette A, Reuss A, Feig M, Kappelmayer L, Siedler A, Eckmanns T, Poggensee G. Under-Reporting 
of Measles—An Evaluation Based on Data From North Rhine–Westphalia Dtsch Arztebl Int 2011. 
Rieder HL, Anderson C, Dara M, Hauer B, Helbling P, Kam KM, Zwahlen M. Methodological issues 
in quantifying the magnitude of the tuberculosis problem in a prison population. Int J Tuberc Lung 
Dis 2011; 15(5):662-667. 
Schaefer B, Brodhun B, Wischnewski N, Chorus L. Legionellen im Trinkwasserbereich: Ergebnisse 
eines Fachgespraches zur Pravention trinkwasserbedingter Legionellosen [Legionella in drinking 
water: outcomes of an exchange of ideas on the prevention of waterborne legionellosis]. 
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2011 ;54(6):671-679.  
Suess T, Remschmidt C, Schink S, Luchtenberg M, Haas W, Krause G, Buchholz U. Facemasks 
and intensified hand hygiene in a German household trial during the 2009/2010 influenza A(H1N1) 
pandemic: adherence and tolerability in children and adults. Epidemiol Infectect 2011; 139(12):1895-
1901.  
Uphoff H, an der Heiden M, Schweiger B, Campe H, Beier D, Helmeke C, Littmann M, Haas W, 
Buda S, Faensen D, Feig M, Altmann D, Wichmann O, Eckmanns T, Buchholz U. Effectiveness of 
the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of 
Two Methods; Germany, 2009/10. PLoS One 2011;6(7):e19932. 
Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, 
Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzalez C, Hongjie Y, Zijian F, Chuang SK, 
Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguichi K, Nakajima K, Shobayashi T, Takayama 
Y, Sunagawa T, Heraud JM, Orelle A, Palacios E, van der Sande MA, Wielders CC, Hunt D, Cutter J, 
Lee VJ, Thomas J, Santa-Olalla P, Sierra-Moros MJ, Hanshaoworakul W, Ungchusak K, Pebody R, 
Jain S, Mounts AW. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: 
a global pooled analysis. PLoS Med 2011; 8(7):e1001053.  
2010 
Buchholz U, Brockmann S, Duwe S, Schweiger B, an der Heiden M, Reinhardt B, Buda S. 
Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza 
A(H1N1) viruses, Germany, 2007-8. Euro Surveill 2010;15(6).  
Buchholz U, Stöcker P, Brodhun B. Legionnaires Disease - Reordered. Infect Control Hosp 
Epidemiol 2010; 31(1):104-105. 
Buda S, Koepke K, Haas W. Epidemiologischer Steckbrief der pandemischen Influenza (H1N1) 
2009 basierend auf Einzelfallmeldungen nach Infektionsschutzgesetz [Epidemiological 
characteristics of the influenza pandemic (H1N1) 2009 in Germany based on the mandatory 
notification of cases]. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 
2010;53(12):1223-1230 
de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, Al-Muhsen S, 
Janniere L, Rose Y, de Suremain M, Kong XF, Filipe-Santos O, Chapgier A, Picard C, Fischer A, 
Dogu F, Ikinciogullari A, Tanir G, Al-Hajjar S, Al-Jumaah S, Frayha HH, AlSum Z, Al-Ajaji S, Alangari 
A, Al-Ghonaium A, Adimi P, Mansouri D, Ben-Mustapha I, Yancoski J, Garty BZ, Rodriguez-Gallego 
C, Caragol I, Kutukculer N, Kumararatne DS, Patel S, Doffinger R, Exley A, Jeppsson O, 
Reichenbach J, Nadal D, Boyko Y, Pietrucha B, Anderson S, Levin M, Schandene L, Schepers K, 
Efira A, Mascart F, Matsuoka M, Sakai T, Siegrist CA, Frecerova K, Bluetters-Sawatzki R, Bernhoft J, 
Freihorst J, Baumann U, Richter D, Haerynck F, De Baets F, Novelli V, Lammas D, Vermylen C, 
Tuerlinckx D, Nieuwhof C, Pac M, Haas W, Muller-Fleckenstein I, Fleckenstein B, Levy J, Raj R, 
Cohen AC, Lewis DB, Holland SM, Yang KD, Wang X, Jiang L, Yang X, Zhu C, Xie Y, Lee PP, Chan 
KW, Chen TX, Castro G, Natera I, Codoceo A, King A, Bezrodnik L, Di Giovani D, Gaillard MI, de 
Moraes-Vasconcelos D, Grumach AS, da Silva Duarte AJ, Aldana R, Espinosa-Rosales FJ, Bejaoui 
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M, Bousfiha AA, Baghdadi JE, Ozbek N, Aksu G, Keser M, Somer A, Hatipoglu N, Aydogmus C, 
Asilsoy S, Camcioglu Y, Gulle S, Ozgur TT, Ozen M, Oleastro M, Bernasconi A, Mamishi S, 
Parvaneh N, Rosenzweig S, Barbouche R, Pedraza S, Lau YL, Ehlayel MS, Fieschi C, Abel L, Sanal O, 
Casanova JL. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. 
Medicine (Baltimore) 2010;89(6):381-402.  
Devaux I, Kreidl P, Penttinen P, Salminen M, Zucs P, Ammon A, surveillance Ewgoi, National 
coordinators for influenza surveillance (Gilsdorf A, Schweiger B, Poggensee G, Krause G, Buda S, 
Eckmanns T). Initial surveillance of 2009 influenza A(H1N1) pandemic in the European Union and 
European Economic Area, April-September 2009. Euro Surveill 2010;15(49).  
Devaux I, Manissero D, Fernandez de la Hoz K, Kremer K, van Soolingen D, Euro, T. B. network (for 
RKI: Haas W, Brodhun B). Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-
2007. Euro Surveill 2010;15(11).  
Haas W, Köpke K, Schweiger B, Buda S, Buchholz U, Harder T, Krause G. Neue Grippe: Die 
Primärversorger sind gefragt. Dtsch Ärztebl 2010;106(19). 
Loddenkemper R, Hauer B. Drug-resistant tuberculosis: a worldwide epidemic poses a new 
challenge. Dtsch Arztebl Int 2010;107(1-2):10-9.  
Poggensee G, Gilsdorf A, Buda S, Eckmanns T, Claus H, Altmann D, rki wgpi, Krause G, Haas W. 
The first wave of pandemic influenza (H1N1) 2009 in Germany: from initiation to acceleration. 
BMC Infect Dis 2010;10(1):155. 
Reuss A, Feig M, Kappelmayer L, Eckmanns T, Poggensee G. Bestimmung von Impfquoten und 
Inzidenzen von Erkrankungen anhand von Daten der Kassenarztlichen Vereinigungen 
[Determination of vaccination coverage and disease incidence using statutory health insurance 
data]. Gesundheitswesen 2010;72(6):340-346. 
Reuss A, Walter D, Feig M, Kappelmayer L, Buchholz U, Eckmanns T, Poggensee G. Influenza 
vaccination coverage in the 2004/05, 2005/06, and 2006/07 seasons: a secondary data analysis 
based on billing data of the German Associations of Statutory Health Insurance Physicians. Dtsch 
Arztebl Int 2010;107(48):845-50. 
Reuss A, Feig M, Kappelmayer L, Siedler A, Eckmanns T, Poggensee G. Varicella vaccination 
coverage of children under two years of age in Germany. BMC Public Health 2010;10:502. 
Schaade L, Reuss A, Haas W, Krause G. Pandemieplanung. Was haben wir aus der Pandemie 
(H1N1) 2009 gelernt? [Pandemic preparedness planning. What did we learn from the influenza 
pandemic (H1N1) 2009?]. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 
2010;53(12):1277-82.  
Schaberg T, Bauer T, Dalhoff K, Ewig S, Kohler D, Lorenz J, Rohde G, Pletz MW, Rosseau S, Schaaf 
B, Suttorp N, Welte T, Haas W, Reuss A. Management der Influenza A/H1N1 - Pandemie im 
Krankenhaus: Update Januar 2010. Eine Stellungnahme der Deutschen Gesellschaft fur 
Pneumologie und Beatmungsmedizin [Management of a new influenza A/H1N1 virus pandemic 
within the hospital. Statement of the German Society of Pneumology]. Pneumologie 
2010;64(2):124-129. 
Suess T, Buchholz U, Dupke S, Grunow R, Heiden Mad, Heider A, Biere B, Schweiger B, Haas W, 
Krause G, Group on Behalf of the Robert Koch Institute Shedding Investigation Group. Shedding 
and Transmission of Novel Influenza Virus A/H1N1 Infection in Households—Germany, 2009. Am 
J Epidem 2010;171(11):1157-1164. 
Wilking H, Buda S, von der Lippe E, Altmann D, Krause G, Eckmanns T, Haas W. Mortality of 
2009 pandemic influenza A(H1N1) in Germany. Euro Surveill 2010;15(49).  
Williams CJ, Buchholz U. Influence of household contacts on the effectiveness of face masks for 
preventing influenza in a healthcare setting: a comment on Cowling et al. (2010). Epidemiol 
Infectect 2010;138(10):1482-3; author reply 3.  
Williams CJ, Schweiger B, Diner G, Gerlach F, Haaman F, Krause G, Nienhaus A, Buchholz U. 
Seasonal influenza risk in hospital healthcare workers is more strongly associated with household 
than occupational exposures: results from a prospective cohort study in Berlin, Germany, 2006/07. 
BMC Infect Dis 2010; 10:8.  
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An der Heiden M, Buchholz U, Krause G, Kirchner G, Claus H, Haas W. Breaking the waves: 
modelling the potential impact of public health measures to defer the epidemic peak of novel 
influenza A/H1N1. PLoS One 2009;4(12):e8356.  
Barniol J, Niemann S, Louis VR, Brodhun B, Dreweck C, Richter E, Becher H, Haas W, Junghanss 
T. Transmission dynamics of pulmonary tuberculosis between autochthonous and immigrant sub-
populations. BMC Infect Dis 2009;9:197.  
Cai W, Schweiger B, Buchholz U, Buda S, Littmann M, Heusler J, Haas W. Protective measures 
and H5N1-seroprevalence among personnel tasked with bird collection during an outbreak of avian 
influenza A/H5N1 in wild birds, Ruegen, Germany, 2006. BMC Infect Dis 2009;9:170.  
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circulating susceptible A(H1N1) viruses. Euro Surveill 2009;14(46).. 
Dettmann M, Poggensee G, Buda S, Claus H, Krause G. Verlauf der Neuen Grippe. Trifft es bald 
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April to the end of August 2009]. MMW Fortschr Med 2009;151(40):35-37.  
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2009;46(3):295-297. 
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aggregated case reports from EU and EFTA countries. Euro Surveill 2009;14(23):19238. 
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Patienten]. Pädiatrische Praxis 2009;73(4):677-8. 
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reasons?]. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009; 52(2):193-202.  
Hollmeyer HG, Hayden F, Poland G, Buchholz U. Influenza vaccination of health care workers in 
hospitals--A review of studies on attitudes and predictors. Vaccine 2009;27(30):3935-3944. 
Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, Opp M, Paget J, van-de-
Kassteele J, Hay A, Zambon M, European Influenza Surveillance Scheme (for Germany: Buchholz 
U, Haas W, Schweiger B). Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. 
Emerg Infect Dis 2009;15(4):552-60.  
Poggensee G, Reuss A, Reiter S, Siedler A. Überblick und Bewertung der verfügbaren Datenquellen 
zur Inzidenz impfpraventabler Krankheiten, zum Durchimpfungsgrad und zum Immunstatus in 
Deutschland. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009;52(11):1019-28. 
Reuss A, Wiese-Posselt M, Weissmann B, Siedler A, Zuschneid I, An der Heiden M, Claus H, von 
Kries R, Haas W. Incidence rate of nontuberculous mycobacterial disease in immunocompetent 
children: a prospective nationwide surveillance study in Germany. Pediatr Infect Dis J 
2009;28(7):642-644.  
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Stöcker P, Brodhun B, Buchholz U. Legionärskrankheit in Deutschland unter besonderer 
Berücksichtigung der im Krankenhaus oder in einer Pflegeeinrichtung erworbenen Erkrankungen, 
2004 – 2006. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2009; 52(2):219-227. 
Novel influenza A(H1N1) investigation team. Description of the early stage of pandemic (H1N1) 
2009 in Germany, 27 April-16 June 2009. Euro Surveill 2009;14(31).  
B) Overview articles or systematic reviews (incl. non peer-review articles) 
2012 
Schaberg T, Bauer T, Castell S, Dalhoff K, Detjen A, Diel R, Greinert U, Hauer B, Lange C, Magdorf 
K, Loddenkemper R: Empfehlungen zur Therapie, Chemopravention und Chemoprophylaxe der 
Tuberkulose im Erwachsenen- und Kindesalter. Deutsches Zentralkomitee zur Bekampfung der 
Tuberkulose (DZK), Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin (DGP) 
[Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults 
and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society 
(DGP)]. Pneumologie. 2012;66(3):133-171.  
Ziegler R, Just HM, Castell S, Diel R, Gastmeier P, Haas W, Hauer B, Loytved G, Mielke M, Moser 
I, Nienhaus A, Richter E, Ruden H, Rusch-Gerdes S, Schaberg T, Wischnewski N, Loddenkemper R: 
Infektionspravention bei Tuberkulose - Empfehlungen des DZK [Tuberculosis infection control - 
recommendations of the DZK]. Gesundheitswesen. 2012;74(6):337-350.  
Ziegler R, Just HM, Castell S, Diel R, Gastmeier P, Haas W, Hauer B, Loytved G, Mielke M, Moser 
I, Nienhaus A, Richter E, Ruden H, Rusch-Gerdes S, Schaberg T, Wischnewski N, Loddenkemper R: 
Infektionspravention bei Tuberkulose--Empfehlungen des DZK [Tuberculosis infection control--
recommendations of the DZK]. Pneumologie 2012;66(5):269-282. 
2011 
Buda S, Burger R, Eckmanns T, Gilsdorf A, Haas W, Hamouda O, Lenz Y, Mielke M, Stark K, 
Krause G, Wichmann O, Gärtner B, Groß U, Hübner J, Jänisch T, Kist M, Kramer MH, Ledig T, Pulz 
M, Suttorp N, Ulbrich U: Prioritization of communicable infectious agents in terms of surveillance 
and epidemiological research: Results of a standardized procedure in Germany in 2011 
[Priorisierung übertragbarer Infektionserreger unter dem aspekt der surveillance und 
epidemiologischen Forschung: Ergebnisse eines standardisierten Vorgehens in Deutschland 2011]. 
Hyg Med 2011;36(12):503-509. 
Buda S, Haas W. Arbeitsgemeinschaft Influenza: Um Unterstützung wird gebeten. Dtsch Ärztebl 
2011;108(4):A-150. 
Remschmidt C, Buchholz U. GrippeWeb – Erste Ergebnisse aus dem neuen Online-Portal des 
Robert Koch Institutes zur Erhebung der Häufigkeit akuter Atemwegserkrankungen auf 
Bevölkerungsebene. UMID 2011(4). 
Diel R, Loytved G, Nienhaus A, Castell S, Detjen A, Geerdes-Fenge H, Haas W, Hauer B, 
Konigstein B, Maffei D, Magdorf K, Priwitzer M, Zellweger JP, Loddenkemper R: Neue 
Empfehlungen fur die Umgebungsuntersuchungen bei Tuberkulose [New recommendations for 
contact tracing in tuberculosis]. Gesundheitswesen 2011;73(6):369-388.  
Diel R, Loytved G, Nienhaus A, Castell S, Detjen A, Geerdes-Fenge H, Haas W, Hauer B, 
Konigstein B, Maffei D, Magdorf K, Priwitzer M, Zellweger JP, Loddenkemper R: Neue 
Empfehlungen fur die Umgebungsuntersuchungen bei Tuberkulose. Deutsches Zentralkomitee zur 
Bekampfung der Tuberkulose [New recommendations for contact tracing in tuberculosis. German 
Central Committee against Tuberculosis]. Pneumologie. 2011;65(6):359-378.. 
Haas W. High time to tackle childhood tuberculosis. Euro Surveill 2011;16(12). 
2010 
Castell S, Hauer B, Manissero D, Ulrichs T, Zaleskis R, Loddenkemper R. Berlin Declaration on 
Tuberculosis: High Level Follow-Up of High Priority Countries for TB Control in the WHO-EURO 
Region 'Double Trouble or Double Success? Bringing Together Diseases and Programs' - ein 
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Symposiumsbericht [Berlin Declaration on Tuberculosis: High Level Follow-Up of High Priority 
Countries for TB Control in the WHO-EURO Region 'Double Trouble or Double Success? Bringing 
Together Diseases and Programs' - a symposium report]. Pneumologie. 2010;64(7):422-429. 
Buchholz U, Haas W, Suess T. Was aus der Influenzapandemie zu lernen ist. Ärztezeitung 
2010(102). 
Buda S. Schweinegrippe - ein Zwischenstand. Wirklich alles halb so schlimm? [Swine influenza - an 
interim state. Really all half so bad?]. MMW Fortschr Med 2010; 152(10):16. 
Erkens CGM, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, Haas W, Migliori GB, Rieder 
HL, Zellweger JP, Lange C. Tuberculosis contact investigation in low prevalence countries: A 
European consensus. Eur Respir J 2010;36(4):925-949. 
2009 
Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K: Empfehlungen fur das 
Tuberkulosescreening vor Gabe von TNF-alpha-Inhibitoren bei rheumatischen Erkrankungen. 
[Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in 
rheumatic diseases]. Pneumologie. 2009;63(6):329-334.  
Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K: Empfehlungen fur das Tuberkulose-
Screening vor Gabe von TNF-alpha-Inhibitoren bei rheumatischen Erkrankungen 
[Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in 
rheumatic diseases]. Z Rheumatol 2009;68(5):411-416.  
Haas W: . Wie kann man sich jetzt noch schützen? Last-Minute-Massnahmen gegen die Grippe 
[How can one still protect oneself ? Last minute measures against the flu (interview by Dr. Beate 
Schumacher)]. MMW Fortschr Med 2009; 151(7):7. 
Haas W, Köpke K, Schweiger B, Buda S, Buchholz U, Harder T, Krause G: Neue Grippe: Die 
Primärversorger sind gefragt. Dtsch Ärztebl 2009; 106(19):A918-A20. 
Haas W, Nuemaier J. New influenza: What you must know about vaccination [Neue influenza: Was 
sie über die impfung wissen müssen]. MMW Fortschr Med 2009;151(34-35):12. 
Koepke K. Influenzaüberwachung: Surveillance der Krankheitslast. Dtsch Ärztebl 2009;106(5):A-
176. 
C) Articles in the Epidemiological Bulletin 
2012 
Auf dem Weg zur Elimination der Masern in Deutschland. Aktuelle Epidemiologie und Erfahrungen 
aus Ausbruchsuntersuchungen 2010 / 2011. Epid Bull 2012;19:165-72. 
Kommentar des Robert Koch Institutes zu: Tuberkuloseausbruch im Kreis Minden-Lübbecke: 
Fallbericht über Erkrankung, Ausbreitung und Therapie mehrfachresistenter Tuberkulose. Epid Bull 
2012(15). 
Welttuberkulosetag 2012 – Tuberkulose im Fokus. Epid Bull 2012(11). 
Syndromische Surveillance akuter Atemwegserkrankungen unter direkter Mitarbeit der 
Allgemeinbevölkerung (Ein Bericht zum ersten Jahr des Bestehens von GrippeWeb). Epid Bull 
2012(40). 
Wirksamkeit der Influenza-Impfung gegen saisonale Influenza A(H3N2) in der Saison 2011/2012. 
Epid Bull 2012(41). 
2011 
Zusammenfassung der Daten zur Epidemiologie der Tuberkulose in Deutschland für 2009. Epid 
Bull 2011(11). 
Schätzung der Influenza-bedingten Todesfälle während der Saison 2008/09 und der pandemischen 
Saison 2009/10. Epid Bull 2011(10). 
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Influenzasurveillance in der ersten postpandemischen Saison. Epid Bull 2011(18). 
Humane Fälle mit Infektion durch Schweineinfluenzaviren. Epid Bull 2011(39).  
Welttuberkulosetag 2011: Aktiv gegen Tuberkulose – Strategien im Licht neuer Entwicklungen. Epid 
Bull 2011(11). 
Kommentar des Robert Koch Institutes zu Tuberkulose-Infektionen im Landkreis Emsland: Zwei 
besondere Fallberichte. Epid Bull 2011(6). 
Kommentar des RKI zu: Neue molekulardiagnostische Verfahren in der Tuberkulose-Diagnostik. 
Epid Bull 2011(34). 
Bevölkerungsbasierte Erhebung der Häufigkeit von akuten Atemwegserkrankungen. Erste 
Ergebnisse aus dem neuen Online-Portal GrippeWeb. Epid Bull 2011(37). 
Haushaltsbasierte Studien zur Influenza-Übertragung. Epid Bull 2011(49). 
Studie zur Effektivität nichtpharmakologischer Interventionen zur Prävention von Influenza-
Übertragungen in Haushalten. Epid Bull 2011(50). 
2010 
Zur Tuberkulose in Deutschland im Jahr 2008. Epid Bull 2010(11). 
Schätzung der Influenza-bedingten Todesfälle während der Saison 2008/09 und der pandemischen 
Saison 2009/10. Epid Bull 2010;10:75-77. 
Rückblick: Epidemiologie und Infektionsschutz im zeitlichen Verlauf der Influenzapandemie 
(H1N1) 2009. Epid Bull 2010(21). 
Welttuberkulosetag 2010: Aktiv gegen Tuberkulose: Neue Ideen für schnelleres Handeln. Epid Bull 
2010(11). 
Influenza - Zum Auftreten von schwer verlaufenden Erkrankungen in England sowie zur aktuellen 
Situation in Deutschland und Europa. Epid Bull 2010(50). 
Zum vermehrten Auftreten von Fällen mit schwer verlaufender Influenza-Erkrankung in England 
sowie zur aktuellen Situation in Deutschland und Europa. Epid Bull 2010(50). 
Zur Dynamik der Virusausscheidung bei Neuer Influenza – weitere Ergebnisse der RKI-
Haushaltsstudie. Epid Bull 2010(6). 
2009 
Zur Tuberkulose in Deutschland im Jahr 2007. Epid Bull 2009(11). 
Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Legionärskrankheit im Jahr 2008. 
Epid Bull 2009(47). 
Kenngrößen der Fälle von Neuer Influenza A/H1N1 während der Sommersaison (KW 18–39/2009). 
Epid Bull 2009(46). 
Influenzasurveillance der Arbeitsgemeinschaft Influenza - Rückblick auf starke saisonale 
Grippewelle im Winter 2008/09, Monitoring der Neuen Influenza im Sommer 2009 und 
Vorausschau auf die Saison 2009/10. Epid Bull 2009(42). 
Zusammenstellung aufgetretener Fallcluster von Neuer Influenza in Deutschland (Würzburg, Köln, 
Düsseldorf). Epid Bull 2009(26). 
Zur Dynamik der Virusausscheidung bei Neuer Influenza A/H1N1 in Haushalten – erste 
Ergebnisse. Epid Bull 2009(42). 
D) Books 
2012 
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Brodhun B, Haas W, Hauer B, Fiebig L, Altmann D. Bericht zur Epidemiologie der Tuberkulose in 
Deutschland für 2010. Robert Koch Institute, editor. Berlin: Robert Koch Institute, MB Medienhaus 
Berlin GmbH; 2012. 
Buda S, Haas W, Köpke K, Luchtenberg M, Prahm K, Buchholz U, Schweiger B, Wedde M, Duwe 
S, an der Heiden M. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2011/12. 
2011/12 ed. Koch-Institut R, editor. Berlin: Robert Koch Institute, Königsdruck, Berlin; 2012. 
2011 
Brodhun B, Haas W, Hauer B, Fiebig L, Altmann D. Bericht zur Epidemiologie der Tuberkulose in 
Deutschland für 2009. Robert Koch Institute, editor. Berlin: Robert Koch Institute; 2011.  
Buda S, Haas W, Köpke K, Luchtenberg M, Schweiger B, Buchholz U, Preuß U, Wedde M, Duwe 
S, an der Heiden M. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2010/11. 
2010/11 ed. Robert Koch Institute, editor. Berlin: Robert Koch Institute, Königsdruck, Berlin; 2011. 
2010 
Buda S, Haas W, Köpke K, Luchtenberg M, Schweiger B, Biere B, Duwe S, Fiebig L, Buchholz U, 
an der Heiden M. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2009/10. 
2009/10 ed. Robert Koch Institute, editor. Berlin: Robert Koch Institute, Mercedes Druck; 2010. 
2009 
Influenza. Prävention, Diagnostik, Therapie und öffentliche Gesundheit. Haas W, editor: Elsevier, 
Urban & Fischer; 2009. 
E) Book chapters 
2012 
Brodhun B, Loddenkemper R, Hauer B. Die Bedeutung der Tuberkulose-Aktuelle Trends und 
Entwicklung. In: Nienhaus A, Brandenburg S, Teschler H, editors. Tuberkulose als Berufskrankheit, 
Ein Leitfaden zur Begutachtung und Vorsorge. 3. aktualisierte Auflage ed. Heidelberg, München, 
Landsberg, Frechen, Hamburg: ecomed Medizin; 2012. p. 41-60. 
Haas W. Tuberkulose-Meldeverfahren nach Einführung des Infektionsschutzgesetzes (IfSG). In: 
Nienhaus A, Brandenburg S, Teschler H, editors. Tuberkulose als Berufskrankheit, Ein Leitfaden zur 
Begutachtung und Vorsorge. 3. aktualisierte Auflage ed. Landsberg, Heidelberg, München, Frechen, 
Hamburg: ecomed Medizin; 2012. p. 61-9. 
Hauer B, Brodhun B, Loddenkemper R. Die Bedeutung der Tuberkulose-Aktuelle Trends und 
Entwicklung. In: Nienhaus A, Brandenburg S, Teschler H, editors. Tuberkulose als Berufskrankheit, 
Ein Leitfaden zur Begutachtung und Vorsorge. 3. aktualisierte Auflage ed. Landsberg, Heidelberg, 
München, Frechen, Hamburg: ecomed Medizin; 2012. p. 41-58. 
Hauer B, Brodhun B, Haas W, Altmann D, Niemann S, Rüsch-Gerdes S. Mykobacterium 
tuberculosis. In: Lebensmittelsicherheit BfVu, editor. GERMAP 2010, Antibiotika-Resistenz und -
Verbrauch. 1. Auflage, November 2011? ed. Rheinbach: Antiinfectives Intelligence, Gesellschaft für 
klinisch-mikrobiologische Forschung und Kommunikation mbH; 2012. p. 75-8. 
Hauer B, Kropp R, Nienhaus A. Die Tuberkulose als Berufskrankheit-ein historischer Abriss. In: 
Nienhaus A, Brandenburg S, Teschler H, editors. Tuberkulose als Berufskrankheit, Ein Leitfaden zur 
Begutachtung und Vorsorge. 3. aktualisierte Auflage ed. Heidelberg, München, Landsberg, Frechen, 
Hamburg: ecomed Medizin; 2012. p. 23-40. 
Hauer B, Loddenkemper R, Castell S. Prävention der berufsbedingten Tuberkulose. In: Nienhaus A, 
Brandenburg S, Teschler H, editors. Tuberkulose als Berufskrankheit, Ein Leitfaden zur 
Begutachtung und Vorsorge. 3. aktualisierte Auflage ed. Heidelberg, München, Landsberg, Frechen, 
Hamburg: ecomed Medizin; 2012. p. 291-303. 
Herold G und Mitarbeiter. Tuberkulose und nicht-tuberkulöse Mykobakteriosen. In: Herold G, 
editor. Innere Medizin 2013/2012. Oktober 2012 ed. Köln: Herold, Gerd; 2012. 
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2011 
Brodhun B, Haas W, Altmann D. Epidemiologie der Tuberkulose in Deutschland 2009. In: DZK 
Tuberkulose, editor. 34. Informationsbericht des Deutschen Zentralkomitee zur Bekämpfung der 
Tuberkulose. 34. Informationsbericht ed. Berlin;2011. p. 27-36. 
Brodhun B, Haas W, Hauer B, Altmann D, Niemann S, Rüsch-Gerdes S. Mycobacterium 
tuberculosis. In: (BVL), editor. Germap 2010, Antibiotika-Resistenz und -Verbrauch. 1. Auflage, 
November 2011 ed. Rheinbach: Antiinfectives Intelligence; 2011. p. 75-8. 
Haas W. In: GUIDANCE E, editor. Use of interferon-gamma release assays in support of TB 
diagnosis. March 2011 ed. Stockholm: ECDC GUIDANCE; 2011. p. 4-29. 
2009 
Haas W. Pandemieplanung. In: Haas W, editor. Influenza Prävention, Diagnostik, Therapie und 
öffentliche Gesundheit. München: Elsevier, Urban und Fischer; 2009. p. 209-30. 
4.1.2. Appendix with selected relevant publications  
A) Five important publications for the scientific community 2009–2012 
1. Suess T, Remschmidt C, Schink S, Schweiger B, Nitsche A, Schroeder K, Doellinger J, 
Milde J, Haas W, Koehler I, Krause G, Buchholz U. The role of facemasks and hand 
hygiene in the prevention of influenza transmission in households: results from a cluster 
randomised trial; Berlin, Germany, 2009-2011. BMC Infect Dis 2012;12(1):26. 
2. Altmann M, Fiebig L, Buda S, von Kries R, Dehnert M, Haas W. Unchanged severity of 
influenza A(H1N1)pdm09 infection in children during first postpandemic season. Emerg 
Infect Dis 2012;18(11). 
3. Fiebig L, Kollan C, Hauer B, Gunsenheimer-Bartmeyer B, An der Heiden M, Hamouda O, 
Haas W. HIV-Prevalence in Tuberculosis Patients in Germany, 2002-2009: An Estimation 
Based on HIV and Tuberculosis Surveillance Data. PLoS One 2012;7(11):e49111.  
4. Dudareva S, Schweiger B, Thamm M, Hohle M, Stark K, Krause G, Buda S, Haas W. 
Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult 
population in pre- and post-pandemic period. PLoS One 2011;6(6):e21340.  
5. An der Heiden M, Buchholz U, Krause G, Kirchner G, Claus H, Haas W. Breaking the 
waves: modelling the potential impact of public health measures to defer the epidemic peak 
of novel influenza A/H1N1. PLoS One 2009;4(12):e8356.  
B) Five important publications for the public 2009–2012 
1. Homepage of the Working Group Influenza (Arbeitsgemeinschaft Influenza): 
http://influenza.rki.de/  
2. Wirksamkeit der Influenza-Impfung gegen saisonale Influenza A(H3N2) in der Saison 
2011/2012. Epid Bull 2012(41). 
3. Syndromische Surveillance akuter Atemwegserkrankungen unter direkter Mitarbeit der 
Allgemeinbevölkerung (Ein Bericht zum ersten Jahr des Bestehens von GrippeWeb). Epid 
Bull 2012(40).  
GrippeWeb-Homepage https://grippeweb.rki.de/ 
4. Welttuberkulosetag 2012 – Tuberkulose im Fokus. Epid Bull 2012(11). 
5. Studie zur Effektivität nichtpharmakologischer Interventionen zur Prävention von Influenza-
Übertragungen in Haushalten. Epid Bull 2011(50). 
4.1.3.  Awards and honours, 2009 - 2012 
2011 
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Dr. Lena Fiebig, Best poster award in the “General category” at the HPA Health Protection 
conference for the poster entitled “Diagnostic findings for childhood tuberculosis by use of gastric 
aspirate, Germany, 2002 to 2009“ 
4.1.4. Overview on collaborations in networks 
ECDC, WHO:  
• Joint ECDC/WHO TB surveillance network 
• European Influenza surveillance Network (EISN) 
• EuroFlu (WHO Euro) 
• National Contact Point for  
o Legionnaire's disease (ELDSNet): Bonita Brodhun (+ NTP-Manager) 
o Influenza: Silke Buda (EISN) 
o Tuberculosis: Walter Haas (+ NTP-Manager) 
• Member of Programm Committee of Wolfheze Tuberculosis-Workshop  
Stop TB Partnership: 
Childhood TB subgroup of WHO Dots Expansion Working Group 
• RKI as NTP-Manager and TB National Contact Point:  
o Walter Haas 
o Barbara Hauer 
Union (former IUATLD): 
• Member of Childhood TB Training Tools Working Group 
 
WHO Euro: 
• Member of steering group fort he development of the WHO M/XDR-TB Actionplan (MAP)  
• Member of Task Forces for the development of Monitoring and Evaluation Frameworks for 
MAP and the Berlin Declaration  
• Member of Programm Committee of Wolfheze-Workshop 
• Member of the Regional Interagency Coordinating Committee on Tuberculosis Control and 
Care (RICC-TB) 
• Observer of WHO Europe Technical advisory group on Tuberculosis control (TAG-TB) 
KNCV/Wolfheze: 
• Member oft he Wolfheze Workshop Programm Committee 
• Member of the Consenus Group on TB control in Big Cities and urban risk groups in the 
EU (including Health Protection Agency, EU Member State representatives for TB from 
e.g.Belgium, France) 
• Member of the consensus working group on TB contact investigation in low prevalence 
countries  
Tuberculosis Surveillance Research Unit (TSRU) 
• Representative for Germany (in collaboration with DZK) 
BIPS (Institute for epidemiology and prevention research, Bremen): 
• BMBF-supported program "Epi goes gender" 
4.1.5. Memberships and participation in Advisory Boards 
PD Dr. Walter Haas 
• ECDC Expert Panel: 
ECDC Guidance: Use of interferon-gamma release assays in support of tuberculosis 
diagnosis. ECDC 2011 ISBN 978-92-9193-240-5 
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• Member of the Pandemic Influenza Working Group (PIWG) of the Global Health Security 
Action Group (GHSAG)  
• DGPI: Scientific adviser, Coordinator for recommenadations on tuberculosis and influenza 
• German Central Committee against Tuberculosis (DZK): Scientific adviser 
Reviews: 
• International Journal for Tuberculosis and Lung Diseases, Pediatric Infectious Disease 
Journal, Emerging Infectious Diseases, Eurosurveillance, BMC Infectious Diseases; 
Assistant Editor BMC Public Health 
Dr. Barbara Hauer 
• Observer of WHO Europe Technical Advisory Group on Tuberculosis Control (TAG-TB) 
• Member of the Regional Interagency Coordinating Committee on Tuberculosis Control and 
Care (RICC-TB) 
• Member of the Steering Group during the development process of the WHO M/XDR-TB 
Actionplan 
• Scientific advisor for the scientific Koch Metschnikov Forum Symposium (yearly on March 
24, World TB day) 
•  Scientific advisor of the Working group „Frequently asked questions 
tuberculosis“Subgroup 1 of the Committee for Occupational Medicine 
Reviews: 
• for European Respiratory Journal (ERJ), International Journal for Tuberculosis and Lung 
Diseases (IJTLD), Public Health Action, Pneumologie 
Dr. Bonita Brodhun 
• Member of the Steering committee of EWGLINet until 2009 (now: ELDSNet) 
Dr. Udo Buchholz 
• EISN: Member of the CNRL-Management team 
Dr. Silke Buda 
• Member of the EISN Coordination Group 
4.1.6.  List of completed habilitation, dissertation or master theses in the Unit, 2009 
– 2012 
Year Title Name Title of thesis University / 
RKI Supervisor 





Tuberculosis as AIDS-defining disease in 
Germany: occurrence, case 
characteristics and treatment 
BSPH / W.Haas 
and L. Fiebig 
2011 Master in 
Public Health 
(MPH) 
Lena Bös Die Tuberkulosesituation im Berliner 
Justizvollzug 2007-2010 
BSPH / W. Haas 





Auswertungsroutinen für eine cluster-
randomisierte Studie zur Wirksamkeit 
nicht-pharmakologischer Präventions-
maßnahmen gegen Influenza 
BHT Berlin /  
U. Buchholz 





Epidemiologie und Kontrolle der 
Tuberkulose in Metropolen europäischer 
Niederinzidenz-Länder 
BSPH / W. Haas 
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4.1.7. Presentations as invited speaker, 2009 – 2012 
Staff from the Respiratory Infections Unit were invited to speak at 75 conferences. 
4.1.8. Reports and written scientific advice to the Ministry of Health, 2009-2012 
There were 188 reports and written scientific advice to the Ministry of Health between 2009 and 
30.09.2012. 
 
